{"PMC7478901": [["IntroductionEdwardsiella tarda is a gram-negative, facultative anaerobe that is a member of the family Enterobacteriaceae and was first described by Ewing et al. in 1965 [1].", [["Edwardsiella tarda", "DISEASE", 12, 30], ["Edwardsiella tarda", "ORGANISM", 12, 30], ["Edwardsiella tarda", "SPECIES", 12, 30], ["Edwardsiella tarda", "SPECIES", 12, 30], ["a gram", "TEST", 34, 40]]], ["Since then, a growing body of literature has reported E. tarda isolates particularly related to brackish water and marine ecosystems, including reptiles, amphibians, and fish [2].", [["E. tarda", "ORGANISM", 54, 62], ["E. tarda", "SPECIES", 54, 62], ["E. tarda", "SPECIES", 54, 62], ["E. tarda isolates", "PROBLEM", 54, 71]]], ["E. tarda human infections are rare and mainly present as gastroenteritis; however, extraintestinal and systemic infections have been reported that, when present, are a potentially life-threatening condition carrying up to 50% risk of mortality [3].", [["human infections", "DISEASE", 9, 25], ["gastroenteritis", "DISEASE", 57, 72], ["extraintestinal and systemic infections", "DISEASE", 83, 122], ["E. tarda", "ORGANISM", 0, 8], ["human", "ORGANISM", 9, 14], ["E. tarda", "SPECIES", 0, 8], ["human", "SPECIES", 9, 14], ["E. tarda human", "SPECIES", 0, 14], ["E. tarda human infections", "PROBLEM", 0, 25], ["gastroenteritis", "PROBLEM", 57, 72], ["extraintestinal and systemic infections", "PROBLEM", 83, 122], ["tarda human", "OBSERVATION_MODIFIER", 3, 14], ["infections", "OBSERVATION", 15, 25], ["gastroenteritis", "OBSERVATION", 57, 72], ["systemic", "OBSERVATION_MODIFIER", 103, 111], ["infections", "OBSERVATION", 112, 122]]], ["Such infections include bacteremia; infections of skin, soft tissue, and biliary tract; liver and tubo-ovarian abscesses; and peritonitis, particularly in immunocompromised hosts [4, 5].", [["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 56, 67], ["biliary tract", "ANATOMY", 73, 86], ["liver", "ANATOMY", 88, 93], ["tubo", "ANATOMY", 98, 102], ["ovarian abscesses", "ANATOMY", 103, 120], ["infections", "DISEASE", 5, 15], ["bacteremia", "DISEASE", 24, 34], ["infections", "DISEASE", 36, 46], ["liver and tubo-ovarian abscesses", "DISEASE", 88, 120], ["peritonitis", "DISEASE", 126, 137], ["skin", "ORGAN", 50, 54], ["soft tissue", "TISSUE", 56, 67], ["biliary tract", "ORGAN", 73, 86], ["liver", "ORGAN", 88, 93], ["ovarian", "ORGAN", 103, 110], ["Such infections", "PROBLEM", 0, 15], ["bacteremia", "PROBLEM", 24, 34], ["infections of skin, soft tissue, and biliary tract", "PROBLEM", 36, 86], ["liver and tubo-ovarian abscesses", "PROBLEM", 88, 120], ["peritonitis", "PROBLEM", 126, 137], ["infections", "OBSERVATION", 5, 15], ["bacteremia", "OBSERVATION", 24, 34], ["infections", "OBSERVATION", 36, 46], ["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 56, 67], ["biliary tract", "ANATOMY", 73, 86], ["liver", "ANATOMY", 88, 93], ["ovarian", "ANATOMY", 103, 110], ["abscesses", "OBSERVATION", 111, 120], ["peritonitis", "OBSERVATION", 126, 137]]], ["We report a case of E. tarda infection that presented as multiple liver abscesses leading to fulminant septic shock in a previously healthy 37-year-old woman.Case presentationA 37-year-old Southeast Asian woman presented to the emergency department of our hospital with a 5-day history of abdominal pain, fever, and vomiting.", [["liver abscesses", "ANATOMY", 66, 81], ["abdominal", "ANATOMY", 289, 298], ["E. tarda infection", "DISEASE", 20, 38], ["liver abscesses", "DISEASE", 66, 81], ["septic shock", "DISEASE", 103, 115], ["abdominal pain", "DISEASE", 289, 303], ["fever", "DISEASE", 305, 310], ["vomiting", "DISEASE", 316, 324], ["E. tarda", "ORGANISM", 20, 28], ["liver", "ORGAN", 66, 71], ["woman", "ORGANISM", 152, 157], ["woman", "ORGANISM", 205, 210], ["abdominal", "ORGANISM_SUBDIVISION", 289, 298], ["E. tarda", "SPECIES", 20, 28], ["woman", "SPECIES", 152, 157], ["woman", "SPECIES", 205, 210], ["E. tarda", "SPECIES", 20, 28], ["E. tarda infection", "PROBLEM", 20, 38], ["multiple liver abscesses", "PROBLEM", 57, 81], ["fulminant septic shock", "PROBLEM", 93, 115], ["abdominal pain", "PROBLEM", 289, 303], ["fever", "PROBLEM", 305, 310], ["vomiting", "PROBLEM", 316, 324], ["E. tarda", "OBSERVATION_MODIFIER", 20, 28], ["infection", "OBSERVATION", 29, 38], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["liver", "ANATOMY", 66, 71], ["abscesses", "OBSERVATION", 72, 81], ["fulminant", "OBSERVATION_MODIFIER", 93, 102], ["septic shock", "OBSERVATION", 103, 115], ["abdominal", "ANATOMY", 289, 298], ["pain", "OBSERVATION", 299, 303], ["fever", "OBSERVATION", 305, 310]]], ["Her past medical history was unremarkable apart from a laparoscopic cholecystectomy 10 months earlier.", [["a laparoscopic cholecystectomy", "TREATMENT", 53, 83], ["unremarkable", "OBSERVATION", 29, 41], ["laparoscopic", "OBSERVATION_MODIFIER", 55, 67], ["cholecystectomy", "OBSERVATION", 68, 83]]], ["Upon presentation, the patient had high-grade fever, tachycardia, and hypotension suggestive of worsening sepsis, which eventually progressed rapidly to septic shock requiring high doses of noradrenaline and vasopressin.", [["fever", "DISEASE", 46, 51], ["tachycardia", "DISEASE", 53, 64], ["hypotension", "DISEASE", 70, 81], ["sepsis", "DISEASE", 106, 112], ["shock", "DISEASE", 160, 165], ["noradrenaline", "CHEMICAL", 190, 203], ["vasopressin", "CHEMICAL", 208, 219], ["noradrenaline", "CHEMICAL", 190, 203], ["vasopressin", "CHEMICAL", 208, 219], ["patient", "ORGANISM", 23, 30], ["noradrenaline", "SIMPLE_CHEMICAL", 190, 203], ["vasopressin", "SIMPLE_CHEMICAL", 208, 219], ["patient", "SPECIES", 23, 30], ["high-grade fever", "PROBLEM", 35, 51], ["tachycardia", "PROBLEM", 53, 64], ["hypotension", "PROBLEM", 70, 81], ["worsening sepsis", "PROBLEM", 96, 112], ["septic shock", "PROBLEM", 153, 165], ["noradrenaline", "TREATMENT", 190, 203], ["vasopressin", "TREATMENT", 208, 219], ["fever", "OBSERVATION", 46, 51], ["tachycardia", "OBSERVATION", 53, 64], ["hypotension", "OBSERVATION", 70, 81], ["suggestive of", "UNCERTAINTY", 82, 95], ["worsening", "OBSERVATION_MODIFIER", 96, 105], ["sepsis", "OBSERVATION", 106, 112], ["septic shock", "OBSERVATION", 153, 165]]], ["She was intubated, mechanically ventilated, and admitted to the intensive care unit (ICU) accordingly.", [["intubated", "TREATMENT", 8, 17]]], ["Upon ICU admission, an abdominal computed tomographic (CT) scan with contrast (Fig. 1) revealed hypodense lesions occupying the right and left liver lobes with calcification foci suspicious of abscesses as well as mild intra-abdominal free fluid collection.", [["hypodense lesions", "ANATOMY", 96, 113], ["right", "ANATOMY", 128, 133], ["left liver lobes", "ANATOMY", 138, 154], ["abscesses", "ANATOMY", 193, 202], ["intra-abdominal", "ANATOMY", 219, 234], ["calcification", "DISEASE", 160, 173], ["abscesses", "DISEASE", 193, 202], ["hypodense lesions", "CANCER", 96, 113], ["liver", "ORGAN", 143, 148], ["abscesses", "PATHOLOGICAL_FORMATION", 193, 202], ["an abdominal computed tomographic (CT) scan with contrast (Fig. 1)", "TEST", 20, 86], ["hypodense lesions", "PROBLEM", 96, 113], ["calcification foci", "PROBLEM", 160, 178], ["abscesses", "PROBLEM", 193, 202], ["mild intra-abdominal free fluid collection", "PROBLEM", 214, 256], ["abdominal", "ANATOMY", 23, 32], ["hypodense", "OBSERVATION_MODIFIER", 96, 105], ["lesions", "OBSERVATION", 106, 113], ["right", "ANATOMY_MODIFIER", 128, 133], ["left", "ANATOMY_MODIFIER", 138, 142], ["liver", "ANATOMY", 143, 148], ["lobes", "ANATOMY_MODIFIER", 149, 154], ["calcification", "OBSERVATION", 160, 173], ["abscesses", "OBSERVATION", 193, 202], ["mild", "OBSERVATION_MODIFIER", 214, 218], ["intra-abdominal", "ANATOMY", 219, 234], ["free", "OBSERVATION_MODIFIER", 235, 239], ["fluid", "OBSERVATION", 240, 245]]], ["Initial investigations revealed a hemoglobin level of 10.4 g/dl and a white blood cell count of 18.9 \u00d7 109/L with 89% neutrophils.", [["white blood cell", "ANATOMY", 70, 86], ["neutrophils", "ANATOMY", 118, 129], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 34, 44], ["blood cell", "CELL", 76, 86], ["neutrophils", "CELL", 118, 129], ["hemoglobin", "PROTEIN", 34, 44], ["neutrophils", "CELL_TYPE", 118, 129], ["Initial investigations", "TEST", 0, 22], ["a hemoglobin level", "TEST", 32, 50], ["a white blood cell count", "TEST", 68, 92], ["neutrophils", "TEST", 118, 129]]], ["Her platelet count was normal.", [["platelet", "ANATOMY", 4, 12], ["platelet", "CELL", 4, 12], ["Her platelet count", "TEST", 0, 18], ["platelet count", "OBSERVATION", 4, 18], ["normal", "OBSERVATION", 23, 29]]], ["Her blood urea nitrogen was raised at 12.1 mmol/L (normal range 2.5\u20136.4 mmol/L), but her serum creatinine was within normal limits at 115 IU/L (normal range 71\u2013115 IU/L).", [["blood", "ANATOMY", 4, 9], ["serum", "ANATOMY", 89, 94], ["blood urea nitrogen", "CHEMICAL", 4, 23], ["creatinine", "CHEMICAL", 95, 105], ["urea", "CHEMICAL", 10, 14], ["nitrogen", "CHEMICAL", 15, 23], ["creatinine", "CHEMICAL", 95, 105], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["urea", "SIMPLE_CHEMICAL", 10, 14], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["creatinine", "SIMPLE_CHEMICAL", 95, 105], ["Her blood urea nitrogen", "TEST", 0, 23], ["her serum creatinine", "TEST", 85, 105]]], ["Her renal function was completely normalized following administration of intravenous fluids a few hours after ICU admission.", [["renal", "ANATOMY", 4, 9], ["intravenous", "ANATOMY", 73, 84], ["renal", "ORGAN", 4, 9], ["intravenous fluids", "TREATMENT", 73, 91], ["renal", "ANATOMY", 4, 9]]], ["The findings of blood film obtained for malarial parasites were negative.", [["blood", "ANATOMY", 16, 21], ["malarial parasites", "DISEASE", 40, 58], ["blood film", "MULTI-TISSUE_STRUCTURE", 16, 26], ["blood film", "TEST", 16, 26], ["malarial parasites", "PROBLEM", 40, 58]]], ["Notwithstanding this, liver function tests were remarkable with a total bilirubin of 25.3 \u03bcmol/L (direct 13.6 \u03bcmol/L, indirect 11.7 \u03bcmol/L), albumin 19.5 g/L, globulin 44.9 g/L, alkaline phosphatase 416 U/L, alanine aminotransferase 549 IU/L, aspartate aminotransferase 765 IU/L, prothrombin time 16.5 with international normalized ratio 1.41, activated partial thromboplastin time 39.9 seconds, and glucose 5.5 mmol/L. The patient\u2019s physical examination and chest x-ray were unremarkable.", [["liver", "ANATOMY", 22, 27], ["bilirubin", "CHEMICAL", 72, 81], ["alanine", "CHEMICAL", 208, 215], ["aspartate", "CHEMICAL", 243, 252], ["glucose", "CHEMICAL", 400, 407], ["bilirubin", "CHEMICAL", 72, 81], ["alanine", "CHEMICAL", 208, 215], ["aspartate", "CHEMICAL", 243, 252], ["glucose", "CHEMICAL", 400, 407], ["liver", "ORGAN", 22, 27], ["bilirubin", "SIMPLE_CHEMICAL", 72, 81], ["albumin", "GENE_OR_GENE_PRODUCT", 141, 148], ["globulin", "GENE_OR_GENE_PRODUCT", 159, 167], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 178, 198], ["alanine", "AMINO_ACID", 208, 215], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 216, 232], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 243, 269], ["prothrombin", "GENE_OR_GENE_PRODUCT", 280, 291], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 362, 376], ["glucose", "SIMPLE_CHEMICAL", 400, 407], ["patient", "ORGANISM", 424, 431], ["albumin", "PROTEIN", 141, 148], ["globulin", "PROTEIN", 159, 167], ["alkaline phosphatase", "PROTEIN", 178, 198], ["alanine aminotransferase", "PROTEIN", 208, 232], ["aspartate aminotransferase", "PROTEIN", 243, 269], ["prothrombin", "PROTEIN", 280, 291], ["patient", "SPECIES", 424, 431], ["liver function tests", "TEST", 22, 42], ["a total bilirubin", "TEST", 64, 81], ["direct", "TEST", 98, 104], ["\u03bcmol", "TEST", 110, 114], ["L", "TEST", 115, 116], ["indirect", "TEST", 118, 126], ["\u03bcmol", "TEST", 132, 136], ["albumin", "TEST", 141, 148], ["g", "TEST", 154, 155], ["globulin", "TEST", 159, 167], ["g", "TEST", 173, 174], ["alkaline phosphatase", "TEST", 178, 198], ["U/L", "TEST", 203, 206], ["alanine aminotransferase", "TEST", 208, 232], ["IU", "TEST", 237, 239], ["aspartate aminotransferase", "TEST", 243, 269], ["IU/L", "TEST", 274, 278], ["prothrombin time", "TEST", 280, 296], ["international normalized ratio", "TEST", 307, 337], ["activated partial thromboplastin time", "TEST", 344, 381], ["glucose", "TEST", 400, 407], ["The patient\u2019s physical examination", "TEST", 420, 454], ["chest x-ray", "TEST", 459, 470], ["liver", "ANATOMY", 22, 27], ["chest", "ANATOMY", 459, 464], ["unremarkable", "OBSERVATION", 476, 488]]], ["CT-guided percutaneous drainage of the liver abscesses with supplementary cultures was performed while blood cultures were derived accordingly.", [["percutaneous", "ANATOMY", 10, 22], ["liver abscesses", "ANATOMY", 39, 54], ["blood", "ANATOMY", 103, 108], ["liver abscesses", "DISEASE", 39, 54], ["liver", "ORGAN", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["CT", "TEST", 0, 2], ["guided percutaneous drainage", "TREATMENT", 3, 31], ["the liver abscesses", "PROBLEM", 35, 54], ["supplementary cultures", "TEST", 60, 82], ["blood cultures", "TEST", 103, 117], ["drainage", "OBSERVATION", 23, 31], ["liver", "ANATOMY", 39, 44], ["abscesses", "OBSERVATION", 45, 54]]], ["The analysis of the fluid drained from the liver abscess showed a high white blood cell count (11.8 \u00d7 103/\u03bcl) with polymorphic predominance (77%) and high bilirubin and lactate dehydrogenase levels.", [["fluid", "ANATOMY", 20, 25], ["liver abscess", "ANATOMY", 43, 56], ["white blood cell", "ANATOMY", 71, 87], ["liver abscess", "DISEASE", 43, 56], ["bilirubin", "CHEMICAL", 155, 164], ["lactate", "CHEMICAL", 169, 176], ["bilirubin", "CHEMICAL", 155, 164], ["lactate", "CHEMICAL", 169, 176], ["liver", "ORGAN", 43, 48], ["blood cell", "CELL", 77, 87], ["bilirubin", "SIMPLE_CHEMICAL", 155, 164], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 169, 190], ["bilirubin", "PROTEIN", 155, 164], ["lactate dehydrogenase", "PROTEIN", 169, 190], ["The analysis", "TEST", 0, 12], ["the fluid", "TEST", 16, 25], ["the liver abscess", "PROBLEM", 39, 56], ["a high white blood cell count", "PROBLEM", 64, 93], ["polymorphic predominance", "PROBLEM", 115, 139], ["high bilirubin and lactate dehydrogenase levels", "PROBLEM", 150, 197], ["fluid", "OBSERVATION", 20, 25], ["liver", "ANATOMY", 43, 48], ["abscess", "OBSERVATION", 49, 56], ["high", "OBSERVATION_MODIFIER", 66, 70], ["high bilirubin", "OBSERVATION", 150, 164]]], ["Moreover, a gram-stained smear of the pus aspirated from the liver abscess showed few gram-negative bacilli and necrotic debris.", [["pus", "ANATOMY", 38, 41], ["liver abscess", "ANATOMY", 61, 74], ["necrotic debris", "ANATOMY", 112, 127], ["liver abscess", "DISEASE", 61, 74], ["necrotic", "DISEASE", 112, 120], ["pus", "PATHOLOGICAL_FORMATION", 38, 41], ["liver", "ORGAN", 61, 66], ["a gram-stained smear", "TEST", 10, 30], ["the pus", "PROBLEM", 34, 41], ["the liver abscess", "PROBLEM", 57, 74], ["few gram-negative bacilli", "PROBLEM", 82, 107], ["necrotic debris", "PROBLEM", 112, 127], ["pus", "OBSERVATION", 38, 41], ["liver", "ANATOMY", 61, 66], ["abscess", "OBSERVATION", 67, 74], ["few", "OBSERVATION_MODIFIER", 82, 85], ["negative bacilli", "OBSERVATION", 91, 107], ["necrotic", "OBSERVATION_MODIFIER", 112, 120], ["debris", "OBSERVATION", 121, 127]]], ["All blood cultures as well as stool samples that were collected for 3 consecutive days grew E. tarda [6].", [["blood cultures", "ANATOMY", 4, 18], ["stool samples", "ANATOMY", 30, 43], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["stool samples", "ORGANISM_SUBSTANCE", 30, 43], ["E. tarda", "SPECIES", 92, 100], ["E. tarda", "SPECIES", 92, 100], ["All blood cultures", "TEST", 0, 18], ["stool samples", "TEST", 30, 43]]], ["Specifically, blood cultures were obtained under sterile conditions and were processed using BacT/ALERT 3D (bioM\u00e9rieux, Marcy l\u2019Etoile, France).", [["blood cultures", "ANATOMY", 14, 28], ["blood cultures", "ORGANISM_SUBSTANCE", 14, 28], ["blood cultures", "TEST", 14, 28]]], ["Strains of E. tarda were identified using the MicroScan WalkAway 96si system (Siemens, Erlangen, Germany).", [["E. tarda", "ORGANISM", 11, 19], ["E. tarda", "SPECIES", 11, 19], ["E. tarda", "SPECIES", 11, 19], ["E. tarda", "OBSERVATION_MODIFIER", 11, 19]]], ["We evaluated the drug susceptibility of the pathogen based on clinical breakpoints set by the Clinical and Laboratory Standards Institute using E-test (bioM\u00e9rieux) [7].", [["the pathogen", "PROBLEM", 40, 52]]]], "4f9d6ff4b4077cfff56d7e27ec73c4d482b3982c": [["Dear Editor,I read with interest the review article of Brown et al. on COVID-19 treatment using convalescent plasma [1] .", [["plasma", "ANATOMY", 109, 115], ["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "CHEMICAL", 71, 79], ["plasma", "ORGANISM_SUBSTANCE", 109, 115], ["COVID", "TREATMENT", 71, 76]]], ["The review highlighted three case series from China, which cumulatively enrolled 19 patients.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92]]], ["The case series were two studies on critically ill (the first and third study), and one study on severely ill patients (the second study).", [["critically ill", "DISEASE", 36, 50], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["two studies", "TEST", 21, 32], ["third study", "TEST", 66, 77], ["one study", "TEST", 84, 93], ["the second study", "TEST", 120, 136]]], ["However, the information in the text and Table was inconsistent and confusing.", [["confusing", "PROBLEM", 68, 77]]], ["The reference numbers in the text are different from those in the Table.", [["numbers", "OBSERVATION_MODIFIER", 14, 21], ["different", "OBSERVATION_MODIFIER", 38, 47]]], ["From the Table, there were three case series of five and four critically ill patients from first (ref. no 14) and third (ref. no 30) studies, and ten severely ill patients from the second study (ref. no 16), while in the text it was stated: \"There have been 3 case series from China for the use of convalescent plasma to treat COVID-19 (19 total patients)\" (reference number 16, 26, 27).", [["plasma", "ANATOMY", 311, 317], ["critically ill", "DISEASE", 62, 76], ["COVID", "DISEASE", 327, 332], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 163, 171], ["convalescent", "ORGANISM", 298, 310], ["plasma", "ORGANISM_SUBSTANCE", 311, 317], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 346, 354], ["studies", "TEST", 133, 140], ["the second study", "TEST", 177, 193], ["convalescent plasma", "TREATMENT", 298, 317], ["COVID", "TEST", 327, 332]]], ["Moreover, there is a confusing statement without a reference: \"In this pilot study, 9 patients received 1 dose of 200 mL convalescent plasma with neutralizing antibody titers of > 1:640.", [["plasma", "ANATOMY", 134, 140], ["patients", "ORGANISM", 86, 94], ["convalescent", "ORGANISM", 121, 133], ["plasma", "ORGANISM_SUBSTANCE", 134, 140], ["patients", "SPECIES", 86, 94], ["this pilot study", "TEST", 66, 82], ["200 mL convalescent plasma", "TREATMENT", 114, 140], ["neutralizing antibody titers", "TEST", 146, 174]]], ["The median time from onset of illness to convalescent plasma transfusion was 16.5 days.", [["plasma", "ANATOMY", 54, 60], ["illness", "DISEASE", 30, 37], ["convalescent", "ORGANISM", 41, 53], ["plasma", "ORGANISM_SUBSTANCE", 54, 60], ["illness", "PROBLEM", 30, 37], ["convalescent plasma transfusion", "TREATMENT", 41, 72]]], ["Within 3 days, the patients showed improved clinical symptoms along with increase of oxyhemoglobin saturation\".", [["oxyhemoglobin", "CHEMICAL", 85, 98], ["patients", "ORGANISM", 19, 27], ["oxyhemoglobin", "SIMPLE_CHEMICAL", 85, 98], ["patients", "SPECIES", 19, 27], ["improved clinical symptoms", "PROBLEM", 35, 61], ["increase of oxyhemoglobin saturation\"", "PROBLEM", 73, 110]]], ["The information of the pilot study concerning information of dose, antibody titres, median time from illness onset to convalescent plasma therapy referred to the second study on ten severely ill patients (ref. no 16), which was available on the Table.", [["plasma", "ANATOMY", 131, 137], ["illness", "DISEASE", 101, 108], ["plasma", "ORGANISM_SUBSTANCE", 131, 137], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["the pilot study", "TEST", 19, 34], ["antibody titres", "TEST", 67, 82], ["illness", "PROBLEM", 101, 108], ["convalescent plasma therapy", "TREATMENT", 118, 145], ["the second study", "TEST", 158, 174]]], ["Therefore, there is an inconsistency in the number of patients.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["inconsistency", "OBSERVATION", 23, 36]]], ["In addition, the time of improvement in clinical symptoms (within 3 days) referred to the first study that enrolled five patients (ref. no 14) .Dear Editor,The results of case series showed improvement of four out of five patients in the first study, and all four patients in the third study.", [["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 222, 230], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 264, 272], ["clinical symptoms", "PROBLEM", 40, 57], ["the first study", "TEST", 86, 101], ["case series", "TEST", 171, 182], ["the first study", "TEST", 234, 249], ["the third study", "TEST", 276, 291]]], ["Though the results seemed promising [1] , they need to be interpreted with caution, as they are not a robust proof compared to a randomized clinical trial.", [["a randomized clinical trial", "TREATMENT", 127, 154]]], ["A recent systematic review on convalescent plasma for COVID-19 reviewed eight studies, which cumulatively enrolled 32 participants that consisted of seven case-series and one prospective single-arm intervention study [2] .", [["plasma", "ANATOMY", 43, 49], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["participants", "SPECIES", 118, 130], ["convalescent plasma", "TEST", 30, 49], ["COVID", "TEST", 54, 59], ["eight studies", "TEST", 72, 85], ["one prospective single-arm intervention study", "TREATMENT", 171, 216]]], ["The systematic review concluded that all outcomes were of very low certainty, as all of the outcomes could be due to other concomitant treatments or the natural course of the disease, rather than convalescent plasma [2] .Dear Editor,Besides discussing the value of convalescence plasma in the treatment of COVID-19, the review also mentioned some considerations to be taken into account, though the case series reported no serious adverse events.", [["plasma", "ANATOMY", 209, 215], ["plasma", "ANATOMY", 279, 285], ["plasma", "ORGANISM_SUBSTANCE", 209, 215], ["plasma", "ORGANISM_SUBSTANCE", 279, 285], ["concomitant treatments", "TREATMENT", 123, 145], ["the disease", "PROBLEM", 171, 182], ["convalescence plasma", "TREATMENT", 265, 285], ["COVID", "TEST", 306, 311], ["serious adverse events", "PROBLEM", 423, 445]]], ["The considerations to be taken into account in convalescent plasma therapy were the possibility of transfusion-related acute lung injury (TRALI), the possibility of immune (antibody dependent) enhancement (ADE) of viral pathogenicity, and safety and requirements of donor plasma [1, 3, 4] .", [["plasma", "ANATOMY", 60, 66], ["lung", "ANATOMY", 125, 129], ["plasma", "ANATOMY", 272, 278], ["acute lung injury", "DISEASE", 119, 136], ["TRALI", "DISEASE", 138, 143], ["convalescent", "ORGANISM", 47, 59], ["plasma", "ORGANISM_SUBSTANCE", 60, 66], ["lung", "ORGAN", 125, 129], ["plasma", "ORGANISM_SUBSTANCE", 272, 278], ["convalescent plasma therapy", "TREATMENT", 47, 74], ["transfusion", "PROBLEM", 99, 110], ["acute lung injury", "PROBLEM", 119, 136], ["TRALI", "PROBLEM", 138, 143], ["immune (antibody dependent) enhancement", "PROBLEM", 165, 204], ["viral pathogenicity", "PROBLEM", 214, 233], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["lung", "ANATOMY", 125, 129], ["injury", "OBSERVATION", 130, 136], ["TRALI", "OBSERVATION", 138, 143], ["possibility of", "UNCERTAINTY", 150, 164], ["viral pathogenicity", "OBSERVATION", 214, 233]]], ["TRALI is a risk in patients with pulmonary disease [1] , while most COVID-19 patients have pulmonary involvement.", [["pulmonary", "ANATOMY", 33, 42], ["pulmonary", "ANATOMY", 91, 100], ["TRALI", "DISEASE", 0, 5], ["pulmonary disease", "DISEASE", 33, 50], ["patients", "ORGANISM", 19, 27], ["pulmonary", "ORGAN", 33, 42], ["patients", "ORGANISM", 77, 85], ["pulmonary", "ORGAN", 91, 100], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 77, 85], ["TRALI", "PROBLEM", 0, 5], ["pulmonary disease", "PROBLEM", 33, 50], ["pulmonary involvement", "PROBLEM", 91, 112], ["pulmonary", "ANATOMY", 33, 42], ["disease", "OBSERVATION", 43, 50], ["pulmonary", "ANATOMY", 91, 100], ["involvement", "OBSERVATION", 101, 112]]], ["The recent systematic review showed that one study of three participants reported one adverse event presumably grade 3 or 4, in the form of severe anaphylactic shock after convalescence plasma transfusion [2] .", [["plasma", "ANATOMY", 186, 192], ["anaphylactic shock", "DISEASE", 147, 165], ["plasma", "ORGANISM_SUBSTANCE", 186, 192], ["participants", "SPECIES", 60, 72], ["The recent systematic review", "TEST", 0, 28], ["one study", "TEST", 41, 50], ["severe anaphylactic shock", "PROBLEM", 140, 165], ["convalescence plasma transfusion", "TREATMENT", 172, 204], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["anaphylactic shock", "OBSERVATION", 147, 165]]], ["In addition, convalescent plasma therapy should consider the possibility of transfusion associated circulatory overload (TACO), the presence of complete immunoglobulin A deficit, which is an absolute contraindication of plasma therapy [3, 4] , and the presence of cytokine storm, as plasma therapy after cytokine storm occurred is not recommended [4] .", [["plasma", "ANATOMY", 26, 32], ["circulatory", "ANATOMY", 99, 110], ["plasma", "ANATOMY", 220, 226], ["plasma", "ANATOMY", 283, 289], ["circulatory overload", "DISEASE", 99, 119], ["TACO", "DISEASE", 121, 125], ["plasma", "ORGANISM_SUBSTANCE", 26, 32], ["immunoglobulin A", "GENE_OR_GENE_PRODUCT", 153, 169], ["plasma", "ORGANISM_SUBSTANCE", 220, 226], ["plasma", "ORGANISM_SUBSTANCE", 283, 289], ["immunoglobulin A", "PROTEIN", 153, 169], ["cytokine", "PROTEIN", 264, 272], ["cytokine", "PROTEIN", 304, 312], ["convalescent plasma therapy", "TREATMENT", 13, 40], ["transfusion associated circulatory overload", "PROBLEM", 76, 119], ["complete immunoglobulin A deficit", "PROBLEM", 144, 177], ["plasma therapy", "TREATMENT", 220, 234], ["cytokine storm", "TREATMENT", 264, 278], ["plasma therapy", "TREATMENT", 283, 297], ["cytokine storm", "TREATMENT", 304, 318], ["circulatory overload", "OBSERVATION", 99, 119], ["cytokine storm", "OBSERVATION", 264, 278]]]], "PMC7244733": [["IntroductionSialolithiasis is the most common cause of obstructive sialadenitis and occurs in approximately 1.2\u20131.5% of the overall population1.", [["IntroductionSialolithiasis", "DISEASE", 0, 26], ["obstructive sialadenitis", "DISEASE", 55, 79], ["population1", "CANCER", 132, 143], ["IntroductionSialolithiasis", "PROBLEM", 0, 26], ["obstructive sialadenitis", "PROBLEM", 55, 79], ["most common", "OBSERVATION_MODIFIER", 34, 45], ["obstructive", "OBSERVATION_MODIFIER", 55, 66], ["sialadenitis", "OBSERVATION", 67, 79], ["overall", "OBSERVATION_MODIFIER", 124, 131], ["population1", "OBSERVATION", 132, 143]]], ["In 80\u201390% of reported cases, these calculi are found within the submandibular gland2,3.", [["calculi", "ANATOMY", 35, 42], ["submandibular gland", "ANATOMY", 64, 83], ["calculi", "DISEASE", 35, 42], ["calculi", "PATHOLOGICAL_FORMATION", 35, 42], ["submandibular gland", "ORGAN", 64, 83], ["these calculi", "PROBLEM", 29, 42], ["calculi", "OBSERVATION", 35, 42], ["submandibular gland", "ANATOMY", 64, 83]]], ["Koch et al. reported that 34% of sialoliths are distributed in the distal duct (ductal stones), 57% within the hilum of the gland (hilar stones), and 9% in the gland parenchyma (intraparenchymal stones)4.", [["sialoliths", "ANATOMY", 33, 43], ["distal duct", "ANATOMY", 67, 78], ["ductal stones", "ANATOMY", 80, 93], ["hilum", "ANATOMY", 111, 116], ["gland", "ANATOMY", 124, 129], ["hilar stones", "ANATOMY", 131, 143], ["gland parenchyma", "ANATOMY", 160, 176], ["intraparenchymal stones", "ANATOMY", 178, 201], ["hilar stones", "DISEASE", 131, 143], ["sialoliths", "CANCER", 33, 43], ["distal duct", "MULTI-TISSUE_STRUCTURE", 67, 78], ["ductal stones", "MULTI-TISSUE_STRUCTURE", 80, 93], ["hilum", "ORGAN", 111, 116], ["gland", "ORGAN", 124, 129], ["hilar stones", "MULTI-TISSUE_STRUCTURE", 131, 143], ["gland parenchyma", "MULTI-TISSUE_STRUCTURE", 160, 176], ["ductal stones", "PROBLEM", 80, 93], ["intraparenchymal stones", "PROBLEM", 178, 201], ["34%", "OBSERVATION_MODIFIER", 26, 29], ["distal", "ANATOMY_MODIFIER", 67, 73], ["duct", "ANATOMY", 74, 78], ["ductal", "ANATOMY", 80, 86], ["stones", "OBSERVATION", 87, 93], ["hilum", "ANATOMY", 111, 116], ["gland", "ANATOMY", 124, 129], ["hilar", "ANATOMY", 131, 136], ["stones", "OBSERVATION", 137, 143], ["gland", "ANATOMY", 160, 165], ["parenchyma", "ANATOMY_MODIFIER", 166, 176], ["intraparenchymal", "ANATOMY_MODIFIER", 178, 194], ["stones", "OBSERVATION", 195, 201]]], ["In these previous studies, the authors propose that the turbulent salivary flow in these 3 regions leads to the formation of mucous plugs that act as niduses for the deposition of inorganic and organic substances, resulting in the formation of sialoliths.IntroductionTreatment requires the removal of the sialoliths, and various methods to do so have been described in the literature.", [["salivary", "ANATOMY", 66, 74], ["mucous plugs", "ANATOMY", 125, 137], ["salivary", "ORGAN", 66, 74], ["mucous plugs", "PATHOLOGICAL_FORMATION", 125, 137], ["inorganic", "SIMPLE_CHEMICAL", 180, 189], ["sialoliths", "PATHOLOGICAL_FORMATION", 244, 254], ["these previous studies", "TEST", 3, 25], ["the turbulent salivary flow", "PROBLEM", 52, 79], ["mucous plugs", "PROBLEM", 125, 137], ["the deposition of inorganic and organic substances", "PROBLEM", 162, 212], ["sialoliths", "PROBLEM", 244, 254], ["the removal of the sialoliths", "TREATMENT", 286, 315], ["turbulent", "OBSERVATION_MODIFIER", 56, 65], ["salivary flow", "OBSERVATION", 66, 79], ["mucous plugs", "OBSERVATION", 125, 137], ["organic substances", "OBSERVATION", 194, 212], ["sialoliths", "OBSERVATION", 244, 254]]], ["Stones in the distal duct are often palpable and can be easily retrieved via an intraoral sialolithotomy under local anesthesia.", [["distal duct", "ANATOMY", 14, 25], ["distal duct", "MULTI-TISSUE_STRUCTURE", 14, 25], ["Stones in the distal duct", "PROBLEM", 0, 25], ["an intraoral sialolithotomy", "TREATMENT", 77, 104], ["local anesthesia", "TREATMENT", 111, 127], ["distal", "ANATOMY_MODIFIER", 14, 20], ["duct", "ANATOMY", 21, 25]]], ["The advent of sialendoscopy-assisted intraoral sialolithotomy reduced the prevalence of submandibulectomies as the default treatment modality for deeper, nonpalpable stones in the duct and hilum5,6.", [["nonpalpable stones", "ANATOMY", 154, 172], ["duct", "ANATOMY", 180, 184], ["hilum", "ANATOMY", 189, 194], ["submandibulectomies", "DISEASE", 88, 107], ["duct", "MULTI-TISSUE_STRUCTURE", 180, 184], ["sialendoscopy-assisted intraoral sialolithotomy", "TREATMENT", 14, 61], ["submandibulectomies", "TREATMENT", 88, 107], ["the default treatment modality", "TREATMENT", 111, 141], ["deeper, nonpalpable stones in the duct and hilum", "PROBLEM", 146, 194], ["nonpalpable", "OBSERVATION_MODIFIER", 154, 165], ["stones", "OBSERVATION", 166, 172], ["duct", "ANATOMY", 180, 184], ["hilum", "ANATOMY", 189, 194]]], ["It has been reported that over 95% of deep hilar stones in the submandibular gland can be endoscopically removed4,7, while for larger stones, laser-beam fragmentation and extracorporeal shock-wave lithotripsy (ESWL) had a 75% effective rate and allowed for the complete retrieval of stones in half of the cases6,8\u201310.", [["hilar stones", "ANATOMY", 43, 55], ["submandibular gland", "ANATOMY", 63, 82], ["stones", "ANATOMY", 134, 140], ["stones", "ANATOMY", 283, 289], ["hilar stones", "MULTI-TISSUE_STRUCTURE", 43, 55], ["submandibular gland", "ORGAN", 63, 82], ["deep hilar stones in the submandibular gland", "PROBLEM", 38, 82], ["larger stones", "PROBLEM", 127, 140], ["laser-beam fragmentation", "TREATMENT", 142, 166], ["extracorporeal shock-wave lithotripsy", "TREATMENT", 171, 208], ["ESWL", "TREATMENT", 210, 214], ["stones", "PROBLEM", 283, 289], ["deep", "ANATOMY_MODIFIER", 38, 42], ["hilar", "ANATOMY", 43, 48], ["stones", "OBSERVATION", 49, 55], ["submandibular gland", "ANATOMY", 63, 82], ["larger", "OBSERVATION_MODIFIER", 127, 133], ["stones", "OBSERVATION", 134, 140], ["beam fragmentation", "OBSERVATION_MODIFIER", 148, 166], ["extracorporeal", "OBSERVATION_MODIFIER", 171, 185], ["shock", "OBSERVATION", 186, 191], ["wave", "OBSERVATION_MODIFIER", 192, 196], ["lithotripsy", "OBSERVATION", 197, 208], ["stones", "OBSERVATION", 283, 289]]], ["However, deeper intraparenchymal stones that are inaccessible to sialendoscopy remain a problem, and previous authors have reported that 5\u201310% of these patients cannot be conservatively treated and should therefore be considered for submandibulectomy as the definitive treatment of choice5,6,10.", [["intraparenchymal stones", "ANATOMY", 16, 39], ["intraparenchymal stones", "PATHOLOGICAL_FORMATION", 16, 39], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["deeper intraparenchymal stones", "PROBLEM", 9, 39], ["sialendoscopy", "TREATMENT", 65, 78], ["submandibulectomy", "TREATMENT", 233, 250], ["the definitive treatment of choice5", "TREATMENT", 254, 289], ["deeper", "OBSERVATION_MODIFIER", 9, 15], ["intraparenchymal", "OBSERVATION_MODIFIER", 16, 32], ["stones", "OBSERVATION", 33, 39]]], ["Furthermore, sialendoscopy and ESWL may not always be readily available due to the need for subspecialization training and the prohibitive costs of procurement and equipment maintenance.", [["sialendoscopy", "TREATMENT", 13, 26], ["ESWL", "TREATMENT", 31, 35], ["subspecialization training", "TREATMENT", 92, 118], ["procurement and equipment maintenance", "TREATMENT", 148, 185]]], ["Both treatment modalities could also cause inadvertent fragmentation and retrograde displacement of ductal and hilar sialoliths deeper into the gland parenchyma.IntroductionWe postulate that intraoral excision of palpable hilar stones could permit the passage of smaller intraparenchymal stones through the same incision site in tandem with extraoral gland massage when performed under general anesthesia, thus avoiding the need for submandibulectomies that are otherwise indicated in such instances.Patients ::: Material and methodsIn all, 104 patients with various submandibular gland sialoliths were treated at the Shanghai Ninth People\u2019s Hospital, China, between October 2018 and May 2019.", [["ductal", "ANATOMY", 100, 106], ["hilar sialoliths", "ANATOMY", 111, 127], ["gland parenchyma", "ANATOMY", 144, 160], ["intraoral", "ANATOMY", 191, 200], ["palpable hilar stones", "ANATOMY", 213, 234], ["intraparenchymal stones", "ANATOMY", 271, 294], ["gland", "ANATOMY", 351, 356], ["submandibular gland", "ANATOMY", 567, 586], ["submandibular gland sialoliths", "DISEASE", 567, 597], ["ductal", "MULTI-TISSUE_STRUCTURE", 100, 106], ["hilar sialoliths", "CANCER", 111, 127], ["gland parenchyma", "MULTI-TISSUE_STRUCTURE", 144, 160], ["hilar stones", "PATHOLOGICAL_FORMATION", 222, 234], ["intraparenchymal stones", "PATHOLOGICAL_FORMATION", 271, 294], ["gland", "ORGAN", 351, 356], ["Patients", "ORGANISM", 500, 508], ["patients", "ORGANISM", 545, 553], ["submandibular gland sialoliths", "CANCER", 567, 597], ["Patients", "SPECIES", 500, 508], ["patients", "SPECIES", 545, 553], ["Both treatment modalities", "TREATMENT", 0, 25], ["inadvertent fragmentation", "PROBLEM", 43, 68], ["retrograde displacement of ductal and hilar sialoliths deeper into the gland parenchyma", "PROBLEM", 73, 160], ["IntroductionWe", "TREATMENT", 161, 175], ["intraoral excision", "TREATMENT", 191, 209], ["palpable hilar stones", "PROBLEM", 213, 234], ["smaller intraparenchymal stones", "PROBLEM", 263, 294], ["the same incision site", "PROBLEM", 303, 325], ["extraoral gland massage", "TREATMENT", 341, 364], ["general anesthesia", "TREATMENT", 386, 404], ["submandibulectomies", "TREATMENT", 433, 452], ["various submandibular gland sialoliths", "PROBLEM", 559, 597], ["could also cause", "UNCERTAINTY", 26, 42], ["inadvertent", "OBSERVATION_MODIFIER", 43, 54], ["fragmentation", "OBSERVATION", 55, 68], ["retrograde", "OBSERVATION_MODIFIER", 73, 83], ["displacement", "OBSERVATION_MODIFIER", 84, 96], ["ductal", "ANATOMY", 100, 106], ["hilar", "ANATOMY", 111, 116], ["gland", "ANATOMY", 144, 149], ["parenchyma", "ANATOMY_MODIFIER", 150, 160], ["palpable", "OBSERVATION_MODIFIER", 213, 221], ["hilar", "ANATOMY", 222, 227], ["stones", "OBSERVATION", 228, 234], ["passage", "OBSERVATION_MODIFIER", 252, 259], ["smaller", "OBSERVATION_MODIFIER", 263, 270], ["intraparenchymal", "OBSERVATION_MODIFIER", 271, 287], ["stones", "OBSERVATION", 288, 294], ["incision", "OBSERVATION", 312, 320], ["extraoral gland", "ANATOMY", 341, 356], ["submandibular gland", "ANATOMY", 567, 586], ["sialoliths", "OBSERVATION", 587, 597]]], ["Of these, only 9 met the inclusion criteria and consented to the study, which was approved by the Shanghai Jiao Tong University School of Medicine Affiliated Ninth People\u2019s Hospital\u2019s Ethics Committee and Review Board.Patients ::: Material and methodsThe study\u2019s inclusion criteria included patients with 1) ultrasonographic and/or computed tomographic verification of multiple submandibular sialoliths, 2) two or more sialoliths located in both the hilar and intraparenchymal regions, 3) at least one palpable stone in the hilum or deep hilar region, 4) the intraparenchymal sialoliths with a maximum diameter of 5 mm, and 5) no history of previous surgical management of the sialoliths.Patients ::: Material and methodsSalivary flow rates were assessed in each patient using the Saxon Test.", [["submandibular sialoliths", "ANATOMY", 378, 402], ["sialoliths", "ANATOMY", 419, 429], ["hilar", "ANATOMY", 450, 455], ["intraparenchymal regions", "ANATOMY", 460, 484], ["palpable stone", "ANATOMY", 502, 516], ["hilum", "ANATOMY", 524, 529], ["hilar region", "ANATOMY", 538, 550], ["intraparenchymal sialoliths", "ANATOMY", 559, 586], ["Salivary", "ANATOMY", 721, 729], ["sialoliths", "DISEASE", 677, 687], ["Patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 291, 299], ["submandibular", "ORGAN", 378, 391], ["sialoliths", "CANCER", 419, 429], ["hilar", "MULTI-TISSUE_STRUCTURE", 450, 455], ["hilum", "ORGAN", 524, 529], ["hilar region", "MULTI-TISSUE_STRUCTURE", 538, 550], ["intraparenchymal sialoliths", "CANCER", 559, 586], ["sialoliths", "PATHOLOGICAL_FORMATION", 677, 687], ["Patients", "ORGANISM", 688, 696], ["Salivary", "ORGAN", 721, 729], ["patient", "ORGANISM", 763, 770], ["Patients", "SPECIES", 218, 226], ["patients", "SPECIES", 291, 299], ["Patients", "SPECIES", 688, 696], ["patient", "SPECIES", 763, 770], ["the study", "TEST", 61, 70], ["The study", "TEST", 251, 260], ["ultrasonographic", "TEST", 308, 324], ["computed tomographic verification", "TEST", 332, 365], ["multiple submandibular sialoliths", "PROBLEM", 369, 402], ["one palpable stone in the hilum", "PROBLEM", 498, 529], ["the intraparenchymal sialoliths", "PROBLEM", 555, 586], ["previous surgical management", "TREATMENT", 641, 669], ["the sialoliths", "PROBLEM", 673, 687], ["Salivary flow rates", "TEST", 721, 740], ["the Saxon Test", "TEST", 777, 791], ["multiple", "OBSERVATION_MODIFIER", 369, 377], ["submandibular", "ANATOMY", 378, 391], ["sialoliths", "OBSERVATION", 392, 402], ["more", "OBSERVATION_MODIFIER", 414, 418], ["sialoliths", "OBSERVATION", 419, 429], ["both", "ANATOMY_MODIFIER", 441, 445], ["hilar", "ANATOMY", 450, 455], ["intraparenchymal", "ANATOMY_MODIFIER", 460, 476], ["one", "OBSERVATION_MODIFIER", 498, 501], ["palpable", "OBSERVATION_MODIFIER", 502, 510], ["stone", "OBSERVATION", 511, 516], ["hilum", "ANATOMY", 524, 529], ["deep", "ANATOMY_MODIFIER", 533, 537], ["hilar", "ANATOMY", 538, 543], ["region", "ANATOMY_MODIFIER", 544, 550], ["intraparenchymal", "ANATOMY_MODIFIER", 559, 575], ["sialoliths", "OBSERVATION", 576, 586], ["maximum", "OBSERVATION_MODIFIER", 594, 601], ["diameter", "OBSERVATION_MODIFIER", 602, 610], ["5 mm", "OBSERVATION_MODIFIER", 614, 618], ["surgical", "OBSERVATION", 650, 658], ["sialoliths", "OBSERVATION", 677, 687]]], ["Patients chewed on a folded sterile sponge for 2 minutes, and the saliva-soaked sponge was then weighed and compared against its original weight.", [["Patients", "ORGANISM", 0, 8], ["saliva", "ORGANISM_SUBSTANCE", 66, 72], ["Patients", "SPECIES", 0, 8], ["a folded sterile sponge", "TREATMENT", 19, 42], ["the saliva-soaked sponge", "TREATMENT", 62, 86]]], ["Computed tomography was also performed in each patient to quantify and determine the exact location of the sialoliths and measure their respective sizes and relative distances from one another.Surgical technique ::: Material and methodsAll 9 patients were operated on under general anesthesia by the same surgical team.", [["patient", "ORGANISM", 47, 54], ["sialoliths", "CANCER", 107, 117], ["patients", "ORGANISM", 242, 250], ["patient", "SPECIES", 47, 54], ["patients", "SPECIES", 242, 250], ["Computed tomography", "TEST", 0, 19], ["general anesthesia", "TREATMENT", 274, 292], ["sizes", "OBSERVATION_MODIFIER", 147, 152]]], ["Anesthetic drugs were standardized for all 9 patients as follows: penehyclidine hydrochloride, 0.01 mg/kg; midazolam, 0.05 mg/kg; fentanyl, 2 \u00b5g/kg; propofol, 1\u20132 mg/kg; cisatracurium, 0.2 mg/kg; and 1.5\u20132.5% sevoflurane and 0.01\u20130.1 \u00b5g/kg/min remifentanil infusion for maintenance.Surgical technique ::: Material and methodsThe palpable stones in the deep hilar regions were first accessed via a mucosal incision made immediately overlying the associated Wharton\u2019s duct in the floor of the mouth.", [["palpable stones", "ANATOMY", 329, 344], ["hilar regions", "ANATOMY", 357, 370], ["mucosal", "ANATOMY", 397, 404], ["Wharton\u2019s duct", "ANATOMY", 456, 470], ["mouth", "ANATOMY", 491, 496], ["penehyclidine hydrochloride", "CHEMICAL", 66, 93], ["midazolam", "CHEMICAL", 107, 116], ["fentanyl", "CHEMICAL", 130, 138], ["propofol", "CHEMICAL", 149, 157], ["cisatracurium", "CHEMICAL", 170, 183], ["sevoflurane", "CHEMICAL", 209, 220], ["remifentanil", "CHEMICAL", 244, 256], ["penehyclidine hydrochloride", "CHEMICAL", 66, 93], ["midazolam", "CHEMICAL", 107, 116], ["fentanyl", "CHEMICAL", 130, 138], ["propofol", "CHEMICAL", 149, 157], ["cisatracurium", "CHEMICAL", 170, 183], ["sevoflurane", "CHEMICAL", 209, 220], ["remifentanil", "CHEMICAL", 244, 256], ["patients", "ORGANISM", 45, 53], ["penehyclidine hydrochloride", "SIMPLE_CHEMICAL", 66, 93], ["midazolam", "SIMPLE_CHEMICAL", 107, 116], ["fentanyl", "SIMPLE_CHEMICAL", 130, 138], ["propofol", "SIMPLE_CHEMICAL", 149, 157], ["cisatracurium", "SIMPLE_CHEMICAL", 170, 183], ["sevoflurane", "SIMPLE_CHEMICAL", 209, 220], ["remifentanil", "SIMPLE_CHEMICAL", 244, 256], ["palpable stones", "CANCER", 329, 344], ["hilar regions", "MULTI-TISSUE_STRUCTURE", 357, 370], ["Wharton\u2019s duct", "MULTI-TISSUE_STRUCTURE", 456, 470], ["floor", "ORGANISM_SUBDIVISION", 478, 483], ["mouth", "ORGANISM_SUBDIVISION", 491, 496], ["patients", "SPECIES", 45, 53], ["Anesthetic drugs", "TREATMENT", 0, 16], ["penehyclidine hydrochloride", "TREATMENT", 66, 93], ["midazolam", "TREATMENT", 107, 116], ["fentanyl", "TREATMENT", 130, 138], ["propofol", "TREATMENT", 149, 157], ["cisatracurium", "TREATMENT", 170, 183], ["sevoflurane", "TREATMENT", 209, 220], ["remifentanil infusion", "TREATMENT", 244, 265], ["The palpable stones in the deep hilar regions", "PROBLEM", 325, 370], ["a mucosal incision", "TREATMENT", 395, 413], ["palpable", "OBSERVATION_MODIFIER", 329, 337], ["stones", "OBSERVATION", 338, 344], ["deep", "ANATOMY_MODIFIER", 352, 356], ["hilar", "ANATOMY", 357, 362], ["mucosal", "ANATOMY", 397, 404], ["incision", "OBSERVATION", 405, 413], ["duct", "ANATOMY", 466, 470], ["floor", "ANATOMY_MODIFIER", 478, 483], ["mouth", "ANATOMY", 491, 496]]], ["Blunt dissection was performed to retract a mucosal flap and expose the duct while taking care to identify and preserve the lingual nerve crossing the duct latero-medially at the posterior aspect.", [["mucosal", "ANATOMY", 44, 51], ["duct", "ANATOMY", 72, 76], ["lingual nerve", "ANATOMY", 124, 137], ["duct", "ANATOMY", 151, 155], ["duct", "MULTI-TISSUE_STRUCTURE", 72, 76], ["lingual nerve", "MULTI-TISSUE_STRUCTURE", 124, 137], ["duct", "MULTI-TISSUE_STRUCTURE", 151, 155], ["Blunt dissection", "PROBLEM", 0, 16], ["a mucosal flap", "TREATMENT", 42, 56], ["dissection", "OBSERVATION", 6, 16], ["mucosal flap", "OBSERVATION", 44, 56], ["duct", "ANATOMY", 72, 76], ["lingual nerve", "ANATOMY", 124, 137], ["duct", "ANATOMY", 151, 155], ["medially", "ANATOMY_MODIFIER", 163, 171], ["posterior", "ANATOMY_MODIFIER", 179, 188]]], ["The application of firm, upwards digital pressure at the submandibular triangle medial to the inferior border of the mandible resulted in the bulging of the medial portion of the gland from the floor of the mouth, thereby enabling the palpation of the calculi within.", [["submandibular triangle medial", "ANATOMY", 57, 86], ["inferior border", "ANATOMY", 94, 109], ["mandible", "ANATOMY", 117, 125], ["medial portion", "ANATOMY", 157, 171], ["gland", "ANATOMY", 179, 184], ["mouth", "ANATOMY", 207, 212], ["calculi", "ANATOMY", 252, 259], ["calculi", "DISEASE", 252, 259], ["submandibular triangle medial", "MULTI-TISSUE_STRUCTURE", 57, 86], ["inferior border", "MULTI-TISSUE_STRUCTURE", 94, 109], ["mandible", "ORGAN", 117, 125], ["gland", "ORGAN", 179, 184], ["floor", "ORGANISM_SUBDIVISION", 194, 199], ["mouth", "ORGAN", 207, 212], ["calculi", "PATHOLOGICAL_FORMATION", 252, 259], ["firm", "PROBLEM", 19, 23], ["the palpation", "TEST", 231, 244], ["the calculi", "PROBLEM", 248, 259], ["firm", "OBSERVATION_MODIFIER", 19, 23], ["upwards", "OBSERVATION_MODIFIER", 25, 32], ["pressure", "OBSERVATION_MODIFIER", 41, 49], ["submandibular", "ANATOMY", 57, 70], ["triangle", "ANATOMY_MODIFIER", 71, 79], ["medial", "ANATOMY_MODIFIER", 80, 86], ["inferior", "ANATOMY_MODIFIER", 94, 102], ["border", "ANATOMY_MODIFIER", 103, 109], ["mandible", "ANATOMY", 117, 125], ["bulging", "OBSERVATION", 142, 149], ["medial", "ANATOMY_MODIFIER", 157, 163], ["gland", "ANATOMY", 179, 184], ["floor", "ANATOMY_MODIFIER", 194, 199], ["mouth", "ANATOMY", 207, 212], ["calculi", "OBSERVATION", 252, 259]]], ["A direct linear incision was made over the roof of the duct to expose the hilar stone for easy retrieval.", [["duct", "ANATOMY", 55, 59], ["hilar stone", "ANATOMY", 74, 85], ["duct", "MULTI-TISSUE_STRUCTURE", 55, 59], ["hilar stone", "MULTI-TISSUE_STRUCTURE", 74, 85], ["A direct linear incision", "TREATMENT", 0, 24], ["the hilar stone", "PROBLEM", 70, 85], ["easy retrieval", "TREATMENT", 90, 104], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["incision", "OBSERVATION", 16, 24], ["roof", "ANATOMY_MODIFIER", 43, 47], ["duct", "ANATOMY", 55, 59], ["hilar", "ANATOMY", 74, 79], ["stone", "OBSERVATION", 80, 85]]], ["Continuous extraoral massaging of the submandibular gland in a posterior-anterior circuitous motion elicited large amounts of salivary drainage from the incision site, leading to the expulsion of the intraparenchymal sialoliths (Fig. 1).", [["submandibular gland", "ANATOMY", 38, 57], ["salivary", "ANATOMY", 126, 134], ["incision site", "ANATOMY", 153, 166], ["intraparenchymal sialoliths", "ANATOMY", 200, 227], ["submandibular gland", "ORGAN", 38, 57], ["salivary", "ORGAN", 126, 134], ["Continuous extraoral massaging of the submandibular gland", "PROBLEM", 0, 57], ["salivary drainage", "PROBLEM", 126, 143], ["the incision site", "PROBLEM", 149, 166], ["the expulsion of the intraparenchymal sialoliths", "PROBLEM", 179, 227], ["extraoral", "ANATOMY_MODIFIER", 11, 20], ["massaging", "OBSERVATION", 21, 30], ["submandibular gland", "ANATOMY", 38, 57], ["posterior", "ANATOMY_MODIFIER", 63, 72], ["anterior", "ANATOMY_MODIFIER", 73, 81], ["circuitous motion", "OBSERVATION", 82, 99], ["large", "OBSERVATION_MODIFIER", 109, 114], ["amounts", "OBSERVATION_MODIFIER", 115, 122], ["salivary", "ANATOMY", 126, 134], ["drainage", "OBSERVATION", 135, 143], ["incision", "OBSERVATION", 153, 161], ["expulsion", "OBSERVATION_MODIFIER", 183, 192], ["intraparenchymal", "ANATOMY_MODIFIER", 200, 216], ["sialoliths", "OBSERVATION", 217, 227]]], ["All stones were accounted for before each duct was copiously flushed with normal saline.", [["stones", "ANATOMY", 4, 10], ["duct", "ANATOMY", 42, 46], ["stones", "PATHOLOGICAL_FORMATION", 4, 10], ["duct", "MULTI-TISSUE_STRUCTURE", 42, 46], ["saline", "SIMPLE_CHEMICAL", 81, 87], ["All stones", "PROBLEM", 0, 10], ["normal saline", "TREATMENT", 74, 87], ["stones", "OBSERVATION", 4, 10], ["duct", "ANATOMY", 42, 46], ["normal saline", "OBSERVATION", 74, 87]]], ["The incised ducts were either left unrepaired beneath a loosely closed mucosa or kept open by sewing their incised edges to the overlying mucosal incision for the purpose of creating a new orifice for salivary drainage.Ethical approval ::: Material and methodsAll procedures performed in studies involving human participants were conducted in accordance with the ethical standards of Shanghai Ninth People\u2019s Hospital\u2019s Ethics Committee and Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.Informed consent ::: Material and methodsInformed consent was obtained from all individual participants included in the study.Case 1 ::: Case presentation ::: ResultsA 23-year-old man presented with recurrent and painful left-sided submandibular swelling for over a month.", [["ducts", "ANATOMY", 12, 17], ["mucosa", "ANATOMY", 71, 77], ["mucosal", "ANATOMY", 138, 145], ["salivary", "ANATOMY", 201, 209], ["submandibular", "ANATOMY", 781, 794], ["submandibular swelling", "DISEASE", 781, 803], ["ducts", "MULTI-TISSUE_STRUCTURE", 12, 17], ["mucosa", "MULTI-TISSUE_STRUCTURE", 71, 77], ["mucosal", "ORGANISM_SUBDIVISION", 138, 145], ["salivary", "ORGAN", 201, 209], ["human", "ORGANISM", 306, 311], ["man", "ORGANISM", 729, 732], ["submandibular", "ORGAN", 781, 794], ["human", "SPECIES", 306, 311], ["participants", "SPECIES", 312, 324], ["participants", "SPECIES", 640, 652], ["man", "SPECIES", 729, 732], ["human", "SPECIES", 306, 311], ["The incised ducts", "PROBLEM", 0, 17], ["a loosely closed mucosa", "PROBLEM", 54, 77], ["the overlying mucosal incision", "PROBLEM", 124, 154], ["a new orifice", "TREATMENT", 183, 196], ["salivary drainage", "TREATMENT", 201, 218], ["All procedures", "TREATMENT", 260, 274], ["the study", "TEST", 665, 674], ["recurrent and painful left-sided submandibular swelling", "PROBLEM", 748, 803], ["incised", "ANATOMY_MODIFIER", 4, 11], ["ducts", "ANATOMY", 12, 17], ["left", "ANATOMY_MODIFIER", 30, 34], ["unrepaired", "OBSERVATION", 35, 45], ["loosely", "OBSERVATION_MODIFIER", 56, 63], ["closed", "OBSERVATION_MODIFIER", 64, 70], ["mucosa", "OBSERVATION", 71, 77], ["incised", "OBSERVATION_MODIFIER", 107, 114], ["edges", "OBSERVATION_MODIFIER", 115, 120], ["overlying", "ANATOMY_MODIFIER", 128, 137], ["mucosal", "ANATOMY", 138, 145], ["incision", "OBSERVATION", 146, 154], ["new", "OBSERVATION_MODIFIER", 185, 188], ["orifice", "OBSERVATION_MODIFIER", 189, 196], ["salivary", "ANATOMY", 201, 209], ["drainage", "OBSERVATION", 210, 218], ["painful", "OBSERVATION_MODIFIER", 762, 769], ["left", "ANATOMY_MODIFIER", 770, 774], ["sided", "ANATOMY_MODIFIER", 775, 780], ["submandibular", "ANATOMY", 781, 794], ["swelling", "OBSERVATION", 795, 803]]], ["A CT scan revealed the presence of one large hilar stone and a separate smaller stone deep in the parenchyma of the gland.", [["hilar stone", "ANATOMY", 45, 56], ["stone", "ANATOMY", 80, 85], ["parenchyma", "ANATOMY", 98, 108], ["gland", "ANATOMY", 116, 121], ["hilar stone", "CANCER", 45, 56], ["parenchyma", "TISSUE", 98, 108], ["gland", "ORGAN", 116, 121], ["A CT scan", "TEST", 0, 9], ["one large hilar stone", "PROBLEM", 35, 56], ["a separate smaller stone deep in the parenchyma of the gland", "PROBLEM", 61, 121], ["one", "OBSERVATION_MODIFIER", 35, 38], ["large", "OBSERVATION_MODIFIER", 39, 44], ["hilar", "ANATOMY", 45, 50], ["stone", "OBSERVATION", 51, 56], ["separate", "OBSERVATION_MODIFIER", 63, 71], ["smaller", "OBSERVATION_MODIFIER", 72, 79], ["stone", "OBSERVATION", 80, 85], ["deep", "ANATOMY_MODIFIER", 86, 90], ["parenchyma", "ANATOMY_MODIFIER", 98, 108], ["gland", "ANATOMY", 116, 121]]], ["The CT 3-dimensional reconstructed image showed that there was a distance of 28.28 mm between the hilar and intraparenchymal sialoliths.", [["hilar", "ANATOMY", 98, 103], ["intraparenchymal sialoliths", "ANATOMY", 108, 135], ["hilar", "MULTI-TISSUE_STRUCTURE", 98, 103], ["intraparenchymal sialoliths", "CANCER", 108, 135], ["The CT 3-dimensional reconstructed image", "TEST", 0, 40], ["the hilar and intraparenchymal sialoliths", "PROBLEM", 94, 135], ["hilar", "ANATOMY", 98, 103], ["intraparenchymal", "ANATOMY_MODIFIER", 108, 124], ["sialoliths", "ANATOMY", 125, 135]]], ["Both stones were successfully retrieved via a transoral sialolithotomy in which the larger stone was directly excised before the smaller stone was eased out of the same incision site via submandibular massage.", [["stones", "ANATOMY", 5, 11], ["stone", "ANATOMY", 91, 96], ["stone", "ANATOMY", 137, 142], ["submandibular", "ANATOMY", 187, 200], ["stones", "PATHOLOGICAL_FORMATION", 5, 11], ["submandibular", "ORGAN", 187, 200], ["Both stones", "PROBLEM", 0, 11], ["a transoral sialolithotomy", "TREATMENT", 44, 70], ["the larger stone", "PROBLEM", 80, 96], ["the smaller stone", "PROBLEM", 125, 142], ["submandibular massage", "TREATMENT", 187, 208], ["stones", "OBSERVATION", 5, 11], ["larger", "OBSERVATION_MODIFIER", 84, 90], ["stone", "OBSERVATION", 91, 96], ["smaller", "OBSERVATION_MODIFIER", 129, 136], ["stone", "OBSERVATION", 137, 142], ["incision", "OBSERVATION", 169, 177], ["submandibular", "ANATOMY", 187, 200], ["massage", "OBSERVATION", 201, 208]]], ["(Fig. 2A).Case 2 ::: Case presentation ::: ResultsA 47-year-old man presented recurrent right-sided painful swelling in the submandibular region on 18 May 2018.", [["submandibular region", "ANATOMY", 124, 144], ["swelling", "DISEASE", 108, 116], ["man", "ORGANISM", 64, 67], ["submandibular", "ORGAN", 124, 137], ["man", "SPECIES", 64, 67], ["recurrent right-sided painful swelling in the submandibular region", "PROBLEM", 78, 144], ["recurrent", "OBSERVATION_MODIFIER", 78, 87], ["right", "ANATOMY_MODIFIER", 88, 93], ["sided", "ANATOMY_MODIFIER", 94, 99], ["painful", "OBSERVATION_MODIFIER", 100, 107], ["swelling", "OBSERVATION", 108, 116], ["submandibular", "ANATOMY", 124, 137], ["region", "ANATOMY_MODIFIER", 138, 144]]], ["Multiple stones in the glandular parenchyma were visualized on CT scans, in which 1 large stone was observed to be lodged in the hilum and 3 smaller stones within the parenchyma.", [["stones", "ANATOMY", 9, 15], ["glandular parenchyma", "ANATOMY", 23, 43], ["stone", "ANATOMY", 90, 95], ["hilum", "ANATOMY", 129, 134], ["stones", "ANATOMY", 149, 155], ["parenchyma", "ANATOMY", 167, 177], ["stones", "PATHOLOGICAL_FORMATION", 9, 15], ["glandular parenchyma", "MULTI-TISSUE_STRUCTURE", 23, 43], ["stone", "CANCER", 90, 95], ["hilum", "MULTI-TISSUE_STRUCTURE", 129, 134], ["parenchyma", "TISSUE", 167, 177], ["Multiple stones in the glandular parenchyma", "PROBLEM", 0, 43], ["CT scans", "TEST", 63, 71], ["1 large stone", "PROBLEM", 82, 95], ["3 smaller stones within the parenchyma", "PROBLEM", 139, 177], ["stones", "OBSERVATION", 9, 15], ["glandular", "ANATOMY", 23, 32], ["parenchyma", "ANATOMY_MODIFIER", 33, 43], ["large", "OBSERVATION_MODIFIER", 84, 89], ["stone", "OBSERVATION", 90, 95], ["lodged", "OBSERVATION", 115, 121], ["hilum", "ANATOMY", 129, 134], ["3 smaller", "OBSERVATION_MODIFIER", 139, 148], ["stones", "OBSERVATION", 149, 155], ["parenchyma", "ANATOMY_MODIFIER", 167, 177]]], ["A CT 3-dimensional reconstructed image showed that the distances between the hilar stone and the 3 intraparenchymal sialoliths were 11.09, 8.58 and 5.95 mm.", [["hilar stone", "ANATOMY", 77, 88], ["intraparenchymal sialoliths", "ANATOMY", 99, 126], ["hilar stone", "MULTI-TISSUE_STRUCTURE", 77, 88], ["intraparenchymal sialoliths", "CANCER", 99, 126], ["A CT 3-dimensional reconstructed image", "TEST", 0, 38], ["the distances between the hilar stone", "PROBLEM", 51, 88], ["the 3 intraparenchymal sialoliths", "TEST", 93, 126], ["hilar", "ANATOMY", 77, 82], ["stone", "OBSERVATION", 83, 88], ["intraparenchymal", "ANATOMY_MODIFIER", 99, 115], ["sialoliths", "ANATOMY_MODIFIER", 116, 126], ["5.95 mm", "OBSERVATION_MODIFIER", 148, 155]]], ["A transoral sialolithotomy was performed to remove the hilar stone before the 3 smaller parenchymal stones were expunged from the same incision site after extraoral massage of the gland.", [["hilar stone", "ANATOMY", 55, 66], ["parenchymal stones", "ANATOMY", 88, 106], ["gland", "ANATOMY", 180, 185], ["hilar stone", "CANCER", 55, 66], ["parenchymal stones", "PATHOLOGICAL_FORMATION", 88, 106], ["gland", "ORGAN", 180, 185], ["A transoral sialolithotomy", "TREATMENT", 0, 26], ["the hilar stone", "PROBLEM", 51, 66], ["the 3 smaller parenchymal stones", "PROBLEM", 74, 106], ["extraoral massage of the gland", "PROBLEM", 155, 185], ["hilar", "ANATOMY", 55, 60], ["stone", "OBSERVATION", 61, 66], ["smaller", "OBSERVATION_MODIFIER", 80, 87], ["parenchymal", "ANATOMY_MODIFIER", 88, 99], ["stones", "OBSERVATION", 100, 106], ["incision", "OBSERVATION", 135, 143], ["massage", "OBSERVATION", 165, 172], ["gland", "ANATOMY", 180, 185]]], ["(Fig. 2B).DiscussionThe prevalence of sialoliths in the submandibular gland can be attributed to multiple factors, such as the gland\u2019s complex anatomical structure and ductal system; the presence of an intervening mylohyoid muscle that separates the larger lateral portion from the smaller medial segment; anti-gravitational salivary flow through the narrow, long and winding Wharton\u2019s duct; and the mucoid salivary component from this mixed sero-mucous gland.", [["submandibular gland", "ANATOMY", 56, 75], ["gland", "ANATOMY", 127, 132], ["ductal system", "ANATOMY", 168, 181], ["mylohyoid muscle", "ANATOMY", 214, 230], ["lateral portion", "ANATOMY", 257, 272], ["medial segment", "ANATOMY", 290, 304], ["salivary", "ANATOMY", 325, 333], ["Wharton\u2019s duct", "ANATOMY", 376, 390], ["mucoid salivary", "ANATOMY", 400, 415], ["sero-mucous gland", "ANATOMY", 442, 459], ["sialoliths", "DISEASE", 38, 48], ["sialoliths", "CANCER", 38, 48], ["submandibular gland", "ORGAN", 56, 75], ["gland", "ORGAN", 127, 132], ["ductal system", "MULTI-TISSUE_STRUCTURE", 168, 181], ["mylohyoid muscle", "TISSUE", 214, 230], ["salivary", "ORGAN", 325, 333], ["Wharton\u2019s duct", "TISSUE", 376, 390], ["mucoid salivary", "ORGAN", 400, 415], ["sero-mucous gland", "ORGAN", 442, 459], ["sialoliths in the submandibular gland", "PROBLEM", 38, 75], ["multiple factors", "PROBLEM", 97, 113], ["the gland\u2019s complex anatomical structure and ductal system", "PROBLEM", 123, 181], ["an intervening mylohyoid muscle", "PROBLEM", 199, 230], ["anti-gravitational salivary flow through the narrow, long and winding Wharton\u2019s duct", "PROBLEM", 306, 390], ["the mucoid salivary component", "PROBLEM", 396, 425], ["this mixed sero-mucous gland", "PROBLEM", 431, 459], ["sialoliths", "OBSERVATION", 38, 48], ["submandibular gland", "ANATOMY", 56, 75], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["factors", "OBSERVATION", 106, 113], ["gland", "ANATOMY", 127, 132], ["ductal system", "ANATOMY", 168, 181], ["mylohyoid muscle", "ANATOMY", 214, 230], ["larger", "OBSERVATION_MODIFIER", 250, 256], ["lateral", "OBSERVATION_MODIFIER", 257, 264], ["smaller", "OBSERVATION_MODIFIER", 282, 289], ["medial", "ANATOMY_MODIFIER", 290, 296], ["segment", "ANATOMY_MODIFIER", 297, 304], ["salivary flow", "OBSERVATION", 325, 338], ["narrow", "OBSERVATION_MODIFIER", 351, 357], ["duct", "ANATOMY", 386, 390], ["mucoid", "OBSERVATION_MODIFIER", 400, 406], ["gland", "ANATOMY", 454, 459]]], ["Marchal et al. suggested that the presence of a sphincter in the first 3 cm of the duct could result in the retrograde migration of various organic and inorganic ingredients, a process that could contribute to the formation of sialoliths11.DiscussionClassical symptoms of submandibular sialolithiasis include swelling and pain over the gland that is exacerbated during meals as well as gritty saliva, a painful lump in the floor of the mouth, and minimal salivary discharge from the associated duct of the orifice.", [["sphincter", "ANATOMY", 48, 57], ["duct", "ANATOMY", 83, 87], ["submandibular sialolithiasis", "ANATOMY", 272, 300], ["gland", "ANATOMY", 336, 341], ["lump", "ANATOMY", 411, 415], ["mouth", "ANATOMY", 436, 441], ["salivary", "ANATOMY", 455, 463], ["duct", "ANATOMY", 494, 498], ["orifice", "ANATOMY", 506, 513], ["sialoliths", "DISEASE", 227, 237], ["submandibular sialolithiasis", "DISEASE", 272, 300], ["swelling", "DISEASE", 309, 317], ["pain", "DISEASE", 322, 326], ["sphincter", "ORGAN", 48, 57], ["duct", "MULTI-TISSUE_STRUCTURE", 83, 87], ["submandibular", "ORGAN", 272, 285], ["gland", "ORGAN", 336, 341], ["saliva", "ORGANISM_SUBSTANCE", 393, 399], ["floor", "ORGANISM_SUBDIVISION", 423, 428], ["mouth", "ORGANISM_SUBDIVISION", 436, 441], ["salivary", "ORGAN", 455, 463], ["duct", "ORGAN", 494, 498], ["orifice", "MULTI-TISSUE_STRUCTURE", 506, 513], ["various organic and inorganic ingredients", "PROBLEM", 132, 173], ["sialoliths", "PROBLEM", 227, 237], ["DiscussionClassical symptoms", "PROBLEM", 240, 268], ["submandibular sialolithiasis", "PROBLEM", 272, 300], ["swelling", "PROBLEM", 309, 317], ["pain over the gland", "PROBLEM", 322, 341], ["gritty saliva", "PROBLEM", 386, 399], ["a painful lump", "PROBLEM", 401, 415], ["minimal salivary discharge", "PROBLEM", 447, 473], ["sphincter", "OBSERVATION", 48, 57], ["duct", "ANATOMY", 83, 87], ["retrograde", "OBSERVATION_MODIFIER", 108, 118], ["migration", "OBSERVATION_MODIFIER", 119, 128], ["various", "OBSERVATION_MODIFIER", 132, 139], ["organic", "OBSERVATION_MODIFIER", 140, 147], ["inorganic ingredients", "OBSERVATION", 152, 173], ["submandibular", "ANATOMY", 272, 285], ["sialolithiasis", "OBSERVATION", 286, 300], ["swelling", "OBSERVATION", 309, 317], ["pain", "OBSERVATION", 322, 326], ["gland", "ANATOMY", 336, 341], ["exacerbated", "OBSERVATION_MODIFIER", 350, 361], ["painful", "OBSERVATION_MODIFIER", 403, 410], ["lump", "OBSERVATION", 411, 415], ["floor", "ANATOMY", 423, 428], ["mouth", "ANATOMY", 436, 441], ["minimal", "OBSERVATION_MODIFIER", 447, 454], ["salivary", "ANATOMY", 455, 463], ["discharge", "OBSERVATION", 464, 473], ["duct", "ANATOMY", 494, 498], ["orifice", "ANATOMY_MODIFIER", 506, 513]]], ["Mandibular occlusal films and dental panoramic radiographs are often the first forms of diagnostic imaging used for visualization of calcified deposits, while computer tomography (CT) and magnetic resonance imaging (MRI) offer greater definition and the ability to exclude other differential diagnoses.", [["Mandibular", "ANATOMY", 0, 10], ["Mandibular occlusal films", "TEST", 0, 25], ["dental panoramic radiographs", "TEST", 30, 58], ["diagnostic imaging", "TEST", 88, 106], ["calcified deposits", "PROBLEM", 133, 151], ["computer tomography", "TEST", 159, 178], ["CT", "TEST", 180, 182], ["magnetic resonance imaging", "TEST", 188, 214], ["MRI", "TEST", 216, 219], ["calcified", "OBSERVATION_MODIFIER", 133, 142], ["deposits", "OBSERVATION", 143, 151]]], ["High-resolution ultrasonography is a comparatively simpler and less expensive alternative with a reportedly higher sensitivity than can be achieved using CT and MRI12,13.", [["High-resolution ultrasonography", "TEST", 0, 31], ["CT", "TEST", 154, 156]]], ["MRI has been demonstrated to be unsuitable for sufficiently diagnosing smaller calculi.", [["calculi", "ANATOMY", 79, 86], ["calculi", "DISEASE", 79, 86], ["calculi", "PATHOLOGICAL_FORMATION", 79, 86], ["MRI", "TEST", 0, 3], ["sufficiently diagnosing smaller calculi", "PROBLEM", 47, 86], ["smaller", "OBSERVATION_MODIFIER", 71, 78], ["calculi", "OBSERVATION", 79, 86]]], ["Definitive management usually commences after the acute inflammatory phase has been suppressed by a course of anti-inflammatory medications and broad-spectrum antibiotics, and various treatment modalities are available, depending on the location, number and sizes of the sialoliths.DiscussionStones in the anterior duct are usually palpable and can be easily excised under local anesthesia via a direct cut-down procedure.", [["anterior duct", "ANATOMY", 306, 319], ["anterior duct", "MULTI-TISSUE_STRUCTURE", 306, 319], ["Definitive management", "TREATMENT", 0, 21], ["the acute inflammatory phase", "PROBLEM", 46, 74], ["anti-inflammatory medications", "TREATMENT", 110, 139], ["broad-spectrum antibiotics", "TREATMENT", 144, 170], ["various treatment modalities", "TREATMENT", 176, 204], ["local anesthesia", "TREATMENT", 373, 389], ["a direct cut-down procedure", "TREATMENT", 394, 421], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["inflammatory", "OBSERVATION", 56, 68], ["sizes", "OBSERVATION_MODIFIER", 258, 263], ["anterior", "ANATOMY_MODIFIER", 306, 314], ["duct", "ANATOMY", 315, 319]]], ["Palpable stones in the hilum can be similarly approached, but this should preferably be done under sedation due to the significant discomfort involved.", [["stones", "ANATOMY", 9, 15], ["hilum", "ANATOMY", 23, 28], ["hilum", "MULTI-TISSUE_STRUCTURE", 23, 28], ["Palpable stones in the hilum", "PROBLEM", 0, 28], ["sedation", "TREATMENT", 99, 107], ["the significant discomfort", "PROBLEM", 115, 141], ["stones", "OBSERVATION", 9, 15], ["hilum", "ANATOMY", 23, 28], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["discomfort", "OBSERVATION", 131, 141]]], ["Intraparenchymal stones are often too deeply located and are consequentially unamenable to direct intraoral access.", [["Intraparenchymal stones", "ANATOMY", 0, 23], ["Intraparenchymal stones", "PROBLEM", 0, 23], ["stones", "OBSERVATION", 17, 23]]], ["Moreover, they are usually much smaller in size and may be conservatively managed with saliva-inducing agents, such as parasympathomimetics (e.g., pilocarpine) or anti-cholinesterases (e.g., neostigmine), to encourage their distal migration into Wharton\u2019s duct.", [["Wharton\u2019s duct", "ANATOMY", 246, 260], ["pilocarpine", "CHEMICAL", 147, 158], ["neostigmine", "CHEMICAL", 191, 202], ["pilocarpine", "CHEMICAL", 147, 158], ["neostigmine", "CHEMICAL", 191, 202], ["saliva", "ORGANISM_SUBSTANCE", 87, 93], ["pilocarpine", "SIMPLE_CHEMICAL", 147, 158], ["anti-cholinesterases", "SIMPLE_CHEMICAL", 163, 183], ["neostigmine", "SIMPLE_CHEMICAL", 191, 202], ["Wharton\u2019s duct", "MULTI-TISSUE_STRUCTURE", 246, 260], ["saliva-inducing agents", "TREATMENT", 87, 109], ["parasympathomimetics", "TREATMENT", 119, 139], ["pilocarpine", "TREATMENT", 147, 158], ["anti-cholinesterases", "TREATMENT", 163, 183], ["neostigmine", "TREATMENT", 191, 202], ["much", "OBSERVATION_MODIFIER", 27, 31], ["smaller", "OBSERVATION_MODIFIER", 32, 39], ["size", "OBSERVATION_MODIFIER", 43, 47], ["may be", "UNCERTAINTY", 52, 58], ["duct", "ANATOMY", 256, 260]]], ["Minimally invasive procedures, such as intervention sialendoscopy, ESWL and combined endoscopic-surgical procedures, are gaining popularity as the first-line treatment option in these patients6,14 as they significantly reduce the need for submandibulectomies15.", [["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 184, 191], ["Minimally invasive procedures", "TREATMENT", 0, 29], ["intervention sialendoscopy", "TREATMENT", 39, 65], ["ESWL", "TREATMENT", 67, 71], ["surgical procedures", "TREATMENT", 96, 115], ["the first-line treatment option", "TREATMENT", 143, 174], ["submandibulectomies", "TREATMENT", 239, 258], ["invasive", "OBSERVATION_MODIFIER", 10, 18]]], ["However, these endoscopic procedures are technically challenging and have variable success and complication rates, and centers lacking appropriate facilities will invariably have to resort to conventional submandibular gland resection.", [["submandibular gland", "ANATOMY", 205, 224], ["submandibular gland", "MULTI-TISSUE_STRUCTURE", 205, 224], ["these endoscopic procedures", "TEST", 9, 36], ["variable success and complication rates", "PROBLEM", 74, 113], ["conventional submandibular gland resection", "TREATMENT", 192, 234], ["submandibular gland", "ANATOMY", 205, 224], ["resection", "OBSERVATION", 225, 234]]], ["The dilemma of whether to spare or resect the entire gland is further compounded by the simultaneous occurrence of other sialoliths that are palpable intraorally and hence amenable to a conservative, gland-preserving approach.DiscussionSaliva production and composition are regulated by the autonomic nervous system, via which sympathetic innervation results in an overall decrease in both saliva production and blood flow to the glands and an increase in protein secretion.", [["gland", "ANATOMY", 53, 58], ["gland", "ANATOMY", 200, 205], ["autonomic nervous system", "ANATOMY", 291, 315], ["saliva", "ANATOMY", 390, 396], ["blood", "ANATOMY", 412, 417], ["glands", "ANATOMY", 430, 436], ["sialoliths", "DISEASE", 121, 131], ["gland", "ORGAN", 53, 58], ["gland", "ORGAN", 200, 205], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 291, 315], ["saliva", "ORGANISM_SUBSTANCE", 390, 396], ["blood", "ORGANISM_SUBSTANCE", 412, 417], ["glands", "ORGAN", 430, 436], ["other sialoliths", "PROBLEM", 115, 131], ["a conservative, gland-preserving approach", "TREATMENT", 184, 225], ["an overall decrease in both saliva production and blood flow to the glands", "PROBLEM", 362, 436], ["an increase in protein secretion", "PROBLEM", 441, 473], ["resect", "OBSERVATION", 35, 41], ["gland", "ANATOMY", 53, 58], ["autonomic nervous", "ANATOMY", 291, 308], ["overall", "OBSERVATION_MODIFIER", 365, 372], ["decrease", "OBSERVATION_MODIFIER", 373, 381], ["glands", "ANATOMY", 430, 436], ["increase", "OBSERVATION_MODIFIER", 444, 452], ["protein secretion", "OBSERVATION", 456, 473]]], ["The parasympathetic system plays a more important role in saliva production as the release of acetylcholine onto muscarinic M3 receptors results in increased production of watery saliva by acinar cells.", [["saliva", "ANATOMY", 58, 64], ["acinar cells", "ANATOMY", 189, 201], ["acetylcholine", "CHEMICAL", 94, 107], ["acetylcholine", "CHEMICAL", 94, 107], ["parasympathetic system", "ANATOMICAL_SYSTEM", 4, 26], ["saliva", "ORGANISM_SUBSTANCE", 58, 64], ["acetylcholine", "SIMPLE_CHEMICAL", 94, 107], ["muscarinic M3 receptors", "GENE_OR_GENE_PRODUCT", 113, 136], ["watery saliva", "ORGANISM_SUBSTANCE", 172, 185], ["acinar cells", "CELL", 189, 201], ["muscarinic M3 receptors", "PROTEIN", 113, 136], ["acinar cells", "CELL_TYPE", 189, 201], ["saliva production", "TREATMENT", 58, 75], ["acetylcholine onto muscarinic M3 receptors", "TREATMENT", 94, 136], ["increased production of watery saliva by acinar cells", "PROBLEM", 148, 201], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["acinar cells", "OBSERVATION", 189, 201]]], ["The combined effects of increased blood flow and contraction of the myoepithelium from parasympathetic innervation further amplify the saliva expulsion rate.", [["blood", "ANATOMY", 34, 39], ["myoepithelium", "ANATOMY", 68, 81], ["parasympathetic innervation", "ANATOMY", 87, 114], ["saliva", "ANATOMY", 135, 141], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["parasympathetic innervation", "MULTI-TISSUE_STRUCTURE", 87, 114], ["saliva", "ORGANISM_SUBSTANCE", 135, 141], ["increased blood flow", "PROBLEM", 24, 44], ["contraction of the myoepithelium", "PROBLEM", 49, 81], ["parasympathetic innervation", "TREATMENT", 87, 114], ["the saliva expulsion rate", "TEST", 131, 156], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["blood flow", "OBSERVATION", 34, 44], ["contraction", "OBSERVATION_MODIFIER", 49, 60]]], ["In patients under general anesthesia, the suppression of sympathetic activity by inhalational anesthetic agents intraoperatively tilts the balance towards a parasympathetic predominance, leading to an increase in saliva production16.", [["patients", "ORGANISM", 3, 11], ["saliva", "ORGANISM_SUBSTANCE", 213, 219], ["patients", "SPECIES", 3, 11], ["general anesthesia", "TREATMENT", 18, 36], ["sympathetic activity", "TREATMENT", 57, 77], ["inhalational anesthetic agents", "TREATMENT", 81, 111], ["a parasympathetic predominance", "PROBLEM", 155, 185], ["an increase in saliva production16", "PROBLEM", 198, 232], ["increase", "OBSERVATION_MODIFIER", 201, 209]]], ["We propose that removing the hilar stones at the onset releases the built-up pressure within the obstructed gland, permitting the drainage of saliva along with the smaller intraparenchymal sialoliths.", [["hilar stones", "ANATOMY", 29, 41], ["obstructed gland", "ANATOMY", 97, 113], ["saliva", "ANATOMY", 142, 148], ["intraparenchymal sialoliths", "ANATOMY", 172, 199], ["hilar stones", "MULTI-TISSUE_STRUCTURE", 29, 41], ["obstructed gland", "ORGAN", 97, 113], ["saliva", "ORGANISM_SUBSTANCE", 142, 148], ["intraparenchymal sialoliths", "PATHOLOGICAL_FORMATION", 172, 199], ["the hilar stones", "PROBLEM", 25, 41], ["the drainage of saliva", "PROBLEM", 126, 148], ["the smaller intraparenchymal sialoliths", "PROBLEM", 160, 199], ["hilar", "ANATOMY", 29, 34], ["stones", "OBSERVATION", 35, 41], ["pressure", "OBSERVATION_MODIFIER", 77, 85], ["obstructed gland", "ANATOMY", 97, 113], ["drainage", "OBSERVATION", 130, 138], ["smaller", "OBSERVATION_MODIFIER", 164, 171], ["intraparenchymal", "OBSERVATION_MODIFIER", 172, 188], ["sialoliths", "OBSERVATION", 189, 199]]], ["Furthermore, the use of muscle relaxants in general anesthesia may also relax the mylohyoid muscle that the submandibular gland is wrapped over, potentially permitting easier passage of the smaller intraglandular sialoliths towards the hilum.", [["muscle", "ANATOMY", 24, 30], ["mylohyoid muscle", "ANATOMY", 82, 98], ["submandibular gland", "ANATOMY", 108, 127], ["intraglandular sialoliths", "ANATOMY", 198, 223], ["hilum", "ANATOMY", 236, 241], ["muscle", "ORGAN", 24, 30], ["mylohyoid muscle", "TISSUE", 82, 98], ["submandibular gland", "ORGAN", 108, 127], ["hilum", "MULTI-TISSUE_STRUCTURE", 236, 241], ["muscle relaxants", "TREATMENT", 24, 40], ["general anesthesia", "TREATMENT", 44, 62], ["muscle", "ANATOMY", 24, 30], ["mylohyoid muscle", "ANATOMY", 82, 98], ["submandibular gland", "ANATOMY", 108, 127], ["passage", "OBSERVATION_MODIFIER", 175, 182], ["smaller", "OBSERVATION_MODIFIER", 190, 197], ["intraglandular sialoliths", "OBSERVATION", 198, 223], ["hilum", "ANATOMY", 236, 241]]], ["The application of circuitous, posterior-anterior extraoral submandibular gland massage serves to encourage anti-gravitational salivary flow from the inferiorly located gland into the medial-superiorly located Wharton\u2019s duct.DiscussionThe largest intraparenchymal stone in our study measured 4.5 mm in diameter, and it remains to be seen whether larger stones would be amenable to this approach.", [["submandibular gland", "ANATOMY", 60, 79], ["salivary", "ANATOMY", 127, 135], ["gland", "ANATOMY", 169, 174], ["Wharton\u2019s duct", "ANATOMY", 210, 224], ["intraparenchymal stone", "ANATOMY", 247, 269], ["stones", "ANATOMY", 353, 359], ["submandibular gland", "MULTI-TISSUE_STRUCTURE", 60, 79], ["salivary", "ORGAN", 127, 135], ["gland", "ORGAN", 169, 174], ["Wharton\u2019s duct", "MULTI-TISSUE_STRUCTURE", 210, 224], ["intraparenchymal stone", "PATHOLOGICAL_FORMATION", 247, 269], ["circuitous, posterior-anterior extraoral submandibular gland massage", "TREATMENT", 19, 87], ["The largest intraparenchymal stone", "PROBLEM", 235, 269], ["our study", "TEST", 273, 282], ["larger stones", "PROBLEM", 346, 359], ["this approach", "TREATMENT", 381, 394], ["posterior", "ANATOMY_MODIFIER", 31, 40], ["anterior", "ANATOMY_MODIFIER", 41, 49], ["extraoral", "ANATOMY_MODIFIER", 50, 59], ["submandibular gland", "ANATOMY", 60, 79], ["inferiorly", "ANATOMY_MODIFIER", 150, 160], ["gland", "ANATOMY", 169, 174], ["medial", "ANATOMY_MODIFIER", 184, 190], ["superiorly", "ANATOMY_MODIFIER", 191, 201], ["duct", "ANATOMY", 220, 224], ["largest", "OBSERVATION_MODIFIER", 239, 246], ["intraparenchymal", "OBSERVATION_MODIFIER", 247, 263], ["stone", "OBSERVATION", 264, 269], ["4.5 mm", "OBSERVATION_MODIFIER", 292, 298], ["diameter", "OBSERVATION_MODIFIER", 302, 310], ["larger", "OBSERVATION_MODIFIER", 346, 352], ["stones", "OBSERVATION", 353, 359]]], ["We recommend that ESWL be considered instead for the fragmentation of larger intraparenchymal sialoliths followed by the use of saliva-inducing medications to encourage their spontaneous discharge.", [["intraparenchymal sialoliths", "ANATOMY", 77, 104], ["saliva", "ORGANISM_SUBSTANCE", 128, 134], ["ESWL", "TREATMENT", 18, 22], ["larger intraparenchymal sialoliths", "PROBLEM", 70, 104], ["saliva-inducing medications", "TREATMENT", 128, 155], ["larger", "OBSERVATION_MODIFIER", 70, 76], ["intraparenchymal", "OBSERVATION_MODIFIER", 77, 93], ["sialoliths", "OBSERVATION", 94, 104]]], ["Alternatively, a combination of ESWL and intraoral sialolithotomy may be considered before proceeding with a conventional submandibulectomy.", [["ESWL", "TREATMENT", 32, 36], ["intraoral sialolithotomy", "TREATMENT", 41, 65], ["a conventional submandibulectomy", "TREATMENT", 107, 139], ["ESWL", "OBSERVATION", 32, 36], ["submandibulectomy", "OBSERVATION", 122, 139]]], ["Further studies comprising larger sample sizes as well as quality of life surveys comparing patients who underwent these procedures versus those who underwent submandibulectomies would be useful to validate the viability of this treatment option.ConclusionApproximately 90% of all submandibular gland sialoliths are located within the Wharton duct, up to the hilum of the gland.", [["submandibular gland", "ANATOMY", 281, 300], ["Wharton duct", "ANATOMY", 335, 347], ["hilum", "ANATOMY", 359, 364], ["gland", "ANATOMY", 372, 377], ["patients", "ORGANISM", 92, 100], ["submandibular gland sialoliths", "CANCER", 281, 311], ["Wharton duct", "MULTI-TISSUE_STRUCTURE", 335, 347], ["hilum", "MULTI-TISSUE_STRUCTURE", 359, 364], ["gland", "ORGAN", 372, 377], ["patients", "SPECIES", 92, 100], ["Further studies", "TEST", 0, 15], ["larger sample sizes", "TREATMENT", 27, 46], ["these procedures", "TREATMENT", 115, 131], ["submandibulectomies", "TREATMENT", 159, 178], ["this treatment option", "TREATMENT", 224, 245], ["ConclusionApproximately", "TEST", 246, 269], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["sizes", "OBSERVATION_MODIFIER", 41, 46], ["all", "ANATOMY_MODIFIER", 277, 280], ["submandibular gland", "ANATOMY", 281, 300], ["sialoliths", "OBSERVATION", 301, 311], ["duct", "ANATOMY", 343, 347], ["hilum", "ANATOMY", 359, 364], ["gland", "ANATOMY", 372, 377]]], ["Deeply located intraparenchymal stones are generally smaller and account for the remaining 10%.", [["intraparenchymal stones", "ANATOMY", 15, 38], ["intraparenchymal stones", "PATHOLOGICAL_FORMATION", 15, 38], ["Deeply located intraparenchymal stones", "PROBLEM", 0, 38], ["intraparenchymal", "ANATOMY_MODIFIER", 15, 31], ["stones", "OBSERVATION", 32, 38], ["generally", "OBSERVATION_MODIFIER", 43, 52], ["smaller", "OBSERVATION_MODIFIER", 53, 60]]], ["Management options for these sialoliths include medications, lithotripsies, sialendoscopies or submandibulectomies7.", [["Management options", "TREATMENT", 0, 18], ["these sialoliths", "TREATMENT", 23, 39], ["medications", "TREATMENT", 48, 59], ["lithotripsies", "TREATMENT", 61, 74], ["sialendoscopies", "TREATMENT", 76, 91], ["submandibulectomies7", "TREATMENT", 95, 115]]], ["In light of the variable success of these approaches, intraoral sialolithotomy is a viable treatment modality for patients with simultaneously occurring deep hilar and intraparenchymal sialoliths.", [["hilar", "ANATOMY", 158, 163], ["intraparenchymal sialoliths", "ANATOMY", 168, 195], ["patients", "ORGANISM", 114, 122], ["hilar", "MULTI-TISSUE_STRUCTURE", 158, 163], ["intraparenchymal sialoliths", "PATHOLOGICAL_FORMATION", 168, 195], ["patients", "SPECIES", 114, 122], ["these approaches", "TREATMENT", 36, 52], ["intraoral sialolithotomy", "TREATMENT", 54, 78], ["a viable treatment modality", "TREATMENT", 82, 109], ["simultaneously occurring deep hilar and intraparenchymal sialoliths", "PROBLEM", 128, 195], ["deep", "ANATOMY_MODIFIER", 153, 157], ["hilar", "ANATOMY", 158, 163], ["intraparenchymal", "ANATOMY_MODIFIER", 168, 184], ["sialoliths", "OBSERVATION", 185, 195]]]], "PMC7141568": [["Inhibition of humoral responsesAntigenic variability was one of the first viral immune-evasion strategies to be identified.", [["the first viral immune-evasion strategies", "TREATMENT", 64, 105]]], ["Because of the low fidelity of RNA polymerases, viral RNA genomes comprise a collection of RNA species (quasispecies) with random mutations.", [["RNA polymerases", "RNA", 31, 46], ["viral RNA genomes", "RNA", 48, 65], ["RNA species", "RNA", 91, 102], ["the low fidelity of RNA polymerases", "PROBLEM", 11, 46], ["viral RNA genomes", "PROBLEM", 48, 65], ["RNA species", "PROBLEM", 91, 102], ["random mutations", "PROBLEM", 123, 139], ["low fidelity", "OBSERVATION_MODIFIER", 15, 27], ["RNA polymerases", "OBSERVATION", 31, 46], ["viral RNA genomes", "OBSERVATION", 48, 65], ["RNA species", "OBSERVATION", 91, 102]]], ["Therefore, in RNA viruses, the generation and selection of variants with different antigenic properties that can evade recognition by neutralizing antibodies is common.", [["neutralizing antibodies", "PROTEIN", 134, 157], ["RNA viruses", "PROBLEM", 14, 25], ["different antigenic properties", "TREATMENT", 73, 103], ["RNA viruses", "OBSERVATION", 14, 25]]], ["Genetic variability can also generate variant peptide sequences that are either new antigens or that do not bind to major histocompatibility complex (MHC) molecules at all.Inhibition of humoral responsesThe complement system is a major non-specific host defense mechanism1, 2, 3.", [["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 116, 148], ["major histocompatibility complex (MHC) molecules", "PROTEIN", 116, 164], ["Genetic variability", "PROBLEM", 0, 19], ["variant peptide sequences", "PROBLEM", 38, 63], ["new antigens", "PROBLEM", 80, 92], ["humoral responses", "TEST", 186, 203], ["a major non-specific host defense mechanism1", "PROBLEM", 228, 272], ["humoral responses", "OBSERVATION", 186, 203], ["major", "OBSERVATION_MODIFIER", 230, 235], ["non-specific", "OBSERVATION_MODIFIER", 236, 248], ["host defense mechanism1", "OBSERVATION", 249, 272]]], ["Viruses encode homologs of complement regulatory proteins that are secreted and block complement activation and neutralization of virus particles (Table 1; Box 1).", [["complement regulatory proteins", "GENE_OR_GENE_PRODUCT", 27, 57], ["Box 1", "GENE_OR_GENE_PRODUCT", 156, 161], ["complement regulatory proteins", "PROTEIN", 27, 57], ["complement regulatory proteins", "PROBLEM", 27, 57], ["block complement activation", "PROBLEM", 80, 107], ["neutralization of virus particles", "TREATMENT", 112, 145]]], ["The cowpox virus (CPV) complement inhibitor, termed inflammation modulatory protein (IMP), blocks immunopathological tissue damage at the site of infection, presumably by inhibiting production of the macrophage chemoattractant factors C3a and C5a (Ref.", [["tissue", "ANATOMY", 117, 123], ["tissue damage", "DISEASE", 117, 130], ["infection", "DISEASE", 146, 155], ["cowpox virus", "ORGANISM", 4, 16], ["CPV", "ORGANISM", 18, 21], ["complement inhibitor, termed inflammation modulatory protein", "GENE_OR_GENE_PRODUCT", 23, 83], ["IMP", "GENE_OR_GENE_PRODUCT", 85, 88], ["tissue", "TISSUE", 117, 123], ["macrophage", "CELL", 200, 210], ["C3a", "GENE_OR_GENE_PRODUCT", 235, 238], ["C5a", "GENE_OR_GENE_PRODUCT", 243, 246], ["inflammation modulatory protein", "PROTEIN", 52, 83], ["IMP", "PROTEIN", 85, 88], ["macrophage chemoattractant factors", "PROTEIN", 200, 234], ["C3a", "PROTEIN", 235, 238], ["C5a", "PROTEIN", 243, 246], ["Ref", "PROTEIN", 248, 251], ["cowpox virus", "SPECIES", 4, 16], ["CPV", "SPECIES", 18, 21], ["The cowpox virus (CPV) complement inhibitor", "TREATMENT", 0, 43], ["termed inflammation modulatory protein (IMP)", "PROBLEM", 45, 89], ["blocks immunopathological tissue damage", "PROBLEM", 91, 130], ["infection", "PROBLEM", 146, 155], ["cowpox virus", "OBSERVATION", 4, 16], ["inflammation", "OBSERVATION", 52, 64], ["immunopathological tissue damage", "OBSERVATION", 98, 130], ["infection", "OBSERVATION", 146, 155], ["macrophage", "OBSERVATION_MODIFIER", 200, 210]]], ["Viruses protect the membranes of infected cells and the lipid envelopes of virus particles from complement lysis by encoding homologs of inhibitors of the membrane-attack complex.", [["membranes", "ANATOMY", 20, 29], ["cells", "ANATOMY", 42, 47], ["membrane", "ANATOMY", 155, 163], ["membranes", "CELLULAR_COMPONENT", 20, 29], ["cells", "CELL", 42, 47], ["membrane", "CELLULAR_COMPONENT", 155, 163], ["infected cells", "CELL_TYPE", 33, 47], ["membrane-attack complex", "PROTEIN", 155, 178], ["Viruses", "PROBLEM", 0, 7], ["infected cells", "PROBLEM", 33, 47], ["virus particles", "PROBLEM", 75, 90], ["complement lysis", "TREATMENT", 96, 112], ["membranes", "OBSERVATION_MODIFIER", 20, 29], ["infected cells", "OBSERVATION", 33, 47], ["virus particles", "OBSERVATION", 75, 90]]], ["Viruses such as HIV, human cytomegalovirus (HCMV) and vaccinia virus (VV) utilize a clever strategy, \u2018borrowing\u2019 host cellular factors, including CD59, which normally protects cells from complement lysis, and incorporating them into the viral envelope.AlcamiAntonioKoszinowskiUlrich H.Box 1Box 1.", [["cellular", "ANATOMY", 118, 126], ["cells", "ANATOMY", 176, 181], ["HIV, human cytomegalovirus (HCMV) and vaccinia virus", "DISEASE", 16, 68], ["HIV", "ORGANISM", 16, 19], ["human cytomegalovirus", "ORGANISM", 21, 42], ["HCMV", "ORGANISM", 44, 48], ["vaccinia virus", "ORGANISM", 54, 68], ["cellular", "CELL", 118, 126], ["CD59", "GENE_OR_GENE_PRODUCT", 146, 150], ["cells", "CELL", 176, 181], ["cellular factors", "PROTEIN", 118, 134], ["CD59", "PROTEIN", 146, 150], ["HIV", "SPECIES", 16, 19], ["human", "SPECIES", 21, 26], ["cytomegalovirus", "SPECIES", 27, 42], ["vaccinia virus", "SPECIES", 54, 68], ["HIV", "SPECIES", 16, 19], ["human cytomegalovirus", "SPECIES", 21, 42], ["HCMV", "SPECIES", 44, 48], ["vaccinia virus", "SPECIES", 54, 68], ["VV", "SPECIES", 70, 72], ["Viruses", "PROBLEM", 0, 7], ["HIV", "PROBLEM", 16, 19], ["human cytomegalovirus (HCMV", "PROBLEM", 21, 48], ["vaccinia virus", "PROBLEM", 54, 68], ["a clever strategy", "TREATMENT", 82, 99], ["CD59", "TEST", 146, 150], ["complement lysis", "TREATMENT", 187, 203]]], ["Abbreviations in Tables2\u20325\u2032OA, 2\u20325\u2032 oligoadenylate; 2\u20325\u2032OS, 2\u20325\u2032 OA synthetase; 3\u03b2-HSD, 3\u03b2-hydroxysteroid dehydrogenase; AHV, alcelaphine herpesvirus; ASFV, African swine fever virus; BHV, bovine herpesvirus; BP, binding protein; BPV, bovine papilloma virus; CaPV, capripox virus; CCI, chemokine inhibitor; CCPH, complement control protein homolog; CK, chemokine; CKBP, chemokine-binding protein; CP, complement control protein; CPV, cowpox virus; Crm, cytokine response modifier; CSF, colony-stimulating factor; dsRNA, double stranded RNA; EBER, EBV-encoded small RNA; EBV, Epstein\u2013Barr virus; EGF, epidermal growth factor; EHV, equine herpesvirus; eIF-2\u03b1, eukaryotic translation initiation factor 2\u03b1; EMCV, encephalomyocarditis virus; ER, endoplasmic reticulum; ESPR, virus-encoded semaphorin protein receptor; EV, ectromelia (mousepox) virus; FLIP, FLICE inhibitory protein; GF, growth factor; GM-CSF, granulocyte\u2013macrophage CSF; gp, glycoprotein; HBV, hepatitis B virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus; HHV, human herpesvirus; HHV-8, human herpesvirus 8 or Kaposi\u2019s-sarcoma-associated herpesvirus; HPIV, human parainfluenza virus; HPV, human papilloma virus; HSV, herpes simplex virus; HTLV, human T cell leukemia virus; HVS, herpesvirus saimiri; I\u03baB, inhibitor of \u03baB; IAP, inhibitor of apoptosis; ICP, infected cell protein; IFN, interferon; Ig, immunoglobulin; IL, interleukin; IRF, interferon regulatory factor; JAK, janus kinase; LMP, latent membrane protein; LT, lymphotoxin; MCK, murine cytomegalovirus chemokine; MCMV, murine cytomegalovirus; MCV, Molluscum contagiosum virus; MeV, measles virus; MGF, myxoma growth factor; MHC, major histocompatibility complex; MHV-68, murine gammaherpesvirus 68; MIP, macrophage inflammatory protein; MPV, murine polyoma virus; MV, myxoma virus; NF-\u03baB, nuclear factor \u03baB; NFAT, nuclear factor activated T cell; NK, natural killer; ORF, open reading frame; OV, Orf virus; PKR, dsRNA-dependent protein kinase; R, receptor; RANTES, regulated upon activation normal T cell expressed and secreted; RCMV, rat cytomegalovirus; RID, receptor internalization and degradation complex; SEMA, semaphorin; serpin, serine protease inhibitor; SeV, Sendai virus; SFV, Shope fibroma virus; SPI, serine protein inhibitor; SPV, swinepox virus; STAT, signal transducers and activators of transcription; SV, simian virus; TAP, transporters associated with antigen processing; TAR, trans-acting response element; TNF, tumor necrosis factor; TPV, Tanapox virus; v, viral; VaV, variola (smallpox) virus; VEGF, vascular endothelial growth factor; VV, vaccinia virus.Inhibition of humoral responsesLastly, some viruses encode Fc receptors1 (Table 1).", [["endoplasmic reticulum", "ANATOMY", 741, 762], ["cell", "ANATOMY", 1337, 1341], ["T cell", "ANATOMY", 1871, 1877], ["NK", "ANATOMY", 1879, 1881], ["T cell", "ANATOMY", 2030, 2036], ["swine fever", "DISEASE", 165, 176], ["bovine papilloma virus", "DISEASE", 235, 257], ["hepatitis B", "DISEASE", 956, 967], ["human cytomegalovirus; HCV, hepatitis C", "DISEASE", 981, 1020], ["Kaposi\u2019s-sarcoma", "DISEASE", 1082, 1098], ["human parainfluenza virus", "DISEASE", 1129, 1154], ["human papilloma virus", "DISEASE", 1161, 1182], ["herpes simplex virus", "DISEASE", 1189, 1209], ["human T cell leukemia virus", "DISEASE", 1217, 1244], ["Molluscum contagiosum", "DISEASE", 1580, 1601], ["myxoma", "DISEASE", 1634, 1640], ["myxoma", "DISEASE", 1800, 1806], ["fibroma", "DISEASE", 2226, 2233], ["tumor necrosis", "DISEASE", 2464, 2478], ["Tables2\u20325\u2032OA, 2\u20325\u2032 oligoadenylate", "CHEMICAL", 17, 50], ["2\u20325\u2032OS", "CHEMICAL", 52, 58], ["3\u03b2-hydroxysteroid", "CHEMICAL", 88, 105], ["serine", "CHEMICAL", 2169, 2175], ["serine", "CHEMICAL", 2246, 2252], ["2\u20325\u2032 oligoadenylate", "SIMPLE_CHEMICAL", 31, 50], ["2\u20325\u2032OS", "SIMPLE_CHEMICAL", 52, 58], ["\u03b2-HSD", "GENE_OR_GENE_PRODUCT", 81, 86], ["3\u03b2-hydroxysteroid dehydrogenase", "GENE_OR_GENE_PRODUCT", 88, 119], ["AHV", "GENE_OR_GENE_PRODUCT", 121, 124], ["alcelaphine herpesvirus", "ORGANISM", 126, 149], ["ASFV", "ORGANISM", 151, 155], ["African swine fever virus", "ORGANISM", 157, 182], ["BHV", "ORGANISM", 184, 187], ["bovine herpesvirus", "ORGANISM", 189, 207], ["BP", "GENE_OR_GENE_PRODUCT", 209, 211], ["BPV", "ORGANISM", 230, 233], ["bovine papilloma virus", "ORGANISM", 235, 257], ["CaPV", "GENE_OR_GENE_PRODUCT", 259, 263], ["capripox virus", "ORGANISM", 265, 279], ["CCPH", "GENE_OR_GENE_PRODUCT", 307, 311], ["complement control protein homolog", "GENE_OR_GENE_PRODUCT", 313, 347], ["CK", "GENE_OR_GENE_PRODUCT", 349, 351], ["CKBP", "GENE_OR_GENE_PRODUCT", 364, 368], ["chemokine-binding protein", "GENE_OR_GENE_PRODUCT", 370, 395], ["CP", "GENE_OR_GENE_PRODUCT", 397, 399], ["complement control protein", "GENE_OR_GENE_PRODUCT", 401, 427], ["CPV", "ORGANISM", 429, 432], ["cowpox virus", "ORGANISM", 434, 446], ["Crm", "GENE_OR_GENE_PRODUCT", 448, 451], ["CSF, colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 481, 511], ["EBER", "GENE_OR_GENE_PRODUCT", 541, 545], ["EBV", "ORGANISM", 547, 550], ["EBV", "ORGANISM", 570, 573], ["Epstein\u2013Barr virus", "ORGANISM", 575, 593], ["EGF", "GENE_OR_GENE_PRODUCT", 595, 598], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 600, 623], ["EHV", "GENE_OR_GENE_PRODUCT", 625, 628], ["equine herpesvirus", "ORGANISM", 630, 648], ["eIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 650, 656], ["eukaryotic translation initiation factor 2\u03b1", "GENE_OR_GENE_PRODUCT", 658, 701], ["EMCV", "ORGANISM", 703, 707], ["encephalomyocarditis virus", "ORGANISM", 709, 735], ["ER", "GENE_OR_GENE_PRODUCT", 737, 739], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 741, 762], ["ESPR", "GENE_OR_GENE_PRODUCT", 764, 768], ["semaphorin protein receptor; EV, ectromelia (mousepox) virus", "ORGANISM", 784, 844], ["FLIP", "GENE_OR_GENE_PRODUCT", 846, 850], ["FLICE inhibitory protein; GF, growth factor", "GENE_OR_GENE_PRODUCT", 852, 895], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 897, 903], ["granulocyte\u2013macrophage CSF", "GENE_OR_GENE_PRODUCT", 905, 931], ["gp", "GENE_OR_GENE_PRODUCT", 933, 935], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 937, 949], ["HBV,", "ORGANISM", 951, 955], ["hepatitis B virus", "ORGANISM", 956, 973], ["HCMV", "ORGANISM", 975, 979], ["human", "ORGANISM", 981, 986], ["cytomegalovirus; HCV,", "ORGANISM", 987, 1008], ["hepatitis C virus", "ORGANISM", 1009, 1026], ["HHV", "ORGANISM", 1028, 1031], ["human herpesvirus", "ORGANISM", 1033, 1050], ["HHV-8", "ORGANISM", 1052, 1057], ["human herpesvirus 8", "ORGANISM", 1059, 1078], ["Kaposi\u2019s-sarcoma-associated herpesvirus", "ORGANISM", 1082, 1121], ["HPIV", "ORGANISM", 1123, 1127], ["human", "ORGANISM", 1129, 1134], ["parainfluenza virus", "ORGANISM", 1135, 1154], ["HPV", "ORGANISM", 1156, 1159], ["human papilloma virus", "ORGANISM", 1161, 1182], ["HSV", "ORGANISM", 1184, 1187], ["herpes simplex virus", "ORGANISM", 1189, 1209], ["HTLV", "ORGANISM", 1211, 1215], ["human T cell leukemia virus", "ORGANISM", 1217, 1244], ["HVS", "ORGANISM", 1246, 1249], ["herpesvirus saimiri", "ORGANISM", 1251, 1270], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 1272, 1275], ["\u03baB", "GENE_OR_GENE_PRODUCT", 1290, 1292], ["IAP", "GENE_OR_GENE_PRODUCT", 1294, 1297], ["cell", "CELL", 1337, 1341], ["IFN", "GENE_OR_GENE_PRODUCT", 1351, 1354], ["interferon", "GENE_OR_GENE_PRODUCT", 1356, 1366], ["Ig", "GENE_OR_GENE_PRODUCT", 1368, 1370], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 1372, 1386], ["IL", "GENE_OR_GENE_PRODUCT", 1388, 1390], ["interleukin", "GENE_OR_GENE_PRODUCT", 1392, 1403], ["IRF", "GENE_OR_GENE_PRODUCT", 1405, 1408], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 1410, 1438], ["JAK", "GENE_OR_GENE_PRODUCT", 1440, 1443], ["janus kinase", "GENE_OR_GENE_PRODUCT", 1445, 1457], ["LMP", "GENE_OR_GENE_PRODUCT", 1459, 1462], ["latent membrane protein", "GENE_OR_GENE_PRODUCT", 1464, 1487], ["LT", "GENE_OR_GENE_PRODUCT", 1489, 1491], ["lymphotoxin", "GENE_OR_GENE_PRODUCT", 1493, 1504], ["MCK", "GENE_OR_GENE_PRODUCT", 1506, 1509], ["murine", "ORGANISM", 1511, 1517], ["cytomegalovirus", "ORGANISM", 1518, 1533], ["MCMV", "ORGANISM", 1545, 1549], ["murine", "ORGANISM", 1551, 1557], ["cytomegalovirus", "ORGANISM", 1558, 1573], ["MCV,", "ORGANISM", 1575, 1579], ["Molluscum contagiosum virus", "ORGANISM", 1580, 1607], ["measles virus", "ORGANISM", 1614, 1627], ["MGF", "GENE_OR_GENE_PRODUCT", 1629, 1632], ["myxoma growth factor", "GENE_OR_GENE_PRODUCT", 1634, 1654], ["MHV-68", "ORGANISM", 1695, 1701], ["murine", "ORGANISM", 1703, 1709], ["gammaherpesvirus 68", "ORGANISM", 1710, 1729], ["MIP", "GENE_OR_GENE_PRODUCT", 1731, 1734], ["macrophage inflammatory protein", "GENE_OR_GENE_PRODUCT", 1736, 1767], ["MPV", "GENE_OR_GENE_PRODUCT", 1769, 1772], ["murine polyoma virus", "ORGANISM", 1774, 1794], ["MV, myxoma virus", "ORGANISM", 1796, 1812], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 1814, 1819], ["nuclear factor \u03baB", "GENE_OR_GENE_PRODUCT", 1821, 1838], ["NFAT", "GENE_OR_GENE_PRODUCT", 1840, 1844], ["T cell", "CELL", 1871, 1877], ["NK", "CELL", 1879, 1881], ["Orf virus", "ORGANISM", 1928, 1937], ["PKR", "GENE_OR_GENE_PRODUCT", 1939, 1942], ["dsRNA-dependent protein kinase; R", "GENE_OR_GENE_PRODUCT", 1944, 1977], ["RANTES", "GENE_OR_GENE_PRODUCT", 1989, 1995], ["T cell", "CELL", 2030, 2036], ["RCMV", "GENE_OR_GENE_PRODUCT", 2061, 2065], ["rat cytomegalovirus", "ORGANISM", 2067, 2086], ["RID", "GENE_OR_GENE_PRODUCT", 2088, 2091], ["receptor internalization and degradation complex", "GENE_OR_GENE_PRODUCT", 2093, 2141], ["SEMA", "GENE_OR_GENE_PRODUCT", 2143, 2147], ["semaphorin", "GENE_OR_GENE_PRODUCT", 2149, 2159], ["serpin", "GENE_OR_GENE_PRODUCT", 2161, 2167], ["serine", "GENE_OR_GENE_PRODUCT", 2169, 2175], ["SeV", "ORGANISM", 2196, 2199], ["Sendai virus", "ORGANISM", 2201, 2213], ["SFV", "ORGANISM", 2215, 2218], ["Shope fibroma virus", "ORGANISM", 2220, 2239], ["SPI", "GENE_OR_GENE_PRODUCT", 2241, 2244], ["SPV", "GENE_OR_GENE_PRODUCT", 2272, 2275], ["swinepox virus", "ORGANISM", 2277, 2291], ["STAT", "GENE_OR_GENE_PRODUCT", 2293, 2297], ["signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 2299, 2349], ["SV", "GENE_OR_GENE_PRODUCT", 2351, 2353], ["simian virus", "ORGANISM", 2355, 2367], ["TAP", "GENE_OR_GENE_PRODUCT", 2369, 2372], ["antigen", "GENE_OR_GENE_PRODUCT", 2403, 2410], ["TAR", "GENE_OR_GENE_PRODUCT", 2423, 2426], ["TNF", "GENE_OR_GENE_PRODUCT", 2459, 2462], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 2464, 2485], ["TPV", "GENE_OR_GENE_PRODUCT", 2487, 2490], ["Tanapox virus", "ORGANISM", 2492, 2505], ["v", "GENE_OR_GENE_PRODUCT", 2507, 2508], ["VaV", "GENE_OR_GENE_PRODUCT", 2517, 2520], ["variola (smallpox) virus", "ORGANISM", 2522, 2546], ["VEGF", "GENE_OR_GENE_PRODUCT", 2548, 2552], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 2554, 2588], ["VV", "ORGANISM", 2590, 2592], ["vaccinia virus", "ORGANISM", 2594, 2608], ["Fc receptors1 (Table 1", "GENE_OR_GENE_PRODUCT", 2668, 2690], ["hydroxysteroid dehydrogenase", "PROTEIN", 91, 119], ["AHV", "PROTEIN", 121, 124], ["BP", "PROTEIN", 209, 211], ["binding protein", "PROTEIN", 213, 228], ["chemokine inhibitor", "PROTEIN", 286, 305], ["CCPH", "PROTEIN", 307, 311], ["complement control protein homolog", "PROTEIN", 313, 347], ["CK", "PROTEIN", 349, 351], ["chemokine", "PROTEIN", 353, 362], ["CKBP", "PROTEIN", 364, 368], ["chemokine", "PROTEIN", 370, 379], ["binding protein", "PROTEIN", 380, 395], ["CP", "PROTEIN", 397, 399], ["complement control protein", "PROTEIN", 401, 427], ["CPV", "PROTEIN", 429, 432], ["Crm", "PROTEIN", 448, 451], ["cytokine", "PROTEIN", 453, 461], ["CSF", "PROTEIN", 481, 484], ["colony-stimulating factor", "PROTEIN", 486, 511], ["dsRNA", "PROTEIN", 513, 518], ["double stranded RNA", "RNA", 520, 539], ["EBER", "PROTEIN", 541, 545], ["EGF", "PROTEIN", 595, 598], ["epidermal growth factor", "PROTEIN", 600, 623], ["EHV", "PROTEIN", 625, 628], ["equine herpesvirus; eIF-2\u03b1", "PROTEIN", 630, 656], ["eukaryotic translation initiation factor 2\u03b1", "PROTEIN", 658, 701], ["EMCV", "PROTEIN", 703, 707], ["ER", "PROTEIN", 737, 739], ["endoplasmic reticulum; ESPR, virus-encoded semaphorin protein receptor", "PROTEIN", 741, 811], ["FLIP", "PROTEIN", 846, 850], ["FLICE inhibitory protein", "PROTEIN", 852, 876], ["GF", "PROTEIN", 878, 880], ["growth factor", "PROTEIN", 882, 895], ["GM", "PROTEIN", 897, 899], ["CSF", "PROTEIN", 900, 903], ["granulocyte\u2013macrophage CSF", "PROTEIN", 905, 931], ["gp", "PROTEIN", 933, 935], ["glycoprotein", "PROTEIN", 937, 949], ["I\u03baB", "PROTEIN", 1272, 1275], ["\u03baB", "PROTEIN", 1290, 1292], ["IAP", "PROTEIN", 1294, 1297], ["inhibitor of apoptosis; ICP, infected cell protein", "PROTEIN", 1299, 1349], ["IFN", "PROTEIN", 1351, 1354], ["interferon", "PROTEIN", 1356, 1366], ["Ig", "PROTEIN", 1368, 1370], ["immunoglobulin", "PROTEIN", 1372, 1386], ["IL", "PROTEIN", 1388, 1390], ["interleukin", "PROTEIN", 1392, 1403], ["IRF", "PROTEIN", 1405, 1408], ["interferon regulatory factor", "PROTEIN", 1410, 1438], ["JAK", "PROTEIN", 1440, 1443], ["janus kinase", "PROTEIN", 1445, 1457], ["LMP", "PROTEIN", 1459, 1462], ["latent membrane protein", "PROTEIN", 1464, 1487], ["LT", "PROTEIN", 1489, 1491], ["lymphotoxin", "PROTEIN", 1493, 1504], ["MCK", "PROTEIN", 1506, 1509], ["murine cytomegalovirus chemokine", "PROTEIN", 1511, 1543], ["MCMV", "PROTEIN", 1545, 1549], ["MGF", "PROTEIN", 1629, 1632], ["myxoma growth factor", "PROTEIN", 1634, 1654], ["MHC", "PROTEIN", 1656, 1659], ["major histocompatibility complex", "PROTEIN", 1661, 1693], ["MHV-68", "PROTEIN", 1695, 1701], ["murine gammaherpesvirus 68", "PROTEIN", 1703, 1729], ["MIP", "PROTEIN", 1731, 1734], ["macrophage inflammatory protein", "PROTEIN", 1736, 1767], ["MPV", "PROTEIN", 1769, 1772], ["NF-\u03baB", "PROTEIN", 1814, 1819], ["nuclear factor \u03baB", "PROTEIN", 1821, 1838], ["NFAT", "PROTEIN", 1840, 1844], ["nuclear factor activated T cell; NK, natural killer", "PROTEIN", 1846, 1897], ["ORF", "DNA", 1899, 1902], ["open reading frame", "DNA", 1904, 1922], ["PKR", "PROTEIN", 1939, 1942], ["dsRNA-dependent protein kinase; R, receptor", "PROTEIN", 1944, 1987], ["RANTES", "PROTEIN", 1989, 1995], ["T cell", "CELL_TYPE", 2030, 2036], ["RCMV", "PROTEIN", 2061, 2065], ["RID", "PROTEIN", 2088, 2091], ["receptor internalization and degradation complex", "PROTEIN", 2093, 2141], ["SEMA", "PROTEIN", 2143, 2147], ["semaphorin", "PROTEIN", 2149, 2159], ["serpin", "PROTEIN", 2161, 2167], ["serine protease inhibitor", "PROTEIN", 2169, 2194], ["SeV", "PROTEIN", 2196, 2199], ["SPI", "PROTEIN", 2241, 2244], ["serine protein inhibitor", "PROTEIN", 2246, 2270], ["SPV", "PROTEIN", 2272, 2275], ["STAT", "PROTEIN", 2293, 2297], ["signal transducers and activators of transcription", "PROTEIN", 2299, 2349], ["SV", "PROTEIN", 2351, 2353], ["TAP", "PROTEIN", 2369, 2372], ["TAR", "PROTEIN", 2423, 2426], ["trans-acting response element", "PROTEIN", 2428, 2457], ["TNF", "PROTEIN", 2459, 2462], ["tumor necrosis factor", "PROTEIN", 2464, 2485], ["VEGF", "PROTEIN", 2548, 2552], ["vascular endothelial growth factor", "PROTEIN", 2554, 2588], ["Fc receptors1", "PROTEIN", 2668, 2681], ["Table 1", "PROTEIN", 2683, 2690], ["African", "SPECIES", 157, 164], ["swine fever virus", "SPECIES", 165, 182], ["bovine", "SPECIES", 189, 195], ["herpesvirus", "SPECIES", 196, 207], ["bovine", "SPECIES", 235, 241], ["papilloma virus", "SPECIES", 242, 257], ["capripox virus", "SPECIES", 265, 279], ["cowpox virus", "SPECIES", 434, 446], ["equine herpesvirus", "SPECIES", 630, 648], ["encephalomyocarditis virus", "SPECIES", 709, 735], ["hepatitis B virus", "SPECIES", 956, 973], ["human", "SPECIES", 981, 986], ["hepatitis C virus", "SPECIES", 1009, 1026], ["human", "SPECIES", 1033, 1038], ["herpesvirus", "SPECIES", 1039, 1050], ["HHV-8", "SPECIES", 1052, 1057], ["human", "SPECIES", 1059, 1064], ["herpesvirus", "SPECIES", 1065, 1076], ["Kaposi\u2019s-sarcoma-associated herpesvirus", "SPECIES", 1082, 1121], ["human", "SPECIES", 1129, 1134], ["parainfluenza virus", "SPECIES", 1135, 1154], ["human", "SPECIES", 1161, 1166], ["papilloma virus", "SPECIES", 1167, 1182], ["herpes simplex virus", "SPECIES", 1189, 1209], ["human", "SPECIES", 1217, 1222], ["herpesvirus saimiri", "SPECIES", 1251, 1270], ["murine", "SPECIES", 1511, 1517], ["murine", "SPECIES", 1551, 1557], ["Molluscum contagiosum virus", "SPECIES", 1580, 1607], ["measles virus", "SPECIES", 1614, 1627], ["murine", "SPECIES", 1703, 1709], ["murine", "SPECIES", 1774, 1780], ["polyoma virus", "SPECIES", 1781, 1794], ["rat", "SPECIES", 2067, 2070], ["Sendai virus", "SPECIES", 2201, 2213], ["simian virus", "SPECIES", 2355, 2367], ["vaccinia virus", "SPECIES", 2594, 2608], ["ASFV", "SPECIES", 151, 155], ["African swine fever virus", "SPECIES", 157, 182], ["BHV", "SPECIES", 184, 187], ["bovine herpesvirus", "SPECIES", 189, 207], ["bovine papilloma virus", "SPECIES", 235, 257], ["CPV", "SPECIES", 429, 432], ["cowpox virus", "SPECIES", 434, 446], ["Epstein\u2013Barr virus", "SPECIES", 575, 593], ["equine herpesvirus", "SPECIES", 630, 648], ["encephalomyocarditis virus", "SPECIES", 709, 735], ["HBV", "SPECIES", 951, 954], ["hepatitis B virus", "SPECIES", 956, 973], ["HCMV", "SPECIES", 975, 979], ["human cytomegalovirus", "SPECIES", 981, 1002], ["HCV", "SPECIES", 1004, 1007], ["hepatitis C virus", "SPECIES", 1009, 1026], ["HHV", "SPECIES", 1028, 1031], ["human herpesvirus; HHV-8", "SPECIES", 1033, 1057], ["human herpesvirus", "SPECIES", 1059, 1076], ["Kaposi\u2019s-sarcoma-associated herpesvirus", "SPECIES", 1082, 1121], ["HPIV", "SPECIES", 1123, 1127], ["human parainfluenza virus", "SPECIES", 1129, 1154], ["human papilloma virus", "SPECIES", 1161, 1182], ["HSV", "SPECIES", 1184, 1187], ["herpes simplex virus", "SPECIES", 1189, 1209], ["human T cell leukemia virus", "SPECIES", 1217, 1244], ["MCMV", "SPECIES", 1545, 1549], ["MCV", "SPECIES", 1575, 1578], ["Molluscum contagiosum virus", "SPECIES", 1580, 1607], ["measles virus", "SPECIES", 1614, 1627], ["MHV-68", "SPECIES", 1695, 1701], ["murine polyoma virus", "SPECIES", 1774, 1794], ["MV", "SPECIES", 1796, 1798], ["Sendai virus", "SPECIES", 2201, 2213], ["SFV", "SPECIES", 2215, 2218], ["Shope fibroma virus", "SPECIES", 2220, 2239], ["simian virus", "SPECIES", 2355, 2367], ["VV", "SPECIES", 2590, 2592], ["vaccinia virus", "SPECIES", 2594, 2608], ["Abbreviations", "TEST", 0, 13], ["Tables2", "TEST", 17, 24], ["oligoadenylate", "TEST", 36, 50], ["OA synthetase", "TEST", 65, 78], ["HSD", "TEST", 83, 86], ["hydroxysteroid dehydrogenase", "PROBLEM", 91, 119], ["AHV", "PROBLEM", 121, 124], ["alcelaphine herpesvirus", "PROBLEM", 126, 149], ["ASFV", "PROBLEM", 151, 155], ["African swine fever virus", "PROBLEM", 157, 182], ["BHV", "PROBLEM", 184, 187], ["bovine herpesvirus", "PROBLEM", 189, 207], ["BP", "TEST", 209, 211], ["binding protein", "TEST", 213, 228], ["BPV", "PROBLEM", 230, 233], ["bovine papilloma virus", "PROBLEM", 235, 257], ["CaPV", "TREATMENT", 259, 263], ["capripox virus", "TREATMENT", 265, 279], ["CCI", "PROBLEM", 281, 284], ["chemokine inhibitor", "TREATMENT", 286, 305], ["CCPH", "TEST", 307, 311], ["complement control protein homolog", "TEST", 313, 347], ["CK", "TEST", 349, 351], ["chemokine", "TEST", 353, 362], ["CKBP", "TEST", 364, 368], ["chemokine-binding protein", "TEST", 370, 395], ["CP", "PROBLEM", 397, 399], ["complement control protein", "TEST", 401, 427], ["CPV", "PROBLEM", 429, 432], ["cowpox virus", "PROBLEM", 434, 446], ["cytokine response modifier", "TEST", 453, 479], ["CSF, colony", "TEST", 481, 492], ["stimulating factor", "PROBLEM", 493, 511], ["dsRNA", "PROBLEM", 513, 518], ["double stranded RNA", "PROBLEM", 520, 539], ["EBV", "TEST", 547, 550], ["small RNA", "PROBLEM", 559, 568], ["EBV", "PROBLEM", 570, 573], ["Epstein\u2013Barr virus", "PROBLEM", 575, 593], ["epidermal growth factor", "PROBLEM", 600, 623], ["EHV", "PROBLEM", 625, 628], ["equine herpesvirus", "PROBLEM", 630, 648], ["eIF", "TEST", 650, 653], ["eukaryotic translation", "TREATMENT", 658, 680], ["factor", "TEST", 692, 698], ["EMCV", "PROBLEM", 703, 707], ["encephalomyocarditis virus", "PROBLEM", 709, 735], ["endoplasmic reticulum", "PROBLEM", 741, 762], ["ESPR", "PROBLEM", 764, 768], ["virus", "PROBLEM", 770, 775], ["semaphorin protein receptor", "TEST", 784, 811], ["ectromelia (mousepox) virus", "PROBLEM", 817, 844], ["FLICE inhibitory protein", "TEST", 852, 876], ["GF", "TEST", 878, 880], ["growth factor", "TEST", 882, 895], ["GM", "TEST", 897, 899], ["CSF", "TEST", 900, 903], ["granulocyte\u2013macrophage", "TEST", 905, 927], ["CSF", "TEST", 928, 931], ["gp", "TEST", 933, 935], ["glycoprotein", "TEST", 937, 949], ["HBV", "PROBLEM", 951, 954], ["hepatitis B virus", "PROBLEM", 956, 973], ["HCMV", "PROBLEM", 975, 979], ["human cytomegalovirus", "PROBLEM", 981, 1002], ["HCV", "PROBLEM", 1004, 1007], ["hepatitis C virus", "PROBLEM", 1009, 1026], ["HHV", "PROBLEM", 1028, 1031], ["human herpesvirus", "PROBLEM", 1033, 1050], ["HHV", "TEST", 1052, 1055], ["human herpesvirus", "PROBLEM", 1059, 1076], ["Kaposi\u2019s", "PROBLEM", 1082, 1090], ["sarcoma", "PROBLEM", 1091, 1098], ["associated herpesvirus", "PROBLEM", 1099, 1121], ["HPIV", "PROBLEM", 1123, 1127], ["human parainfluenza virus", "PROBLEM", 1129, 1154], ["HPV", "PROBLEM", 1156, 1159], ["human papilloma virus", "PROBLEM", 1161, 1182], ["HSV", "PROBLEM", 1184, 1187], ["herpes simplex virus", "PROBLEM", 1189, 1209], ["HTLV", "PROBLEM", 1211, 1215], ["human T cell leukemia virus", "PROBLEM", 1217, 1244], ["HVS", "PROBLEM", 1246, 1249], ["herpesvirus saimiri", "TREATMENT", 1251, 1270], ["IAP, inhibitor", "TREATMENT", 1294, 1308], ["apoptosis", "PROBLEM", 1312, 1321], ["ICP", "TEST", 1323, 1326], ["infected cell protein", "TREATMENT", 1328, 1349], ["IFN", "TREATMENT", 1351, 1354], ["interferon", "TREATMENT", 1356, 1366], ["Ig", "TREATMENT", 1368, 1370], ["immunoglobulin", "TREATMENT", 1372, 1386], ["IL", "TREATMENT", 1388, 1390], ["interleukin", "TREATMENT", 1392, 1403], ["IRF", "PROBLEM", 1405, 1408], ["interferon regulatory factor", "TEST", 1410, 1438], ["JAK, janus kinase", "TEST", 1440, 1457], ["LMP", "PROBLEM", 1459, 1462], ["latent membrane protein", "TEST", 1464, 1487], ["LT", "TEST", 1489, 1491], ["lymphotoxin", "TEST", 1493, 1504], ["MCK", "TEST", 1506, 1509], ["murine cytomegalovirus chemokine", "TEST", 1511, 1543], ["MCMV", "PROBLEM", 1545, 1549], ["murine cytomegalovirus", "PROBLEM", 1551, 1573], ["MCV", "TEST", 1575, 1578], ["Molluscum contagiosum virus", "PROBLEM", 1580, 1607], ["MeV", "PROBLEM", 1609, 1612], ["measles virus", "PROBLEM", 1614, 1627], ["MGF", "PROBLEM", 1629, 1632], ["myxoma growth factor", "PROBLEM", 1634, 1654], ["MHV", "TEST", 1695, 1698], ["murine gammaherpesvirus", "TEST", 1703, 1726], ["MIP", "TEST", 1731, 1734], ["macrophage inflammatory protein", "PROBLEM", 1736, 1767], ["MPV", "TEST", 1769, 1772], ["murine polyoma virus", "PROBLEM", 1774, 1794], ["MV", "TEST", 1796, 1798], ["myxoma virus", "PROBLEM", 1800, 1812], ["NF", "TEST", 1814, 1816], ["nuclear factor", "TEST", 1821, 1835], ["NFAT", "PROBLEM", 1840, 1844], ["nuclear factor activated T cell", "PROBLEM", 1846, 1877], ["NK", "PROBLEM", 1879, 1881], ["natural killer", "PROBLEM", 1883, 1897], ["ORF", "PROBLEM", 1899, 1902], ["open reading frame", "TEST", 1904, 1922], ["OV", "PROBLEM", 1924, 1926], ["Orf virus", "PROBLEM", 1928, 1937], ["PKR", "TEST", 1939, 1942], ["dsRNA", "TEST", 1944, 1949], ["dependent protein kinase", "PROBLEM", 1950, 1974], ["RANTES", "PROBLEM", 1989, 1995], ["RCMV", "PROBLEM", 2061, 2065], ["rat cytomegalovirus", "PROBLEM", 2067, 2086], ["RID, receptor internalization", "TREATMENT", 2088, 2117], ["degradation complex", "PROBLEM", 2122, 2141], ["semaphorin", "TREATMENT", 2149, 2159], ["serpin", "TREATMENT", 2161, 2167], ["serine protease inhibitor", "TREATMENT", 2169, 2194], ["SeV", "PROBLEM", 2196, 2199], ["Sendai virus", "PROBLEM", 2201, 2213], ["SFV", "PROBLEM", 2215, 2218], ["Shope fibroma virus", "PROBLEM", 2220, 2239], ["serine protein inhibitor", "TREATMENT", 2246, 2270], ["SPV, swinepox virus", "TREATMENT", 2272, 2291], ["activators of transcription", "TREATMENT", 2322, 2349], ["simian virus", "PROBLEM", 2355, 2367], ["TAP", "TREATMENT", 2369, 2372], ["antigen processing", "TREATMENT", 2403, 2421], ["TAR, trans-acting response element", "TREATMENT", 2423, 2457], ["TNF", "PROBLEM", 2459, 2462], ["tumor necrosis factor", "PROBLEM", 2464, 2485], ["TPV", "PROBLEM", 2487, 2490], ["Tanapox virus", "PROBLEM", 2492, 2505], ["viral", "PROBLEM", 2510, 2515], ["VaV", "PROBLEM", 2517, 2520], ["variola (smallpox) virus", "TREATMENT", 2522, 2546], ["VEGF", "PROBLEM", 2548, 2552], ["vascular endothelial growth factor", "PROBLEM", 2554, 2588], ["VV", "PROBLEM", 2590, 2592], ["vaccinia virus", "PROBLEM", 2594, 2608], ["humoral responsesLastly", "PROBLEM", 2623, 2646], ["cowpox virus", "OBSERVATION", 434, 446], ["small RNA", "ANATOMY", 559, 568], ["endoplasmic reticulum", "ANATOMY", 741, 762], ["hepatitis", "ANATOMY", 1009, 1018], ["sarcoma", "OBSERVATION", 1091, 1098], ["papilloma virus", "OBSERVATION", 1167, 1182], ["cell leukemia virus", "OBSERVATION", 1225, 1244], ["LT", "ANATOMY", 1489, 1491], ["lymphotoxin", "ANATOMY", 1493, 1504], ["macrophage", "ANATOMY", 1736, 1746], ["polyoma virus", "OBSERVATION", 1781, 1794], ["myxoma", "OBSERVATION", 1800, 1806], ["NFAT", "ANATOMY", 1840, 1844], ["SFV", "ANATOMY", 2215, 2218], ["SV", "ANATOMY", 2351, 2353], ["TNF", "ANATOMY", 2459, 2462], ["tumor necrosis", "OBSERVATION", 2464, 2478], ["VaV", "ANATOMY", 2517, 2520], ["vascular endothelial", "ANATOMY", 2554, 2574], ["vaccinia virus", "OBSERVATION", 2594, 2608], ["humoral", "ANATOMY", 2623, 2630]]], ["Antibodies bound to infected cells or virus particles might therefore be bound at the Fc region, thereby inhibiting Fc-dependent immune activation of complement and phagocytes.", [["cells", "ANATOMY", 29, 34], ["phagocytes", "ANATOMY", 165, 175], ["cells", "CELL", 29, 34], ["Fc", "GENE_OR_GENE_PRODUCT", 116, 118], ["complement", "GENE_OR_GENE_PRODUCT", 150, 160], ["phagocytes", "CELL", 165, 175], ["infected cells", "CELL_TYPE", 20, 34], ["Fc region", "PROTEIN", 86, 95], ["Fc", "PROTEIN", 116, 118], ["phagocytes", "CELL_TYPE", 165, 175], ["Antibodies bound", "PROBLEM", 0, 16], ["infected cells", "PROBLEM", 20, 34], ["virus particles", "PROBLEM", 38, 53], ["infected cells", "OBSERVATION", 20, 34]]], ["Fc receptors probably have additional functions in vivo4.Interference with interferonsInterferons (IFNs) were discovered because of their ability to protect cells from viral infection.", [["cells", "ANATOMY", 157, 162], ["viral infection", "DISEASE", 168, 183], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 0, 12], ["interferonsInterferons", "GENE_OR_GENE_PRODUCT", 75, 97], ["IFNs", "GENE_OR_GENE_PRODUCT", 99, 103], ["cells", "CELL", 157, 162], ["Fc receptors", "PROTEIN", 0, 12], ["interferonsInterferons", "PROTEIN", 75, 97], ["IFNs", "PROTEIN", 99, 103], ["interferonsInterferons (IFNs)", "TREATMENT", 75, 104], ["viral infection", "PROBLEM", 168, 183], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["infection", "OBSERVATION", 174, 183]]], ["The key role of both type I (\u03b1 and \u03b2) and type II (\u03b3) IFNs as one of the first anti-viral defense mechanisms is highlighted by the fact that anti-IFN strategies are present in most viruses (Table 2)5, 6, 7.", [["type I", "GENE_OR_GENE_PRODUCT", 21, 27], ["\u03b1", "GENE_OR_GENE_PRODUCT", 29, 30], ["\u03b2", "GENE_OR_GENE_PRODUCT", 35, 36], ["type II (\u03b3) IFNs", "GENE_OR_GENE_PRODUCT", 42, 58], ["anti-IFN", "GENE_OR_GENE_PRODUCT", 141, 149], ["type I (\u03b1 and \u03b2) and type II (\u03b3) IFNs", "PROTEIN", 21, 58], ["type II (\u03b3) IFNs", "PROBLEM", 42, 58], ["anti-IFN strategies", "TREATMENT", 141, 160]]], ["Viruses block IFN- induced transcriptional responses and the janus kinase (JAK)/signal transducers and activators of transcription (STAT) signal transduction pathways, and also inhibit the activation of IFN effector pathways that induce an anti-viral state in the cell and limit virus replication.", [["cell", "ANATOMY", 264, 268], ["IFN", "CHEMICAL", 14, 17], ["IFN", "GENE_OR_GENE_PRODUCT", 14, 17], ["janus kinase", "GENE_OR_GENE_PRODUCT", 61, 73], ["JAK", "GENE_OR_GENE_PRODUCT", 75, 78], ["signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 80, 130], ["STAT", "GENE_OR_GENE_PRODUCT", 132, 136], ["IFN", "GENE_OR_GENE_PRODUCT", 203, 206], ["cell", "CELL", 264, 268], ["IFN", "PROTEIN", 14, 17], ["janus kinase", "PROTEIN", 61, 73], ["JAK", "PROTEIN", 75, 78], ["signal transducers and activators of transcription", "PROTEIN", 80, 130], ["STAT", "PROTEIN", 132, 136], ["IFN", "PROTEIN", 203, 206], ["Viruses block IFN", "PROBLEM", 0, 17], ["the janus kinase", "TEST", 57, 73], ["signal transducers", "TEST", 80, 98], ["activators of transcription", "TREATMENT", 103, 130], ["IFN effector pathways", "PROBLEM", 203, 224], ["an anti-viral state in the cell", "PROBLEM", 237, 268]]], ["This is mainly achieved by inhibiting double-stranded (ds)-RNA-dependent protein kinase (PKR) activation, the phosphorylation of eukaryotic translation initiation factor-2\u03b1 (eIF-2\u03b1) and the RNase L system, which might degrade viral RNA and arrest translation in the host cell.Interference with interferonsPoxviruses encode soluble versions of receptors for IFN-\u03b1 and-\u03b2 (IFN-\u03b1/\u03b2R) and IFN-\u03b3 (IFN-\u03b3R), which also block the immune functions of IFNs6.", [["cell", "ANATOMY", 271, 275], ["RNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 59, 87], ["PKR", "GENE_OR_GENE_PRODUCT", 89, 92], ["eukaryotic translation initiation factor-2\u03b1", "GENE_OR_GENE_PRODUCT", 129, 172], ["eIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 174, 180], ["RNase L", "GENE_OR_GENE_PRODUCT", 190, 197], ["host cell", "CELL", 266, 275], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 357, 362], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 366, 368], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 370, 375], ["\u03b2R", "GENE_OR_GENE_PRODUCT", 376, 378], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 384, 389], ["IFN-\u03b3R", "GENE_OR_GENE_PRODUCT", 391, 397], ["IFNs6", "GENE_OR_GENE_PRODUCT", 441, 446], ["protein kinase", "PROTEIN", 73, 87], ["PKR", "PROTEIN", 89, 92], ["eukaryotic translation initiation factor-2\u03b1 (eIF-2\u03b1", "PROTEIN", 129, 180], ["RNase L", "PROTEIN", 190, 197], ["viral RNA", "RNA", 226, 235], ["host cell", "CELL_TYPE", 266, 275], ["interferons", "PROTEIN", 294, 305], ["IFN", "PROTEIN", 357, 360], ["\u03b1", "PROTEIN", 361, 362], ["\u03b2", "PROTEIN", 367, 368], ["IFN", "PROTEIN", 370, 373], ["\u03b1", "PROTEIN", 374, 375], ["\u03b2R", "PROTEIN", 376, 378], ["IFN", "PROTEIN", 384, 387], ["\u03b3", "PROTEIN", 388, 389], ["IFN", "PROTEIN", 391, 394], ["\u03b3R", "PROTEIN", 395, 397], ["IFNs6", "PROTEIN", 441, 446], ["RNA-dependent protein kinase", "TEST", 59, 87], ["eukaryotic translation initiation factor", "TEST", 129, 169], ["eIF", "TEST", 174, 177], ["the RNase L system", "TREATMENT", 186, 204], ["viral RNA", "PROBLEM", 226, 235], ["arrest translation in the host cell", "PROBLEM", 240, 275], ["interferonsPoxviruses", "TREATMENT", 294, 315], ["receptors", "TEST", 343, 352], ["IFN", "TEST", 357, 360], ["\u03b1", "TEST", 361, 362], ["IFN", "TEST", 370, 373], ["\u03b2R", "TEST", 376, 378], ["IFN", "TEST", 384, 387], ["IFN", "TEST", 391, 394], ["viral RNA", "OBSERVATION", 226, 235], ["host cell", "OBSERVATION", 266, 275]]], ["The VV-secreted IFN-\u03b1/\u03b2R is also localized at the cell surface to protect cells from IFN (Table 3).", [["cell surface", "ANATOMY", 50, 62], ["cells", "ANATOMY", 74, 79], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["\u03b2R", "GENE_OR_GENE_PRODUCT", 22, 24], ["cell surface", "CELLULAR_COMPONENT", 50, 62], ["cells", "CELL", 74, 79], ["IFN", "GENE_OR_GENE_PRODUCT", 85, 88], ["IFN", "PROTEIN", 16, 19], ["\u03b1", "PROTEIN", 20, 21], ["\u03b2R", "PROTEIN", 22, 24], ["IFN", "PROTEIN", 85, 88], ["VV", "SPECIES", 4, 6], ["The VV", "TEST", 0, 6], ["secreted IFN", "TEST", 7, 19]]], ["Additionally, several viruses inhibit the activity of IFN-\u03b3, a key activator of cellular immunity, by blocking the synthesis or activity of factors required for its production, such as interleukin (IL)-18 or IL-12 (Table 4): CPV cytokine response modifier (Crm)A inhibits caspase-1, which processes the mature forms of IL-1\u03b2 and IL-18 (2, 6); various poxviruses encode soluble IL-18-binding proteins (IL-18BPs)8, 9, 10; measles virus (MeV) binds CD46 in macrophages and inhibits IL-12 production1; and herpesviruses and poxviruses express IL-10 homologs that diminish the Th1 response by downregulating the production of IL-12 (1, 11, 12).Inhibition and modulation of cytokines and chemokinesCytokines play a key role in the initiation and regulation of the innate and adaptive immune responses, and viruses have learned how to block cytokine production, activity and signal transduction (Table 3, Table 4).", [["cellular", "ANATOMY", 80, 88], ["macrophages", "ANATOMY", 454, 465], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 54, 59], ["cellular", "CELL", 80, 88], ["interleukin (IL)-18", "GENE_OR_GENE_PRODUCT", 185, 204], ["IL-12", "GENE_OR_GENE_PRODUCT", 208, 213], ["CPV", "ORGANISM", 225, 228], ["Crm)A", "SIMPLE_CHEMICAL", 257, 262], ["caspase-1", "GENE_OR_GENE_PRODUCT", 272, 281], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 319, 324], ["IL-18", "GENE_OR_GENE_PRODUCT", 329, 334], ["2", "GENE_OR_GENE_PRODUCT", 336, 337], ["poxviruses", "ORGANISM", 351, 361], ["IL-18-binding proteins", "GENE_OR_GENE_PRODUCT", 377, 399], ["IL-18BPs", "GENE_OR_GENE_PRODUCT", 401, 409], ["10", "GENE_OR_GENE_PRODUCT", 416, 418], ["measles virus", "ORGANISM", 420, 433], ["CD46", "GENE_OR_GENE_PRODUCT", 446, 450], ["macrophages", "CELL", 454, 465], ["IL-12", "GENE_OR_GENE_PRODUCT", 479, 484], ["herpesviruses", "ORGANISM", 502, 515], ["poxviruses", "ORGANISM", 520, 530], ["IL-10", "GENE_OR_GENE_PRODUCT", 539, 544], ["IL-12", "GENE_OR_GENE_PRODUCT", 621, 626], ["IFN", "PROTEIN", 54, 57], ["\u03b3", "PROTEIN", 58, 59], ["interleukin (IL)-18", "PROTEIN", 185, 204], ["IL-12", "PROTEIN", 208, 213], ["CPV cytokine response modifier (Crm)A", "PROTEIN", 225, 262], ["caspase-1", "PROTEIN", 272, 281], ["IL-1\u03b2", "PROTEIN", 319, 324], ["IL-18-binding proteins (IL-18BPs)8, 9, 10", "PROTEIN", 377, 418], ["CD46", "PROTEIN", 446, 450], ["macrophages", "CELL_TYPE", 454, 465], ["IL-12 production1", "PROTEIN", 479, 496], ["IL-10 homologs", "PROTEIN", 539, 553], ["IL", "PROTEIN", 621, 623], ["cytokines", "PROTEIN", 668, 677], ["chemokines", "PROTEIN", 682, 692], ["Cytokines", "PROTEIN", 692, 701], ["cytokine", "PROTEIN", 834, 842], ["measles virus", "SPECIES", 420, 433], ["CPV", "SPECIES", 225, 228], ["measles virus", "SPECIES", 420, 433], ["several viruses", "PROBLEM", 14, 29], ["IFN", "TEST", 54, 57], ["interleukin (IL)", "TREATMENT", 185, 201], ["CPV cytokine response modifier (Crm)A inhibits caspase", "TREATMENT", 225, 279], ["IL", "TEST", 319, 321], ["IL", "TEST", 329, 331], ["soluble IL", "TEST", 369, 379], ["binding proteins", "TEST", 383, 399], ["IL", "TEST", 401, 403], ["measles virus", "PROBLEM", 420, 433], ["macrophages", "TEST", 454, 465], ["IL", "TEST", 479, 481], ["herpesviruses", "PROBLEM", 502, 515], ["poxviruses express IL", "TREATMENT", 520, 541], ["Inhibition", "TREATMENT", 639, 649], ["cytokines", "TREATMENT", 668, 677], ["chemokines", "TREATMENT", 682, 692], ["Cytokines", "TREATMENT", 692, 701], ["viruses", "PROBLEM", 800, 807], ["block cytokine production", "PROBLEM", 828, 853], ["signal transduction", "TEST", 868, 887], ["several", "OBSERVATION_MODIFIER", 14, 21], ["viruses", "OBSERVATION", 22, 29], ["activity", "OBSERVATION_MODIFIER", 42, 50], ["macrophages", "ANATOMY", 454, 465]]], ["African swine fever virus (ASFV) replicates in macrophages and encodes an I\u03baB homolog that blocks cytokine expression mediated by nuclear factor (NF)-\u03baB and the nuclear factor activated T cell (NFAT) transcription factors13.", [["macrophages", "ANATOMY", 47, 58], ["swine fever", "DISEASE", 8, 19], ["African swine fever virus", "ORGANISM", 0, 25], ["ASFV", "ORGANISM", 27, 31], ["macrophages", "CELL", 47, 58], ["I\u03baB homolog", "GENE_OR_GENE_PRODUCT", 74, 85], ["nuclear factor (NF)-\u03baB", "GENE_OR_GENE_PRODUCT", 130, 152], ["nuclear factor activated T cell", "GENE_OR_GENE_PRODUCT", 161, 192], ["NFAT", "GENE_OR_GENE_PRODUCT", 194, 198], ["macrophages", "CELL_TYPE", 47, 58], ["I\u03baB homolog", "PROTEIN", 74, 85], ["cytokine", "PROTEIN", 98, 106], ["nuclear factor (NF)-\u03baB", "PROTEIN", 130, 152], ["nuclear factor activated T cell (NFAT) transcription factors13", "PROTEIN", 161, 223], ["African swine fever virus", "SPECIES", 0, 25], ["African swine fever virus", "SPECIES", 0, 25], ["ASFV", "SPECIES", 27, 31], ["African swine fever virus (ASFV", "PROBLEM", 0, 31], ["an I\u03baB homolog", "TREATMENT", 71, 85], ["nuclear factor", "TEST", 130, 144], ["transcription factors", "TEST", 200, 221]]], ["Many viruses block signal tranduction by ligands of the tumor necrosis factor (TNF) family, whereas others deliberately induce some cytokine pathways; for example, the Epstein\u2013Barr virus (EBV) latent membrane protein 1 (LMP1) recruits components of the TNF receptor (TNFR) and CD40 transduction machinery to mimic cytokine responses that could be beneficial for the virus, such as cell proliferation14 (Table 4).Inhibition and modulation of cytokines and chemokinesOne of the most interesting mechanisms identified in recent years is the mimicry of cytokines (virokines) and cytokine receptors (viroceptors) by large DNA viruses (herpesviruses and poxviruses)1, 2, 11, 15, 16 (Table 3).", [["cell", "ANATOMY", 381, 385], ["tumor", "DISEASE", 56, 61], ["necrosis", "DISEASE", 62, 70], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 56, 77], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["Epstein\u2013Barr virus", "ORGANISM", 168, 186], ["EBV", "ORGANISM", 188, 191], ["latent membrane protein 1", "GENE_OR_GENE_PRODUCT", 193, 218], ["LMP1", "GENE_OR_GENE_PRODUCT", 220, 224], ["TNF receptor", "GENE_OR_GENE_PRODUCT", 253, 265], ["TNFR", "GENE_OR_GENE_PRODUCT", 267, 271], ["CD40", "GENE_OR_GENE_PRODUCT", 277, 281], ["cell", "CELL", 381, 385], ["virokines", "GENE_OR_GENE_PRODUCT", 560, 569], ["viroceptors", "GENE_OR_GENE_PRODUCT", 595, 606], ["DNA", "CELLULAR_COMPONENT", 617, 620], ["tumor necrosis factor (TNF) family", "PROTEIN", 56, 90], ["cytokine", "PROTEIN", 132, 140], ["Epstein\u2013Barr virus (EBV) latent membrane protein 1", "PROTEIN", 168, 218], ["LMP1", "PROTEIN", 220, 224], ["TNF receptor", "PROTEIN", 253, 265], ["TNFR", "PROTEIN", 267, 271], ["CD40", "PROTEIN", 277, 281], ["cytokine", "PROTEIN", 314, 322], ["cytokines", "PROTEIN", 441, 450], ["chemokines", "PROTEIN", 455, 465], ["cytokines", "PROTEIN", 549, 558], ["virokines", "PROTEIN", 560, 569], ["cytokine receptors", "PROTEIN", 575, 593], ["viroceptors", "PROTEIN", 595, 606], ["Epstein\u2013Barr virus", "SPECIES", 168, 186], ["EBV", "SPECIES", 188, 191], ["Many viruses block signal tranduction", "PROBLEM", 0, 37], ["the tumor necrosis factor", "PROBLEM", 52, 77], ["some cytokine pathways", "PROBLEM", 127, 149], ["the Epstein\u2013Barr virus", "TEST", 164, 186], ["latent membrane protein", "TEST", 193, 216], ["the TNF receptor (TNFR)", "TREATMENT", 249, 272], ["CD40 transduction machinery", "TREATMENT", 277, 304], ["the virus", "PROBLEM", 362, 371], ["Inhibition", "TREATMENT", 412, 422], ["cytokines", "TREATMENT", 441, 450], ["chemokines", "TREATMENT", 455, 465], ["cytokines (virokines)", "TREATMENT", 549, 570], ["cytokine receptors (viroceptors)", "TREATMENT", 575, 607], ["large DNA viruses", "PROBLEM", 611, 628], ["viruses", "OBSERVATION", 5, 12], ["tumor", "OBSERVATION_MODIFIER", 56, 61], ["necrosis", "OBSERVATION", 62, 70], ["most interesting", "OBSERVATION_MODIFIER", 476, 492], ["large", "OBSERVATION_MODIFIER", 611, 616], ["DNA viruses", "OBSERVATION", 617, 628]]], ["The functions of these molecules in the animal host are diverse.", [["diverse", "OBSERVATION_MODIFIER", 56, 63]]], ["Soluble viral cytokine receptors might neutralize cytokine activity and cytokine homologs might redirect the immune response for the benefit of the virus.", [["Soluble viral cytokine receptors", "PROTEIN", 0, 32], ["cytokine", "PROTEIN", 50, 58], ["cytokine homologs", "PROTEIN", 72, 89], ["Soluble viral cytokine receptors", "TREATMENT", 0, 32], ["cytokine activity", "TREATMENT", 50, 67], ["cytokine homologs", "TREATMENT", 72, 89], ["the virus", "PROBLEM", 144, 153]]], ["Alternatively, viruses that infect immune cells might use these homologs to induce signaling pathways in the infected cell that promote virus replication.Inhibition and modulation of cytokines and chemokinesThe herpesvirus cytokine homologs vIL-6 and vIL-17 might have immunomodulatory activity but might also increase proliferation of cells that are targets for viral replication1, 11.", [["immune cells", "ANATOMY", 35, 47], ["cell", "ANATOMY", 118, 122], ["cells", "ANATOMY", 336, 341], ["immune cells", "CELL", 35, 47], ["cell", "CELL", 118, 122], ["herpesvirus", "ORGANISM", 211, 222], ["vIL-6", "GENE_OR_GENE_PRODUCT", 241, 246], ["vIL-17", "GENE_OR_GENE_PRODUCT", 251, 257], ["cells", "CELL", 336, 341], ["immune cells", "CELL_TYPE", 35, 47], ["cytokines", "PROTEIN", 183, 192], ["chemokines", "PROTEIN", 197, 207], ["herpesvirus cytokine homologs", "PROTEIN", 211, 240], ["vIL-6", "PROTEIN", 241, 246], ["vIL-17", "PROTEIN", 251, 257], ["viruses", "PROBLEM", 15, 22], ["infect immune cells", "PROBLEM", 28, 47], ["these homologs", "TREATMENT", 58, 72], ["signaling pathways", "PROBLEM", 83, 101], ["the infected cell", "PROBLEM", 105, 122], ["virus replication", "TREATMENT", 136, 153], ["Inhibition", "TREATMENT", 154, 164], ["cytokines", "TREATMENT", 183, 192], ["chemokines", "TREATMENT", 197, 207], ["The herpesvirus cytokine homologs", "TEST", 207, 240], ["vIL", "TEST", 241, 244], ["vIL", "TEST", 251, 254], ["immunomodulatory activity", "PROBLEM", 269, 294], ["proliferation of cells", "PROBLEM", 319, 341], ["viral replication1", "TEST", 363, 381], ["infected cell", "OBSERVATION", 109, 122], ["increase", "OBSERVATION_MODIFIER", 310, 318], ["proliferation", "OBSERVATION", 319, 332]]], ["Viral semaphorin homologs have uncovered a role for the semaphorin family\u2013 previously known as chemoattractants or chemorepellents involved in axonal guidance during development\u2013 in the immune system, and have identified a semaphorin receptor in macrophages that mediates cytokine production17.Inhibition and modulation of cytokines and chemokinesSecreted cytokine receptors or binding proteins are mainly encoded by poxviruses2, 6, 11, 15, 18.", [["axonal", "ANATOMY", 143, 149], ["immune system", "ANATOMY", 186, 199], ["macrophages", "ANATOMY", 246, 257], ["semaphorin", "GENE_OR_GENE_PRODUCT", 6, 16], ["semaphorin", "GENE_OR_GENE_PRODUCT", 56, 66], ["immune system", "ANATOMICAL_SYSTEM", 186, 199], ["semaphorin receptor", "GENE_OR_GENE_PRODUCT", 223, 242], ["macrophages", "CELL", 246, 257], ["poxviruses2", "GENE_OR_GENE_PRODUCT", 417, 428], ["Viral semaphorin homologs", "PROTEIN", 0, 25], ["semaphorin family\u2013", "PROTEIN", 56, 74], ["chemoattractants", "PROTEIN", 95, 111], ["chemorepellents", "PROTEIN", 115, 130], ["semaphorin receptor", "PROTEIN", 223, 242], ["macrophages", "CELL_TYPE", 246, 257], ["cytokine", "PROTEIN", 272, 280], ["cytokines", "PROTEIN", 323, 332], ["chemokines", "PROTEIN", 337, 347], ["cytokine receptors", "PROTEIN", 356, 374], ["binding proteins", "PROTEIN", 378, 394], ["poxviruses2, 6, 11, 15, 18", "PROTEIN", 417, 443], ["Viral semaphorin homologs", "TREATMENT", 0, 25], ["the semaphorin family\u2013", "TREATMENT", 52, 74], ["a semaphorin receptor in macrophages", "TREATMENT", 221, 257], ["Inhibition", "TREATMENT", 294, 304], ["modulation of cytokines", "TREATMENT", 309, 332], ["chemokinesSecreted cytokine receptors", "TREATMENT", 337, 374], ["binding proteins", "PROBLEM", 378, 394]]], ["These proteins were originally identified as homologs of host TNFRs, IL-1Rs and IFN-\u03b3Rs.", [["TNFRs", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-1Rs", "GENE_OR_GENE_PRODUCT", 69, 75], ["IFN-\u03b3Rs", "GENE_OR_GENE_PRODUCT", 80, 87], ["host TNFRs, IL-1Rs and IFN-\u03b3Rs", "PROTEIN", 57, 87], ["These proteins", "TEST", 0, 14], ["IL", "TREATMENT", 69, 71]]], ["The discovery of four distinct soluble poxvirus TNFRs, and a membrane TNF-binding activity in VV infections, is remarkable and suggests that viral TNFRs might have additional functions18, 19, 20 (M. Saraiva and A. Alcami, unpublished).", [["membrane", "ANATOMY", 61, 69], ["infections", "DISEASE", 97, 107], ["poxvirus", "ORGANISM", 39, 47], ["TNFRs", "GENE_OR_GENE_PRODUCT", 48, 53], ["membrane", "CELLULAR_COMPONENT", 61, 69], ["TNF", "GENE_OR_GENE_PRODUCT", 70, 73], ["VV", "ORGANISM", 94, 96], ["TNFRs", "GENE_OR_GENE_PRODUCT", 147, 152], ["poxvirus TNFRs", "PROTEIN", 39, 53], ["TNF", "PROTEIN", 70, 73], ["viral TNFRs", "PROTEIN", 141, 152], ["VV", "SPECIES", 94, 96], ["four distinct soluble poxvirus TNFRs", "TREATMENT", 17, 53], ["a membrane TNF", "TEST", 59, 73], ["VV infections", "PROBLEM", 94, 107], ["viral TNFRs", "PROBLEM", 141, 152], ["four distinct", "OBSERVATION_MODIFIER", 17, 30], ["soluble", "OBSERVATION_MODIFIER", 31, 38], ["poxvirus", "OBSERVATION", 39, 47], ["infections", "OBSERVATION", 97, 107]]], ["Binding and activity assays have identified secreted proteins that bind IFN-\u03b1 and-\u03b2, chemokines (CKs) or granuloctye\u2013macrophage colony-stimulating factor (GM-CSF) and IL-2, and that have no sequence similarity to cellular counterparts6, 18, 21.", [["cellular", "ANATOMY", 213, 221], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 83], ["CKs", "GENE_OR_GENE_PRODUCT", 97, 100], ["granuloctye\u2013macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 105, 153], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 155, 161], ["IL-2", "GENE_OR_GENE_PRODUCT", 167, 171], ["cellular", "CELL", 213, 221], ["secreted proteins", "PROTEIN", 44, 61], ["IFN", "PROTEIN", 72, 75], ["\u03b1", "PROTEIN", 76, 77], ["\u03b2", "PROTEIN", 82, 83], ["chemokines", "PROTEIN", 85, 95], ["CKs", "PROTEIN", 97, 100], ["granuloctye\u2013macrophage colony-stimulating factor", "PROTEIN", 105, 153], ["GM", "PROTEIN", 155, 157], ["CSF", "PROTEIN", 158, 161], ["IL", "PROTEIN", 167, 169], ["Binding and activity assays", "TEST", 0, 27], ["secreted proteins", "TEST", 44, 61], ["IFN", "TEST", 72, 75], ["\u03b1", "TEST", 76, 77], ["chemokines", "TEST", 85, 95], ["CKs", "TEST", 97, 100], ["granuloctye\u2013macrophage colony", "PROBLEM", 105, 134], ["stimulating factor", "PROBLEM", 135, 153], ["IL", "TEST", 167, 169], ["cellular counterparts6", "TEST", 213, 235]]], ["In poxviruses, three distinct secreted IL-18BPs that have recently been identified are homologs of human and mouse secreted IL-18BPs but not of membrane IL-18Rs8, 9, 10.", [["membrane", "ANATOMY", 144, 152], ["IL-18BPs", "GENE_OR_GENE_PRODUCT", 39, 47], ["human", "ORGANISM", 99, 104], ["mouse", "ORGANISM", 109, 114], ["IL-18BPs", "GENE_OR_GENE_PRODUCT", 124, 132], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["IL-18Rs8", "GENE_OR_GENE_PRODUCT", 153, 161], ["IL", "PROTEIN", 39, 41], ["18BPs", "PROTEIN", 42, 47], ["IL", "PROTEIN", 124, 126], ["18BPs", "PROTEIN", 127, 132], ["membrane IL-18Rs8, 9, 10", "PROTEIN", 144, 168], ["human", "SPECIES", 99, 104], ["mouse", "SPECIES", 109, 114], ["human", "SPECIES", 99, 104], ["mouse", "SPECIES", 109, 114], ["membrane IL", "TEST", 144, 155], ["distinct", "OBSERVATION_MODIFIER", 21, 29], ["secreted", "OBSERVATION_MODIFIER", 30, 38], ["IL", "OBSERVATION_MODIFIER", 39, 41]]], ["Inactivation of poxvirus cytokine receptor genes results in virus attenuation in vivo but, interestingly, deletion of the VV IL-1\u03b2R enhances virus virulence and the onset of fever, suggesting that the purpose of some immune-evasion mechanisms is to reduce the immunopathology caused by viral infection18.Inhibition and modulation of cytokines and chemokinesHerpesviruses and poxviruses modulate the activity of chemoattractant cytokines or CKs that regulate leukocyte trafficking to sites of infection16, 18, 22.", [["leukocyte", "ANATOMY", 458, 467], ["sites", "ANATOMY", 483, 488], ["fever", "DISEASE", 174, 179], ["immunopathology", "DISEASE", 260, 275], ["viral infection", "DISEASE", 286, 301], ["poxvirus cytokine receptor", "GENE_OR_GENE_PRODUCT", 16, 42], ["IL-1", "GENE_OR_GENE_PRODUCT", 125, 129], ["R", "GENE_OR_GENE_PRODUCT", 130, 131], ["Herpesviruses", "GENE_OR_GENE_PRODUCT", 357, 370], ["CKs", "GENE_OR_GENE_PRODUCT", 440, 443], ["leukocyte", "CELL", 458, 467], ["poxvirus cytokine receptor genes", "DNA", 16, 48], ["VV IL-1\u03b2", "DNA", 122, 130], ["cytokines", "PROTEIN", 333, 342], ["chemokines", "PROTEIN", 347, 357], ["chemoattractant cytokines", "PROTEIN", 411, 436], ["CKs", "PROTEIN", 440, 443], ["VV", "SPECIES", 122, 124], ["poxvirus cytokine receptor genes", "TREATMENT", 16, 48], ["virus attenuation", "PROBLEM", 60, 77], ["R enhances virus virulence", "PROBLEM", 130, 156], ["fever", "PROBLEM", 174, 179], ["the immunopathology", "PROBLEM", 256, 275], ["viral infection", "PROBLEM", 286, 301], ["Inhibition", "TREATMENT", 304, 314], ["cytokines", "TREATMENT", 333, 342], ["chemokinesHerpesviruses", "TREATMENT", 347, 370], ["poxviruses", "TREATMENT", 375, 385], ["chemoattractant cytokines", "TEST", 411, 436], ["CKs", "TEST", 440, 443], ["leukocyte trafficking", "TEST", 458, 479], ["infection16", "PROBLEM", 492, 503], ["virus virulence", "OBSERVATION", 141, 156], ["fever", "OBSERVATION", 174, 179], ["viral", "OBSERVATION_MODIFIER", 286, 291], ["infection", "OBSERVATION", 292, 301], ["cytokines", "OBSERVATION", 333, 342], ["chemokinesHerpesviruses", "OBSERVATION", 347, 370]]], ["Virus-encoded CKs are either antagonists that block leukocyte recruitment to sites of infection, or agonists that could enhance the recruitment of cells that support viral replication or prevent Th1 anti-viral responses.", [["leukocyte", "ANATOMY", 52, 61], ["sites", "ANATOMY", 77, 82], ["cells", "ANATOMY", 147, 152], ["infection", "DISEASE", 86, 95], ["Virus", "ORGANISM", 0, 5], ["CKs", "GENE_OR_GENE_PRODUCT", 14, 17], ["leukocyte", "CELL", 52, 61], ["cells", "CELL", 147, 152], ["Th1", "GENE_OR_GENE_PRODUCT", 195, 198], ["CKs", "PROTEIN", 14, 17], ["Virus", "PROBLEM", 0, 5], ["encoded CKs", "TEST", 6, 17], ["antagonists", "TREATMENT", 29, 40], ["block leukocyte recruitment", "TREATMENT", 46, 73], ["infection", "PROBLEM", 86, 95], ["agonists", "PROBLEM", 100, 108], ["the recruitment of cells", "PROBLEM", 128, 152], ["viral replication", "TREATMENT", 166, 183], ["infection", "OBSERVATION", 86, 95]]], ["Murine cytomegalovirus (MCMV) chemokine 1 (MCK-1) activates monocytes in vitro and increases monocyte-associated viremia in vivo23.", [["monocytes", "ANATOMY", 60, 69], ["monocyte", "ANATOMY", 93, 101], ["viremia", "DISEASE", 113, 120], ["Murine cytomegalovirus", "ORGANISM", 0, 22], ["MCMV) chemokine 1", "GENE_OR_GENE_PRODUCT", 24, 41], ["MCK-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["monocytes", "CELL", 60, 69], ["monocyte", "CELL", 93, 101], ["Murine cytomegalovirus (MCMV) chemokine 1 (MCK-1", "PROTEIN", 0, 48], ["monocytes", "CELL_TYPE", 60, 69], ["Murine", "SPECIES", 0, 6], ["Murine cytomegalovirus", "SPECIES", 0, 22], ["MCMV", "SPECIES", 24, 28], ["Murine cytomegalovirus", "TEST", 0, 22], ["chemokine", "TEST", 30, 39], ["MCK", "TEST", 43, 46], ["monocytes", "TEST", 60, 69], ["vitro", "TEST", 73, 78], ["monocyte", "TEST", 93, 101], ["viremia in vivo23", "PROBLEM", 113, 130], ["cytomegalovirus", "OBSERVATION", 7, 22], ["increases monocyte", "OBSERVATION", 83, 101], ["viremia", "OBSERVATION", 113, 120]]], ["HIV Tat is partially homologous to CKs and is a potent monocyte chemoattractant24.", [["monocyte", "ANATOMY", 55, 63], ["HIV", "DISEASE", 0, 3], ["Tat", "GENE_OR_GENE_PRODUCT", 4, 7], ["CKs", "GENE_OR_GENE_PRODUCT", 35, 38], ["monocyte", "CELL", 55, 63], ["Tat", "PROTEIN", 4, 7], ["CKs", "PROTEIN", 35, 38], ["monocyte chemoattractant24", "PROTEIN", 55, 81], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["CKs", "TEST", 35, 38], ["a potent monocyte chemoattractant24", "TREATMENT", 46, 81]]], ["Herpesviruses encode many CK receptors (vCKRs) but their function is not clear.", [["CK receptors", "GENE_OR_GENE_PRODUCT", 26, 38], ["vCKRs", "GENE_OR_GENE_PRODUCT", 40, 45], ["Herpesviruses", "PROTEIN", 0, 13], ["CK receptors", "PROTEIN", 26, 38], ["vCKRs", "PROTEIN", 40, 45], ["Herpesviruses encode many CK receptors", "PROBLEM", 0, 38], ["vCKRs", "TEST", 40, 45], ["not", "UNCERTAINTY", 69, 72], ["clear", "OBSERVATION", 73, 78]]], ["Kaposi\u2019s-sarcoma-associated virus [human herpesvirus 8 (HHV-8)] open reading frame (ORF) 74 is constitutively activated and induces cell proliferation, which might favor virus replication. vCKRs encoded by HCMV and HHV-6 reduce the amount of the factor regulated upon activation normal T-cell expressed and secreted (RANTES) in tissue culture and/or its transcription and might inhibit CK activity locally16, 25.", [["cell", "ANATOMY", 132, 136], ["T-cell", "ANATOMY", 286, 292], ["tissue culture", "ANATOMY", 328, 342], ["Kaposi\u2019s-sarcoma", "DISEASE", 0, 16], ["Kaposi\u2019s-sarcoma-associated virus", "ORGANISM", 0, 33], ["human herpesvirus 8", "ORGANISM", 35, 54], ["HHV-8", "ORGANISM", 56, 61], ["cell", "CELL", 132, 136], ["vCKRs", "GENE_OR_GENE_PRODUCT", 189, 194], ["HCMV", "ORGANISM", 206, 210], ["HHV-6", "ORGANISM", 215, 220], ["T-cell", "CELL", 286, 292], ["RANTES", "GENE_OR_GENE_PRODUCT", 317, 323], ["tissue culture", "CELL", 328, 342], ["CK", "GENE_OR_GENE_PRODUCT", 386, 388], ["open reading frame (ORF) 74", "DNA", 64, 91], ["vCKRs", "PROTEIN", 189, 194], ["HCMV and HHV-6", "PROTEIN", 206, 220], ["RANTES", "PROTEIN", 317, 323], ["CK", "PROTEIN", 386, 388], ["Kaposi\u2019s-sarcoma-associated virus", "SPECIES", 0, 33], ["human", "SPECIES", 35, 40], ["herpesvirus", "SPECIES", 41, 52], ["Kaposi\u2019s-sarcoma-associated virus", "SPECIES", 0, 33], ["human herpesvirus 8 (HHV-8", "SPECIES", 35, 61], ["HCMV", "SPECIES", 206, 210], ["Kaposi\u2019s", "TEST", 0, 8], ["sarcoma", "PROBLEM", 9, 16], ["associated virus", "PROBLEM", 17, 33], ["human herpesvirus", "TEST", 35, 52], ["HHV", "TEST", 56, 59], ["open reading frame", "TEST", 64, 82], ["cell proliferation", "PROBLEM", 132, 150], ["virus replication", "PROBLEM", 170, 187], ["vCKRs", "TEST", 189, 194], ["HCMV", "TEST", 206, 210], ["HHV", "TEST", 215, 218], ["the factor", "PROBLEM", 242, 252], ["tissue culture", "TEST", 328, 342], ["CK activity", "TEST", 386, 397], ["sarcoma", "OBSERVATION", 9, 16], ["cell proliferation", "OBSERVATION", 132, 150], ["HCMV", "OBSERVATION", 206, 210]]], ["A role for vCKRs in vivo has been shown for MCMV. vCKs and vCKRs might contribute directly to pathology.", [["vCKRs", "GENE_OR_GENE_PRODUCT", 11, 16], ["MCMV", "ORGANISM", 44, 48], ["vCKs", "GENE_OR_GENE_PRODUCT", 50, 54], ["vCKRs", "GENE_OR_GENE_PRODUCT", 59, 64], ["vCKRs", "PROTEIN", 11, 16], ["vCKs", "PROTEIN", 50, 54], ["vCKRs", "PROTEIN", 59, 64], ["MCMV", "SPECIES", 44, 48], ["vCKRs in vivo", "TREATMENT", 11, 24], ["MCMV", "PROBLEM", 44, 48], ["vCKs", "TEST", 50, 54], ["vCKRs", "TEST", 59, 64]]], ["The angiogenic properties of HHV-8 macrophage inflammatory protein 1 (vMIP-1) could account for the increased vascularization found in HHV-8-associated tumors, human cytomegalovirus (HCMV) US28 mediates vascular smooth muscle cell migration and perhaps vascular disease26, and expression of HHV-8 ORF74 in transgenic mice results in Kaposi\u2019s-sarcoma-like lesions27.Inhibition and modulation of cytokines and chemokinesThree soluble vCKBPs have been identified that have no sequence similarity to cellular CKRs2, 15, 16, 18. vCKBP-I is a soluble IFN-\u03b3R encoded by MV, but not VV, which binds the heparin-binding domain of a wide range of CKs and might prevent the correct localization of CKs in vivo by blocking their interaction with proteoglycans.", [["tumors", "ANATOMY", 152, 158], ["vascular smooth muscle cell", "ANATOMY", 203, 230], ["vascular", "ANATOMY", 253, 261], ["Kaposi\u2019s-sarcoma-like lesions27", "ANATOMY", 333, 364], ["cellular", "ANATOMY", 496, 504], ["tumors", "DISEASE", 152, 158], ["Kaposi\u2019s-sarcoma", "DISEASE", 333, 349], ["heparin", "CHEMICAL", 595, 602], ["HHV-8 macrophage inflammatory protein 1", "GENE_OR_GENE_PRODUCT", 29, 68], ["vMIP-1", "GENE_OR_GENE_PRODUCT", 70, 76], ["HHV-8", "ORGANISM", 135, 140], ["tumors", "CANCER", 152, 158], ["human cytomegalovirus", "ORGANISM", 160, 181], ["HCMV", "ORGANISM", 183, 187], ["US28", "CELL", 189, 193], ["vascular smooth muscle cell", "CELL", 203, 230], ["vascular", "MULTI-TISSUE_STRUCTURE", 253, 261], ["HHV-8", "GENE_OR_GENE_PRODUCT", 291, 296], ["ORF74", "GENE_OR_GENE_PRODUCT", 297, 302], ["transgenic mice", "ORGANISM", 306, 321], ["Kaposi\u2019s-sarcoma-like lesions27", "CANCER", 333, 364], ["vCKBPs", "GENE_OR_GENE_PRODUCT", 432, 438], ["cellular", "CELL", 496, 504], ["vCKBP-I", "GENE_OR_GENE_PRODUCT", 524, 531], ["IFN-\u03b3R", "GENE_OR_GENE_PRODUCT", 545, 551], ["MV", "ORGANISM", 563, 565], ["VV", "ORGANISM", 575, 577], ["heparin", "SIMPLE_CHEMICAL", 595, 602], ["CKs", "GENE_OR_GENE_PRODUCT", 637, 640], ["CKs", "GENE_OR_GENE_PRODUCT", 687, 690], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 734, 747], ["macrophage inflammatory protein 1", "PROTEIN", 35, 68], ["vMIP-1", "PROTEIN", 70, 76], ["vascular smooth muscle cell", "CELL_TYPE", 203, 230], ["HHV", "PROTEIN", 291, 294], ["ORF74", "PROTEIN", 297, 302], ["cytokines", "PROTEIN", 394, 403], ["chemokines", "PROTEIN", 408, 418], ["vCKBPs", "PROTEIN", 432, 438], ["cellular CKRs2, 15, 16, 18", "PROTEIN", 496, 522], ["vCKBP", "PROTEIN", 524, 529], ["IFN", "PROTEIN", 545, 548], ["heparin-binding domain", "PROTEIN", 595, 617], ["CKs", "PROTEIN", 637, 640], ["CKs", "PROTEIN", 687, 690], ["human", "SPECIES", 160, 165], ["mice", "SPECIES", 317, 321], ["HHV-8", "SPECIES", 135, 140], ["human cytomegalovirus", "SPECIES", 160, 181], ["HCMV", "SPECIES", 183, 187], ["mice", "SPECIES", 317, 321], ["MV", "SPECIES", 563, 565], ["VV", "SPECIES", 575, 577], ["HHV", "TEST", 29, 32], ["macrophage inflammatory protein", "TEST", 35, 66], ["vMIP", "TEST", 70, 74], ["the increased vascularization", "PROBLEM", 96, 125], ["HHV", "TEST", 135, 138], ["associated tumors", "PROBLEM", 141, 158], ["human cytomegalovirus (HCMV) US28 mediates vascular smooth muscle cell migration", "PROBLEM", 160, 240], ["vascular disease26", "PROBLEM", 253, 271], ["HHV", "TEST", 291, 294], ["Kaposi\u2019s", "TEST", 333, 341], ["sarcoma", "PROBLEM", 342, 349], ["lesions27", "PROBLEM", 355, 364], ["Inhibition", "TREATMENT", 365, 375], ["cytokines", "TREATMENT", 394, 403], ["chemokines", "TREATMENT", 408, 418], ["Three soluble vCKBPs", "TEST", 418, 438], ["cellular CKRs2", "TEST", 496, 510], ["a soluble IFN", "TREATMENT", 535, 548], ["VV", "PROBLEM", 575, 577], ["the heparin", "TREATMENT", 591, 602], ["CKs", "TEST", 637, 640], ["proteoglycans", "TREATMENT", 734, 747], ["HHV", "OBSERVATION", 29, 32], ["8 macrophage", "OBSERVATION_MODIFIER", 33, 45], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["vascularization", "OBSERVATION", 110, 125], ["tumors", "OBSERVATION", 152, 158], ["cytomegalovirus", "OBSERVATION", 166, 181], ["vascular", "ANATOMY", 203, 211], ["smooth muscle cell migration", "OBSERVATION", 212, 240], ["vascular", "ANATOMY", 253, 261], ["Kaposi", "OBSERVATION", 333, 339], ["sarcoma", "OBSERVATION", 342, 349]]], ["The poxvirus-secreted vCKBP-II, which has a novel protein structure28, binds CC CKs with high affinity and blocks their activity.", [["CC", "CHEMICAL", 77, 79], ["poxvirus", "ORGANISM", 4, 12], ["vCKBP-II", "GENE_OR_GENE_PRODUCT", 22, 30], ["structure28", "GENE_OR_GENE_PRODUCT", 58, 69], ["CC CKs", "GENE_OR_GENE_PRODUCT", 77, 83], ["poxvirus-secreted vCKBP-II", "PROTEIN", 4, 30], ["structure28", "PROTEIN", 58, 69], ["CC CKs", "PROTEIN", 77, 83], ["The poxvirus", "TEST", 0, 12], ["a novel protein structure28", "PROBLEM", 42, 69], ["binds CC CKs", "TEST", 71, 83], ["high affinity", "PROBLEM", 89, 102], ["high affinity", "OBSERVATION_MODIFIER", 89, 102]]], ["Murine gamma-herpesvirus 68 (MHV-68) has recently been shown to encode a distinct secreted protein (vCKBP-III) that sequesters C, CC, CXC and CX3C CKs29.Inhibitors of apoptosisApoptosis, or programmed cell death, can be triggered by a variety of inducers, including ligands of the TNF family, irradiation, cell-cycle inhibitors or infectious agents such as viruses.", [["cell", "ANATOMY", 201, 205], ["cell", "ANATOMY", 306, 310], ["apoptosisApoptosis", "DISEASE", 167, 185], ["programmed cell death", "DISEASE", 190, 211], ["Murine gamma-herpesvirus 68", "ORGANISM", 0, 27], ["MHV-68", "ORGANISM", 29, 35], ["vCKBP-III", "GENE_OR_GENE_PRODUCT", 100, 109], ["C", "GENE_OR_GENE_PRODUCT", 127, 128], ["CC", "GENE_OR_GENE_PRODUCT", 130, 132], ["CXC", "GENE_OR_GENE_PRODUCT", 134, 137], ["CX3C CKs29", "GENE_OR_GENE_PRODUCT", 142, 152], ["cell", "CELL", 201, 205], ["TNF", "GENE_OR_GENE_PRODUCT", 281, 284], ["cell", "CELL", 306, 310], ["secreted protein", "PROTEIN", 82, 98], ["vCKBP", "PROTEIN", 100, 105], ["III", "PROTEIN", 106, 109], ["C", "PROTEIN", 127, 128], ["CC", "PROTEIN", 130, 132], ["CXC", "PROTEIN", 134, 137], ["CX3C CKs29", "PROTEIN", 142, 152], ["TNF family", "PROTEIN", 281, 291], ["Murine", "SPECIES", 0, 6], ["Murine gamma-herpesvirus 68 (MHV-68", "SPECIES", 0, 35], ["Murine gamma-herpesvirus", "TEST", 0, 24], ["MHV", "TEST", 29, 32], ["CXC", "TEST", 134, 137], ["CX3C CKs29", "TEST", 142, 152], ["Inhibitors", "TREATMENT", 153, 163], ["apoptosisApoptosis", "PROBLEM", 167, 185], ["programmed cell death", "PROBLEM", 190, 211], ["the TNF family", "TREATMENT", 277, 291], ["irradiation", "TREATMENT", 293, 304], ["cell-cycle inhibitors", "TREATMENT", 306, 327], ["infectious agents", "TREATMENT", 331, 348], ["viruses", "PROBLEM", 357, 364], ["cell death", "OBSERVATION", 201, 211]]], ["Apoptosis can be considered an innate cellular response to limit viral propagation, and viruses express proteins that block the death response (Table 5); however, apoptosis might also facilitate virus dissemination, and viral pro-apoptotic mechanisms have been described30.", [["cellular", "ANATOMY", 38, 46], ["death", "DISEASE", 128, 133], ["cellular", "CELL", 38, 46], ["Apoptosis", "PROBLEM", 0, 9], ["viral propagation", "PROBLEM", 65, 82], ["apoptosis", "PROBLEM", 163, 172], ["virus dissemination", "PROBLEM", 195, 214], ["viral pro-apoptotic mechanisms", "PROBLEM", 220, 250]]], ["In addition, cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells kill virus-infected cells by inducing apoptosis via secretion of cytokines such as TNF, the release of perforin and granzymes, or the activation of Fas in the target cell.Inhibitors of apoptosisThe cellular proteins implicated in the control of apoptosis are targeted by viral anti-apoptotic mechanisms1, 5, 30, 31.", [["cytotoxic T lymphocytes", "ANATOMY", 13, 36], ["CTLs", "ANATOMY", 38, 42], ["natural killer (NK) cells", "ANATOMY", 48, 73], ["cells", "ANATOMY", 94, 99], ["cell", "ANATOMY", 240, 244], ["cellular", "ANATOMY", 272, 280], ["cytotoxic T lymphocytes", "CELL", 13, 36], ["CTLs", "CELL", 38, 42], ["natural killer (NK) cells", "CELL", 48, 73], ["cells", "CELL", 94, 99], ["TNF", "GENE_OR_GENE_PRODUCT", 157, 160], ["perforin", "GENE_OR_GENE_PRODUCT", 177, 185], ["granzymes", "GENE_OR_GENE_PRODUCT", 190, 199], ["Fas", "GENE_OR_GENE_PRODUCT", 222, 225], ["cell", "CELL", 240, 244], ["cellular", "CELL", 272, 280], ["cytotoxic T lymphocytes", "CELL_TYPE", 13, 36], ["CTLs", "CELL_TYPE", 38, 42], ["natural killer (NK) cells", "CELL_TYPE", 48, 73], ["virus-infected cells", "CELL_TYPE", 79, 99], ["cytokines", "PROTEIN", 139, 148], ["TNF", "PROTEIN", 157, 160], ["perforin", "PROTEIN", 177, 185], ["granzymes", "PROTEIN", 190, 199], ["Fas", "PROTEIN", 222, 225], ["target cell", "CELL_TYPE", 233, 244], ["cellular proteins", "PROTEIN", 272, 289], ["viral anti-apoptotic mechanisms1, 5, 30, 31", "PROTEIN", 345, 388], ["cytotoxic T lymphocytes", "TEST", 13, 36], ["CTLs", "TEST", 38, 42], ["natural killer (NK) cells kill virus", "PROBLEM", 48, 84], ["infected cells", "PROBLEM", 85, 99], ["secretion of cytokines", "TREATMENT", 126, 148], ["TNF", "TREATMENT", 157, 160], ["perforin and granzymes", "TREATMENT", 177, 199], ["Inhibitors", "TREATMENT", 245, 255], ["apoptosis", "PROBLEM", 259, 268], ["The cellular proteins", "PROBLEM", 268, 289], ["apoptosis", "PROBLEM", 319, 328], ["cytotoxic T lymphocytes", "OBSERVATION", 13, 36], ["infected cells", "OBSERVATION", 85, 99], ["target cell", "OBSERVATION", 233, 244], ["apoptosis", "OBSERVATION", 259, 268], ["cellular proteins", "OBSERVATION", 272, 289], ["apoptosis", "OBSERVATION", 319, 328]]], ["Viruses inhibit activation of caspases, encode homologs of the anti-apoptotic protein Bcl-2, block apoptotic signals triggered by activation of TNFR family members by encoding death-effector-domain-containing proteins, and inactivate IFN- induced PKR and the tumor suppressor p53, both of which promote apoptosis.", [["tumor", "ANATOMY", 259, 264], ["tumor", "DISEASE", 259, 264], ["caspases", "GENE_OR_GENE_PRODUCT", 30, 38], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["TNFR", "GENE_OR_GENE_PRODUCT", 144, 148], ["IFN", "GENE_OR_GENE_PRODUCT", 234, 237], ["PKR", "GENE_OR_GENE_PRODUCT", 247, 250], ["tumor", "CANCER", 259, 264], ["p53", "GENE_OR_GENE_PRODUCT", 276, 279], ["caspases", "PROTEIN", 30, 38], ["anti-apoptotic protein Bcl-2", "PROTEIN", 63, 91], ["TNFR family members", "PROTEIN", 144, 163], ["death-effector-domain-containing proteins", "PROTEIN", 176, 217], ["IFN", "PROTEIN", 234, 237], ["PKR", "PROTEIN", 247, 250], ["tumor suppressor p53", "PROTEIN", 259, 279], ["Viruses", "PROBLEM", 0, 7], ["caspases", "PROBLEM", 30, 38], ["the anti-apoptotic protein Bcl", "TEST", 59, 89], ["block apoptotic signals", "PROBLEM", 93, 116], ["proteins", "TREATMENT", 209, 217], ["IFN", "TREATMENT", 234, 237], ["PKR", "PROBLEM", 247, 250], ["the tumor suppressor p53", "TREATMENT", 255, 279], ["apoptosis", "OBSERVATION", 303, 312]]], ["An alternative mechanism is provided by the glutathione peroxidase of Molluscum contagiosum virus (MCV), which provides protection from peroxide- or UV-induced apoptosis, and perhaps from peroxides induced by TNF, macrophages or neutrophils.Evading CTLs and NKs and modulating MHC functionHow to achieve persistence in the face of a vigorous host immune response is a problem that must be solved by viruses that establish life-long infections.", [["macrophages", "ANATOMY", 214, 225], ["neutrophils", "ANATOMY", 229, 240], ["glutathione", "CHEMICAL", 44, 55], ["Molluscum contagiosum", "DISEASE", 70, 91], ["UV", "CHEMICAL", 149, 151], ["infections", "DISEASE", 432, 442], ["glutathione", "CHEMICAL", 44, 55], ["peroxide", "CHEMICAL", 136, 144], ["peroxides", "CHEMICAL", 188, 197], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 44, 66], ["Molluscum contagiosum virus", "ORGANISM", 70, 97], ["MCV", "ORGANISM", 99, 102], ["peroxide", "SIMPLE_CHEMICAL", 136, 144], ["peroxides", "SIMPLE_CHEMICAL", 188, 197], ["TNF", "GENE_OR_GENE_PRODUCT", 209, 212], ["macrophages", "CELL", 214, 225], ["neutrophils", "CELL", 229, 240], ["CTLs", "CELL", 249, 253], ["NKs", "GENE_OR_GENE_PRODUCT", 258, 261], ["glutathione peroxidase", "PROTEIN", 44, 66], ["TNF", "PROTEIN", 209, 212], ["macrophages", "CELL_TYPE", 214, 225], ["neutrophils", "CELL_TYPE", 229, 240], ["CTLs", "CELL_TYPE", 249, 253], ["NKs", "PROTEIN", 258, 261], ["MHC", "PROTEIN", 277, 280], ["Molluscum contagiosum virus", "SPECIES", 70, 97], ["Molluscum contagiosum virus", "SPECIES", 70, 97], ["MCV", "SPECIES", 99, 102], ["the glutathione peroxidase", "TEST", 40, 66], ["Molluscum contagiosum virus", "PROBLEM", 70, 97], ["peroxide", "TREATMENT", 136, 144], ["UV", "PROBLEM", 149, 151], ["apoptosis", "PROBLEM", 160, 169], ["TNF", "PROBLEM", 209, 212], ["macrophages", "PROBLEM", 214, 225], ["neutrophils", "PROBLEM", 229, 240], ["long infections", "PROBLEM", 427, 442]]], ["Cellular proteins are degraded by the proteasome, the complex major intracellular protease, and the resulting peptides are translocated by transporters associated with antigen processing (TAP) molecules into the endoplasmic reticulum (ER), where they contribute to the assembly of MHC class I molecules1, 11, 32, 33, 34.", [["Cellular", "ANATOMY", 0, 8], ["intracellular", "ANATOMY", 68, 81], ["endoplasmic reticulum", "ANATOMY", 212, 233], ["ER", "ANATOMY", 235, 237], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["antigen processing (TAP) molecules", "GENE_OR_GENE_PRODUCT", 168, 202], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 212, 233], ["ER", "GENE_OR_GENE_PRODUCT", 235, 237], ["MHC class I molecules1", "GENE_OR_GENE_PRODUCT", 281, 303], ["Cellular proteins", "PROTEIN", 0, 17], ["proteasome", "PROTEIN", 38, 48], ["complex major intracellular protease", "PROTEIN", 54, 90], ["antigen processing (TAP) molecules", "PROTEIN", 168, 202], ["ER", "PROTEIN", 235, 237], ["MHC class I molecules1, 11, 32, 33, 34", "PROTEIN", 281, 319], ["Cellular proteins", "TEST", 0, 17], ["the complex major intracellular protease", "PROBLEM", 50, 90], ["the resulting peptides", "PROBLEM", 96, 118], ["antigen processing (TAP) molecules", "TREATMENT", 168, 202], ["intracellular protease", "OBSERVATION", 68, 90], ["endoplasmic reticulum", "ANATOMY", 212, 233]]], ["MHC class I molecules indicate the composition of cellular proteins to cells of the immune system.", [["cellular", "ANATOMY", 50, 58], ["cells", "ANATOMY", 71, 76], ["immune system", "ANATOMY", 84, 97], ["MHC class I", "GENE_OR_GENE_PRODUCT", 0, 11], ["cellular", "CELL", 50, 58], ["cells", "CELL", 71, 76], ["immune system", "ANATOMICAL_SYSTEM", 84, 97], ["MHC class I molecules", "PROTEIN", 0, 21], ["cellular proteins", "PROTEIN", 50, 67], ["cellular proteins", "OBSERVATION", 50, 67], ["immune system", "OBSERVATION", 84, 97]]], ["The presentation of foreign peptides activates and attracts cytolytic CD8+ T cells.", [["CD8+ T cells", "ANATOMY", 70, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["cytolytic CD8+ T cells", "CELL_TYPE", 60, 82], ["foreign peptides activates", "PROBLEM", 20, 46], ["foreign peptides", "OBSERVATION", 20, 36]]], ["Interference with antigen processing [e.g. Epstein\u2013Barr nuclear antigen A1 (EBNA1)] or TAP function [e.g. herpes simplex virus (HSV) infected cell protein 47 (ICP47) and HCMV US6 and pp65] prevents peptide generation and transport either specifically or generally (Table 6).", [["herpes simplex", "DISEASE", 106, 120], ["Barr nuclear antigen A1", "GENE_OR_GENE_PRODUCT", 51, 74], ["EBNA1", "GENE_OR_GENE_PRODUCT", 76, 81], ["TAP", "GENE_OR_GENE_PRODUCT", 87, 90], ["herpes simplex virus", "ORGANISM", 106, 126], ["HSV", "ORGANISM", 128, 131], ["infected cell protein 47", "GENE_OR_GENE_PRODUCT", 133, 157], ["ICP47", "GENE_OR_GENE_PRODUCT", 159, 164], ["HCMV", "ORGANISM", 170, 174], ["US6", "GENE_OR_GENE_PRODUCT", 175, 178], ["pp65", "GENE_OR_GENE_PRODUCT", 183, 187], ["Barr nuclear antigen A1", "PROTEIN", 51, 74], ["EBNA1", "PROTEIN", 76, 81], ["TAP", "PROTEIN", 87, 90], ["herpes simplex virus (HSV) infected cell protein 47", "PROTEIN", 106, 157], ["ICP47", "PROTEIN", 159, 164], ["HCMV US6", "PROTEIN", 170, 178], ["pp65", "PROTEIN", 183, 187], ["herpes simplex virus", "SPECIES", 106, 126], ["herpes simplex virus", "SPECIES", 106, 126], ["HSV", "SPECIES", 128, 131], ["HCMV", "SPECIES", 170, 174], ["Barr nuclear antigen A1", "TEST", 51, 74], ["EBNA1", "TEST", 76, 81], ["TAP function", "TEST", 87, 99], ["e.g. herpes simplex virus", "PROBLEM", 101, 126], ["HSV", "TEST", 128, 131], ["infected cell protein", "TEST", 133, 154], ["ICP47", "TEST", 159, 164], ["HCMV US6", "TEST", 170, 178], ["pp65", "TEST", 183, 187], ["peptide generation", "PROBLEM", 198, 216]]], ["Various mechanisms in different viruses directly target maturation, assembly and export of MHC class I molecules.", [["MHC class I molecules", "GENE_OR_GENE_PRODUCT", 91, 112], ["MHC class I molecules", "PROTEIN", 91, 112], ["Various mechanisms", "PROBLEM", 0, 18], ["different", "OBSERVATION_MODIFIER", 22, 31], ["viruses", "OBSERVATION", 32, 39]]], ["To date, no cellular homologs have been found for the proteins and functions that target peptide processing, transport and MHC maturation.", [["cellular", "ANATOMY", 12, 20], ["cellular", "CELL", 12, 20], ["MHC", "GENE_OR_GENE_PRODUCT", 123, 126], ["MHC", "PROTEIN", 123, 126]]], ["With few exceptions35, the viral proteins bind their target molecule directly.", [["viral proteins", "PROTEIN", 27, 41]]], ["There is only limited functional homology and no sequence homology among the different viral effectors.", [["viral effectors", "PROTEIN", 87, 102], ["sequence homology", "PROBLEM", 49, 66], ["viral effectors", "OBSERVATION", 87, 102]]], ["Nevertheless, the general outcome of these functions is the same: downregulation of MHC class I molecules or of some MHC class I alleles.", [["MHC class I molecules", "PROTEIN", 84, 105], ["MHC class I alleles", "DNA", 117, 136]]], ["The study of MHC class I regulation has revealed additional genes in herpesviruses of different species36, 37, 38, which might affect many cell types or only those tissues relevant for virus maintenance.Evading CTLs and NKs and modulating MHC functionAlthough the downregulation of MHC class I expression prevents CD8+ T-cell recognition, cells that downregulate these molecules are targets for NK cells1, 11, 32, 33, 34.", [["cell", "ANATOMY", 139, 143], ["tissues", "ANATOMY", 164, 171], ["CTLs", "ANATOMY", 211, 215], ["NKs", "ANATOMY", 220, 223], ["CD8+ T-cell", "ANATOMY", 314, 325], ["cells", "ANATOMY", 339, 344], ["NK cells1", "ANATOMY", 395, 404], ["MHC class I", "GENE_OR_GENE_PRODUCT", 13, 24], ["herpesviruses", "ORGANISM", 69, 82], ["species36", "GENE_OR_GENE_PRODUCT", 96, 105], ["cell", "CELL", 139, 143], ["tissues", "TISSUE", 164, 171], ["CTLs", "CELL", 211, 215], ["NKs", "GENE_OR_GENE_PRODUCT", 220, 223], ["MHC class I", "GENE_OR_GENE_PRODUCT", 282, 293], ["CD8", "GENE_OR_GENE_PRODUCT", 314, 317], ["cells", "CELL", 339, 344], ["NK cells1", "CELL", 395, 404], ["MHC class I", "PROTEIN", 13, 24], ["CTLs", "CELL_TYPE", 211, 215], ["NKs", "PROTEIN", 220, 223], ["MHC", "PROTEIN", 239, 242], ["MHC class I", "PROTEIN", 282, 293], ["CD8", "PROTEIN", 314, 317], ["The study", "TEST", 0, 9], ["additional genes in herpesviruses", "PROBLEM", 49, 82], ["virus maintenance", "TREATMENT", 185, 202], ["NKs", "TEST", 220, 223], ["NK cells1", "TEST", 395, 404], ["cell types", "OBSERVATION", 139, 149]]], ["NK cells, the first line of cellular defense against viruses, have receptors for certain MHC molecules.", [["NK cells", "ANATOMY", 0, 8], ["cellular", "ANATOMY", 28, 36], ["NK cells", "CELL", 0, 8], ["cellular", "CELL", 28, 36], ["NK cells", "CELL_TYPE", 0, 8], ["MHC molecules", "PROTEIN", 89, 102], ["NK cells", "PROBLEM", 0, 8], ["viruses", "PROBLEM", 53, 60], ["cellular defense", "OBSERVATION", 28, 44]]], ["Some of these receptors silence the cytolytic machinery of NK cells and act as killer cell inhibitory receptors (KIR).", [["NK cells", "ANATOMY", 59, 67], ["killer cell", "ANATOMY", 79, 90], ["NK cells", "CELL", 59, 67], ["killer cell inhibitory receptors", "GENE_OR_GENE_PRODUCT", 79, 111], ["KIR", "GENE_OR_GENE_PRODUCT", 113, 116], ["NK cells", "CELL_TYPE", 59, 67], ["killer cell inhibitory receptors", "PROTEIN", 79, 111], ["KIR", "PROTEIN", 113, 116], ["NK cells", "OBSERVATION", 59, 67]]], ["Other receptors, designated leukocyte immunoglobulin-like receptors (LIR), are expressed mainly on monocytes and B cells.", [["monocytes", "ANATOMY", 99, 108], ["B cells", "ANATOMY", 113, 120], ["leukocyte immunoglobulin-like receptors", "GENE_OR_GENE_PRODUCT", 28, 67], ["LIR", "GENE_OR_GENE_PRODUCT", 69, 72], ["monocytes", "CELL", 99, 108], ["B cells", "CELL", 113, 120], ["leukocyte immunoglobulin-like receptors", "PROTEIN", 28, 67], ["LIR", "PROTEIN", 69, 72], ["monocytes", "CELL_TYPE", 99, 108], ["B cells", "CELL_TYPE", 113, 120], ["Other receptors", "TEST", 0, 15], ["designated leukocyte immunoglobulin", "TEST", 17, 52], ["monocytes", "TEST", 99, 108], ["leukocyte immunoglobulin", "OBSERVATION", 28, 52], ["B cells", "OBSERVATION", 113, 120]]], ["Engagement of an NK receptor can also result in NK activation as not all receptors carry an intracellular silencing domain.", [["NK", "ANATOMY", 17, 19], ["NK", "ANATOMY", 48, 50], ["intracellular", "ANATOMY", 92, 105], ["NK receptor", "GENE_OR_GENE_PRODUCT", 17, 28], ["NK", "CELL", 48, 50], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["NK receptor", "PROTEIN", 17, 28], ["intracellular silencing domain", "PROTEIN", 92, 122], ["an NK receptor", "TREATMENT", 14, 28]]], ["The HCMV protein UL18 and the MCMV m144 protein, which are homologous to MHC class I, could be associated with NK killing, and UL18 was instrumental in the identification of LIR-1.", [["NK", "ANATOMY", 111, 113], ["HCMV", "ORGANISM", 4, 8], ["UL18", "GENE_OR_GENE_PRODUCT", 17, 21], ["MCMV m144", "GENE_OR_GENE_PRODUCT", 30, 39], ["MHC class I", "GENE_OR_GENE_PRODUCT", 73, 84], ["NK", "CELL", 111, 113], ["UL18", "GENE_OR_GENE_PRODUCT", 127, 131], ["LIR-1", "GENE_OR_GENE_PRODUCT", 174, 179], ["HCMV protein", "PROTEIN", 4, 16], ["UL18", "PROTEIN", 17, 21], ["MCMV m144 protein", "PROTEIN", 30, 47], ["MHC class I", "PROTEIN", 73, 84], ["UL18", "PROTEIN", 127, 131], ["LIR", "PROTEIN", 174, 177], ["HCMV", "SPECIES", 4, 8], ["The HCMV protein UL18", "TEST", 0, 21], ["the MCMV m144 protein", "TEST", 26, 47], ["NK killing", "PROBLEM", 111, 121], ["UL18", "TEST", 127, 131], ["could be associated with", "UNCERTAINTY", 86, 110], ["NK killing", "OBSERVATION", 111, 121]]], ["In addition, the HCMV UL40 protein provides a peptide selectively required for the maturation of the HLA-E molecule, an NK target39, 40.", [["NK", "ANATOMY", 120, 122], ["HCMV", "ORGANISM", 17, 21], ["UL40", "GENE_OR_GENE_PRODUCT", 22, 26], ["HLA-E molecule", "GENE_OR_GENE_PRODUCT", 101, 115], ["HCMV UL40 protein", "PROTEIN", 17, 34], ["HLA-E molecule", "PROTEIN", 101, 115], ["HCMV", "SPECIES", 17, 21], ["the HCMV UL40 protein", "TEST", 13, 34]]], ["However, clinical isolates of HCMV confer a much stronger NK resistance than the laboratory strains sequenced and tested so far, and this resistance is unrelated to MHC class I expression and LIR-1 (Ref.", [["NK", "ANATOMY", 58, 60], ["HCMV", "ORGANISM", 30, 34], ["NK", "CELL", 58, 60], ["MHC class I", "GENE_OR_GENE_PRODUCT", 165, 176], ["LIR-1", "GENE_OR_GENE_PRODUCT", 192, 197], ["MHC class I", "PROTEIN", 165, 176], ["LIR-1", "DNA", 192, 197], ["HCMV", "SPECIES", 30, 34], ["HCMV", "PROBLEM", 30, 34], ["the laboratory strains", "TEST", 77, 99]]], ["Clinical isolates carry additional genes, and in vitro propagation has probably led to a loss of certain NK-specific gene functions.Evading CTLs and NKs and modulating MHC functionEffects on MHC class II expression fall into two classes, namely effects on transcription and post-translational effects1, 11, 32, 33, 34.", [["NK", "ANATOMY", 105, 107], ["NK", "CELL", 105, 107], ["CTLs", "CELL", 140, 144], ["NKs", "GENE_OR_GENE_PRODUCT", 149, 152], ["MHC class II", "GENE_OR_GENE_PRODUCT", 191, 203], ["CTLs", "CELL_TYPE", 140, 144], ["NKs", "PROTEIN", 149, 152], ["MHC", "PROTEIN", 168, 171], ["MHC class II", "PROTEIN", 191, 203], ["a loss of certain NK", "PROBLEM", 87, 107], ["post-translational effects1", "TEST", 274, 301]]], ["Adenovirus, MCMV and HCMV affect MHC class II transcription but the target in the signal cascade, although known to be different for these viruses, has not been defined and the viral gene or genes responsible are unknown.", [["Adenovirus", "ORGANISM", 0, 10], ["MCMV", "ORGANISM", 12, 16], ["HCMV", "ORGANISM", 21, 25], ["MHC class II", "GENE_OR_GENE_PRODUCT", 33, 45], ["MHC class II", "PROTEIN", 33, 45], ["viral gene", "DNA", 177, 187], ["Adenovirus", "SPECIES", 0, 10], ["MCMV", "SPECIES", 12, 16], ["HCMV", "SPECIES", 21, 25], ["Adenovirus", "PROBLEM", 0, 10], ["MCMV", "PROBLEM", 12, 16], ["these viruses", "PROBLEM", 133, 146], ["MCMV", "OBSERVATION", 12, 16], ["HCMV", "OBSERVATION", 21, 25], ["viruses", "OBSERVATION", 139, 146]]], ["At the post-translational level, the HCMV US2 protein, which affects MHC class I, apparently also translocates the DR\u03b1 and the DM\u03b1 chain into the cytosol for degradation by the proteasome.", [["cytosol", "ANATOMY", 146, 153], ["HCMV", "ORGANISM", 37, 41], ["US2", "GENE_OR_GENE_PRODUCT", 42, 45], ["MHC class I", "GENE_OR_GENE_PRODUCT", 69, 80], ["DR\u03b1", "GENE_OR_GENE_PRODUCT", 115, 118], ["DM\u03b1 chain", "GENE_OR_GENE_PRODUCT", 127, 136], ["cytosol", "CELLULAR_COMPONENT", 146, 153], ["HCMV US2 protein", "PROTEIN", 37, 53], ["MHC class I", "PROTEIN", 69, 80], ["DR\u03b1", "PROTEIN", 115, 118], ["DM\u03b1 chain", "PROTEIN", 127, 136], ["proteasome", "PROTEIN", 177, 187], ["HCMV", "SPECIES", 37, 41], ["the HCMV US2 protein", "TEST", 33, 53], ["the proteasome", "TREATMENT", 173, 187]]], ["Another target involved in interference with MHC class II function is the shuttling between endosomal peptide loading and surface expression.", [["endosomal", "ANATOMY", 92, 101], ["surface", "ANATOMY", 122, 129], ["MHC class II", "GENE_OR_GENE_PRODUCT", 45, 57], ["endosomal", "CELLULAR_COMPONENT", 92, 101], ["surface", "CELLULAR_COMPONENT", 122, 129], ["MHC class II", "PROTEIN", 45, 57], ["endosomal peptide loading", "TREATMENT", 92, 117]]], ["Human papilloma virus (HPV) and HIV Nef affect vesicle traffic as well as the function of the endocytic machinery.", [["vesicle", "ANATOMY", 47, 54], ["Human papilloma virus", "DISEASE", 0, 21], ["Human papilloma virus", "ORGANISM", 0, 21], ["HPV", "ORGANISM", 23, 26], ["HIV Nef", "ORGANISM", 32, 39], ["vesicle", "CELLULAR_COMPONENT", 47, 54], ["HIV Nef", "PROTEIN", 32, 39], ["Human papilloma virus", "SPECIES", 0, 21], ["HIV", "SPECIES", 32, 35], ["Human papilloma virus", "SPECIES", 0, 21], ["HPV", "SPECIES", 23, 26], ["HIV", "SPECIES", 32, 35], ["Human papilloma virus (HPV)", "PROBLEM", 0, 27], ["HIV Nef affect vesicle traffic", "PROBLEM", 32, 62], ["papilloma virus", "OBSERVATION", 6, 21]]], ["Accordingly, in addition to MHC class II, other proteins that use this pathway, for example the CD4 molecule, are also affected.Future perspectivesAn understanding of the functions of the viral immunoregulatory genes isolated to date is now emerging.", [["MHC class II", "GENE_OR_GENE_PRODUCT", 28, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 96, 99], ["MHC class II", "PROTEIN", 28, 40], ["CD4 molecule", "PROTEIN", 96, 108], ["viral immunoregulatory genes", "DNA", 188, 216], ["this pathway", "TREATMENT", 66, 78], ["the CD4 molecule", "PROBLEM", 92, 108], ["the viral immunoregulatory genes", "PROBLEM", 184, 216], ["CD4 molecule", "OBSERVATION", 96, 108]]], ["Additionally, it is unclear when and why a virus deploys one specific function rather than another.", [["a virus", "PROBLEM", 41, 48]]], ["Many questions therefore remain unanswered, including which genes are needed during primary infection to \u2018conquer the territory\u2019; which genes are required to support active replication; and which genes are required to ensure transmission to a new host in the face of a vigorous host immune response?", [["primary infection", "DISEASE", 84, 101], ["primary infection", "PROBLEM", 84, 101], ["active replication", "TREATMENT", 166, 184]]], ["Moreover, why is there such complexity and functional redundancy?", [["functional redundancy", "PROBLEM", 43, 64], ["functional redundancy", "OBSERVATION", 43, 64]]], ["Is there a hierarchy in terms of general importance or do some functions operate only in certain tissues?", [["tissues", "ANATOMY", 97, 104], ["tissues", "TISSUE", 97, 104], ["hierarchy", "OBSERVATION", 11, 20]]], ["Is complexity and redundancy a viral strategy to enable viruses to infect individuals resistant to some functions?", [["a viral strategy", "TREATMENT", 29, 45], ["viral strategy", "OBSERVATION", 31, 45]]], ["Are the functions of an individual viral gene modulated by its genetic context, and is there any evidence for cooperativity?", [["viral gene", "DNA", 35, 45]]], ["To date, we only have limited information because the construction of virus mutants and the in vivo testing of the predicted gene function is still in its infancy and, additionally, owing to the species specificity of many viruses, this information can only be gathered from some animal models.Future perspectivesThe identification of novel immune-evasion strategies and the analysis of their functions in the context of a viral infection should lead to a better understanding of the immune system and the interaction of viruses with their hosts.", [["immune system", "ANATOMY", 484, 497], ["viral infection", "DISEASE", 423, 438], ["virus mutants", "PROBLEM", 70, 83], ["the in vivo testing", "TEST", 88, 107], ["many viruses", "PROBLEM", 218, 230], ["novel immune-evasion strategies", "TREATMENT", 335, 366], ["the analysis", "TEST", 371, 383], ["a viral infection", "PROBLEM", 421, 438], ["viruses", "OBSERVATION", 223, 230], ["viral", "OBSERVATION_MODIFIER", 423, 428], ["infection", "OBSERVATION", 429, 438]]], ["This will help us to treat virus-induced pathology, to design safer and more immunogenic virus vectors as vaccines or gene delivery systems, and to identify new strategies of immune modulation.AcknowledgementsThe work in the authors\u2019 laboratories is funded by the Wellcome Trust and the Deutsche Forschungsgemeinschaft.", [["virus", "PROBLEM", 27, 32], ["induced pathology", "PROBLEM", 33, 50], ["immunogenic virus vectors", "TREATMENT", 77, 102], ["vaccines", "TREATMENT", 106, 114], ["gene delivery systems", "TREATMENT", 118, 139], ["immune modulation", "TREATMENT", 175, 192], ["immune modulation", "OBSERVATION", 175, 192]]]], "c051ae3e13770b683df8beca5ae92f808aa9f907": [["IntroductionInterferons (IFNs) are the key components of innate immunity in response to viral infection.", [["viral infection", "DISEASE", 88, 103], ["Interferons", "GENE_OR_GENE_PRODUCT", 12, 23], ["IFNs", "GENE_OR_GENE_PRODUCT", 25, 29], ["Interferons", "PROTEIN", 12, 23], ["IFNs", "PROTEIN", 25, 29], ["IntroductionInterferons (IFNs)", "TREATMENT", 0, 30], ["innate immunity", "TREATMENT", 57, 72], ["viral infection", "PROBLEM", 88, 103], ["viral", "OBSERVATION_MODIFIER", 88, 93], ["infection", "OBSERVATION", 94, 103]]], ["Among the three type IFNs (types I, II, and III), type III IFN-lambda (IFN-L) was recently discovered as a member of the IL-10 superfamily of cytokines (Dellgren et al., 2009; Kotenko et al., 2003; Lazear et al., 2015; review; Mordstein et al., 2010) .", [["type III IFN-lambda", "GENE_OR_GENE_PRODUCT", 50, 69], ["IFN-L", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-10", "GENE_OR_GENE_PRODUCT", 121, 126], ["IFNs", "PROTEIN", 21, 25], ["type III IFN-lambda (IFN-L", "PROTEIN", 50, 76], ["IL-10 superfamily", "PROTEIN", 121, 138], ["cytokines", "PROTEIN", 142, 151], ["type III IFN-lambda", "PROBLEM", 50, 69]]], ["Similar to type I IFN, IFN-L is a multigene family of closely related cytokines, consisting of four members in humans (IFN-L1, IFN-L2, IFN-L3, and IFN-L4) and two in mice (IFN-L2 and -L3) (Dellgren et al., 2009; Lazear et al., 2015; review) .", [["type I IFN", "GENE_OR_GENE_PRODUCT", 11, 21], ["IFN-L", "GENE_OR_GENE_PRODUCT", 23, 28], ["humans", "ORGANISM", 111, 117], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 119, 125], ["IFN-L2", "GENE_OR_GENE_PRODUCT", 127, 133], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 135, 141], ["IFN-L4", "GENE_OR_GENE_PRODUCT", 147, 153], ["mice", "ORGANISM", 166, 170], ["IFN-L2", "ORGANISM", 172, 178], ["-L3", "CELL", 183, 186], ["type I IFN", "PROTEIN", 11, 21], ["IFN-L", "PROTEIN", 23, 28], ["cytokines", "PROTEIN", 70, 79], ["IFN", "PROTEIN", 119, 122], ["L1", "PROTEIN", 123, 125], ["IFN", "PROTEIN", 127, 130], ["L2", "PROTEIN", 131, 133], ["IFN", "PROTEIN", 135, 138], ["L3", "PROTEIN", 139, 141], ["IFN", "PROTEIN", 147, 150], ["L4", "PROTEIN", 151, 153], ["IFN", "PROTEIN", 172, 175], ["humans", "SPECIES", 111, 117], ["mice", "SPECIES", 166, 170], ["humans", "SPECIES", 111, 117], ["mice", "SPECIES", 166, 170], ["IFN-L2", "TREATMENT", 127, 133], ["IFN-L3, and IFN-L4", "TREATMENT", 135, 153], ["two in mice (IFN-L2 and -L3", "TREATMENT", 159, 186], ["L1", "ANATOMY", 123, 125], ["L2", "ANATOMY", 131, 133], ["L3", "ANATOMY", 139, 141], ["L4", "ANATOMY", 151, 153], ["L2", "ANATOMY", 176, 178], ["L3", "ANATOMY", 184, 186]]], ["So far, only two members of porcine IFN-Ls (IFN-L1 and IFN-L3) have been cloned and expressed (Sang et al., 2010; Wang et al., 2011) .", [["porcine", "ORGANISM", 28, 35], ["IFN-Ls", "GENE_OR_GENE_PRODUCT", 36, 42], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 44, 50], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 55, 61], ["IFN", "PROTEIN", 36, 39], ["Ls", "PROTEIN", 40, 42], ["IFN", "PROTEIN", 44, 47], ["L1", "PROTEIN", 48, 50], ["IFN", "PROTEIN", 55, 58], ["L3", "PROTEIN", 59, 61], ["porcine IFN-Ls (IFN-L1 and IFN-L3", "TREATMENT", 28, 61], ["L1", "ANATOMY", 48, 50], ["L3", "ANATOMY", 59, 61]]], ["Recently, IFN-L was shown to predominantly act in mucosal organs, including epithelial surfaces of the liver, respiratory, and gastrointestinal systems, which are major entry points for many pathogens review; Mordstein et al., 2010; Pott et al., 2011) .", [["mucosal organs", "ANATOMY", 50, 64], ["epithelial surfaces", "ANATOMY", 76, 95], ["liver", "ANATOMY", 103, 108], ["respiratory", "ANATOMY", 110, 121], ["gastrointestinal systems", "ANATOMY", 127, 151], ["respiratory, and gastrointestinal systems", "DISEASE", 110, 151], ["IFN-L", "GENE_OR_GENE_PRODUCT", 10, 15], ["mucosal organs", "TISSUE", 50, 64], ["epithelial surfaces", "TISSUE", 76, 95], ["liver", "ORGAN", 103, 108], ["gastrointestinal", "ORGAN", 127, 143], ["IFN", "PROTEIN", 10, 13], ["mucosal organs", "ANATOMY", 50, 64], ["epithelial", "ANATOMY_MODIFIER", 76, 86], ["liver", "ANATOMY", 103, 108], ["respiratory", "ANATOMY", 110, 121], ["gastrointestinal systems", "ANATOMY", 127, 151]]], ["Similar to type I IFNs, IFN-L is rapidly produced after infection and, following engagement with its receptor, induces IFN-stimulated gene (ISG) expression to mediate antiviral activity (Hernandez et al., 2015; Kotenko et al., 2003) .", [["infection", "DISEASE", 56, 65], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 11, 22], ["IFN-L", "GENE_OR_GENE_PRODUCT", 24, 29], ["IFN-stimulated gene", "GENE_OR_GENE_PRODUCT", 119, 138], ["ISG", "GENE_OR_GENE_PRODUCT", 140, 143], ["type I IFNs", "PROTEIN", 11, 22], ["IFN-L", "PROTEIN", 24, 29], ["IFN", "PROTEIN", 119, 122], ["ISG", "DNA", 140, 143], ["type I IFNs", "PROBLEM", 11, 22], ["IFN", "PROBLEM", 24, 27], ["infection", "PROBLEM", 56, 65], ["its receptor", "TREATMENT", 97, 109], ["infection", "OBSERVATION", 56, 65]]], ["Although type I IFN and IFN-L induce similar proximal signaling events and downstream transcriptional responses, the IFN-L receptor is structurally and genetically distinct from the type I IFN (alpha) receptor (IFNAR) (Kotenko et al., 2003; Lazear et al., 2015; review; Sommereyns et al., 2008) .", [["type I IFN", "GENE_OR_GENE_PRODUCT", 9, 19], ["IFN-L", "GENE_OR_GENE_PRODUCT", 24, 29], ["IFN-L receptor", "GENE_OR_GENE_PRODUCT", 117, 131], ["type I IFN (alpha) receptor", "GENE_OR_GENE_PRODUCT", 182, 209], ["IFNAR", "GENE_OR_GENE_PRODUCT", 211, 216], ["type I IFN", "PROTEIN", 9, 19], ["IFN-L", "PROTEIN", 24, 29], ["IFN-L receptor", "PROTEIN", 117, 131], ["type I IFN (alpha) receptor", "PROTEIN", 182, 209], ["IFNAR", "PROTEIN", 211, 216], ["type I IFN", "PROBLEM", 9, 19], ["IFN", "TREATMENT", 24, 27], ["similar proximal signaling events", "PROBLEM", 37, 70], ["downstream transcriptional responses", "PROBLEM", 75, 111], ["proximal", "ANATOMY_MODIFIER", 45, 53], ["signaling events", "OBSERVATION", 54, 70]]], ["The IFN-L receptor is a single heterodimeric receptor complex consisting of the IFNLR1 signaling chain and the IL-10Rb accessory chain (Kotenko et al., 2003; Sommereyns et al., 2008) .", [["IFN-L receptor", "GENE_OR_GENE_PRODUCT", 4, 18], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 80, 86], ["IL-10Rb", "GENE_OR_GENE_PRODUCT", 111, 118], ["IFN-L receptor", "PROTEIN", 4, 18], ["heterodimeric receptor complex", "PROTEIN", 31, 61], ["IFNLR1 signaling chain", "PROTEIN", 80, 102], ["IL-10Rb accessory chain", "PROTEIN", 111, 134], ["chain", "OBSERVATION_MODIFIER", 97, 102]]], ["IFNLR1 is preferentially expressed on epithelial cells unlike IFNAR and IL-10Rb, each of which is expressed broadly on many types of cells and tissues (Sommereyns et al., 2008) .", [["epithelial cells", "ANATOMY", 38, 54], ["cells", "ANATOMY", 133, 138], ["tissues", "ANATOMY", 143, 150], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 0, 6], ["epithelial cells", "CELL", 38, 54], ["IFNAR", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-10Rb", "GENE_OR_GENE_PRODUCT", 72, 79], ["cells", "CELL", 133, 138], ["tissues", "TISSUE", 143, 150], ["IFNLR1", "PROTEIN", 0, 6], ["epithelial cells", "CELL_TYPE", 38, 54], ["IFNAR", "PROTEIN", 62, 67], ["IL", "PROTEIN", 72, 74], ["10Rb", "PROTEIN", 75, 79], ["IL", "TEST", 72, 74], ["epithelial cells", "OBSERVATION", 38, 54]]], ["Given that IFNLR1 is predominantly expressed on mucosal epithelia, IFN-L may provide a more focused antiviral response at mucosal barrier sites to reduce the side effects associated with a systemic pro-inflammatory immune response, such as that of type I IFN.", [["mucosal epithelia", "ANATOMY", 48, 65], ["mucosal barrier sites", "ANATOMY", 122, 143], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 11, 17], ["mucosal epithelia", "TISSUE", 48, 65], ["IFN-L", "GENE_OR_GENE_PRODUCT", 67, 72], ["mucosal barrier sites", "MULTI-TISSUE_STRUCTURE", 122, 143], ["type I IFN", "GENE_OR_GENE_PRODUCT", 248, 258], ["IFNLR1", "PROTEIN", 11, 17], ["IFN", "PROTEIN", 67, 70], ["type I IFN", "PROTEIN", 248, 258], ["IFN", "TREATMENT", 67, 70], ["mucosal barrier sites", "TREATMENT", 122, 143], ["the side effects", "PROBLEM", 154, 170], ["a systemic pro-inflammatory immune response", "PROBLEM", 187, 230], ["predominantly", "OBSERVATION_MODIFIER", 21, 34], ["mucosal epithelia", "ANATOMY", 48, 65]]], ["Therefore, IFN-L may be a potential antiviral therapeutic for targeting mucosal infections.IntroductionPorcine epidemic diarrhea virus (PEDV) is an enteropathogenic alpha coronavirus and causes swine disease with huge economic relevance (Madson et al., 2014; Wang et al., 2014; Zhang and Yoo, 2016; review) .", [["mucosal", "ANATOMY", 72, 79], ["IFN", "CHEMICAL", 11, 14], ["mucosal infections", "DISEASE", 72, 90], ["IntroductionPorcine epidemic diarrhea", "DISEASE", 91, 128], ["swine disease", "DISEASE", 194, 207], ["IFN-L", "GENE_OR_GENE_PRODUCT", 11, 16], ["mucosal", "ORGANISM_SUBDIVISION", 72, 79], ["IntroductionPorcine epidemic diarrhea virus", "ORGANISM", 91, 134], ["alpha coronavirus", "ORGANISM", 165, 182], ["IFN", "PROTEIN", 11, 14], ["diarrhea virus", "SPECIES", 120, 134], ["swine", "SPECIES", 194, 199], ["IntroductionPorcine epidemic diarrhea virus", "SPECIES", 91, 134], ["PEDV", "SPECIES", 136, 140], ["enteropathogenic alpha coronavirus", "SPECIES", 148, 182], ["swine", "SPECIES", 194, 199], ["IFN", "TREATMENT", 11, 14], ["targeting mucosal infections", "PROBLEM", 62, 90], ["IntroductionPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 91, 140], ["an enteropathogenic alpha coronavirus", "PROBLEM", 145, 182], ["swine disease", "PROBLEM", 194, 207], ["mucosal", "ANATOMY", 72, 79], ["infections", "OBSERVATION", 80, 90], ["enteropathogenic alpha coronavirus", "OBSERVATION", 148, 182]]], ["PEDV primarily infects small intestinal epithelial cells in vivo, and infection causes pronounced villous atrophy that results in an acute malabsorption syndrome with symptoms of watery diarrhea, vomiting and anorexia in pigs of all ages (Li et al., 2012; Wang et al., 2014) .", [["intestinal epithelial cells", "ANATOMY", 29, 56], ["villous", "ANATOMY", 98, 105], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 70, 79], ["villous atrophy", "DISEASE", 98, 113], ["acute malabsorption syndrome", "DISEASE", 133, 161], ["watery diarrhea", "DISEASE", 179, 194], ["vomiting", "DISEASE", 196, 204], ["anorexia", "DISEASE", 209, 217], ["small intestinal epithelial cells", "CELL", 23, 56], ["villous", "TISSUE", 98, 105], ["pigs", "ORGANISM", 221, 225], ["PEDV", "PROTEIN", 0, 4], ["small intestinal epithelial cells", "CELL_TYPE", 23, 56], ["pigs", "SPECIES", 221, 225], ["PEDV", "SPECIES", 0, 4], ["pigs", "SPECIES", 221, 225], ["PEDV", "PROBLEM", 0, 4], ["small intestinal epithelial cells in vivo", "PROBLEM", 23, 64], ["infection", "PROBLEM", 70, 79], ["pronounced villous atrophy", "PROBLEM", 87, 113], ["an acute malabsorption syndrome", "PROBLEM", 130, 161], ["symptoms", "PROBLEM", 167, 175], ["watery diarrhea", "PROBLEM", 179, 194], ["vomiting", "PROBLEM", 196, 204], ["anorexia", "PROBLEM", 209, 217], ["infects", "OBSERVATION_MODIFIER", 15, 22], ["small", "OBSERVATION_MODIFIER", 23, 28], ["intestinal epithelial cells", "OBSERVATION", 29, 56], ["infection", "OBSERVATION", 70, 79], ["pronounced", "OBSERVATION_MODIFIER", 87, 97], ["villous atrophy", "OBSERVATION", 98, 113], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["malabsorption syndrome", "OBSERVATION", 139, 161], ["watery", "OBSERVATION_MODIFIER", 179, 185], ["diarrhea", "OBSERVATION", 186, 194]]], ["PEDV infection causes high morbidity and mortality, particularly in newborn piglets, which results in a significant economic loss in the pig industry (Jung et al., 2015; Li et al., 2012) .", [["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 5, 14], ["piglets", "ORGANISM", 76, 83], ["pig", "ORGANISM", 137, 140], ["piglets", "SPECIES", 76, 83], ["pig", "SPECIES", 137, 140], ["PEDV", "SPECIES", 0, 4], ["pig", "SPECIES", 137, 140], ["PEDV infection", "PROBLEM", 0, 14], ["high morbidity", "PROBLEM", 22, 36], ["a significant economic loss", "PROBLEM", 102, 129], ["infection", "OBSERVATION", 5, 14], ["high", "OBSERVATION_MODIFIER", 22, 26], ["morbidity", "OBSERVATION", 27, 36], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["economic", "OBSERVATION_MODIFIER", 116, 124], ["loss", "OBSERVATION", 125, 129]]], ["Although there are several commercial PEDV vaccines available in China, the PEDV endemic has persisted in China since 2011 (Chen et al., 2012; Li et al., 2012) .", [["PEDV", "SPECIES", 38, 42], ["commercial PEDV vaccines", "TREATMENT", 27, 51], ["the PEDV endemic", "PROBLEM", 72, 88], ["several", "OBSERVATION_MODIFIER", 19, 26], ["commercial", "OBSERVATION_MODIFIER", 27, 37], ["PEDV", "OBSERVATION", 38, 42]]], ["Therefore, the development of anti-PEDV therapeutics is urgently needed.", [["anti-PEDV", "SIMPLE_CHEMICAL", 30, 39], ["anti-PEDV", "SPECIES", 30, 39], ["anti-PEDV therapeutics", "TREATMENT", 30, 52]]], ["IFN-L has been shown to inhibit replication of many viruses in vitro and in vivo Hernandez et al., 2015; Sommereyns et al., 2008) .", [["IFN", "CHEMICAL", 0, 3], ["IFN-L", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "PROTEIN", 0, 3]]], ["However, there are no reports regarding whether porcine IFN-L inhibits the coronavirus PEDV.Cells and virusesAfrican green monkey epithelial Vero E6 cells were used to amplify PEDV.", [["Cells", "ANATOMY", 92, 97], ["epithelial Vero E6 cells", "ANATOMY", 130, 154], ["IFN", "CHEMICAL", 56, 59], ["porcine", "ORGANISM", 48, 55], ["IFN-L", "GENE_OR_GENE_PRODUCT", 56, 61], ["coronavirus", "ORGANISM", 75, 86], ["PEDV", "ORGANISM", 87, 91], ["Cells", "CELL", 92, 97], ["virusesAfrican green monkey epithelial Vero E6 cells", "CELL", 102, 154], ["porcine IFN-L", "PROTEIN", 48, 61], ["coronavirus PEDV", "PROTEIN", 75, 91], ["virusesAfrican green monkey epithelial Vero E6 cells", "CELL_LINE", 102, 154], ["PEDV", "PROTEIN", 176, 180], ["coronavirus", "SPECIES", 75, 86], ["virusesAfrican green monkey", "SPECIES", 102, 129], ["Vero E6", "SPECIES", 141, 148], ["PEDV", "SPECIES", 176, 180], ["porcine IFN", "PROBLEM", 48, 59], ["the coronavirus PEDV", "PROBLEM", 71, 91], ["Cells", "TEST", 92, 97], ["virusesAfrican", "TEST", 102, 116], ["epithelial Vero E6 cells", "TREATMENT", 130, 154], ["PEDV", "PROBLEM", 176, 180], ["coronavirus PEDV", "OBSERVATION", 75, 91], ["Vero E6 cells", "OBSERVATION", 141, 154]]], ["Vero E6 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with antibiotics (100 units/ ml of penicillin and 100 mg/ml of streptomycin) and 10% heatinactivated fetal bovine serum (FBS) (Gibco).", [["Vero E6 cells", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 184, 202], ["FBS", "ANATOMY", 204, 207], ["penicillin", "CHEMICAL", 118, 128], ["streptomycin", "CHEMICAL", 146, 158], ["penicillin", "CHEMICAL", 118, 128], ["streptomycin", "CHEMICAL", 146, 158], ["Vero E6 cells", "CELL", 0, 13], ["penicillin", "SIMPLE_CHEMICAL", 118, 128], ["streptomycin", "SIMPLE_CHEMICAL", 146, 158], ["bovine", "ORGANISM", 190, 196], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["FBS", "ORGANISM_SUBSTANCE", 204, 207], ["Vero E6 cells", "CELL_LINE", 0, 13], ["bovine", "SPECIES", 190, 196], ["Vero E6", "SPECIES", 0, 7], ["bovine", "SPECIES", 190, 196], ["Vero E6 cells", "PROBLEM", 0, 13], ["Dulbecco's Modified Eagle's Medium (DMEM", "TREATMENT", 28, 68], ["antibiotics", "TREATMENT", 88, 99], ["penicillin", "TREATMENT", 118, 128], ["streptomycin", "TREATMENT", 146, 158], ["10% heatinactivated fetal bovine serum (FBS", "TREATMENT", 164, 207], ["E6 cells", "OBSERVATION", 5, 13]]], ["The intestinal porcine epithelial cell line J2 (IPEC-J2) (kindly provided by Dr. Anthony Blikslager, North Carolina State University, Raleigh, NC, USA) was maintained in Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 (DMEM/F12) supplemented with antibiotics (100 units/ml of penicillin, 100 mg/ml of streptomycin, and 0.25 mg/ml of Fungizone \u00ae ), 0.1 mM HEPES (Gibco), and 10% heat-inactivated fetal bovine serum (FBS) (Gibco).", [["intestinal porcine epithelial cell line J2", "ANATOMY", 4, 46], ["fetal bovine serum", "ANATOMY", 404, 422], ["FBS", "ANATOMY", 424, 427], ["penicillin", "CHEMICAL", 285, 295], ["streptomycin", "CHEMICAL", 310, 322], ["Fungizone", "CHEMICAL", 342, 351], ["penicillin", "CHEMICAL", 285, 295], ["streptomycin", "CHEMICAL", 310, 322], ["HEPES", "CHEMICAL", 364, 369], ["intestinal porcine epithelial cell line J2", "CELL", 4, 46], ["IPEC-J2", "CELL", 48, 55], ["penicillin", "SIMPLE_CHEMICAL", 285, 295], ["streptomycin", "SIMPLE_CHEMICAL", 310, 322], ["Fungizone", "SIMPLE_CHEMICAL", 342, 351], ["\u00ae", "SIMPLE_CHEMICAL", 352, 353], ["bovine", "ORGANISM", 410, 416], ["serum", "ORGANISM_SUBSTANCE", 417, 422], ["FBS", "ORGANISM_SUBSTANCE", 424, 427], ["intestinal porcine epithelial cell line J2", "CELL_LINE", 4, 46], ["IPEC", "CELL_LINE", 48, 52], ["J2", "CELL_LINE", 53, 55], ["porcine", "SPECIES", 15, 22], ["bovine", "SPECIES", 410, 416], ["bovine", "SPECIES", 410, 416], ["The intestinal porcine epithelial cell line J2", "TREATMENT", 0, 46], ["antibiotics", "TREATMENT", 256, 267], ["penicillin", "TREATMENT", 285, 295], ["streptomycin", "TREATMENT", 310, 322], ["Fungizone", "TREATMENT", 342, 351], ["fetal bovine serum", "TEST", 404, 422], ["intestinal porcine", "ANATOMY", 4, 22], ["epithelial cell line", "OBSERVATION", 23, 43], ["J2", "OBSERVATION_MODIFIER", 44, 46]]], ["PEDV strain CV777 of genotype 1 (GenBank accession No KT323979) and PEDV strain LNCT2 of genotype 2 (GenBank accession No KT323980) were maintained at the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, Harbin.Determination of antiviral units (AUs) of rpIFN-L1 and L3The biological antiviral activity of E. coli-derived recombinant porcine IFN-lambda (rpIFN-L)1 and 3 were prepared in our laboratory and evaluated in MDBK cells using a recombinant vesicular stomatitis virus (VSV) expressing a GFP reporter as described previously .", [["MDBK cells", "ANATOMY", 455, 465], ["vesicular stomatitis", "DISEASE", 486, 506], ["genotype 1", "ORGANISM", 21, 31], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 290, 298], ["L3The", "SIMPLE_CHEMICAL", 303, 308], ["E. coli-derived", "ORGANISM", 342, 357], ["porcine", "ORGANISM", 370, 377], ["IFN-lambda", "GENE_OR_GENE_PRODUCT", 378, 388], ["rpIFN-L)1", "GENE_OR_GENE_PRODUCT", 390, 399], ["3", "ORGANISM", 404, 405], ["MDBK cells", "CELL", 455, 465], ["recombinant", "ORGANISM", 474, 485], ["vesicular stomatitis virus", "ORGANISM", 486, 512], ["VSV", "ORGANISM", 514, 517], ["GFP", "GENE_OR_GENE_PRODUCT", 532, 535], ["rpIFN", "PROTEIN", 290, 295], ["E. coli-derived recombinant porcine IFN-lambda (rpIFN-L)1 and 3", "PROTEIN", 342, 405], ["MDBK cells", "CELL_LINE", 455, 465], ["GFP reporter", "DNA", 532, 544], ["porcine", "SPECIES", 370, 377], ["vesicular stomatitis virus", "SPECIES", 486, 512], ["PEDV", "SPECIES", 0, 4], ["GenBank accession No KT323979", "SPECIES", 33, 62], ["E. coli-derived recombinant porcine IFN-lambda", "SPECIES", 342, 388], ["MDBK", "SPECIES", 455, 459], ["stomatitis virus", "SPECIES", 496, 512], ["VSV", "SPECIES", 514, 517], ["PEDV strain", "TEST", 0, 11], ["genotype", "TEST", 21, 29], ["GenBank accession", "TEST", 33, 50], ["PEDV strain", "TEST", 68, 79], ["genotype 2", "PROBLEM", 89, 99], ["antiviral units", "TREATMENT", 265, 280], ["AUs", "TEST", 282, 285], ["rpIFN", "TEST", 290, 295], ["L1 and L3The biological antiviral activity", "TREATMENT", 296, 338], ["E. coli-derived recombinant porcine IFN", "TREATMENT", 342, 381], ["rpIFN", "TEST", 390, 395], ["MDBK cells", "PROBLEM", 455, 465], ["a recombinant vesicular stomatitis virus", "PROBLEM", 472, 512], ["L1", "ANATOMY", 296, 298], ["antiviral activity", "OBSERVATION", 320, 338], ["vesicular stomatitis", "OBSERVATION", 486, 506]]], ["The weight-activity unit (U/ml) of samples was calculated using porcine IFN-a as a reference.Antiviral assayTo determine the anti-PEDV activity of E. coli-derived rpIFN-L1 and 3 prepared in our laboratory, Vero E6 or IPEC-J2 cells were seeded in 24-well plates and either left untreated or pre-treated with the indicated concentrations of rpIFN-L for 24 h.", [["samples", "ANATOMY", 35, 42], ["IPEC-J2 cells", "ANATOMY", 217, 230], ["porcine", "ORGANISM", 64, 71], ["IFN", "GENE_OR_GENE_PRODUCT", 72, 75], ["Vero", "ORGANISM", 206, 210], ["E6", "ORGANISM", 211, 213], ["IPEC-J2 cells", "CELL", 217, 230], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 339, 346], ["IFN", "PROTEIN", 72, 75], ["Vero E6", "CELL_LINE", 206, 213], ["IPEC-J2 cells", "CELL_LINE", 217, 230], ["rpIFN", "PROTEIN", 339, 344], ["E. coli-derived rpIFN-L1", "SPECIES", 147, 171], ["Vero E6", "SPECIES", 206, 213], ["The weight", "TEST", 0, 10], ["samples", "TEST", 35, 42], ["porcine IFN", "TREATMENT", 64, 75], ["Antiviral assayTo", "TREATMENT", 93, 110], ["E. coli-derived rpIFN", "TEST", 147, 168], ["Vero E6", "TREATMENT", 206, 213], ["IPEC-J2 cells", "TREATMENT", 217, 230], ["rpIFN", "TREATMENT", 339, 344], ["L1", "ANATOMY", 169, 171], ["left", "ANATOMY_MODIFIER", 272, 276]]], ["The cells were then infected with PEDV strain CV777 or strain LNCT2 at an MOI of 0.1 for 2 h and then cultured with medium in the absence of rpIFN-L for 36 h before harvesting the cell supernatant.", [["cells", "ANATOMY", 4, 9], ["cell supernatant", "ANATOMY", 180, 196], ["LNCT2", "CHEMICAL", 62, 67], ["cells", "CELL", 4, 9], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 141, 148], ["cell", "CELL", 180, 184], ["rpIFN", "PROTEIN", 141, 146], ["PEDV strain CV777", "SPECIES", 34, 51], ["PEDV strain", "PROBLEM", 34, 45], ["strain LNCT2", "PROBLEM", 55, 67], ["an MOI", "TEST", 71, 77], ["rpIFN", "TEST", 141, 146], ["cell supernatant", "OBSERVATION", 180, 196]]], ["For measuring the inhibition kinetics of rpIFN-L1 against PEDV infection, Vero E6 cells were stimulated or unstimulated for 24 h with 100 ng/ml of rpIFN-L1 and then infected with PEDV for 2 h followed by culturing in the absence of rpIFN-L for the indicated hours before quantifying PEDV infection.", [["Vero E6 cells", "ANATOMY", 74, 87], ["infection", "DISEASE", 63, 72], ["PEDV", "CHEMICAL", 179, 183], ["infection", "DISEASE", 288, 297], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 41, 49], ["PEDV", "ORGANISM", 58, 62], ["Vero E6 cells", "CELL", 74, 87], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 147, 155], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 232, 239], ["PEDV", "ORGANISM", 283, 287], ["rpIFN", "PROTEIN", 41, 46], ["L1", "DNA", 47, 49], ["Vero E6 cells", "CELL_LINE", 74, 87], ["rpIFN", "PROTEIN", 147, 152], ["rpIFN", "PROTEIN", 232, 237], ["PEDV", "SPECIES", 58, 62], ["Vero E6", "SPECIES", 74, 81], ["PEDV", "SPECIES", 179, 183], ["PEDV", "SPECIES", 283, 287], ["rpIFN", "TEST", 41, 46], ["PEDV infection", "PROBLEM", 58, 72], ["Vero E6 cells", "TREATMENT", 74, 87], ["rpIFN-L1", "TREATMENT", 147, 155], ["PEDV", "TREATMENT", 179, 183], ["culturing", "TEST", 204, 213], ["rpIFN", "TEST", 232, 237], ["PEDV infection", "PROBLEM", 283, 297], ["L1", "ANATOMY", 47, 49], ["infection", "OBSERVATION", 63, 72], ["L1", "ANATOMY", 153, 155], ["infected", "OBSERVATION", 165, 173], ["PEDV", "OBSERVATION_MODIFIER", 283, 287], ["infection", "OBSERVATION", 288, 297]]], ["To examine the level of ISG expression in IPEC-J2 cells following IFN stimulation, the cells were stimulated with the indicated concentrations of IFNs in 24-well plates for 24 h.", [["IPEC-J2 cells", "ANATOMY", 42, 55], ["cells", "ANATOMY", 87, 92], ["ISG", "GENE_OR_GENE_PRODUCT", 24, 27], ["IPEC-J2 cells", "CELL", 42, 55], ["cells", "CELL", 87, 92], ["IPEC-J2 cells", "CELL_LINE", 42, 55], ["IFN", "PROTEIN", 66, 69], ["IFNs", "PROTEIN", 146, 150], ["IPEC-J2 cells", "TREATMENT", 42, 55], ["IFN stimulation", "TREATMENT", 66, 81], ["the cells", "TREATMENT", 83, 92], ["IFNs", "TREATMENT", 146, 150]]], ["Cells were then lysed, and total RNA was extracted for subsequent qPCR analysis.Real-time quantitative PCR (qPCR)Total RNA was extracted from the cellular supernatant or cell lysates using the Simply P Total RNA Extraction Kit (BioFlux, China) according to the manufacturer's instructions.", [["Cells", "ANATOMY", 0, 5], ["cellular supernatant", "ANATOMY", 146, 166], ["cell lysates", "ANATOMY", 170, 182], ["Cells", "CELL", 0, 5], ["cellular", "CELL", 146, 154], ["cell lysates", "ORGANISM_SUBSTANCE", 170, 182], ["total RNA", "TEST", 27, 36], ["subsequent qPCR analysis", "TEST", 55, 79], ["quantitative PCR", "TEST", 90, 106], ["Total RNA", "TEST", 113, 122], ["cell lysates", "TREATMENT", 170, 182], ["Total RNA Extraction Kit (BioFlux, China", "TREATMENT", 202, 242], ["cell lysates", "OBSERVATION", 170, 182]]], ["Reverse transcription was performed using the PrimeScript\u2122 II 1st Strand cDNA Synthesis Kit (TAKARA), and qPCR was performed in a LightCycler480 \u2161 (Roche, Switzerland) with power SYBR Green PCR Master Mix (Applied Biosystems).", [["the PrimeScript\u2122 II 1st Strand cDNA Synthesis Kit (TAKARA)", "TREATMENT", 42, 100], ["qPCR", "TEST", 106, 110], ["power SYBR Green PCR Master Mix", "TREATMENT", 173, 204]]], ["The thermal cycling conditions were 95 C for 10 min, followed by 40 cycles of 95 C for 30 s, and 60 C for 1 min.", [["The thermal cycling conditions", "PROBLEM", 0, 30]]], ["All acquired data were obtained using LightCycler 480 real time PCR machines (Roche) and analyzed with LightCycler 480 software 1.5 based on the cycle threshold (DDCT) method (Schmittgen and Livak, 2008) .", [["LightCycler", "TREATMENT", 38, 49], ["LightCycler", "TEST", 103, 114]]], ["Primers were designed using Oligo 6 software and are shown in Table 1 .Real-time quantitative PCR (qPCR)Quantification of PEDV RNA was calculated based on a standard curve with known amounts of in vitro-transcribed PEDV RNA.Immunofluorescence assayVero E6 or IPEC-J2 cells were seeded in 96-well plates, and each confluent monolayer of cells was stimulated with indicated concentrations of either type of rpIFN-L for 24 h before PEDV infection.", [["Vero", "ANATOMY", 248, 252], ["IPEC-J2 cells", "ANATOMY", 259, 272], ["monolayer", "ANATOMY", 323, 332], ["cells", "ANATOMY", 336, 341], ["PEDV", "CHEMICAL", 429, 433], ["infection", "DISEASE", 434, 443], ["PEDV", "GENE_OR_GENE_PRODUCT", 215, 219], ["Vero E6", "CELL", 248, 255], ["IPEC-J2 cells", "CELL", 259, 272], ["monolayer", "CELL", 323, 332], ["cells", "CELL", 336, 341], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 405, 412], ["PEDV RNA", "RNA", 122, 130], ["PEDV RNA", "RNA", 215, 223], ["Vero E6", "CELL_LINE", 248, 255], ["IPEC-J2 cells", "CELL_LINE", 259, 272], ["PEDV", "SPECIES", 122, 126], ["Vero E6", "SPECIES", 248, 255], ["PEDV", "SPECIES", 429, 433], ["Oligo 6 software", "TREATMENT", 28, 44], ["quantitative PCR", "TEST", 81, 97], ["PEDV RNA", "PROBLEM", 122, 130], ["a standard curve", "TEST", 155, 171], ["Immunofluorescence assay", "TEST", 224, 248], ["Vero E6", "TEST", 248, 255], ["IPEC-J2 cells", "TREATMENT", 259, 272], ["each confluent monolayer of cells", "PROBLEM", 308, 341], ["rpIFN", "TREATMENT", 405, 410], ["PEDV infection", "PROBLEM", 429, 443], ["amounts", "OBSERVATION_MODIFIER", 183, 190], ["PEDV RNA", "OBSERVATION", 215, 223], ["confluent", "OBSERVATION_MODIFIER", 313, 322], ["infection", "OBSERVATION", 434, 443]]], ["The cells were then infected with PEDV strain CV777 at an MOI of 0.1.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PEDV", "SPECIES", 34, 38], ["PEDV strain", "PROBLEM", 34, 45], ["an MOI", "TEST", 55, 61], ["infected", "OBSERVATION_MODIFIER", 20, 28]]], ["PEDV infection was analyzed using an immunofluorescence assay (IFA) at 36 h post-infection.", [["infection", "DISEASE", 5, 14], ["infection", "DISEASE", 81, 90], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV infection", "PROBLEM", 0, 14], ["an immunofluorescence assay", "TEST", 34, 61], ["infection", "PROBLEM", 81, 90], ["infection", "OBSERVATION", 5, 14], ["infection", "OBSERVATION", 81, 90]]], ["Briefly, the cells were fixed with 4% paraformaldehyde at 4 C for 30 min and washed with 1 \u00c2 PBS.", [["cells", "ANATOMY", 13, 18], ["paraformaldehyde", "CHEMICAL", 38, 54], ["cells", "CELL", 13, 18], ["paraformaldehyde", "SIMPLE_CHEMICAL", 38, 54], ["4% paraformaldehyde", "TREATMENT", 35, 54], ["1 \u00c2 PBS", "TREATMENT", 89, 96]]], ["Fixed cells were permeabilized with 0.2% Triton X-100 for 15 min at room temperature and blocked with blocking buffer (PBS with 10% FBS) for 1 h.", [["cells", "ANATOMY", 6, 11], ["Triton X-100", "CHEMICAL", 41, 53], ["cells", "CELL", 6, 11], ["Triton X-100", "SIMPLE_CHEMICAL", 41, 53], ["FBS", "ORGANISM_SUBSTANCE", 132, 135], ["Fixed cells", "PROBLEM", 0, 11], ["blocking buffer (PBS", "TREATMENT", 102, 122], ["10% FBS", "TREATMENT", 128, 135]]], ["The preparations were labeled with the mouse anti-PEDV nucleocapsid monoclonal antibody (mAb) 2G3 stocked in our laboratory (1:100 dilution) at 37 C for 2 h followed by labeling with the Alexa Fluor 546 goat anti-mouse IgG antibody (1:200 dilution) (ThermoFisher Scientific) for 1 h at 37 C. DAPI (1:100 dilution) was used to stain cell nuclei.", [["cell nuclei", "ANATOMY", 332, 343], ["Alexa Fluor 546", "CHEMICAL", 187, 202], ["DAPI", "CHEMICAL", 292, 296], ["mouse", "ORGANISM", 39, 44], ["Alexa Fluor", "SIMPLE_CHEMICAL", 187, 198], ["DAPI", "SIMPLE_CHEMICAL", 292, 296], ["cell nuclei", "CELL", 332, 343], ["mouse anti-PEDV nucleocapsid monoclonal antibody (mAb) 2G3", "PROTEIN", 39, 97], ["Alexa Fluor 546 goat anti-mouse IgG antibody", "PROTEIN", 187, 231], ["mouse", "SPECIES", 39, 44], ["goat", "SPECIES", 203, 207], ["anti-mouse", "SPECIES", 208, 218], ["mouse", "SPECIES", 39, 44], ["anti-PEDV", "SPECIES", 45, 54], ["Alexa Fluor 546 goat", "SPECIES", 187, 207], ["the mouse anti-PEDV nucleocapsid monoclonal antibody", "TREATMENT", 35, 87], ["the Alexa Fluor", "TREATMENT", 183, 198], ["goat anti-mouse IgG antibody", "TEST", 203, 231], ["cell nuclei", "OBSERVATION", 332, 343]]], ["The stained cells wereCloning and expression of porcine IFITM1 and IFITM3Primers for swine IFITM1 and 3 were designed according to available sequences from the NCBI database (Genbank accession No.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["porcine", "ORGANISM", 48, 55], ["IFITM1", "GENE_OR_GENE_PRODUCT", 56, 62], ["IFITM3Primers", "GENE_OR_GENE_PRODUCT", 67, 80], ["IFITM1", "GENE_OR_GENE_PRODUCT", 91, 97], ["3", "GENE_OR_GENE_PRODUCT", 102, 103], ["porcine IFITM1", "PROTEIN", 48, 62], ["IFITM3Primers", "PROTEIN", 67, 80], ["swine IFITM1 and 3", "DNA", 85, 103], ["NCBI database", "DNA", 160, 173], ["swine", "SPECIES", 85, 90], ["swine", "SPECIES", 85, 90], ["The stained cells", "PROBLEM", 0, 17], ["porcine IFITM1", "TREATMENT", 48, 62], ["swine IFITM1", "TEST", 85, 97], ["stained cells", "OBSERVATION", 4, 17]]], ["XM_003124230.2 for IFITM1 and NM_001201382 for IFITM3).", [["NM_001201382", "GENE_OR_GENE_PRODUCT", 30, 42], ["IFITM1", "PROTEIN", 19, 25], ["IFITM3", "PROTEIN", 47, 53], ["IFITM1", "TEST", 19, 25], ["IFITM3", "PROBLEM", 47, 53]]], ["Swine IFITM1 and 3 were amplified by PCR from cDNA obtained from IFNstimulated IPEC-J2 cells using the PrimeScript\u2122 II 1st Strand cDNA Synthesis Kit (TAKARA) according to the manufacturer's instructions.", [["IPEC-J2 cells", "ANATOMY", 79, 92], ["IFITM1", "GENE_OR_GENE_PRODUCT", 6, 12], ["3", "GENE_OR_GENE_PRODUCT", 17, 18], ["IPEC-J2 cells", "CELL", 79, 92], ["Swine IFITM1 and 3", "DNA", 0, 18], ["IFNstimulated IPEC-J2 cells", "CELL_LINE", 65, 92], ["Swine", "SPECIES", 0, 5], ["cDNA", "TEST", 46, 50], ["J2 cells", "TREATMENT", 84, 92], ["the PrimeScript\u2122 II 1st Strand cDNA Synthesis Kit (TAKARA)", "TREATMENT", 99, 157]]], ["The PCR products of porcine IFITM1 and IFITM3 were amplified with the primers listed in Table 1 , and then cloned into a pCAGGS-HA vector (Clontech) to obtain pIFITM1-HA and pIFITM3-HA using EcoRI and KpnI restriction enzyme sites.", [["porcine", "ORGANISM", 20, 27], ["IFITM1", "GENE_OR_GENE_PRODUCT", 28, 34], ["IFITM3", "GENE_OR_GENE_PRODUCT", 39, 45], ["Clontech", "GENE_OR_GENE_PRODUCT", 139, 147], ["pIFITM1-HA", "GENE_OR_GENE_PRODUCT", 159, 169], ["pIFITM3-HA", "GENE_OR_GENE_PRODUCT", 174, 184], ["EcoRI", "GENE_OR_GENE_PRODUCT", 191, 196], ["KpnI restriction enzyme", "GENE_OR_GENE_PRODUCT", 201, 224], ["PCR products", "DNA", 4, 16], ["porcine IFITM1", "DNA", 20, 34], ["IFITM3", "DNA", 39, 45], ["Table 1", "DNA", 88, 95], ["pCAGGS-HA vector", "DNA", 121, 137], ["Clontech", "DNA", 139, 147], ["pIFITM1", "PROTEIN", 159, 166], ["HA", "DNA", 167, 169], ["pIFITM3", "DNA", 174, 181], ["HA", "DNA", 182, 184], ["EcoRI and KpnI restriction enzyme sites", "DNA", 191, 230], ["porcine", "SPECIES", 20, 27], ["porcine", "SPECIES", 20, 27], ["The PCR products", "TREATMENT", 0, 16], ["porcine IFITM1 and IFITM3", "TREATMENT", 20, 45], ["a pCAGGS-HA vector", "TREATMENT", 119, 137], ["pIFITM1", "TEST", 159, 166], ["HA", "PROBLEM", 167, 169], ["pIFITM3", "TEST", 174, 181], ["HA", "PROBLEM", 182, 184], ["EcoRI and KpnI restriction enzyme sites", "TREATMENT", 191, 230]]], ["The recombinant plasmids were verified by sequencing.", [["plasmids", "ANATOMY", 16, 24], ["recombinant plasmids", "DNA", 4, 24], ["The recombinant plasmids", "TREATMENT", 0, 24], ["plasmids", "OBSERVATION", 16, 24]]], ["Expression of porcine IFITM1 and IFITM3 from the recombinant plasmids was verified by western blotting using the mouse anti-HA mAb HA-7 (Sigma).Cell viability measurementCell viability was determined using the cell counting kit-8 (CCK-8) assay kit (Beyotime, Hangzhou, China) according to the manufacturer's instructions.", [["plasmids", "ANATOMY", 61, 69], ["Cell", "ANATOMY", 144, 148], ["Cell", "ANATOMY", 170, 174], ["cell", "ANATOMY", 210, 214], ["porcine", "ORGANISM", 14, 21], ["IFITM1", "GENE_OR_GENE_PRODUCT", 22, 28], ["IFITM3", "GENE_OR_GENE_PRODUCT", 33, 39], ["mouse", "ORGANISM", 113, 118], ["Cell", "CELL", 144, 148], ["Cell", "CELL", 170, 174], ["cell", "CELL", 210, 214], ["kit-8", "GENE_OR_GENE_PRODUCT", 224, 229], ["CCK-8", "GENE_OR_GENE_PRODUCT", 231, 236], ["porcine IFITM1", "PROTEIN", 14, 28], ["IFITM3", "PROTEIN", 33, 39], ["recombinant plasmids", "DNA", 49, 69], ["mouse anti-HA mAb HA-7", "PROTEIN", 113, 135], ["Sigma", "PROTEIN", 137, 142], ["porcine", "SPECIES", 14, 21], ["mouse", "SPECIES", 113, 118], ["mouse", "SPECIES", 113, 118], ["porcine IFITM1 and IFITM3", "TREATMENT", 14, 39], ["the recombinant plasmids", "TREATMENT", 45, 69], ["the mouse anti-HA mAb HA", "TREATMENT", 109, 133], ["Cell viability measurement", "TEST", 144, 170], ["Cell viability", "TEST", 170, 184], ["the cell counting kit", "TEST", 206, 227], ["CCK", "TEST", 231, 234]]], ["Vero E6 or IPEC-J2 cells were seeded in 96well cell culture plates at a density of 2 \u00c2 10 4 cells/well and grown at 37 C for 24 h.", [["Vero", "ANATOMY", 0, 4], ["IPEC-J2 cells", "ANATOMY", 11, 24], ["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 92, 97], ["Vero E6", "ORGANISM", 0, 7], ["IPEC-J2 cells", "CELL", 11, 24], ["96well cell", "CELL", 40, 51], ["cells", "CELL", 92, 97], ["Vero E6", "CELL_LINE", 0, 7], ["IPEC-J2 cells", "CELL_LINE", 11, 24], ["Vero E6", "SPECIES", 0, 7], ["Vero E6", "TREATMENT", 0, 7], ["IPEC-J2 cells", "TREATMENT", 11, 24], ["a density", "TEST", 70, 79], ["J2 cells", "OBSERVATION", 16, 24]]], ["Indicated concentrations of rpIFN-L1 or rpIFN-L3 were added to each well, and blank control wells (without cells and IFN) and cells only control wells (with cells but without IFN) were included.", [["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 126, 131], ["cells", "ANATOMY", 157, 162], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 28, 36], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 40, 48], ["cells", "CELL", 107, 112], ["IFN", "CELL", 117, 120], ["cells", "CELL", 126, 131], ["cells", "CELL", 157, 162], ["rpIFN", "PROTEIN", 28, 33], ["L1", "PROTEIN", 34, 36], ["rpIFN", "PROTEIN", 40, 45], ["L3", "PROTEIN", 46, 48], ["IFN", "PROTEIN", 117, 120], ["IFN", "PROTEIN", 175, 178], ["rpIFN", "TEST", 28, 33], ["L1 or rpIFN-L3", "TREATMENT", 34, 48], ["L1", "ANATOMY", 34, 36], ["L3", "ANATOMY", 46, 48]]], ["After 60 h, 10 ml of the CCK8 reagent was added to each well, and the plate was incubated for 4 h at 37 C. The absorbance was measured at 450 nm using a microplate reader, and 50% cellular cytotoxicity (CC 50 ) was calculated using GraphPad Prism (GraphPad Software, Inc).Statistical analysesAll statistical analyses were analyzed in GraphPad Prism (GraphPad Software, Inc).", [["cellular", "ANATOMY", 180, 188], ["CCK8", "CHEMICAL", 25, 29], ["CCK8", "CHEMICAL", 25, 29], ["CCK8", "SIMPLE_CHEMICAL", 25, 29], ["cellular", "CELL", 180, 188], ["the CCK8 reagent", "TREATMENT", 21, 37], ["The absorbance", "TEST", 107, 121], ["a microplate reader", "TREATMENT", 151, 170], ["Statistical analyses", "TEST", 272, 292], ["All statistical analyses", "TEST", 292, 316]]], ["The difference between two treatments was determined using an Unpaired T-test.", [["an Unpaired T-test", "TEST", 59, 77]]], ["Differences were considered significant if the P value was <0.05.", [["the P value", "TEST", 43, 54]]], ["P values are indicated as follows: P < 0.001.rpIFN-L1 inhibits PEDV infection in Vero E6 cells and small intestinal epithelial cellsWe prokaryotically expressed recombinant porcine IFN-L1 (rpIFN-L1) and rpIFN-L3 and purified each by Ni \u00fe affinity chromatography in our laboratory (unpublished results). rpIFN-L1 and rpIFN-L3 were determined to be biologically active and exhibit anti-VSV activity in MDBK cells using a VSV-GFP reporter assay.", [["Vero E6 cells", "ANATOMY", 81, 94], ["small intestinal epithelial cells", "ANATOMY", 99, 132], ["MDBK cells", "ANATOMY", 400, 410], ["infection", "DISEASE", 68, 77], ["Ni", "CHEMICAL", 233, 235], ["Ni", "CHEMICAL", 233, 235], [".rpIFN-L1", "GENE_OR_GENE_PRODUCT", 44, 53], ["PEDV", "ORGANISM", 63, 67], ["Vero E6 cells", "CELL", 81, 94], ["small intestinal epithelial cells", "CELL", 99, 132], ["porcine", "ORGANISM", 173, 180], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 181, 187], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 189, 197], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 203, 211], ["Ni \u00fe", "SIMPLE_CHEMICAL", 233, 237], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 303, 311], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 316, 324], ["anti-VSV", "CANCER", 379, 387], ["MDBK cells", "CELL", 400, 410], ["VSV", "ORGANISM", 419, 422], ["GFP", "GENE_OR_GENE_PRODUCT", 423, 426], ["P", "DNA", 0, 1], ["Vero E6 cells", "CELL_LINE", 81, 94], ["small intestinal epithelial cells", "CELL_TYPE", 99, 132], ["recombinant porcine IFN-L1", "PROTEIN", 161, 187], ["rpIFN", "PROTEIN", 189, 194], ["L1", "PROTEIN", 195, 197], ["rpIFN", "PROTEIN", 203, 208], ["L3", "DNA", 209, 211], ["rpIFN", "PROTEIN", 303, 308], ["L1", "DNA", 309, 311], ["rpIFN", "PROTEIN", 316, 321], ["L3", "DNA", 322, 324], ["MDBK cells", "CELL_LINE", 400, 410], ["porcine", "SPECIES", 173, 180], ["PEDV", "SPECIES", 63, 67], ["Vero E6", "SPECIES", 81, 88], ["MDBK", "SPECIES", 400, 404], ["VSV", "SPECIES", 419, 422], ["P values", "TEST", 0, 8], ["P", "TEST", 35, 36], [".rpIFN", "TEST", 44, 50], ["PEDV infection", "PROBLEM", 63, 77], ["Vero E6 cells", "PROBLEM", 81, 94], ["small intestinal epithelial cells", "PROBLEM", 99, 132], ["recombinant porcine IFN-L1 (rpIFN-L1", "TREATMENT", 161, 197], ["rpIFN", "TEST", 203, 208], ["Ni \u00fe affinity chromatography", "TEST", 233, 261], ["rpIFN", "TEST", 303, 308], ["L1 and rpIFN-L3", "TREATMENT", 309, 324], ["anti-VSV activity in MDBK cells", "PROBLEM", 379, 410], ["a VSV", "TEST", 417, 422], ["GFP reporter assay", "TEST", 423, 441], ["L1", "ANATOMY", 51, 53], ["infection", "OBSERVATION", 68, 77], ["Vero E6 cells", "OBSERVATION", 81, 94], ["small", "OBSERVATION_MODIFIER", 99, 104], ["intestinal epithelial cells", "OBSERVATION", 105, 132], ["recombinant porcine IFN", "OBSERVATION", 161, 184], ["L1", "ANATOMY", 195, 197], ["L3", "ANATOMY", 209, 211], ["L1", "ANATOMY", 309, 311], ["L3", "ANATOMY", 322, 324]]], ["Previous studies have demonstrated that the antiviral unit (AU) of IFN is closely related to the virus and target cells used in the reporter assay; thus, we normalized the input of IFN by protein concentration instead of by AU throughout the study (Dellgren et al., 2009) .rpIFN-L1 inhibits PEDV infection in Vero E6 cells and small intestinal epithelial cellsPEDV is generally grown and amplified in vitro in Vero E6 cells that have lost the capacity to produce type I IFNs due to a chromosomal deletion (Diaz et al., 1988) .", [["cells", "ANATOMY", 114, 119], ["Vero E6 cells", "ANATOMY", 309, 322], ["intestinal epithelial", "ANATOMY", 333, 354], ["cells", "ANATOMY", 418, 423], ["chromosomal", "ANATOMY", 484, 495], ["infection", "DISEASE", 296, 305], ["IFN", "GENE_OR_GENE_PRODUCT", 67, 70], ["cells", "CELL", 114, 119], ["IFN", "GENE_OR_GENE_PRODUCT", 181, 184], [".rpIFN-L1", "GENE_OR_GENE_PRODUCT", 272, 281], ["PEDV", "ORGANISM", 291, 295], ["Vero E6 cells", "CELL", 309, 322], ["intestinal epithelial cellsPEDV", "CELL", 333, 364], ["Vero E6 cells", "CELL", 410, 423], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 463, 474], ["chromosomal", "CELLULAR_COMPONENT", 484, 495], ["IFN", "PROTEIN", 67, 70], ["target cells", "CELL_TYPE", 107, 119], ["IFN", "PROTEIN", 181, 184], ["Vero E6 cells", "CELL_LINE", 309, 322], ["Vero E6 cells", "CELL_LINE", 410, 423], ["type I IFNs", "PROTEIN", 463, 474], ["PEDV", "SPECIES", 291, 295], ["Vero E6", "SPECIES", 309, 316], ["Vero E6", "SPECIES", 410, 417], ["Previous studies", "TEST", 0, 16], ["the antiviral unit (AU) of IFN", "TREATMENT", 40, 70], ["the virus", "PROBLEM", 93, 102], ["IFN by protein concentration", "TREATMENT", 181, 209], ["the study", "TEST", 238, 247], [".rpIFN", "TREATMENT", 272, 278], ["PEDV infection", "PROBLEM", 291, 305], ["Vero E6 cells", "PROBLEM", 309, 322], ["small intestinal epithelial cellsPEDV", "PROBLEM", 327, 364], ["vitro in Vero E6 cells", "TREATMENT", 401, 423], ["the capacity", "PROBLEM", 439, 451], ["type I IFNs", "PROBLEM", 463, 474], ["a chromosomal deletion", "PROBLEM", 482, 504], ["L1", "ANATOMY", 279, 281], ["infection", "OBSERVATION", 296, 305], ["Vero E6 cells", "OBSERVATION", 309, 322], ["small", "OBSERVATION_MODIFIER", 327, 332], ["intestinal epithelial", "ANATOMY", 333, 354]]], ["A previous study has demonstrated that Vero E6 cells can respond to recombinant human IFN-L1 and induce antiviral responses following human IFN-L1 stimulation (Stoltz and Klingstrom, 2010) .", [["Vero E6 cells", "ANATOMY", 39, 52], ["Vero E6 cells", "CELL", 39, 52], ["human", "ORGANISM", 80, 85], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 86, 92], ["human", "ORGANISM", 134, 139], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 140, 146], ["Vero E6 cells", "CELL_LINE", 39, 52], ["recombinant human IFN-L1", "PROTEIN", 68, 92], ["IFN", "PROTEIN", 140, 143], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 134, 139], ["Vero E6", "SPECIES", 39, 46], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 134, 139], ["A previous study", "TEST", 0, 16], ["Vero E6 cells", "PROBLEM", 39, 52], ["recombinant human IFN-L1", "TREATMENT", 68, 92], ["antiviral responses", "TREATMENT", 104, 123], ["human IFN-L1 stimulation", "TREATMENT", 134, 158]]], ["First, we evaluated the antiviral activity of rpIFN-L1 against infection with the PEDV classical strain CV777 in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 113, 126], ["rpIFN-L1", "CHEMICAL", 46, 54], ["infection", "DISEASE", 63, 72], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 46, 54], ["Vero E6 cells", "CELL", 113, 126], ["rpIFN", "PROTEIN", 46, 51], ["L1", "PROTEIN", 52, 54], ["Vero E6 cells", "CELL_LINE", 113, 126], ["PEDV", "SPECIES", 82, 86], ["Vero E6", "SPECIES", 113, 120], ["rpIFN", "TEST", 46, 51], ["infection", "PROBLEM", 63, 72], ["the PEDV classical strain", "PROBLEM", 78, 103], ["Vero E6 cells", "TREATMENT", 113, 126], ["L1", "ANATOMY", 52, 54], ["infection", "OBSERVATION", 63, 72], ["E6 cells", "OBSERVATION", 118, 126]]], ["Vero E6 cells were pre-treated with increasing doses of rpIFN-L1 for 24 h prior to infection with PEDV strain CV777. rpIFN-L1 treatment potently inhibited PEDV replication in Vero E6 cells in a dose-dependent manner.", [["Vero E6 cells", "ANATOMY", 0, 13], ["Vero E6 cells", "ANATOMY", 175, 188], ["rpIFN-L1", "CHEMICAL", 56, 64], ["infection", "DISEASE", 83, 92], ["rpIFN-L1", "CHEMICAL", 117, 125], ["Vero E6 cells", "CELL", 0, 13], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 56, 64], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 117, 125], ["PEDV", "SIMPLE_CHEMICAL", 155, 159], ["Vero E6 cells", "CELL", 175, 188], ["Vero E6 cells", "CELL_LINE", 0, 13], ["rpIFN", "PROTEIN", 56, 61], ["rpIFN", "PROTEIN", 117, 122], ["Vero E6 cells", "CELL_LINE", 175, 188], ["Vero E6", "SPECIES", 0, 7], ["PEDV", "SPECIES", 98, 102], ["PEDV", "SPECIES", 155, 159], ["Vero E6", "SPECIES", 175, 182], ["Vero E6 cells", "TREATMENT", 0, 13], ["increasing doses of rpIFN-L1", "TREATMENT", 36, 64], ["infection", "PROBLEM", 83, 92], ["PEDV strain", "PROBLEM", 98, 109], ["rpIFN", "TREATMENT", 117, 122], ["L1 treatment", "TREATMENT", 123, 135], ["PEDV replication", "TREATMENT", 155, 171], ["Vero E6 cells", "TREATMENT", 175, 188], ["E6 cells", "OBSERVATION", 5, 13], ["infection", "OBSERVATION", 83, 92], ["L1", "ANATOMY", 123, 125]]], ["By measuring PEDV viral RNA, it was found that rpIFN-L1 at concentrations of 1000 ng/ml and 100 ng/ml significantly inhibited PEDV infection.", [["rpIFN-L1", "CHEMICAL", 47, 55], ["PEDV", "CHEMICAL", 126, 130], ["infection", "DISEASE", 131, 140], ["PEDV", "GENE_OR_GENE_PRODUCT", 13, 17], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 47, 55], ["PEDV", "SIMPLE_CHEMICAL", 126, 130], ["PEDV viral RNA", "RNA", 13, 27], ["rpIFN", "PROTEIN", 47, 52], ["L1", "PROTEIN", 53, 55], ["PEDV", "SPECIES", 13, 17], ["PEDV", "SPECIES", 126, 130], ["measuring PEDV viral RNA", "PROBLEM", 3, 27], ["rpIFN", "TEST", 47, 52], ["PEDV infection", "PROBLEM", 126, 140], ["viral RNA", "OBSERVATION", 18, 27], ["L1", "ANATOMY", 53, 55], ["PEDV", "OBSERVATION_MODIFIER", 126, 130], ["infection", "OBSERVATION", 131, 140]]], ["Compared with the control (1.77 \u00c2 10 8 copies), 1000 ng/ ml and 100 ng/ml rpIFN-L1 reduced the level of PEDV viral RNA to 1.72 \u00c2 10 7 and 3.57 \u00c2 10 7 copies, respectively, resulting in more than 90% and 80% inhibition of PEDV infection, respectively.", [["PEDV", "CHEMICAL", 221, 225], ["infection", "DISEASE", 226, 235], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 74, 82], ["PEDV", "GENE_OR_GENE_PRODUCT", 104, 108], ["rpIFN", "PROTEIN", 74, 79], ["PEDV viral RNA", "RNA", 104, 118], ["PEDV", "SPECIES", 104, 108], ["PEDV", "SPECIES", 221, 225], ["ng/ml rpIFN", "TEST", 68, 79], ["PEDV viral RNA", "TEST", 104, 118], ["PEDV infection", "PROBLEM", 221, 235], ["L1", "ANATOMY", 80, 82], ["PEDV", "ANATOMY", 104, 108], ["viral RNA", "OBSERVATION", 109, 118], ["PEDV", "OBSERVATION_MODIFIER", 221, 225], ["infection", "OBSERVATION", 226, 235]]], ["Additionally, 10 ng/ml rpIFN-L1 resulted in a 57.76% inhibition of infection in Vero E6 (Fig. 1A) .", [["infection", "DISEASE", 67, 76], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 23, 31], ["Vero E6", "ORGANISM", 80, 87], ["rpIFN", "PROTEIN", 23, 28], ["L1", "PROTEIN", 29, 31], ["Vero E6", "SPECIES", 80, 87], ["10 ng/ml rpIFN-L1", "TREATMENT", 14, 31], ["infection", "PROBLEM", 67, 76], ["L1", "ANATOMY", 29, 31], ["infection", "OBSERVATION", 67, 76]]], ["The dose-dependent inhibition of PEDV by rpIFN-L1 was further confirmed by measuring PEDVinfected cells using IFA detection of PEDV nucleocapsid (N) protein ( Fig. 2A) .", [["cells", "ANATOMY", 98, 103], ["PEDV", "SIMPLE_CHEMICAL", 33, 37], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 41, 49], ["PEDVinfected cells", "CELL", 85, 103], ["PEDV nucleocapsid (N) protein", "GENE_OR_GENE_PRODUCT", 127, 156], ["PEDV", "PROTEIN", 33, 37], ["rpIFN", "PROTEIN", 41, 46], ["L1", "DNA", 47, 49], ["PEDVinfected cells", "CELL_LINE", 85, 103], ["PEDV nucleocapsid (N) protein", "PROTEIN", 127, 156], ["Fig. 2A", "PROTEIN", 159, 166], ["PEDV", "SPECIES", 33, 37], ["PEDV", "SPECIES", 127, 131], ["PEDV", "PROBLEM", 33, 37], ["IFA detection", "TEST", 110, 123], ["PEDV nucleocapsid", "PROBLEM", 127, 144], ["L1", "ANATOMY", 47, 49]]], ["Next, we determined the stages of infection at which inhibition by rpIFN-L1 occurred by measuring virus production in the culture supernatant at different hours post-infection (hpi) (Fig. 1B) .", [["supernatant", "ANATOMY", 130, 141], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 166, 175], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 67, 75], ["rpIFN", "PROTEIN", 67, 72], ["L1", "DNA", 73, 75], ["infection", "PROBLEM", 34, 43], ["measuring virus production", "PROBLEM", 88, 114], ["the culture", "TEST", 118, 129], ["infection", "PROBLEM", 166, 175], ["infection", "OBSERVATION", 34, 43], ["L1", "ANATOMY", 73, 75], ["infection", "OBSERVATION", 166, 175]]], ["Pre-treatment with rpIFN-L1 at a concentration of 100 ng/ ml reduced viral replication in Vero E6 cells at 12, 24, and 36 hpi (Fig. 1B) .", [["Vero E6 cells", "ANATOMY", 90, 103], ["rpIFN-L1", "CHEMICAL", 19, 27], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 19, 27], ["Vero E6 cells", "CELL", 90, 103], ["rpIFN", "PROTEIN", 19, 24], ["Vero E6 cells", "CELL_LINE", 90, 103], ["Vero E6", "SPECIES", 90, 97], ["rpIFN-L1", "TREATMENT", 19, 27], ["viral replication", "TREATMENT", 69, 86], ["Vero E6 cells", "TEST", 90, 103], ["L1", "ANATOMY", 25, 27]]], ["These results indicate that rpIFN-L1 exhibits antiviral activity against PEDV strain CV777 in Vero E6 cells independently of the responses induced by type I IFNs.rpIFN-L1 inhibits PEDV infection in Vero E6 cells and small intestinal epithelial cellsIntestinal epithelial cells of pig small intestine are the primary target cells of PEDV in vivo.", [["Vero E6 cells", "ANATOMY", 94, 107], ["Vero E6 cells", "ANATOMY", 198, 211], ["small intestinal epithelial cells", "ANATOMY", 216, 249], ["Intestinal epithelial cells", "ANATOMY", 249, 276], ["small intestine", "ANATOMY", 284, 299], ["cells", "ANATOMY", 323, 328], ["rpIFN-L1", "CHEMICAL", 28, 36], ["infection", "DISEASE", 185, 194], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 28, 36], ["PEDV strain CV777", "ORGANISM", 73, 90], ["Vero E6 cells", "CELL", 94, 107], ["type I IFNs.rpIFN-L1", "GENE_OR_GENE_PRODUCT", 150, 170], ["PEDV", "ORGANISM", 180, 184], ["Vero E6 cells", "CELL", 198, 211], ["small intestinal epithelial cells", "CELL", 216, 249], ["Intestinal epithelial cells", "CELL", 249, 276], ["pig", "ORGANISM", 280, 283], ["small intestine", "ORGAN", 284, 299], ["cells", "CELL", 323, 328], ["PEDV", "CELL", 332, 336], ["rpIFN", "PROTEIN", 28, 33], ["L1", "DNA", 34, 36], ["Vero E6 cells", "CELL_LINE", 94, 107], ["type I IFNs.rpIFN-L1", "PROTEIN", 150, 170], ["Vero E6 cells", "CELL_LINE", 198, 211], ["small intestinal epithelial cells", "CELL_TYPE", 216, 249], ["Intestinal epithelial cells", "CELL_TYPE", 249, 276], ["primary target cells", "CELL_TYPE", 308, 328], ["pig", "SPECIES", 280, 283], ["PEDV", "SPECIES", 73, 77], ["CV777", "SPECIES", 85, 90], ["PEDV", "SPECIES", 180, 184], ["Vero E6", "SPECIES", 198, 205], ["pig", "SPECIES", 280, 283], ["PEDV", "SPECIES", 332, 336], ["rpIFN", "TEST", 28, 33], ["antiviral activity", "PROBLEM", 46, 64], ["PEDV strain", "PROBLEM", 73, 84], ["Vero E6 cells", "TREATMENT", 94, 107], ["type I IFNs.rpIFN-L1 inhibits", "PROBLEM", 150, 179], ["PEDV infection", "PROBLEM", 180, 194], ["Vero E6 cells", "PROBLEM", 198, 211], ["small intestinal epithelial cells", "PROBLEM", 216, 249], ["Intestinal epithelial cells of pig small intestine", "PROBLEM", 249, 299], ["PEDV in vivo", "TREATMENT", 332, 344], ["L1", "ANATOMY", 34, 36], ["antiviral activity", "OBSERVATION", 46, 64], ["L1", "ANATOMY", 168, 170], ["infection", "OBSERVATION", 185, 194], ["Vero E6 cells", "OBSERVATION", 198, 211], ["small", "OBSERVATION_MODIFIER", 216, 221], ["intestinal epithelial cells", "OBSERVATION", 222, 249], ["epithelial cells", "OBSERVATION", 260, 276], ["pig", "OBSERVATION_MODIFIER", 280, 283], ["small", "OBSERVATION_MODIFIER", 284, 289], ["intestine", "ANATOMY", 290, 299], ["target cells", "OBSERVATION", 316, 328]]], ["We next investigated the antiviral effect of rpIFN-L1 against PEDV infection in intestinal epithelial cells in vitro using the IPEC-J2 cell line, a non-transformed, non-tumorigenic intestinal epithelial cell line isolated from the jejunal epithelium of a neonatal unsuckled piglet (Geens and Niewold, 2011; Zakrzewski et al., 2013) .", [["intestinal epithelial cells", "ANATOMY", 80, 107], ["IPEC-J2 cell line", "ANATOMY", 127, 144], ["non-tumorigenic intestinal epithelial cell line", "ANATOMY", 165, 212], ["jejunal epithelium", "ANATOMY", 231, 249], ["piglet", "ANATOMY", 274, 280], ["rpIFN-L1", "CHEMICAL", 45, 53], ["PEDV", "CHEMICAL", 62, 66], ["infection", "DISEASE", 67, 76], ["rpIFN-L1", "SIMPLE_CHEMICAL", 45, 53], ["PEDV", "ORGANISM", 62, 66], ["intestinal epithelial cells", "CELL", 80, 107], ["IPEC-J2 cell line", "CELL", 127, 144], ["intestinal epithelial cell line", "CELL", 181, 212], ["jejunal epithelium", "TISSUE", 231, 249], ["piglet", "ORGANISM", 274, 280], ["rpIFN", "PROTEIN", 45, 50], ["intestinal epithelial cells", "CELL_TYPE", 80, 107], ["IPEC-J2 cell line", "CELL_LINE", 127, 144], ["non-transformed, non-tumorigenic intestinal epithelial cell line", "CELL_LINE", 148, 212], ["piglet", "SPECIES", 274, 280], ["PEDV", "SPECIES", 62, 66], ["rpIFN", "TREATMENT", 45, 50], ["L1", "TREATMENT", 51, 53], ["PEDV infection", "PROBLEM", 62, 76], ["intestinal epithelial cells", "PROBLEM", 80, 107], ["the IPEC-J2 cell line", "TREATMENT", 123, 144], ["a non-transformed, non-tumorigenic intestinal epithelial cell line", "PROBLEM", 146, 212], ["infection", "OBSERVATION", 67, 76], ["intestinal epithelial cells", "OBSERVATION", 80, 107], ["J2 cell line", "OBSERVATION", 132, 144], ["non-tumorigenic", "OBSERVATION_MODIFIER", 165, 180], ["intestinal epithelial cell line", "OBSERVATION", 181, 212], ["jejunal", "ANATOMY", 231, 238], ["epithelium", "ANATOMY_MODIFIER", 239, 249]]], ["This cell line has been reported as an ideal in vitro model of porcine intestinal infections (Liu et al., 2010) .", [["cell line", "ANATOMY", 5, 14], ["intestinal", "ANATOMY", 71, 81], ["intestinal infections", "DISEASE", 71, 92], ["cell line", "CELL", 5, 14], ["porcine", "ORGANISM", 63, 70], ["intestinal", "ORGAN", 71, 81], ["cell line", "CELL_LINE", 5, 14], ["porcine", "SPECIES", 63, 70], ["porcine", "SPECIES", 63, 70], ["This cell line", "TREATMENT", 0, 14], ["porcine intestinal infections", "PROBLEM", 63, 92], ["cell line", "OBSERVATION", 5, 14], ["porcine", "OBSERVATION_MODIFIER", 63, 70], ["intestinal", "ANATOMY", 71, 81], ["infections", "OBSERVATION", 82, 92]]], ["As in the Vero E6 cell experiments, IPEC-J2 cells were infected with PEDV strain CV777 after stimulating with rpIFN-L1.", [["cell", "ANATOMY", 18, 22], ["IPEC-J2 cells", "ANATOMY", 36, 49], ["Vero E6 cell", "CELL", 10, 22], ["IPEC-J2 cells", "CELL", 36, 49], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 110, 118], ["Vero E6 cell", "CELL_LINE", 10, 22], ["IPEC-J2 cells", "CELL_LINE", 36, 49], ["rpIFN", "PROTEIN", 110, 115], ["L1", "DNA", 116, 118], ["Vero E6", "SPECIES", 10, 17], ["PEDV", "SPECIES", 69, 73], ["the Vero E6 cell experiments", "TEST", 6, 34], ["IPEC", "TEST", 36, 40], ["J2 cells", "PROBLEM", 41, 49], ["PEDV strain", "PROBLEM", 69, 80], ["stimulating with rpIFN-L1", "TREATMENT", 93, 118], ["J2 cells", "OBSERVATION_MODIFIER", 41, 49], ["L1", "ANATOMY", 116, 118]]], ["At concentrations of 1000 ng/ml and 100 ng/ml, rpIFN-L1 significantly reduced infection to 2.89 \u00b1 2.19% and 12.0 \u00b1 4.37% of the untreated control, respectively.", [["rpIFN-L1", "CHEMICAL", 47, 55], ["infection", "DISEASE", 78, 87], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 47, 55], ["rpIFN", "PROTEIN", 47, 52], ["rpIFN", "TEST", 47, 52], ["L1 significantly reduced infection", "PROBLEM", 53, 87], ["L1", "ANATOMY", 53, 55], ["reduced", "OBSERVATION_MODIFIER", 70, 77], ["infection", "OBSERVATION", 78, 87]]], ["As observed in Vero E6 cells, pre-treatment with rpIFN-L1 reduced PEDV infection in a dose-dependent manner (Fig. 1A) .", [["Vero E6 cells", "ANATOMY", 15, 28], ["rpIFN-L1", "CHEMICAL", 49, 57], ["PEDV", "CHEMICAL", 66, 70], ["infection", "DISEASE", 71, 80], ["Vero E6 cells", "CELL", 15, 28], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 49, 57], ["PEDV", "SIMPLE_CHEMICAL", 66, 70], ["Vero E6 cells", "CELL_LINE", 15, 28], ["rpIFN", "PROTEIN", 49, 54], ["Vero E6", "SPECIES", 15, 22], ["PEDV", "SPECIES", 66, 70], ["Vero E6 cells", "TREATMENT", 15, 28], ["rpIFN", "TREATMENT", 49, 54], ["L1 reduced PEDV infection", "PROBLEM", 55, 80], ["E6 cells", "OBSERVATION", 20, 28], ["L1", "ANATOMY", 55, 57], ["reduced", "OBSERVATION_MODIFIER", 58, 65], ["PEDV", "OBSERVATION_MODIFIER", 66, 70], ["infection", "OBSERVATION", 71, 80]]], ["These results demonstrate that rpIFN-L1 is capable of inhibiting PEDV infection in both IPEC-J2 and Vero E6 cells.rpIFN-L3 inhibits PEDV infection in Vero E6 cells and small intestinal epithelial cellsTwo members of porcine IFN-L have been reported (Sang et al., 2010) ; therefore, we next investigated the antiviral activity of rpIFN-L3 against PEDV infection.", [["IPEC-J2", "ANATOMY", 88, 95], ["cells", "ANATOMY", 108, 113], ["Vero E6 cells", "ANATOMY", 150, 163], ["small intestinal epithelial cells", "ANATOMY", 168, 201], ["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 137, 146], ["rpIFN-L3", "CHEMICAL", 329, 337], ["PEDV infection", "DISEASE", 346, 360], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 31, 39], ["PEDV", "GENE_OR_GENE_PRODUCT", 65, 69], ["IPEC-J2", "CELL", 88, 95], ["Vero E6 cells", "CELL", 100, 113], [".rpIFN-L3", "GENE_OR_GENE_PRODUCT", 113, 122], ["PEDV", "ORGANISM", 132, 136], ["Vero E6 cells", "CELL", 150, 163], ["small intestinal epithelial cells", "CELL", 168, 201], ["porcine", "ORGANISM", 216, 223], ["IFN-L", "GENE_OR_GENE_PRODUCT", 224, 229], ["rpIFN-L3", "SIMPLE_CHEMICAL", 329, 337], ["PEDV", "ORGANISM", 346, 350], ["rpIFN", "PROTEIN", 31, 36], ["L1", "DNA", 37, 39], ["IPEC-J2", "CELL_LINE", 88, 95], ["Vero E6 cells", "CELL_LINE", 100, 113], ["Vero E6 cells", "CELL_LINE", 150, 163], ["small intestinal epithelial cells", "CELL_TYPE", 168, 201], ["porcine IFN-L", "PROTEIN", 216, 229], ["rpIFN", "PROTEIN", 329, 334], ["porcine", "SPECIES", 216, 223], ["PEDV", "SPECIES", 65, 69], ["PEDV", "SPECIES", 132, 136], ["Vero E6", "SPECIES", 150, 157], ["PEDV", "SPECIES", 346, 350], ["rpIFN", "TEST", 31, 36], ["inhibiting PEDV infection", "PROBLEM", 54, 79], ["IPEC", "TEST", 88, 92], ["Vero E6 cells", "TEST", 100, 113], [".rpIFN", "TEST", 113, 119], ["PEDV infection", "PROBLEM", 132, 146], ["Vero E6 cells", "PROBLEM", 150, 163], ["small intestinal epithelial cells", "PROBLEM", 168, 201], ["porcine IFN", "TREATMENT", 216, 227], ["rpIFN", "TREATMENT", 329, 334], ["PEDV infection", "PROBLEM", 346, 360], ["L1", "ANATOMY", 37, 39], ["PEDV", "OBSERVATION_MODIFIER", 65, 69], ["infection", "OBSERVATION", 70, 79], ["J2", "ANATOMY", 93, 95], ["E6 cells", "OBSERVATION", 105, 113], ["L3", "ANATOMY", 120, 122], ["PEDV", "OBSERVATION_MODIFIER", 132, 136], ["infection", "OBSERVATION", 137, 146], ["Vero E6 cells", "OBSERVATION", 150, 163], ["small", "OBSERVATION_MODIFIER", 168, 173], ["intestinal epithelial cells", "OBSERVATION", 174, 201], ["L3", "ANATOMY", 335, 337], ["infection", "OBSERVATION", 351, 360]]], ["Analogous to treatment with rpIFN-L1, we measured the inhibitory effect of rpIFN-L3 in Vero E6 cells and IPEC-J2 infected with PEDV strain CV777 (Fig. 1A) .", [["Vero E6 cells", "ANATOMY", 87, 100], ["IPEC-J2", "ANATOMY", 105, 112], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 28, 36], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 75, 83], ["Vero E6 cells", "CELL", 87, 100], ["IPEC-J2", "CELL", 105, 112], ["PEDV strain CV777", "ORGANISM", 127, 144], ["Fig. 1A", "ORGANISM", 146, 153], ["rpIFN", "PROTEIN", 28, 33], ["L1", "PROTEIN", 34, 36], ["rpIFN", "PROTEIN", 75, 80], ["Vero E6 cells", "CELL_LINE", 87, 100], ["IPEC-J2", "CELL_LINE", 105, 112], ["Vero E6", "SPECIES", 87, 94], ["PEDV", "SPECIES", 127, 131], ["Analogous to treatment", "TREATMENT", 0, 22], ["rpIFN-L1", "TREATMENT", 28, 36], ["rpIFN", "TEST", 75, 80], ["Vero E6 cells", "TREATMENT", 87, 100], ["IPEC", "TEST", 105, 109], ["PEDV strain", "PROBLEM", 127, 138], ["L1", "ANATOMY", 34, 36], ["L3", "ANATOMY", 81, 83], ["E6 cells", "OBSERVATION", 92, 100], ["J2", "ANATOMY", 110, 112]]], ["As with rpIFN-L1, treatment with rpIFN-L3 significantly inhibited PEDV infection in both cell types in a dose-dependent manner (Fig. 1A) .", [["cell", "ANATOMY", 89, 93], ["rpIFN-L3", "CHEMICAL", 33, 41], ["PEDV", "CHEMICAL", 66, 70], ["infection", "DISEASE", 71, 80], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 8, 16], ["rpIFN-L3", "SIMPLE_CHEMICAL", 33, 41], ["PEDV", "SIMPLE_CHEMICAL", 66, 70], ["cell", "CELL", 89, 93], ["rpIFN", "PROTEIN", 8, 13], ["L1", "DNA", 14, 16], ["rpIFN", "PROTEIN", 33, 38], ["PEDV", "SPECIES", 66, 70], ["rpIFN-L1", "TREATMENT", 8, 16], ["treatment", "TREATMENT", 18, 27], ["rpIFN", "TREATMENT", 33, 38], ["PEDV infection", "PROBLEM", 66, 80], ["L1", "ANATOMY", 14, 16], ["L3", "ANATOMY", 39, 41], ["PEDV", "OBSERVATION_MODIFIER", 66, 70], ["infection", "OBSERVATION", 71, 80], ["both cell types", "OBSERVATION", 84, 99]]], ["The inhibition of PEDV infection by rpIFN-L3 was further assessed by IFA (Fig. 2B) .", [["infection", "DISEASE", 23, 32], ["PEDV", "GENE_OR_GENE_PRODUCT", 18, 22], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 36, 44], ["rpIFN", "PROTEIN", 36, 41], ["PEDV", "SPECIES", 18, 22], ["PEDV infection", "PROBLEM", 18, 32], ["PEDV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["L3", "ANATOMY", 42, 44]]], ["Compared with rpIFN-L1, rpIFN-L3 exhibited a reduced (2-fold) viral inhibitory effect in Vero E6 cells when treated with lower doses of rpIFN-Ls (18.73 \u00b1 10.16% for rpIFN-L1 versus 45.06 \u00b1 7.24% for rpIFN-L3 at 100 ng/ml; 42.24 \u00b1 15.01% for rpIFN-L1 versus 77.84 \u00b1 11.31% for rpIFN-L3 at 10 ng/ml) (Fig. 1A) .", [["Vero E6 cells", "ANATOMY", 89, 102], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 14, 22], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 24, 32], ["Vero E6 cells", "CELL", 89, 102], ["rpIFN-Ls", "SIMPLE_CHEMICAL", 136, 144], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 165, 173], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 199, 207], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 241, 249], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 276, 284], ["rpIFN", "PROTEIN", 14, 19], ["L1", "DNA", 20, 22], ["rpIFN", "PROTEIN", 24, 29], ["Vero E6 cells", "CELL_LINE", 89, 102], ["rpIFN", "PROTEIN", 136, 141], ["rpIFN", "PROTEIN", 165, 170], ["rpIFN", "PROTEIN", 199, 204], ["rpIFN", "PROTEIN", 241, 246], ["L1", "PROTEIN", 247, 249], ["rpIFN", "PROTEIN", 276, 281], ["L3", "PROTEIN", 282, 284], ["Vero E6", "SPECIES", 89, 96], ["rpIFN", "TEST", 14, 19], ["rpIFN", "TEST", 24, 29], ["a reduced (2-fold) viral inhibitory effect", "PROBLEM", 43, 85], ["Vero E6 cells", "TREATMENT", 89, 102], ["rpIFN", "TEST", 136, 141], ["Ls", "TEST", 142, 144], ["rpIFN", "TEST", 165, 170], ["rpIFN", "TEST", 199, 204], ["rpIFN", "TEST", 241, 246], ["rpIFN", "TEST", 276, 281], ["L1", "ANATOMY", 20, 22], ["L3", "ANATOMY", 30, 32], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["E6 cells", "OBSERVATION", 94, 102], ["L3", "ANATOMY", 205, 207], ["L3", "ANATOMY", 282, 284]]], ["Interestingly, unlike the infection of Vero E6 cells, rpIFN-L3 exhibited a more potent activity against PEDV infection of IPEC-J2 cells at lower doses than that of rpIFN-L1 (Fig. 1A) .", [["Vero E6 cells", "ANATOMY", 39, 52], ["IPEC-J2 cells", "ANATOMY", 122, 135], ["infection", "DISEASE", 26, 35], ["infection", "DISEASE", 109, 118], ["Vero E6 cells", "CELL", 39, 52], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 54, 62], ["PEDV", "SIMPLE_CHEMICAL", 104, 108], ["IPEC-J2 cells", "CELL", 122, 135], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 164, 172], ["Vero E6 cells", "CELL_LINE", 39, 52], ["rpIFN-L3", "PROTEIN", 54, 62], ["IPEC-J2 cells", "CELL_LINE", 122, 135], ["rpIFN", "PROTEIN", 164, 169], ["L1", "PROTEIN", 170, 172], ["Vero E6", "SPECIES", 39, 46], ["PEDV", "SPECIES", 104, 108], ["the infection of Vero E6 cells", "PROBLEM", 22, 52], ["rpIFN", "TEST", 54, 59], ["PEDV infection of IPEC", "PROBLEM", 104, 126], ["J2 cells", "PROBLEM", 127, 135], ["rpIFN", "TEST", 164, 169], ["infection", "OBSERVATION", 26, 35], ["Vero E6 cells", "OBSERVATION", 39, 52], ["L3", "ANATOMY", 60, 62], ["more potent", "OBSERVATION_MODIFIER", 75, 86], ["infection", "OBSERVATION", 109, 118], ["J2 cells", "OBSERVATION_MODIFIER", 127, 135], ["L1", "ANATOMY", 170, 172]]], ["These results indicate that rpIFN-L3 substantially inhibits PEDV infection in both Vero E6 and IPEC-J2 cells in a similar manner to rpIFN-L1.rpIFN-L inhibits genotype 2 PEDV (strain) LNCT2There are two circulating PEDV genotypes, G1 and G2, which are based on the amino acid sequence of the PEDV spike protein (Wang et al., 2016) .", [["IPEC-J2 cells", "ANATOMY", 95, 108], ["rpIFN-L3", "CHEMICAL", 28, 36], ["PEDV", "CHEMICAL", 60, 64], ["infection", "DISEASE", 65, 74], ["amino acid", "CHEMICAL", 264, 274], ["amino acid", "CHEMICAL", 264, 274], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 28, 36], ["PEDV", "GENE_OR_GENE_PRODUCT", 60, 64], ["Vero E6", "ORGANISM", 83, 90], ["IPEC-J2 cells", "CELL", 95, 108], ["rpIFN-L1.rpIFN-L", "GENE_OR_GENE_PRODUCT", 132, 148], ["genotype 2 PEDV", "ORGANISM", 158, 173], ["LNCT2There", "GENE_OR_GENE_PRODUCT", 183, 193], ["amino acid", "AMINO_ACID", 264, 274], ["rpIFN", "PROTEIN", 28, 33], ["Vero E6 and IPEC-J2 cells", "CELL_LINE", 83, 108], ["rpIFN", "PROTEIN", 132, 137], ["L1.rpIFN", "PROTEIN", 138, 146], ["amino acid sequence", "PROTEIN", 264, 283], ["PEDV spike protein", "PROTEIN", 291, 309], ["PEDV", "SPECIES", 60, 64], ["Vero E6", "SPECIES", 83, 90], ["rpIFN", "TEST", 28, 33], ["PEDV infection", "PROBLEM", 60, 74], ["both Vero E6", "TEST", 78, 90], ["J2 cells", "PROBLEM", 100, 108], ["rpIFN", "TEST", 132, 137], ["L1.rpIFN", "TEST", 138, 146], ["the amino acid sequence", "TEST", 260, 283], ["L3", "ANATOMY", 34, 36], ["PEDV", "OBSERVATION_MODIFIER", 60, 64], ["infection", "OBSERVATION", 65, 74], ["J2 cells", "OBSERVATION", 100, 108]]], ["The classical strain CV777 is of the G1 genotype and is a Vero E6-adapted strain.", [["Vero E6", "ORGANISM", 58, 65], ["The classical strain", "TEST", 0, 20], ["the G1 genotype", "PROBLEM", 33, 48], ["a Vero E6-adapted strain", "PROBLEM", 56, 80]]], ["Strain LNCT2, a wild isolate obtained by our laboratory, is of the G2 genotype and replicates less efficiently in both Vero E6 and IPEC-J2 cells in vitro compared with the celladapted CV777 strain (Wang et al., 2016) .", [["IPEC-J2 cells", "ANATOMY", 131, 144], ["LNCT2", "CHEMICAL", 7, 12], ["LNCT2", "GENE_OR_GENE_PRODUCT", 7, 12], ["Vero E6", "CELL", 119, 126], ["IPEC-J2 cells", "CELL", 131, 144], ["Vero E6", "CELL_LINE", 119, 126], ["IPEC-J2 cells", "CELL_LINE", 131, 144], ["Vero E6", "SPECIES", 119, 126], ["Strain LNCT2", "TEST", 0, 12], ["the G2 genotype", "PROBLEM", 63, 78], ["J2 cells", "OBSERVATION", 136, 144]]], ["To determine whether rpIFN-L1 and rpIFN-L3 are capable of inhibiting infection with strain LNCT2, IPEC-J2 cells were infected with LNCT2 after pretreatment with rpIFN-L1 or rpIFN-L3.", [["IPEC-J2 cells", "ANATOMY", 98, 111], ["infection", "DISEASE", 69, 78], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 21, 29], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 34, 42], ["LNCT2", "CELL", 91, 96], ["IPEC-J2 cells", "CELL", 98, 111], ["LNCT2", "GENE_OR_GENE_PRODUCT", 131, 136], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 161, 169], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 173, 181], ["rpIFN", "PROTEIN", 21, 26], ["L1", "PROTEIN", 27, 29], ["rpIFN", "PROTEIN", 34, 39], ["L3", "DNA", 40, 42], ["IPEC-J2 cells", "CELL_LINE", 98, 111], ["LNCT2", "PROTEIN", 131, 136], ["rpIFN", "PROTEIN", 161, 166], ["L1", "DNA", 167, 169], ["rpIFN", "PROTEIN", 173, 178], ["L3", "DNA", 179, 181], ["LNCT2", "SPECIES", 91, 96], ["rpIFN", "TEST", 21, 26], ["inhibiting infection", "PROBLEM", 58, 78], ["strain LNCT2", "TEST", 84, 96], ["IPEC", "TEST", 98, 102], ["J2 cells", "PROBLEM", 103, 111], ["pretreatment", "TEST", 143, 155], ["rpIFN", "TEST", 161, 166], ["L1", "ANATOMY", 27, 29], ["L3", "ANATOMY", 40, 42], ["infection", "OBSERVATION", 69, 78], ["J2", "ANATOMY", 103, 105], ["L1", "ANATOMY", 167, 169], ["L3", "ANATOMY", 179, 181]]], ["Both rpIFN-L1 and rpIFN-L3 significantly suppressed infection of IPEC-J2 cells with strain LNCT2 in a dose-dependent manner, as determined by measuring viral RNA in the cellular supernatant (Fig. 3) .", [["IPEC-J2 cells", "ANATOMY", 65, 78], ["cellular supernatant", "ANATOMY", 169, 189], ["infection", "DISEASE", 52, 61], ["LNCT2", "CHEMICAL", 91, 96], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 5, 13], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 18, 26], ["IPEC-J2 cells", "CELL", 65, 78], ["LNCT2", "SIMPLE_CHEMICAL", 91, 96], ["cellular", "CELL", 169, 177], ["rpIFN", "PROTEIN", 5, 10], ["L1", "DNA", 11, 13], ["rpIFN", "PROTEIN", 18, 23], ["L3", "DNA", 24, 26], ["IPEC-J2 cells", "CELL_LINE", 65, 78], ["viral RNA", "RNA", 152, 161], ["Both rpIFN", "TEST", 0, 10], ["rpIFN", "TEST", 18, 23], ["L3 significantly suppressed infection of IPEC", "PROBLEM", 24, 69], ["J2 cells", "PROBLEM", 70, 78], ["strain LNCT2", "TEST", 84, 96], ["L1", "ANATOMY", 11, 13], ["L3", "ANATOMY", 24, 26], ["suppressed", "OBSERVATION_MODIFIER", 41, 51], ["infection", "OBSERVATION", 52, 61], ["J2 cells", "OBSERVATION_MODIFIER", 70, 78], ["viral RNA", "OBSERVATION", 152, 161]]], ["Although rpIFN-L1 and rpIFN-L3 exhibited a similar level of viral inhibition at 1000 ng/ml, rpIFN-L3 more efficiently inhibited LNCT2 infection in IPEC-J2 when using concentrations of 100 ng/ml to 1 ng/ml than rpIFN-L1.", [["IPEC-J2", "ANATOMY", 147, 154], ["LNCT2", "CHEMICAL", 128, 133], ["infection", "DISEASE", 134, 143], ["IPEC-J2", "CHEMICAL", 147, 154], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 9, 17], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 22, 30], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 92, 100], ["LNCT2", "SIMPLE_CHEMICAL", 128, 133], ["IPEC-J2", "CELL", 147, 154], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 210, 218], ["rpIFN", "PROTEIN", 9, 14], ["L1", "DNA", 15, 17], ["rpIFN", "PROTEIN", 22, 27], ["L3", "DNA", 28, 30], ["rpIFN", "PROTEIN", 92, 97], ["IPEC-J2", "CELL_LINE", 147, 154], ["rpIFN", "PROTEIN", 210, 215], ["rpIFN", "TEST", 9, 14], ["rpIFN", "TEST", 22, 27], ["viral inhibition", "PROBLEM", 60, 76], ["rpIFN", "TEST", 92, 97], ["LNCT2 infection", "PROBLEM", 128, 143], ["concentrations", "TEST", 166, 180], ["L1", "ANATOMY", 15, 17], ["L3", "ANATOMY", 28, 30], ["L3", "ANATOMY", 98, 100], ["infection", "OBSERVATION", 134, 143], ["J2", "ANATOMY", 152, 154], ["L1", "ANATOMY", 216, 218]]], ["These results demonstrate that rpIFN-L inhibits infection of PEDV G2 genotype in porcine intestinal epithelial cells.rpIFN-L has greater antiviral activity against PEDV in IPEC-J2 than IFN-aGrowing evidences have demonstrated that the primary type of IFN acting in the gastrointestinal tract is type III rather than type I Pott et al., 2011; Sommereyns et al., 2008) .", [["intestinal epithelial", "ANATOMY", 89, 110], ["gastrointestinal tract", "ANATOMY", 269, 291], ["rpIFN-L", "CHEMICAL", 31, 38], ["infection", "DISEASE", 48, 57], ["IFN", "CHEMICAL", 251, 254], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 31, 38], ["PEDV G2 genotype", "ORGANISM", 61, 77], ["porcine", "ORGANISM", 81, 88], ["intestinal epithelial cells.rpIFN-L", "CELL", 89, 124], ["PEDV", "SIMPLE_CHEMICAL", 164, 168], ["IPEC-J2", "CELL", 172, 179], ["IFN", "GENE_OR_GENE_PRODUCT", 251, 254], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 269, 291], ["rpIFN", "PROTEIN", 31, 36], ["IFN", "PROTEIN", 185, 188], ["IFN", "PROTEIN", 251, 254], ["porcine", "SPECIES", 81, 88], ["PEDV", "SPECIES", 61, 65], ["porcine", "SPECIES", 81, 88], ["PEDV", "SPECIES", 164, 168], ["rpIFN", "TEST", 31, 36], ["L inhibits infection", "PROBLEM", 37, 57], ["PEDV G2 genotype in porcine intestinal epithelial cells.rpIFN", "PROBLEM", 61, 122], ["greater antiviral activity", "TREATMENT", 129, 155], ["PEDV", "PROBLEM", 164, 168], ["infection", "OBSERVATION", 48, 57], ["intestinal epithelial", "ANATOMY", 89, 110], ["antiviral activity", "OBSERVATION", 137, 155], ["gastrointestinal tract", "ANATOMY", 269, 291]]], ["We compared the antiviral activity of rpIFN-L1 and porcine IFN-a against PEDV infection in IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 91, 104], ["IFN", "CHEMICAL", 59, 62], ["PEDV", "CHEMICAL", 73, 77], ["infection", "DISEASE", 78, 87], ["rpIFN-L1", "SIMPLE_CHEMICAL", 38, 46], ["porcine", "ORGANISM", 51, 58], ["IFN", "GENE_OR_GENE_PRODUCT", 59, 62], ["PEDV", "ORGANISM", 73, 77], ["IPEC-J2 cells", "CELL", 91, 104], ["rpIFN", "PROTEIN", 38, 43], ["L1", "PROTEIN", 44, 46], ["IFN", "PROTEIN", 59, 62], ["IPEC-J2 cells", "CELL_LINE", 91, 104], ["porcine", "SPECIES", 51, 58], ["PEDV", "SPECIES", 73, 77], ["rpIFN-L1", "TREATMENT", 38, 46], ["porcine IFN", "TREATMENT", 51, 62], ["PEDV infection", "PROBLEM", 73, 87], ["J2 cells", "PROBLEM", 96, 104], ["L1", "ANATOMY", 44, 46], ["infection", "OBSERVATION", 78, 87], ["J2 cells", "OBSERVATION", 96, 104]]], ["Although both IFN-a and IPEC-J2 cells were pre-treated with rpIFN-L1 or rpIFN-L3 at indicated concentrations for 24 h in 24-well plates and then were infected with PEDV (LNCT2).", [["IPEC-J2 cells", "ANATOMY", 24, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 14, 17], ["IPEC-J2 cells", "CELL", 24, 37], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 60, 68], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 72, 80], ["IFN", "PROTEIN", 14, 17], ["IPEC-J2 cells", "CELL_LINE", 24, 37], ["rpIFN", "PROTEIN", 60, 65], ["L1", "DNA", 66, 68], ["rpIFN", "PROTEIN", 72, 77], ["L3", "DNA", 78, 80], ["PEDV", "PROTEIN", 164, 168], ["PEDV", "SPECIES", 164, 168], ["IFN", "TEST", 14, 17], ["a and IPEC-J2 cells", "TREATMENT", 18, 37], ["rpIFN", "TEST", 60, 65], ["rpIFN-L3", "TREATMENT", 72, 80], ["L1", "ANATOMY", 66, 68], ["L3", "ANATOMY", 78, 80], ["infected", "OBSERVATION", 150, 158]]], ["Cells were further cultured for another 36 h prior to PEDV RNA quantification by RT-qPCR.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PEDV RNA", "RNA", 54, 62], ["PEDV", "SPECIES", 54, 58], ["PEDV RNA quantification", "TEST", 54, 77], ["RT", "TEST", 81, 83]]], ["The results are presented as the mean \u00b1 SEM (N \u00bc 3). *P < 0.05; **P < 0.01. rpIFN-L1 displayed antiviral effects against PEDV in IPEC-J2 cells in a dose-dependent manner, copies of viral RNA in the cellular supernatant were consistently higher in IFN-a-treated cells at concentrations of 1000 ng/ml to 10 ng/ml than in cells treated with equal concentrations of rpIFN-L1 (74,964 \u00b1 58,768 copies for IFN-a versus 7845 \u00b1 1196 for rpIFN-L1 at 1000 ng/ml; 1,095,148 \u00b1 701,538 copies for IFN-a versus 140,109 \u00b1 56,171 copies for rpIFN-L1 at 10 ng/ml), and rpIFN-L1 more significantly inhibited PEDV infection than IFN-a at 100 ng/ml and 10 ng/ml, indicating that IFN-a is less effective at inhibiting PEDV infection than rpIFN-L1 (Fig. 4) .", [["IPEC-J2 cells", "ANATOMY", 129, 142], ["cellular supernatant", "ANATOMY", 198, 218], ["cells", "ANATOMY", 261, 266], ["cells", "ANATOMY", 319, 324], ["IFN", "CHEMICAL", 247, 250], ["PEDV", "CHEMICAL", 589, 593], ["infection", "DISEASE", 594, 603], ["IFN", "CHEMICAL", 609, 612], ["IFN", "CHEMICAL", 658, 661], ["infection", "DISEASE", 701, 710], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 76, 84], ["PEDV", "SIMPLE_CHEMICAL", 121, 125], ["IPEC-J2 cells", "CELL", 129, 142], ["cellular", "CELL", 198, 206], ["IFN-a-", "GENE_OR_GENE_PRODUCT", 247, 253], ["cells", "CELL", 261, 266], ["cells", "CELL", 319, 324], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 362, 370], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 428, 436], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 524, 532], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 551, 559], ["PEDV", "SIMPLE_CHEMICAL", 589, 593], ["IFN", "GENE_OR_GENE_PRODUCT", 658, 661], ["PEDV", "SIMPLE_CHEMICAL", 696, 700], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 716, 724], ["rpIFN", "PROTEIN", 76, 81], ["L1", "DNA", 82, 84], ["IPEC-J2 cells", "CELL_LINE", 129, 142], ["viral RNA", "RNA", 181, 190], ["IFN-a-treated cells", "CELL_LINE", 247, 266], ["rpIFN", "PROTEIN", 362, 367], ["IFN", "PROTEIN", 399, 402], ["rpIFN", "PROTEIN", 428, 433], ["IFN", "PROTEIN", 483, 486], ["rpIFN", "PROTEIN", 524, 529], ["L1", "PROTEIN", 530, 532], ["rpIFN", "PROTEIN", 551, 556], ["IFN", "PROTEIN", 609, 612], ["IFN", "PROTEIN", 658, 661], ["rpIFN", "PROTEIN", 716, 721], ["L1", "DNA", 722, 724], ["PEDV", "SPECIES", 121, 125], ["PEDV", "SPECIES", 589, 593], ["PEDV", "SPECIES", 696, 700], ["rpIFN", "TEST", 76, 81], ["antiviral effects", "TREATMENT", 95, 112], ["PEDV", "PROBLEM", 121, 125], ["J2 cells", "PROBLEM", 134, 142], ["a dose-dependent manner", "TREATMENT", 146, 169], ["viral RNA", "PROBLEM", 181, 190], ["the cellular supernatant", "TEST", 194, 218], ["IFN", "TEST", 247, 250], ["a-treated cells", "TREATMENT", 251, 266], ["rpIFN", "TEST", 362, 367], ["IFN", "TEST", 399, 402], ["rpIFN", "TEST", 428, 433], ["IFN", "TEST", 483, 486], ["copies", "TEST", 513, 519], ["rpIFN", "TEST", 524, 529], ["rpIFN", "TEST", 551, 556], ["PEDV infection", "PROBLEM", 589, 603], ["IFN", "TEST", 609, 612], ["IFN", "PROBLEM", 658, 661], ["PEDV infection", "PROBLEM", 696, 710], ["rpIFN", "TEST", 716, 721], ["L1", "ANATOMY", 82, 84], ["antiviral effects", "OBSERVATION", 95, 112], ["J2 cells", "OBSERVATION_MODIFIER", 134, 142], ["viral RNA", "OBSERVATION", 181, 190], ["L1", "ANATOMY", 368, 370], ["L1", "ANATOMY", 557, 559], ["infection", "OBSERVATION", 594, 603], ["L1", "ANATOMY", 722, 724]]], ["These results clearly demonstrate that IFN-L1 preferentially inhibits enteropathogenic PEDV in IPEC-J2 compared with IFN-a.rpIFN-L inhibits PEDV infection by activating multiple mechanismsISG15 (Lenschow et al., 2007) , MxA (Kochs and Haller, 1999) , and the 2 0 ,5 0 -oligoadenylate synthetase (OAS)-directed RNaseL (OASL) ) are three of the most important antiviral proteins induced by IFN.", [["IPEC-J2", "CHEMICAL", 95, 102], ["infection", "DISEASE", 145, 154], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 39, 45], ["IPEC-J2", "CELL", 95, 102], ["IFN-a.rpIFN-L", "GENE_OR_GENE_PRODUCT", 117, 130], ["PEDV", "ORGANISM", 140, 144], ["MxA", "GENE_OR_GENE_PRODUCT", 220, 223], ["2 0 ,5 0 -oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 259, 294], ["RNaseL", "GENE_OR_GENE_PRODUCT", 310, 316], ["OASL", "GENE_OR_GENE_PRODUCT", 318, 322], ["IFN", "GENE_OR_GENE_PRODUCT", 388, 391], ["IFN", "PROTEIN", 39, 42], ["L1", "PROTEIN", 43, 45], ["enteropathogenic PEDV", "PROTEIN", 70, 91], ["IPEC-J2", "CELL_LINE", 95, 102], ["IFN", "PROTEIN", 117, 120], ["a.rpIFN", "PROTEIN", 121, 128], ["MxA", "PROTEIN", 220, 223], ["-oligoadenylate synthetase", "PROTEIN", 268, 294], ["OAS", "PROTEIN", 296, 299], ["RNaseL", "PROTEIN", 310, 316], ["OASL", "PROTEIN", 318, 322], ["antiviral proteins", "PROTEIN", 358, 376], ["IFN", "PROTEIN", 388, 391], ["PEDV", "SPECIES", 140, 144], ["IFN", "TEST", 39, 42], ["enteropathogenic PEDV", "PROBLEM", 70, 91], ["IPEC", "TEST", 95, 99], ["IFN", "TEST", 117, 120], ["a.rpIFN", "TEST", 121, 128], ["PEDV infection", "PROBLEM", 140, 154], ["activating multiple mechanismsISG15", "PROBLEM", 158, 193], ["MxA", "TEST", 220, 223], ["antiviral proteins", "TREATMENT", 358, 376], ["enteropathogenic", "OBSERVATION_MODIFIER", 70, 86], ["PEDV", "OBSERVATION", 87, 91], ["J2", "ANATOMY", 100, 102], ["infection", "OBSERVATION", 145, 154]]], ["We next sought to determine whether an ISG antiviral response in IPEC-J2 was induced following rpIFN-L1 and rpIFN-L3 stimulation.", [["IPEC-J2", "CHEMICAL", 65, 72], ["IPEC-J2", "CELL", 65, 72], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 95, 103], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 108, 116], ["IPEC-J2", "CELL_LINE", 65, 72], ["rpIFN", "PROTEIN", 95, 100], ["rpIFN", "PROTEIN", 108, 113], ["an ISG antiviral response", "TEST", 36, 61], ["rpIFN", "TEST", 95, 100], ["L1 and rpIFN-L3 stimulation", "TREATMENT", 101, 128], ["L1", "ANATOMY", 101, 103], ["L3", "ANATOMY", 114, 116]]], ["The relative quantities of mRNA of 3 representative ISGs (i.e., ISG15, OASL, MxA) relative to their expression in control cells were determined by RT-qPCR.", [["cells", "ANATOMY", 122, 127], ["ISGs", "GENE_OR_GENE_PRODUCT", 52, 56], ["ISG15", "GENE_OR_GENE_PRODUCT", 64, 69], ["OASL", "GENE_OR_GENE_PRODUCT", 71, 75], ["MxA", "GENE_OR_GENE_PRODUCT", 77, 80], ["cells", "CELL", 122, 127], ["mRNA", "RNA", 27, 31], ["ISGs", "PROTEIN", 52, 56], ["ISG15", "PROTEIN", 64, 69], ["OASL", "PROTEIN", 71, 75], ["MxA", "PROTEIN", 77, 80], ["ISG15", "TEST", 64, 69], ["quantities", "OBSERVATION_MODIFIER", 13, 23]]], ["Transcriptional expression was up-regulated by approximately 171-fold for ISG15, 232-fold for MxA, and more than 2000-fold for OASL when cells were treated with 1000 ng/ml rpIFN-L1 (Fig. 5) .", [["cells", "ANATOMY", 137, 142], ["ISG15", "GENE_OR_GENE_PRODUCT", 74, 79], ["MxA", "GENE_OR_GENE_PRODUCT", 94, 97], ["cells", "CELL", 137, 142], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 172, 180], ["ISG15", "PROTEIN", 74, 79], ["MxA", "PROTEIN", 94, 97], ["OASL", "PROTEIN", 127, 131], ["rpIFN", "PROTEIN", 172, 177], ["Transcriptional expression", "PROBLEM", 0, 26], ["ISG15", "TEST", 74, 79], ["MxA", "TEST", 94, 97], ["OASL when cells", "PROBLEM", 127, 142], ["L1", "ANATOMY", 178, 180]]], ["The expression of the three antiviral genes exhibited a dose-dependent response to rpIFN-L1 stimulation in IPEC-J2 cells and was correlated with the antiviral activity against PEDV infection of IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 107, 120], ["IPEC-J2 cells", "ANATOMY", 194, 207], ["infection", "DISEASE", 181, 190], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 83, 91], ["IPEC-J2 cells", "CELL", 107, 120], ["PEDV", "SIMPLE_CHEMICAL", 176, 180], ["IPEC-J2 cells", "CELL", 194, 207], ["antiviral genes", "DNA", 28, 43], ["rpIFN", "PROTEIN", 83, 88], ["IPEC-J2 cells", "CELL_LINE", 107, 120], ["IPEC-J2 cells", "CELL_LINE", 194, 207], ["PEDV", "SPECIES", 176, 180], ["rpIFN-L1 stimulation", "TREATMENT", 83, 103], ["J2 cells", "PROBLEM", 112, 120], ["the antiviral activity", "TREATMENT", 145, 167], ["PEDV infection of IPEC", "PROBLEM", 176, 198], ["J2 cells", "PROBLEM", 199, 207], ["L1", "ANATOMY", 89, 91], ["J2", "ANATOMY", 112, 114], ["J2 cells", "OBSERVATION", 199, 207]]], ["Similar to rpIFN-L1, both rpIFN-L3 and IFN-a up-regulated the expression of all three antiviral genes after 24 h stimulation of IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 128, 141], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 11, 19], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 26, 34], ["IFN-a", "GENE_OR_GENE_PRODUCT", 39, 44], ["IPEC-J2 cells", "CELL", 128, 141], ["rpIFN", "PROTEIN", 11, 16], ["L1", "DNA", 17, 19], ["rpIFN", "PROTEIN", 26, 31], ["L3", "PROTEIN", 32, 34], ["IFN", "PROTEIN", 39, 42], ["antiviral genes", "DNA", 86, 101], ["IPEC-J2 cells", "CELL_LINE", 128, 141], ["rpIFN", "TEST", 11, 16], ["IFN", "TEST", 39, 42], ["J2 cells", "PROBLEM", 133, 141], ["L1", "ANATOMY_MODIFIER", 17, 19], ["both", "ANATOMY_MODIFIER", 21, 25], ["rpIFN", "ANATOMY_MODIFIER", 26, 31], ["L3", "ANATOMY", 32, 34], ["J2 cells", "OBSERVATION", 133, 141]]], ["Interestingly, rpIFN-L3 elicited significantly lower OASL than rpIFN-L1 (P < 0.05), even though rpIFN-L1 and rpIFN-L3 induced similar levels of MxA, and rpIFN-L3 induced significantly higher levels of ISG15 at 100 ng/ml than rpIFN-L1 ( Fig. 5B and C) .", [["OASL", "ANATOMY", 53, 57], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 15, 23], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 63, 71], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 96, 104], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 109, 117], ["MxA", "GENE_OR_GENE_PRODUCT", 144, 147], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 153, 161], ["ISG15", "GENE_OR_GENE_PRODUCT", 201, 206], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 225, 233], ["C", "CELL", 248, 249], ["rpIFN", "PROTEIN", 15, 20], ["OASL", "PROTEIN", 53, 57], ["rpIFN", "PROTEIN", 63, 68], ["rpIFN", "PROTEIN", 96, 101], ["L1", "PROTEIN", 102, 104], ["rpIFN", "PROTEIN", 109, 114], ["L3", "PROTEIN", 115, 117], ["MxA", "PROTEIN", 144, 147], ["rpIFN", "PROTEIN", 153, 158], ["L3", "PROTEIN", 159, 161], ["ISG15", "PROTEIN", 201, 206], ["rpIFN", "PROTEIN", 225, 230], ["rpIFN", "TEST", 15, 20], ["rpIFN", "TEST", 63, 68], ["rpIFN", "TEST", 96, 101], ["rpIFN", "TEST", 109, 114], ["MxA", "TEST", 144, 147], ["rpIFN", "TEST", 153, 158], ["ISG15", "TEST", 201, 206], ["rpIFN", "TEST", 225, 230], ["L3", "ANATOMY_MODIFIER", 21, 23], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["lower", "OBSERVATION_MODIFIER", 47, 52], ["L1", "ANATOMY", 69, 71], ["L1", "ANATOMY", 102, 104], ["L3", "ANATOMY_MODIFIER", 115, 117], ["L3", "ANATOMY_MODIFIER", 159, 161], ["L1", "ANATOMY", 231, 233]]], ["Consistent with a greater antiviral efficacy in IPEC-J2 cells by rpIFN-L1 compared with IFN-a, rpIFN-L1 induced greater mRNA expression of antiviral genes ISG15, OASL, and MxA than IFN-a, especially when using a high dose of 1000 ng/ml (Fig. 5) .", [["IPEC-J2 cells", "ANATOMY", 48, 61], ["IPEC-J2 cells", "CELL", 48, 61], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 65, 73], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 95, 103], ["ISG15", "GENE_OR_GENE_PRODUCT", 155, 160], ["OASL", "GENE_OR_GENE_PRODUCT", 162, 166], ["MxA", "GENE_OR_GENE_PRODUCT", 172, 175], ["IPEC-J2 cells", "CELL_LINE", 48, 61], ["rpIFN", "PROTEIN", 65, 70], ["L1", "PROTEIN", 71, 73], ["IFN", "PROTEIN", 88, 91], ["rpIFN", "PROTEIN", 95, 100], ["L1", "PROTEIN", 101, 103], ["antiviral genes", "DNA", 139, 154], ["ISG15", "PROTEIN", 155, 160], ["OASL", "PROTEIN", 162, 166], ["MxA", "PROTEIN", 172, 175], ["IFN", "PROTEIN", 181, 184], ["a greater antiviral efficacy", "PROBLEM", 16, 44], ["rpIFN", "TEST", 65, 70], ["IFN", "TEST", 88, 91], ["rpIFN", "TEST", 95, 100], ["antiviral genes ISG15", "PROBLEM", 139, 160], ["OASL", "TEST", 162, 166], ["MxA", "TEST", 172, 175], ["IFN", "TEST", 181, 184], ["greater", "OBSERVATION_MODIFIER", 18, 25], ["antiviral efficacy", "OBSERVATION", 26, 44], ["J2 cells", "OBSERVATION_MODIFIER", 53, 61], ["L1", "ANATOMY", 71, 73], ["L1", "ANATOMY", 101, 103], ["antiviral genes", "OBSERVATION", 139, 154]]], ["These data suggest that IPEC-J2 cells preferentially respond to rpIFN-L, although both IFN-a and rpIFN-L have antiviral activity in these cells.rpIFN-L inhibits PEDV infection by activating multiple mechanismsIn addition, interferon-induced transmembrane proteins (IFITMs) have been recently identified as a related family of broadly potent antiviral cellular inhibitors, especially IFITM3, which exhibits robust antiviral activity against multiple enveloped RNA viruses include influenza virus, HIV-1, SARS coronavirus, and Degue virus (Brass et al., 2009; Diamond and Farzan, 2013; review) .", [["IPEC-J2 cells", "ANATOMY", 24, 37], ["cells", "ANATOMY", 138, 143], ["transmembrane", "ANATOMY", 241, 254], ["cellular", "ANATOMY", 351, 359], ["rpIFN-L", "CHEMICAL", 144, 151], ["infection", "DISEASE", 166, 175], ["influenza virus", "DISEASE", 479, 494], ["SARS coronavirus", "DISEASE", 503, 519], ["IPEC-J2 cells", "CELL", 24, 37], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 64, 71], ["IFN-a", "GENE_OR_GENE_PRODUCT", 87, 92], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 97, 104], ["cells", "CELL", 138, 143], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 144, 151], ["PEDV", "ORGANISM", 161, 165], ["interferon-induced transmembrane proteins", "GENE_OR_GENE_PRODUCT", 222, 263], ["IFITMs", "GENE_OR_GENE_PRODUCT", 265, 271], ["cellular", "CELL", 351, 359], ["IFITM3", "GENE_OR_GENE_PRODUCT", 383, 389], ["influenza virus", "ORGANISM", 479, 494], ["HIV-1", "ORGANISM", 496, 501], ["SARS coronavirus", "ORGANISM", 503, 519], ["Degue virus", "ORGANISM", 525, 536], ["IPEC-J2 cells", "CELL_LINE", 24, 37], ["rpIFN", "PROTEIN", 64, 69], ["IFN", "PROTEIN", 87, 90], ["rpIFN", "PROTEIN", 97, 102], ["rpIFN", "PROTEIN", 144, 149], ["interferon", "PROTEIN", 222, 232], ["transmembrane proteins", "PROTEIN", 241, 263], ["IFITMs", "PROTEIN", 265, 271], ["IFITM3", "PROTEIN", 383, 389], ["influenza virus", "SPECIES", 479, 494], ["HIV-1", "SPECIES", 496, 501], ["SARS coronavirus", "SPECIES", 503, 519], ["PEDV", "SPECIES", 161, 165], ["HIV-1", "SPECIES", 496, 501], ["SARS coronavirus", "SPECIES", 503, 519], ["Degue virus", "SPECIES", 525, 536], ["These data", "TEST", 0, 10], ["IPEC", "TEST", 24, 28], ["J2 cells", "PROBLEM", 29, 37], ["rpIFN", "TEST", 64, 69], ["IFN", "TEST", 87, 90], ["rpIFN", "TEST", 97, 102], ["antiviral activity in these cells", "PROBLEM", 110, 143], ["rpIFN", "TEST", 144, 149], ["L inhibits PEDV infection", "PROBLEM", 150, 175], ["interferon", "TREATMENT", 222, 232], ["transmembrane proteins", "PROBLEM", 241, 263], ["broadly potent antiviral cellular inhibitors", "TREATMENT", 326, 370], ["IFITM3", "PROBLEM", 383, 389], ["robust antiviral activity", "PROBLEM", 406, 431], ["multiple enveloped RNA viruses", "PROBLEM", 440, 470], ["influenza virus", "PROBLEM", 479, 494], ["HIV", "PROBLEM", 496, 499], ["SARS coronavirus", "PROBLEM", 503, 519], ["Degue virus", "PROBLEM", 525, 536], ["J2 cells", "OBSERVATION", 29, 37], ["antiviral activity", "OBSERVATION", 110, 128], ["L inhibits", "OBSERVATION_MODIFIER", 150, 160], ["PEDV", "OBSERVATION_MODIFIER", 161, 165], ["infection", "OBSERVATION", 166, 175], ["antiviral activity", "OBSERVATION", 413, 431]]], ["IFITMs primarily restrict the early life cycle of enveloped viruses and inhibit viral entry by blocking viral fusion.", [["IFITMs", "GENE_OR_GENE_PRODUCT", 0, 6], ["enveloped viruses", "PROBLEM", 50, 67], ["viral entry", "PROBLEM", 80, 91], ["blocking viral fusion", "TREATMENT", 95, 116], ["viruses", "OBSERVATION", 60, 67], ["viral fusion", "OBSERVATION", 104, 116]]], ["As expected, the expression of porcine IFITM1 and IFITM3 were induced in a dosedependent manner in IPEC-J2 cells following stimulation with either rpIFN-L or IFN-a ( Fig. 5D and E) .", [["IPEC-J2 cells", "ANATOMY", 99, 112], ["porcine", "ORGANISM", 31, 38], ["IFITM1", "GENE_OR_GENE_PRODUCT", 39, 45], ["IFITM3", "GENE_OR_GENE_PRODUCT", 50, 56], ["IPEC-J2 cells", "CELL", 99, 112], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 147, 154], ["E", "SIMPLE_CHEMICAL", 178, 179], ["porcine IFITM1", "PROTEIN", 31, 45], ["IFITM3", "PROTEIN", 50, 56], ["IPEC-J2 cells", "CELL_LINE", 99, 112], ["rpIFN", "PROTEIN", 147, 152], ["IFN", "PROTEIN", 158, 161], ["porcine IFITM1 and IFITM3", "TREATMENT", 31, 56], ["rpIFN", "TEST", 147, 152], ["IFN", "TREATMENT", 158, 161]]], ["Unexpectedly, unlike the expression profiling of ISG15, OASL, and MxA, IFN-a up-regulated similar levels of IFITM1 and IFITM3 expression to those of rpIFN- Fig. 5 . rpIFN-L and IFN-a induced the expression of ISG genes in IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 222, 235], ["IFN", "CHEMICAL", 177, 180], ["ISG15", "GENE_OR_GENE_PRODUCT", 49, 54], ["OASL", "GENE_OR_GENE_PRODUCT", 56, 60], ["MxA", "GENE_OR_GENE_PRODUCT", 66, 69], ["IFN", "GENE_OR_GENE_PRODUCT", 71, 74], ["IFITM1", "GENE_OR_GENE_PRODUCT", 108, 114], ["IFITM3", "GENE_OR_GENE_PRODUCT", 119, 125], ["rpIFN", "GENE_OR_GENE_PRODUCT", 149, 154], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 165, 172], ["IFN", "GENE_OR_GENE_PRODUCT", 177, 180], ["ISG", "GENE_OR_GENE_PRODUCT", 209, 212], ["IPEC-J2 cells", "CELL", 222, 235], ["ISG15", "PROTEIN", 49, 54], ["OASL", "PROTEIN", 56, 60], ["MxA", "PROTEIN", 66, 69], ["IFN", "PROTEIN", 71, 74], ["IFITM1", "PROTEIN", 108, 114], ["IFITM3", "PROTEIN", 119, 125], ["rpIFN", "PROTEIN", 149, 154], ["rpIFN", "PROTEIN", 165, 170], ["IFN", "PROTEIN", 177, 180], ["ISG genes", "DNA", 209, 218], ["IPEC-J2 cells", "CELL_LINE", 222, 235], ["ISG15", "TEST", 49, 54], ["OASL", "TEST", 56, 60], ["MxA", "TEST", 66, 69], ["IFN", "TEST", 71, 74], ["IFITM1", "PROBLEM", 108, 114], ["IFITM3 expression", "PROBLEM", 119, 136], ["rpIFN", "TEST", 149, 154], ["rpIFN", "TEST", 165, 170], ["ISG genes in IPEC-J2 cells", "PROBLEM", 209, 235], ["L", "ANATOMY_MODIFIER", 171, 172], ["ISG genes", "OBSERVATION", 209, 218], ["J2 cells", "OBSERVATION", 227, 235]]], ["IPEC-J2 were stimulated with IFN at indicated concentrations for 24 h in 24-well plates, and the mRNA of ISG15, OASL, MxA, IFITM1 or IFITM3 was measured by relative RT-qPCR.", [["IFN", "CHEMICAL", 29, 32], ["IPEC-J2", "CELL", 0, 7], ["IFN", "GENE_OR_GENE_PRODUCT", 29, 32], ["ISG15", "GENE_OR_GENE_PRODUCT", 105, 110], ["OASL", "GENE_OR_GENE_PRODUCT", 112, 116], ["MxA", "GENE_OR_GENE_PRODUCT", 118, 121], ["IFITM1", "GENE_OR_GENE_PRODUCT", 123, 129], ["IFITM3", "GENE_OR_GENE_PRODUCT", 133, 139], ["IPEC-J2", "CELL_LINE", 0, 7], ["IFN", "PROTEIN", 29, 32], ["mRNA", "RNA", 97, 101], ["ISG15", "PROTEIN", 105, 110], ["OASL", "PROTEIN", 112, 116], ["MxA", "PROTEIN", 118, 121], ["IFITM1", "PROTEIN", 123, 129], ["IFITM3", "PROTEIN", 133, 139], ["IPEC", "TEST", 0, 4], ["IFN", "TREATMENT", 29, 32], ["ISG15", "TEST", 105, 110], ["OASL", "TEST", 112, 116], ["MxA", "TEST", 118, 121], ["IFITM1", "TEST", 123, 129], ["IFITM3", "PROBLEM", 133, 139], ["J2", "ANATOMY", 5, 7]]], ["L1.", [["L1", "DNA", 0, 2]]], ["By contrast, rpIFN-L3 induced the highest levels of IFITM3 expression among the three IFNs at both 1000 ng/ml and 100 ng/ ml.", [["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 13, 21], ["IFITM3", "GENE_OR_GENE_PRODUCT", 52, 58], ["IFNs", "GENE_OR_GENE_PRODUCT", 86, 90], ["rpIFN", "PROTEIN", 13, 18], ["L3", "PROTEIN", 19, 21], ["IFITM3", "PROTEIN", 52, 58], ["IFNs", "PROTEIN", 86, 90], ["rpIFN", "TEST", 13, 18], ["IFITM3 expression", "PROBLEM", 52, 69], ["L3", "ANATOMY", 19, 21], ["IFITM3 expression", "OBSERVATION", 52, 69]]], ["These results indicate that both IFITM1 and IFITM3 are induced by IFNs but exhibit various sensitivity to the stimulation of different IFNs and that rpIFN-L1 and rpIFN-L3 induce a different profile of antiviral genes even though they use the same receptor.", [["IFITM1", "GENE_OR_GENE_PRODUCT", 33, 39], ["IFITM3", "GENE_OR_GENE_PRODUCT", 44, 50], ["IFNs", "GENE_OR_GENE_PRODUCT", 66, 70], ["IFNs", "GENE_OR_GENE_PRODUCT", 135, 139], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 149, 157], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 162, 170], ["IFITM1", "PROTEIN", 33, 39], ["IFITM3", "PROTEIN", 44, 50], ["IFNs", "PROTEIN", 66, 70], ["IFNs", "PROTEIN", 135, 139], ["rpIFN", "PROTEIN", 149, 154], ["L1", "PROTEIN", 155, 157], ["rpIFN", "PROTEIN", 162, 167], ["L3", "DNA", 168, 170], ["antiviral genes", "DNA", 201, 216], ["IFNs", "PROBLEM", 66, 70], ["various sensitivity", "PROBLEM", 83, 102], ["different IFNs", "TREATMENT", 125, 139], ["rpIFN", "TEST", 149, 154], ["antiviral genes", "TREATMENT", 201, 216], ["L1", "ANATOMY", 155, 157], ["L3", "ANATOMY", 168, 170], ["antiviral genes", "OBSERVATION", 201, 216]]], ["We further cloned porcine IFITM1 and IFITM3 into a pCAGGS-HA vector.", [["porcine", "ORGANISM", 18, 25], ["IFITM1", "GENE_OR_GENE_PRODUCT", 26, 32], ["IFITM3", "GENE_OR_GENE_PRODUCT", 37, 43], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 51, 57], ["IFITM1", "PROTEIN", 26, 32], ["IFITM3", "PROTEIN", 37, 43], ["pCAGGS-HA vector", "DNA", 51, 67], ["porcine", "SPECIES", 18, 25], ["further cloned porcine IFITM1", "TREATMENT", 3, 32], ["a pCAGGS-HA vector", "TREATMENT", 49, 67]]], ["The transient expression of IFITM1 and IFITM3 was verified by western blotting (data not shown).", [["IFITM1", "GENE_OR_GENE_PRODUCT", 28, 34], ["IFITM3", "GENE_OR_GENE_PRODUCT", 39, 45], ["IFITM1", "PROTEIN", 28, 34], ["IFITM3", "PROTEIN", 39, 45], ["IFITM1 and IFITM3", "PROBLEM", 28, 45], ["western blotting", "TEST", 62, 78], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["expression", "OBSERVATION_MODIFIER", 14, 24]]], ["The transient over-expression of IFITM1 and IFITM3 in Vero E6 cells inhibited PEDV infection, especially for IFITM3, which resulted in a 40% decrease of PEDV infection (Fig. 6 ).", [["Vero E6 cells", "ANATOMY", 54, 67], ["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 158, 167], ["IFITM1", "GENE_OR_GENE_PRODUCT", 33, 39], ["IFITM3", "GENE_OR_GENE_PRODUCT", 44, 50], ["Vero E6 cells", "CELL", 54, 67], ["PEDV", "CANCER", 78, 82], ["IFITM3", "GENE_OR_GENE_PRODUCT", 109, 115], ["IFITM1", "PROTEIN", 33, 39], ["IFITM3", "PROTEIN", 44, 50], ["Vero E6 cells", "CELL_LINE", 54, 67], ["IFITM3", "PROTEIN", 109, 115], ["Vero E6", "SPECIES", 54, 61], ["PEDV", "SPECIES", 78, 82], ["PEDV", "SPECIES", 153, 157], ["IFITM1", "PROBLEM", 33, 39], ["IFITM3", "PROBLEM", 44, 50], ["Vero E6 cells", "PROBLEM", 54, 67], ["PEDV infection", "PROBLEM", 78, 92], ["IFITM3", "PROBLEM", 109, 115], ["PEDV infection", "PROBLEM", 153, 167], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["PEDV", "OBSERVATION_MODIFIER", 78, 82], ["infection", "OBSERVATION", 83, 92], ["PEDV", "OBSERVATION_MODIFIER", 153, 157], ["infection", "OBSERVATION", 158, 167]]], ["All these results indicate that rpIFN-L induces the expression of multiple host antiviral genes to inhibit viral infection.CytotoxicityTo exclude the potential of cytotoxicity by rpIFN-L treatment of cells, we measured cell viability using the CCK-8 assay.", [["cells", "ANATOMY", 200, 205], ["cell", "ANATOMY", 219, 223], ["viral infection", "DISEASE", 107, 122], ["CCK-8", "CHEMICAL", 244, 249], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 32, 39], ["rpIFN-L", "SIMPLE_CHEMICAL", 179, 186], ["cells", "CELL", 200, 205], ["cell", "CELL", 219, 223], ["CCK-8", "GENE_OR_GENE_PRODUCT", 244, 249], ["rpIFN", "PROTEIN", 32, 37], ["antiviral genes", "DNA", 80, 95], ["rpIFN", "PROTEIN", 179, 184], ["rpIFN", "TEST", 32, 37], ["multiple host antiviral genes", "TREATMENT", 66, 95], ["viral infection", "PROBLEM", 107, 122], ["Cytotoxicity", "TEST", 123, 135], ["cytotoxicity", "PROBLEM", 163, 175], ["rpIFN", "TEST", 179, 184], ["L treatment of cells", "TREATMENT", 185, 205], ["the CCK", "TEST", 240, 247], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["host antiviral genes", "OBSERVATION", 75, 95], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122], ["cell viability", "OBSERVATION", 219, 233]]], ["No cytotoxicity was observed in the cells following IFN treatment for 60 h from 5000 ng/ml to 1 ng/ml.", [["cells", "ANATOMY", 36, 41], ["IFN", "CHEMICAL", 52, 55], ["cells", "CELL", 36, 41], ["IFN", "PROTEIN", 52, 55], ["cytotoxicity", "PROBLEM", 3, 15], ["IFN treatment", "TREATMENT", 52, 65], ["cytotoxicity", "OBSERVATION", 3, 15]]], ["The percentages of CCK-8 OD values for rpIFN-L-treated Vero E6 or IPEC-J2 cells ranged from 90.69 \u00b1 5.00% to 114.12 \u00b1 4.36% of the controls, indicating no cytotoxicity.", [["Vero", "ANATOMY", 55, 59], ["IPEC-J2 cells", "ANATOMY", 66, 79], ["rpIFN-L", "CHEMICAL", 39, 46], ["CCK-8", "GENE_OR_GENE_PRODUCT", 19, 24], ["rpIFN-L", "SIMPLE_CHEMICAL", 39, 46], ["Vero", "ORGANISM", 55, 59], ["E6", "ORGANISM", 60, 62], ["IPEC-J2 cells", "CELL", 66, 79], ["CCK", "PROTEIN", 19, 22], ["rpIFN-L-treated Vero E6", "CELL_LINE", 39, 62], ["IPEC-J2 cells", "CELL_LINE", 66, 79], ["CCK", "TEST", 19, 22], ["OD values", "TEST", 25, 34], ["rpIFN", "TEST", 39, 44], ["Vero E6", "TEST", 55, 62], ["IPEC", "TEST", 66, 70], ["J2 cells", "TEST", 71, 79], ["cytotoxicity", "PROBLEM", 155, 167], ["no", "UNCERTAINTY", 152, 154], ["cytotoxicity", "OBSERVATION", 155, 167]]], ["The CC 50 of rpIFN-L1 and rpIFN-L3 was over 1.7 mg/ml, which is 1000-fold more than the concentration of rpIFN-L used in this study.DiscussionInterferons are one of the most important molecules of innate immunity in response to viral infection.", [["CC", "CHEMICAL", 4, 6], ["viral infection", "DISEASE", 228, 243], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 13, 21], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 26, 34], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 105, 112], ["rpIFN", "PROTEIN", 13, 18], ["L1", "PROTEIN", 19, 21], ["rpIFN", "PROTEIN", 26, 31], ["rpIFN", "PROTEIN", 105, 110], ["Interferons", "PROTEIN", 142, 153], ["The CC", "TEST", 0, 6], ["rpIFN-L1 and rpIFN-L3", "TREATMENT", 13, 34], ["rpIFN-L", "TREATMENT", 105, 112], ["this study", "TEST", 121, 131], ["Interferons", "TREATMENT", 142, 153], ["viral infection", "PROBLEM", 228, 243], ["L1", "ANATOMY", 19, 21], ["L3", "ANATOMY", 32, 34], ["viral", "OBSERVATION_MODIFIER", 228, 233], ["infection", "OBSERVATION", 234, 243]]], ["IFN-L is increasingly being shown to play a pivotal role in inhibiting viral infections at mucosal surfaces.", [["mucosal", "ANATOMY", 91, 98], ["IFN", "CHEMICAL", 0, 3], ["viral infections", "DISEASE", 71, 87], ["IFN-L", "GENE_OR_GENE_PRODUCT", 0, 5], ["mucosal surfaces", "PATHOLOGICAL_FORMATION", 91, 107], ["IFN", "PROTEIN", 0, 3], ["viral infections at mucosal surfaces", "PROBLEM", 71, 107], ["infections", "OBSERVATION", 77, 87]]], ["However, there is no information available about whether porcine IFN-L inhibits swine enteric pathogenic coronaviruses.", [["IFN", "CHEMICAL", 65, 68], ["enteric pathogenic coronaviruses", "DISEASE", 86, 118], ["porcine", "ORGANISM", 57, 64], ["IFN-L", "GENE_OR_GENE_PRODUCT", 65, 70], ["swine enteric pathogenic coronaviruses", "ORGANISM", 80, 118], ["porcine IFN-L", "PROTEIN", 57, 70], ["swine", "SPECIES", 80, 85], ["swine", "SPECIES", 80, 85], ["porcine IFN-L inhibits swine enteric pathogenic coronaviruses", "PROBLEM", 57, 118], ["no", "UNCERTAINTY", 18, 20], ["pathogenic coronaviruses", "OBSERVATION", 94, 118]]], ["PEDV is an alpha coronavirus that causes economically significant swine diseases.", [["PEDV", "CHEMICAL", 0, 4], ["swine diseases", "DISEASE", 66, 80], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["alpha coronavirus", "ORGANISM", 11, 28], ["swine", "SPECIES", 66, 71], ["PEDV", "SPECIES", 0, 4], ["alpha coronavirus", "SPECIES", 11, 28], ["swine", "SPECIES", 66, 71], ["PEDV", "PROBLEM", 0, 4], ["an alpha coronavirus", "PROBLEM", 8, 28], ["significant swine diseases", "PROBLEM", 54, 80], ["alpha coronavirus", "OBSERVATION", 11, 28], ["economically", "OBSERVATION_MODIFIER", 41, 53], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["swine", "OBSERVATION_MODIFIER", 66, 71], ["diseases", "OBSERVATION", 72, 80]]], ["In this study, we investigated the relative contribution of porcine IFN-L toward controlling the infection of PEDV in vitro.DiscussionIFN-L preferentially acts on epithelial cells because IFNLR1 is expressed primarily on the epithelial cells of the gastrointestinal and respiratory tracts (Mordstein et al., 2010; Pott et al., 2011; Sommereyns et al., 2008) .", [["epithelial cells", "ANATOMY", 163, 179], ["epithelial cells", "ANATOMY", 225, 241], ["gastrointestinal", "ANATOMY", 249, 265], ["respiratory tracts", "ANATOMY", 270, 288], ["infection", "DISEASE", 97, 106], ["PEDV", "CHEMICAL", 110, 114], ["porcine", "ORGANISM", 60, 67], ["IFN-L", "GENE_OR_GENE_PRODUCT", 68, 73], ["PEDV", "ORGANISM", 110, 114], ["DiscussionIFN-L", "GENE_OR_GENE_PRODUCT", 124, 139], ["epithelial cells", "CELL", 163, 179], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 188, 194], ["epithelial cells", "CELL", 225, 241], ["gastrointestinal", "ORGAN", 249, 265], ["porcine IFN-L", "PROTEIN", 60, 73], ["epithelial cells", "CELL_TYPE", 163, 179], ["IFNLR1", "PROTEIN", 188, 194], ["epithelial cells", "CELL_TYPE", 225, 241], ["PEDV", "SPECIES", 110, 114], ["this study", "TEST", 3, 13], ["porcine IFN", "TREATMENT", 60, 71], ["PEDV", "PROBLEM", 110, 114], ["epithelial cells", "TREATMENT", 163, 179], ["infection", "OBSERVATION", 97, 106], ["PEDV", "OBSERVATION", 110, 114], ["epithelial cells", "OBSERVATION", 225, 241], ["gastrointestinal", "ANATOMY", 249, 265], ["respiratory tracts", "ANATOMY", 270, 288]]], ["Here we report that both rpIFN-L1 and rpIFN-L3 have robust antiviral activity against PEDV infection in both IPEC-J2 and Vero E6 cells.", [["IPEC-J2", "ANATOMY", 109, 116], ["Vero E6 cells", "ANATOMY", 121, 134], ["infection", "DISEASE", 91, 100], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 25, 33], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 38, 46], ["PEDV", "SIMPLE_CHEMICAL", 86, 90], ["IPEC-J2", "CELL", 109, 116], ["Vero E6 cells", "CELL", 121, 134], ["rpIFN", "PROTEIN", 25, 30], ["L1", "DNA", 31, 33], ["rpIFN", "PROTEIN", 38, 43], ["L3", "DNA", 44, 46], ["IPEC-J2", "CELL_LINE", 109, 116], ["Vero E6 cells", "CELL_LINE", 121, 134], ["PEDV", "SPECIES", 86, 90], ["Vero E6", "SPECIES", 121, 128], ["rpIFN", "TEST", 25, 30], ["robust antiviral activity", "PROBLEM", 52, 77], ["PEDV infection", "PROBLEM", 86, 100], ["Vero E6 cells", "PROBLEM", 121, 134], ["L1", "ANATOMY", 31, 33], ["L3", "ANATOMY", 44, 46], ["antiviral activity", "OBSERVATION", 59, 77], ["infection", "OBSERVATION", 91, 100], ["J2", "ANATOMY", 114, 116], ["Vero E6 cells", "OBSERVATION", 121, 134]]], ["Recent studies have demonstrated that IFN-L plays a vital role in restricting enteric viral infections relative to type I IFN (Mordstein et al., 2010; Pott et al., 2011; Sommereyns et al., 2008) .", [["enteric viral infections", "DISEASE", 78, 102], ["IFN-L", "GENE_OR_GENE_PRODUCT", 38, 43], ["type I IFN", "GENE_OR_GENE_PRODUCT", 115, 125], ["IFN-L", "PROTEIN", 38, 43], ["type I IFN", "PROTEIN", 115, 125], ["Recent studies", "TEST", 0, 14], ["IFN", "PROBLEM", 38, 41], ["enteric viral infections", "PROBLEM", 78, 102], ["viral infections", "OBSERVATION", 86, 102]]], ["Our results of the comparison of rpIFN-L1 and IFN-a against PEDV infection in IPEC-J2 cells also demonstrate that rpIFN-L more efficiently inhibits PEDV infection in IPEC-J2 cells than IFN-a, although both inhibit PEDV infection.", [["IPEC-J2 cells", "ANATOMY", 78, 91], ["IPEC-J2 cells", "ANATOMY", 166, 179], ["infection", "DISEASE", 65, 74], ["infection", "DISEASE", 153, 162], ["infection", "DISEASE", 219, 228], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 33, 41], ["IFN-a", "SIMPLE_CHEMICAL", 46, 51], ["PEDV", "ORGANISM", 60, 64], ["IPEC-J2 cells", "CELL", 78, 91], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 114, 121], ["PEDV", "SIMPLE_CHEMICAL", 148, 152], ["IPEC-J2 cells", "CELL", 166, 179], ["IFN-a", "GENE_OR_GENE_PRODUCT", 185, 190], ["PEDV", "GENE_OR_GENE_PRODUCT", 214, 218], ["rpIFN", "PROTEIN", 33, 38], ["L1", "PROTEIN", 39, 41], ["IFN", "PROTEIN", 46, 49], ["IPEC-J2 cells", "CELL_LINE", 78, 91], ["rpIFN", "PROTEIN", 114, 119], ["IPEC-J2 cells", "CELL_LINE", 166, 179], ["IFN", "PROTEIN", 185, 188], ["PEDV", "SPECIES", 60, 64], ["PEDV", "SPECIES", 148, 152], ["PEDV", "SPECIES", 214, 218], ["rpIFN", "TEST", 33, 38], ["IFN", "TREATMENT", 46, 49], ["PEDV infection", "PROBLEM", 60, 74], ["J2 cells", "PROBLEM", 83, 91], ["rpIFN", "TEST", 114, 119], ["PEDV infection", "PROBLEM", 148, 162], ["J2 cells", "PROBLEM", 171, 179], ["IFN", "TEST", 185, 188], ["PEDV infection", "PROBLEM", 214, 228], ["L1", "ANATOMY", 39, 41], ["infection", "OBSERVATION", 65, 74], ["L more", "OBSERVATION_MODIFIER", 120, 126], ["PEDV", "OBSERVATION_MODIFIER", 148, 152], ["infection", "OBSERVATION", 153, 162], ["J2 cells", "OBSERVATION_MODIFIER", 171, 179], ["PEDV", "OBSERVATION_MODIFIER", 214, 218], ["infection", "OBSERVATION", 219, 228]]], ["Consistent with these results, rpIFN-L1 induced higher levels of antiviral gene expression (ISG15, OASL, and MxA) in IPEC-J2 cells compared with IFN-a, indicating that the ISGs induced by IFN-L confer an antiviral state in IPEC-J2.", [["IPEC-J2 cells", "ANATOMY", 117, 130], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 31, 39], ["ISG15", "GENE_OR_GENE_PRODUCT", 92, 97], ["OASL", "GENE_OR_GENE_PRODUCT", 99, 103], ["MxA", "GENE_OR_GENE_PRODUCT", 109, 112], ["IPEC-J2 cells", "CELL", 117, 130], ["IFN-a", "GENE_OR_GENE_PRODUCT", 145, 150], ["IFN-L", "GENE_OR_GENE_PRODUCT", 188, 193], ["IPEC-J2", "CELL", 223, 230], ["rpIFN", "PROTEIN", 31, 36], ["L1", "DNA", 37, 39], ["ISG15", "PROTEIN", 92, 97], ["OASL", "PROTEIN", 99, 103], ["MxA", "PROTEIN", 109, 112], ["IPEC-J2 cells", "CELL_LINE", 117, 130], ["IFN", "PROTEIN", 145, 148], ["ISGs", "PROTEIN", 172, 176], ["IFN", "PROTEIN", 188, 191], ["IPEC-J2", "CELL_LINE", 223, 230], ["rpIFN", "TEST", 31, 36], ["antiviral gene expression", "PROBLEM", 65, 90], ["ISG15", "TEST", 92, 97], ["OASL", "TEST", 99, 103], ["MxA", "TEST", 109, 112], ["IFN", "TEST", 145, 148], ["the ISGs", "PROBLEM", 168, 176], ["IFN", "TEST", 188, 191], ["antiviral gene", "OBSERVATION", 65, 79], ["J2", "ANATOMY", 122, 124], ["antiviral", "OBSERVATION", 204, 213], ["J2", "ANATOMY", 228, 230]]], ["Timothy J. Nice et al. demonstrated that IFN-L alone can prevent and cure the enteric persistent infection of murine norovirus (MNoV) without the help of adaptive immunity .", [["IFN-L", "CHEMICAL", 41, 46], ["infection", "DISEASE", 97, 106], ["IFN-L", "GENE_OR_GENE_PRODUCT", 41, 46], ["murine norovirus", "ORGANISM", 110, 126], ["MNoV", "CANCER", 128, 132], ["IFN", "PROTEIN", 41, 44], ["murine", "SPECIES", 110, 116], ["murine norovirus", "SPECIES", 110, 126], ["MNoV", "SPECIES", 128, 132], ["IFN", "TREATMENT", 41, 44], ["the enteric persistent infection of murine norovirus", "PROBLEM", 74, 126], ["adaptive immunity", "TREATMENT", 154, 171], ["enteric", "OBSERVATION_MODIFIER", 78, 85], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["infection", "OBSERVATION", 97, 106]]], ["The study of another virus targeting intestinal epithelia, rotavirus, confirms that IFN-L but not type I IFN inhibits rotavirus infection in vivo (Pott et al., 2011) .", [["intestinal epithelia", "ANATOMY", 37, 57], ["IFN", "CHEMICAL", 105, 108], ["rotavirus infection", "DISEASE", 118, 137], ["intestinal epithelia", "TISSUE", 37, 57], ["rotavirus", "ORGANISM", 59, 68], ["IFN-L", "GENE_OR_GENE_PRODUCT", 84, 89], ["type I IFN", "GENE_OR_GENE_PRODUCT", 98, 108], ["rotavirus", "ORGANISM", 118, 127], ["IFN-L", "PROTEIN", 84, 89], ["type I IFN", "PROTEIN", 98, 108], ["rotavirus", "SPECIES", 118, 127], ["The study", "TEST", 0, 9], ["another virus targeting intestinal epithelia", "PROBLEM", 13, 57], ["rotavirus", "PROBLEM", 59, 68], ["IFN", "TEST", 84, 87], ["type I IFN", "PROBLEM", 98, 108], ["rotavirus infection", "PROBLEM", 118, 137], ["intestinal epithelia", "ANATOMY", 37, 57], ["rotavirus", "OBSERVATION_MODIFIER", 118, 127], ["infection", "OBSERVATION", 128, 137]]], ["All these imply that IFN-L preferably provides the critical antiviral defenses of the intestinal epithelium compared with type I IFN.DiscussionThe IFN-L family consists of two members in mice and four members in humans review) .", [["intestinal epithelium", "ANATOMY", 86, 107], ["IFN-L", "GENE_OR_GENE_PRODUCT", 21, 26], ["intestinal epithelium", "TISSUE", 86, 107], ["type I IFN", "GENE_OR_GENE_PRODUCT", 122, 132], ["IFN-L", "GENE_OR_GENE_PRODUCT", 147, 152], ["mice", "ORGANISM", 187, 191], ["humans", "ORGANISM", 212, 218], ["IFN-L", "PROTEIN", 21, 26], ["type I IFN", "PROTEIN", 122, 132], ["IFN-L family", "PROTEIN", 147, 159], ["mice", "SPECIES", 187, 191], ["humans", "SPECIES", 212, 218], ["humans", "SPECIES", 212, 218], ["IFN-L", "TREATMENT", 21, 26], ["antiviral defenses", "OBSERVATION", 60, 78], ["intestinal epithelium", "ANATOMY", 86, 107]]], ["Two members of porcine IFN-L have been reported so far (Sang et al., 2010) .", [["porcine", "ORGANISM", 15, 22], ["IFN-L", "GENE_OR_GENE_PRODUCT", 23, 28], ["porcine IFN-L", "PROTEIN", 15, 28], ["porcine", "SPECIES", 15, 22], ["porcine IFN", "TREATMENT", 15, 26]]], ["Although porcine IFN-L1 and IFN-L3 both belong to the type III interferon family, porcine IFN-L1 (GenBank accession no. ACZ63406.1) and IFN-L3 (GenBank accession no. NP_001159962.1) have only 52.4% amino acid identity.", [["ACZ63406.1", "CHEMICAL", 120, 130], ["NP_001159962.1", "CHEMICAL", 166, 180], ["amino acid", "CHEMICAL", 198, 208], ["amino acid", "CHEMICAL", 198, 208], ["porcine", "ORGANISM", 9, 16], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 17, 23], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 28, 34], ["type III interferon", "GENE_OR_GENE_PRODUCT", 54, 73], ["porcine", "ORGANISM", 82, 89], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 90, 96], ["ACZ63406.1", "GENE_OR_GENE_PRODUCT", 120, 130], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 136, 142], ["amino acid", "AMINO_ACID", 198, 208], ["IFN", "PROTEIN", 17, 20], ["L1", "PROTEIN", 21, 23], ["IFN", "PROTEIN", 28, 31], ["L3", "PROTEIN", 32, 34], ["type III interferon family", "PROTEIN", 54, 80], ["porcine IFN-L1", "DNA", 82, 96], ["ACZ63406.1", "PROTEIN", 120, 130], ["IFN-L3", "DNA", 136, 142], ["porcine", "SPECIES", 9, 16], ["porcine IFN-L1 and IFN-L3", "TREATMENT", 9, 34], ["porcine IFN", "TREATMENT", 82, 93], ["L1", "ANATOMY", 21, 23], ["L3", "ANATOMY", 32, 34], ["L1", "ANATOMY", 94, 96], ["L3", "ANATOMY", 140, 142]]], ["Among the four members of human IFN-L, IFN-L1 and IFN-L3 are studied most and show some differences in their antiviral activities (Dellgren et al., 2009; Lazear et al., 2015; review) .", [["human", "ORGANISM", 26, 31], ["IFN-L", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 39, 45], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 50, 56], ["human IFN-L", "PROTEIN", 26, 37], ["IFN", "PROTEIN", 39, 42], ["L1", "PROTEIN", 43, 45], ["IFN", "PROTEIN", 50, 53], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human IFN", "TREATMENT", 26, 35], ["IFN-L1 and IFN-L3", "TREATMENT", 39, 56], ["L1", "ANATOMY", 43, 45], ["L3", "ANATOMY", 54, 56]]], ["Previous studies have shown that human IFN-L3 has the highest antiviral activity in an in vitro model of encephalomyocarditis viral infection (Palma-Ocampo et al., 2015) .", [["encephalomyocarditis viral infection", "DISEASE", 105, 141], ["human", "ORGANISM", 33, 38], ["IFN-L3", "GENE_OR_GENE_PRODUCT", 39, 45], ["encephalomyocarditis viral", "ORGANISM", 105, 131], ["human IFN-L3", "PROTEIN", 33, 45], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["encephalomyocarditis", "SPECIES", 105, 125], ["Previous studies", "TEST", 0, 16], ["human IFN-L3", "TREATMENT", 33, 45], ["encephalomyocarditis viral infection", "PROBLEM", 105, 141], ["L3", "ANATOMY", 43, 45], ["highest", "OBSERVATION_MODIFIER", 54, 61], ["antiviral activity", "OBSERVATION", 62, 80], ["encephalomyocarditis viral infection", "OBSERVATION", 105, 141]]], ["This finding is consistent with our results comparing the anti-PEDV activity of rpIFN-L1 and L3, as we found that rpIFN-L3 exhibited more anti-PEDV activity at lower concentrations (from 100 ng/ml to 10 ng/ml) than rpIFN-L1 in IPEC-J2 cells (Figs.", [["IPEC-J2 cells", "ANATOMY", 227, 240], ["anti-PEDV", "CANCER", 58, 67], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 80, 88], ["L3", "CELL", 93, 95], ["rpIFN-L3", "SIMPLE_CHEMICAL", 114, 122], ["anti-PEDV", "SIMPLE_CHEMICAL", 138, 147], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 215, 223], ["IPEC-J2 cells", "CELL", 227, 240], ["rpIFN", "PROTEIN", 80, 85], ["L1", "PROTEIN", 86, 88], ["L3", "PROTEIN", 93, 95], ["rpIFN", "PROTEIN", 114, 119], ["rpIFN", "PROTEIN", 215, 220], ["IPEC-J2 cells", "CELL_LINE", 227, 240], ["rpIFN", "TEST", 114, 119], ["rpIFN", "TEST", 215, 220], ["consistent with", "UNCERTAINTY", 16, 31], ["L1", "ANATOMY", 86, 88], ["L3", "ANATOMY", 93, 95], ["L3", "ANATOMY", 120, 122], ["L1", "ANATOMY", 221, 223], ["J2 cells", "OBSERVATION", 232, 240]]], ["In addition, rpIFN-L3 exhibited approximately 30-fold more anti-VSV activity in the bovine kidney MDBK cell line than rpIFN-L1 (data not shown).", [["kidney MDBK cell line", "ANATOMY", 91, 112], ["rpIFN-L1", "ANATOMY", 118, 126], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 13, 21], ["anti-VSV", "CANCER", 59, 67], ["bovine", "ORGANISM", 84, 90], ["kidney MDBK cell line", "CELL", 91, 112], ["rpIFN-L1", "CELL", 118, 126], ["rpIFN", "PROTEIN", 13, 18], ["L3", "PROTEIN", 19, 21], ["bovine kidney MDBK cell line", "CELL_LINE", 84, 112], ["rpIFN", "PROTEIN", 118, 123], ["L1", "CELL_LINE", 124, 126], ["bovine", "SPECIES", 84, 90], ["bovine", "SPECIES", 84, 90], ["rpIFN", "TEST", 13, 18], ["rpIFN", "TEST", 118, 123], ["L3", "ANATOMY", 19, 21], ["bovine", "ANATOMY_MODIFIER", 84, 90], ["kidney", "ANATOMY", 91, 97], ["MDBK cell line", "OBSERVATION", 98, 112], ["L1", "ANATOMY", 124, 126]]], ["However, the higher anti-PEDV activity of rpIFN-L3 in IPEC-J2, compared to rpIFN-L1 is not observed in the Vero E6 infection model of PEDV.", [["IPEC-J2", "CHEMICAL", 54, 61], ["infection", "DISEASE", 115, 124], ["PEDV", "CHEMICAL", 134, 138], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 42, 50], ["IPEC-J2", "CELL", 54, 61], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 75, 83], ["Vero E6", "ORGANISM", 107, 114], ["PEDV", "CANCER", 134, 138], ["anti-PEDV", "PROTEIN", 20, 29], ["rpIFN", "PROTEIN", 42, 47], ["L3", "PROTEIN", 48, 50], ["J2", "CELL_LINE", 59, 61], ["rpIFN", "PROTEIN", 75, 80], ["L1", "DNA", 81, 83], ["Vero E6", "SPECIES", 107, 114], ["PEDV", "SPECIES", 134, 138], ["rpIFN", "TEST", 42, 47], ["PEDV", "PROBLEM", 134, 138], ["higher", "OBSERVATION_MODIFIER", 13, 19], ["L3", "ANATOMY", 48, 50], ["J2", "ANATOMY", 59, 61], ["L1", "ANATOMY", 81, 83], ["not observed", "UNCERTAINTY", 87, 99]]], ["The difference in antiviral activity between Vero E6 and IPEC-J2 cells may be attributed to a difference in protein affinity of rpIFN-L1 or rpIFN-L3 to IFNLR1, given that both recombinant proteins only have a 52.4% amino acid identity.", [["IPEC-J2 cells", "ANATOMY", 57, 70], ["amino acid", "CHEMICAL", 215, 225], ["amino acid", "CHEMICAL", 215, 225], ["Vero E6", "ORGANISM", 45, 52], ["IPEC-J2 cells", "CELL", 57, 70], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 128, 136], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 140, 148], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 152, 158], ["amino acid", "AMINO_ACID", 215, 225], ["Vero E6", "CELL_LINE", 45, 52], ["IPEC-J2 cells", "CELL_LINE", 57, 70], ["rpIFN", "PROTEIN", 128, 133], ["L1", "PROTEIN", 134, 136], ["rpIFN", "PROTEIN", 140, 145], ["L3", "PROTEIN", 146, 148], ["IFNLR1", "PROTEIN", 152, 158], ["recombinant proteins", "PROTEIN", 176, 196], ["Vero E6", "SPECIES", 45, 52], ["The difference in antiviral activity", "PROBLEM", 0, 36], ["Vero E6 and IPEC-J2 cells", "TREATMENT", 45, 70], ["protein affinity", "TEST", 108, 124], ["rpIFN", "TEST", 128, 133], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["antiviral activity", "OBSERVATION", 18, 36], ["L1", "ANATOMY", 134, 136], ["L3", "ANATOMY", 146, 148]]], ["Our results indicate the importance of the specific cell type used when evaluating the antiviral activity of IFN.", [["cell", "ANATOMY", 52, 56], ["IFN", "CHEMICAL", 109, 112], ["cell", "CELL", 52, 56], ["IFN", "GENE_OR_GENE_PRODUCT", 109, 112], ["IFN", "PROTEIN", 109, 112], ["the specific cell type", "TREATMENT", 39, 61], ["the antiviral activity of IFN", "TREATMENT", 83, 112], ["antiviral activity", "OBSERVATION", 87, 105]]], ["Therefore, pIFN-L3 exhibits a more potent, or at least similar, antiviral activity than pIFN-L1.DiscussionType I IFN-a and Type III IFN-L induce overlapping proximal signaling events and downstream antiviral responses, despite engaging different heterodimeric receptors (Kotenko et al., 2003; Lazear et al., 2015; review; Zhang and Yoo, 2016; review) .", [["pIFN-L3", "CHEMICAL", 11, 18], ["pIFN-L3", "GENE_OR_GENE_PRODUCT", 11, 18], ["pIFN-L1", "GENE_OR_GENE_PRODUCT", 88, 95], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 106, 116], ["Type III IFN-L", "GENE_OR_GENE_PRODUCT", 123, 137], ["pIFN", "PROTEIN", 11, 15], ["pIFN", "PROTEIN", 88, 92], ["Type I IFN", "PROTEIN", 106, 116], ["Type III IFN-L", "PROTEIN", 123, 137], ["heterodimeric receptors", "PROTEIN", 246, 269], ["pIFN-L3", "TREATMENT", 11, 18], ["Type I IFN", "PROBLEM", 106, 116], ["a and Type III IFN", "TREATMENT", 117, 135], ["proximal signaling events", "PROBLEM", 157, 182], ["downstream antiviral responses", "PROBLEM", 187, 217], ["L3", "ANATOMY", 16, 18], ["more potent", "OBSERVATION_MODIFIER", 30, 41], ["antiviral activity", "OBSERVATION", 64, 82], ["L1", "ANATOMY", 93, 95], ["proximal", "ANATOMY_MODIFIER", 157, 165], ["signaling events", "OBSERVATION", 166, 182]]], ["Consistent with this result, all three IFNs (IFN-a, rpIFN-L1, and rpIFN-L3) provoked the expression of the antiviral genes ISG15, OASL, MxA, and IFITM1, 3 in IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 158, 171], ["IFNs", "GENE_OR_GENE_PRODUCT", 39, 43], ["IFN-a", "GENE_OR_GENE_PRODUCT", 45, 50], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 52, 60], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 66, 74], ["ISG15", "GENE_OR_GENE_PRODUCT", 123, 128], ["OASL", "GENE_OR_GENE_PRODUCT", 130, 134], ["MxA", "GENE_OR_GENE_PRODUCT", 136, 139], ["IFITM1", "GENE_OR_GENE_PRODUCT", 145, 151], ["3", "GENE_OR_GENE_PRODUCT", 153, 154], ["IPEC-J2 cells", "CELL", 158, 171], ["IFNs", "PROTEIN", 39, 43], ["IFN", "PROTEIN", 45, 48], ["rpIFN", "PROTEIN", 52, 57], ["L1", "PROTEIN", 58, 60], ["rpIFN", "PROTEIN", 66, 71], ["L3", "PROTEIN", 72, 74], ["antiviral genes", "DNA", 107, 122], ["ISG15", "DNA", 123, 128], ["OASL", "DNA", 130, 134], ["MxA", "DNA", 136, 139], ["IFITM1", "DNA", 145, 151], ["IPEC-J2 cells", "CELL_LINE", 158, 171], ["IFN", "TEST", 45, 48], ["rpIFN", "TEST", 52, 57], ["the antiviral genes ISG15", "PROBLEM", 103, 128], ["OASL", "TEST", 130, 134], ["MxA", "TEST", 136, 139], ["IFITM1", "TEST", 145, 151], ["L3", "ANATOMY", 72, 74], ["J2 cells", "OBSERVATION", 163, 171]]], ["However, the magnitude of these antiviral responses triggered by IFN-a and rpIFN-L were dissimilar, as 1000 ng/ml IFN-a stimulation resulted in an approximately 2fold reduced expression of ISG15 and MxA compared with rpIFN-L 1 and rpIFN-L3, but IFN-a more efficiently up-regulated IFITM1 expression than rpIFN-L1 (Fig. 5) .", [["IFN-a", "GENE_OR_GENE_PRODUCT", 65, 70], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 75, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 114, 117], ["ISG15", "GENE_OR_GENE_PRODUCT", 189, 194], ["MxA", "GENE_OR_GENE_PRODUCT", 199, 202], ["rpIFN-L 1", "GENE_OR_GENE_PRODUCT", 217, 226], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 231, 239], ["IFN", "GENE_OR_GENE_PRODUCT", 245, 248], ["IFITM1", "GENE_OR_GENE_PRODUCT", 281, 287], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 304, 312], ["IFN", "PROTEIN", 65, 68], ["rpIFN", "PROTEIN", 75, 80], ["IFN", "PROTEIN", 114, 117], ["ISG15", "PROTEIN", 189, 194], ["MxA", "PROTEIN", 199, 202], ["rpIFN", "PROTEIN", 217, 222], ["rpIFN", "PROTEIN", 231, 236], ["IFN", "PROTEIN", 245, 248], ["IFITM1", "PROTEIN", 281, 287], ["rpIFN", "PROTEIN", 304, 309], ["L1", "DNA", 310, 312], ["IFN", "TEST", 65, 68], ["rpIFN", "TEST", 75, 80], ["a stimulation", "TEST", 118, 131], ["ISG15", "TEST", 189, 194], ["MxA", "TEST", 199, 202], ["rpIFN", "TEST", 217, 222], ["rpIFN", "TEST", 231, 236], ["IFN", "TEST", 245, 248], ["rpIFN", "TEST", 304, 309], ["antiviral", "OBSERVATION", 32, 41], ["L3", "ANATOMY", 237, 239], ["L1", "ANATOMY", 310, 312]]], ["Although the different expression of IFNAR and IFNLR1 in epithelial cells accounts for the variation of the profiles of the induced antiviral genes, distinct signaling events of IFN-a and IFN-L might contribute to the different levels of antiviral genes observed in this study.", [["epithelial cells", "ANATOMY", 57, 73], ["IFNAR", "GENE_OR_GENE_PRODUCT", 37, 42], ["IFNLR1", "GENE_OR_GENE_PRODUCT", 47, 53], ["epithelial cells", "CELL", 57, 73], ["IFN-a", "GENE_OR_GENE_PRODUCT", 178, 183], ["IFN-L", "GENE_OR_GENE_PRODUCT", 188, 193], ["IFNAR", "PROTEIN", 37, 42], ["IFNLR1", "PROTEIN", 47, 53], ["epithelial cells", "CELL_TYPE", 57, 73], ["antiviral genes", "DNA", 132, 147], ["IFN", "PROTEIN", 178, 181], ["IFN", "PROTEIN", 188, 191], ["antiviral genes", "DNA", 238, 253], ["IFNAR and IFNLR1 in epithelial cells", "TREATMENT", 37, 73], ["the induced antiviral genes", "PROBLEM", 120, 147], ["IFN", "TEST", 178, 181], ["IFN", "TEST", 188, 191], ["antiviral genes", "PROBLEM", 238, 253], ["this study", "TEST", 266, 276], ["epithelial cells", "OBSERVATION", 57, 73], ["antiviral genes", "OBSERVATION", 132, 147], ["antiviral genes", "OBSERVATION", 238, 253]]], ["Recent studies have demonstrated that IFN-L specifically activates JAK2, although both IFN-L and IFN-a/b lead to the activation of the receptor-associated tyrosine kinases JAK1 and TYK2 (Odendall et al., 2014; Odendall and Kagan, 2015; review) .", [["tyrosine", "CHEMICAL", 155, 163], ["tyrosine", "CHEMICAL", 155, 163], ["IFN-L", "GENE_OR_GENE_PRODUCT", 38, 43], ["JAK2", "GENE_OR_GENE_PRODUCT", 67, 71], ["IFN-L", "GENE_OR_GENE_PRODUCT", 87, 92], ["IFN-a/b", "GENE_OR_GENE_PRODUCT", 97, 104], ["JAK1", "GENE_OR_GENE_PRODUCT", 172, 176], ["TYK2", "GENE_OR_GENE_PRODUCT", 181, 185], ["IFN-L", "PROTEIN", 38, 43], ["JAK2", "PROTEIN", 67, 71], ["IFN", "PROTEIN", 87, 90], ["IFN", "PROTEIN", 97, 100], ["tyrosine kinases", "PROTEIN", 155, 171], ["JAK1", "PROTEIN", 172, 176], ["TYK2", "PROTEIN", 181, 185], ["Recent studies", "TEST", 0, 14], ["IFN", "TEST", 38, 41], ["JAK2", "TEST", 67, 71], ["IFN", "TEST", 87, 90], ["IFN", "PROBLEM", 97, 100], ["associated tyrosine kinases JAK1", "PROBLEM", 144, 176], ["tyrosine kinases JAK1", "OBSERVATION", 155, 176]]], ["In addition, interestingly, the transcriptional profiles of antiviral genes elicited by rpIFN-L1 and rpIFN-L3 are not the same, even though rpIFN-L1 and rpIFN-L3 engage the same receptor (Fig. 5) .", [["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 88, 96], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 101, 109], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 140, 148], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 153, 161], ["antiviral genes", "DNA", 60, 75], ["rpIFN", "PROTEIN", 88, 93], ["L1", "DNA", 94, 96], ["rpIFN", "PROTEIN", 101, 106], ["L3", "DNA", 107, 109], ["rpIFN", "PROTEIN", 140, 145], ["L1", "DNA", 146, 148], ["rpIFN", "PROTEIN", 153, 158], ["L3", "DNA", 159, 161], ["antiviral genes", "PROBLEM", 60, 75], ["rpIFN", "TEST", 88, 93], ["rpIFN", "TEST", 140, 145], ["rpIFN", "TEST", 153, 158], ["antiviral genes", "OBSERVATION", 60, 75], ["L1", "ANATOMY", 94, 96], ["L3", "ANATOMY", 107, 109], ["L1", "ANATOMY", 146, 148], ["L3", "ANATOMY_MODIFIER", 159, 161]]], ["Further studies are needed to identify the Collectively, we demonstrated that rpIFN-L1 and rpIFN-L3 displayed robust antiviral activity against PEDV infection in both IPEC-J2 and Vero E6 cells. rpIFN-L up-regulated the expression of several antiviral proteins, including OASL, ISG15, MxA, and IFITMs.", [["IPEC-J2", "ANATOMY", 167, 174], ["Vero E6 cells", "ANATOMY", 179, 192], ["infection", "DISEASE", 149, 158], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 78, 86], ["rpIFN-L3", "GENE_OR_GENE_PRODUCT", 91, 99], ["PEDV", "SIMPLE_CHEMICAL", 144, 148], ["IPEC-J2", "CELL", 167, 174], ["Vero E6 cells", "CELL", 179, 192], ["rpIFN-L", "GENE_OR_GENE_PRODUCT", 194, 201], ["OASL", "GENE_OR_GENE_PRODUCT", 271, 275], ["ISG15", "GENE_OR_GENE_PRODUCT", 277, 282], ["MxA", "GENE_OR_GENE_PRODUCT", 284, 287], ["IFITMs", "GENE_OR_GENE_PRODUCT", 293, 299], ["rpIFN", "PROTEIN", 78, 83], ["L1", "PROTEIN", 84, 86], ["rpIFN", "PROTEIN", 91, 96], ["L3", "DNA", 97, 99], ["IPEC-J2", "CELL_LINE", 167, 174], ["Vero E6 cells", "CELL_LINE", 179, 192], ["rpIFN", "PROTEIN", 194, 199], ["antiviral proteins", "PROTEIN", 241, 259], ["OASL", "PROTEIN", 271, 275], ["ISG15", "PROTEIN", 277, 282], ["MxA", "PROTEIN", 284, 287], ["IFITMs", "PROTEIN", 293, 299], ["PEDV", "SPECIES", 144, 148], ["Vero E6", "SPECIES", 179, 186], ["Further studies", "TEST", 0, 15], ["rpIFN", "TEST", 78, 83], ["robust antiviral activity", "PROBLEM", 110, 135], ["PEDV infection", "PROBLEM", 144, 158], ["Vero E6 cells", "PROBLEM", 179, 192], ["rpIFN", "TEST", 194, 199], ["several antiviral proteins", "TREATMENT", 233, 259], ["OASL", "TEST", 271, 275], ["ISG15", "TREATMENT", 277, 282], ["MxA", "TEST", 284, 287], ["IFITMs", "TREATMENT", 293, 299], ["L1", "ANATOMY", 84, 86], ["L3", "ANATOMY", 97, 99], ["robust", "OBSERVATION_MODIFIER", 110, 116], ["antiviral activity", "OBSERVATION", 117, 135], ["infection", "OBSERVATION", 149, 158], ["J2", "ANATOMY", 172, 174], ["Vero E6 cells", "OBSERVATION", 179, 192], ["L", "ANATOMY_MODIFIER", 200, 201], ["several", "OBSERVATION_MODIFIER", 233, 240], ["antiviral proteins", "OBSERVATION", 241, 259]]], ["The transient expression of IFITM1 and 3 inhibited PEDV infection in vitro.", [["PEDV", "CHEMICAL", 51, 55], ["infection", "DISEASE", 56, 65], ["IFITM1", "GENE_OR_GENE_PRODUCT", 28, 34], ["3", "GENE_OR_GENE_PRODUCT", 39, 40], ["PEDV", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFITM1 and 3", "PROTEIN", 28, 40], ["PEDV", "SPECIES", 51, 55], ["IFITM1 and 3 inhibited PEDV infection in vitro", "PROBLEM", 28, 74], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["expression", "OBSERVATION_MODIFIER", 14, 24], ["infection", "OBSERVATION", 56, 65]]], ["Moreover, rpIFN-L1 provided better viral inhibition against PEDV infection of IPEC-J2 cells than porcine IFN-a.", [["IPEC-J2 cells", "ANATOMY", 78, 91], ["infection", "DISEASE", 65, 74], ["rpIFN-L1", "GENE_OR_GENE_PRODUCT", 10, 18], ["PEDV", "ORGANISM", 60, 64], ["IPEC-J2 cells", "CELL", 78, 91], ["porcine", "ORGANISM", 97, 104], ["IFN-a.", "GENE_OR_GENE_PRODUCT", 105, 111], ["rpIFN", "PROTEIN", 10, 15], ["L1", "DNA", 16, 18], ["IPEC-J2 cells", "CELL_LINE", 78, 91], ["IFN", "PROTEIN", 105, 108], ["porcine", "SPECIES", 97, 104], ["PEDV", "SPECIES", 60, 64], ["rpIFN", "TEST", 10, 15], ["PEDV infection of IPEC", "PROBLEM", 60, 82], ["J2 cells", "PROBLEM", 83, 91], ["L1", "ANATOMY", 16, 18], ["infection", "OBSERVATION", 65, 74], ["J2 cells", "OBSERVATION_MODIFIER", 83, 91]]], ["Our findings indicate that porcine IFN-L might represent a promising therapeutic agent for PED in the future.", [["IFN", "CHEMICAL", 35, 38], ["PED", "DISEASE", 91, 94], ["porcine", "ORGANISM", 27, 34], ["IFN-L", "GENE_OR_GENE_PRODUCT", 35, 40], ["IFN", "PROTEIN", 35, 38], ["porcine IFN", "TREATMENT", 27, 38]]]], "PMC7418645": [["MethodsClinical records were reviewed for all inpatients aged <18 years with laboratory-confirmed COVID-19 hospitalized at Belmont Behavioral Hospital between March 23 and April 21, 2020.", [["COVID", "TEST", 98, 103]]], ["This standalone psychiatric hospital serves up to 109 child and adolescent patients aged 5\u201317 years on five units, distributed by age and psychiatric diagnosis.", [["psychiatric", "DISEASE", 16, 27], ["psychiatric", "DISEASE", 138, 149], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["Seventy-one adult patients are hospitalized in separate units in the same building.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["The facility has contracted with a local children's hospital to provide onsite medical care since 2018, which involves assessment of all patients at admission and additional consultation per psychiatrist discretion.", [["children", "ORGANISM", 41, 49], ["patients", "ORGANISM", 137, 145], ["children", "SPECIES", 41, 49], ["patients", "SPECIES", 137, 145]]], ["Institutional review board exemption was granted by the Children's Hospital of Philadelphia Institutional Review Board.Medical course ::: Clinical ObservationsAmong the 19 positive patients, the most common initial symptoms were sore throat (37%), nausea/vomiting (32%), and cough (26%).", [["sore throat", "DISEASE", 229, 240], ["nausea/vomiting", "DISEASE", 248, 263], ["cough", "DISEASE", 275, 280], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["initial symptoms", "PROBLEM", 207, 223], ["sore throat", "PROBLEM", 229, 240], ["nausea", "PROBLEM", 248, 254], ["vomiting", "PROBLEM", 255, 263], ["cough", "PROBLEM", 275, 280], ["19 positive", "OBSERVATION_MODIFIER", 169, 180], ["cough", "OBSERVATION", 275, 280]]], ["Only one patient (5%) presented with fever, defined as temperature greater than 100.4 F. Four of the 19 patients (21%) were asymptomatic at diagnosis and tested on the basis of high-risk exposures.", [["fever", "DISEASE", 37, 42], ["patient", "ORGANISM", 9, 16], ["patients", "ORGANISM", 104, 112], ["patient", "SPECIES", 9, 16], ["patients", "SPECIES", 104, 112], ["fever", "PROBLEM", 37, 42], ["temperature", "TEST", 55, 66], ["asymptomatic", "PROBLEM", 124, 136], ["high-risk exposures", "PROBLEM", 177, 196], ["fever", "OBSERVATION", 37, 42]]], ["The most common comorbid medical diagnosis was asthma (32%).", [["asthma", "DISEASE", 47, 53], ["asthma", "PROBLEM", 47, 53], ["asthma", "OBSERVATION", 47, 53]]], ["One 12-year-old required administration of intravenous fluids at the emergency department of the affiliated children's hospital.", [["intravenous", "ANATOMY", 43, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 54], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116], ["intravenous fluids", "TREATMENT", 43, 61]]], ["None of the 19 patients required supplemental oxygen or inpatient medical care.", [["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["patients", "ORGANISM", 15, 23], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["patients", "SPECIES", 15, 23], ["supplemental oxygen", "TREATMENT", 33, 52], ["inpatient medical care", "TREATMENT", 56, 78]]], ["None of the patients had physical symptoms necessitating changes to psychiatric medical management.Psychiatric course ::: Clinical ObservationsAmong positive patients, the most common psychiatric diagnosis was posttraumatic stress disorder (63%), followed by disruptive mood dysregulation disorder (42%), attention-deficit/hyperactivity disorder (42%), major depressive disorder (37%), and oppositional defiant disorder (32%).", [["psychiatric", "DISEASE", 68, 79], ["psychiatric", "DISEASE", 184, 195], ["posttraumatic stress disorder", "DISEASE", 210, 239], ["disruptive mood dysregulation disorder", "DISEASE", 259, 297], ["attention-deficit/hyperactivity disorder", "DISEASE", 305, 345], ["major depressive disorder", "DISEASE", 353, 378], ["oppositional defiant disorder", "DISEASE", 390, 419], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 158, 166], ["physical symptoms", "PROBLEM", 25, 42], ["psychiatric medical management", "TREATMENT", 68, 98], ["posttraumatic stress disorder", "PROBLEM", 210, 239], ["disruptive mood dysregulation disorder", "PROBLEM", 259, 297], ["hyperactivity disorder", "PROBLEM", 323, 345], ["major depressive disorder", "PROBLEM", 353, 378], ["oppositional defiant disorder", "PROBLEM", 390, 419]]], ["Depression and anxiety symptoms were noted to escalate early in the disease course.", [["Depression", "DISEASE", 0, 10], ["anxiety", "DISEASE", 15, 22], ["Depression", "PROBLEM", 0, 10], ["anxiety symptoms", "PROBLEM", 15, 31]]], ["Externalizing behaviors increased as physical health improved.Management strategies ::: Clinical ObservationsThe average pediatric census during this time was 81 (range 78\u2013101).", [["Externalizing behaviors", "PROBLEM", 0, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["Patients under investigation for COVID-19 infection were monitored in a private room on their unit and asked to wear a face mask until test results were obtained.", [["infection", "DISEASE", 42, 51], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 33, 38], ["infection", "PROBLEM", 42, 51], ["a face mask", "TREATMENT", 117, 128], ["infection", "OBSERVATION", 42, 51]]], ["After the first test-positive patient was identified, patients were redistributed to create one mixed-gender general psychiatric unit limited to known COVID-19\u2013positive patients.", [["psychiatric", "DISEASE", 117, 128], ["patient", "ORGANISM", 30, 37], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 169, 177], ["patient", "SPECIES", 30, 37], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 169, 177], ["the first test", "TEST", 6, 20]]], ["All test-positive patients were moved to the designated pediatric COVID-19 unit, where patients were not asked to physically distance from one another or wear face masks.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 87, 95], ["COVID-19 unit", "DNA", 66, 79], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 87, 95], ["All test", "TEST", 0, 8], ["face masks", "TREATMENT", 159, 169]]], ["Typical group activities such as playing cards, arts and crafts, and video games continued.", [["video games", "TEST", 69, 80]]], ["Patients received daily medical assessment by the onsite pediatrician and were prescribed antipyretics, antiemetics, and oral rehydration as needed.", [["oral", "ANATOMY", 121, 125], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["Patients", "SPECIES", 0, 8], ["daily medical assessment", "TEST", 18, 42], ["antipyretics", "TREATMENT", 90, 102], ["antiemetics", "TREATMENT", 104, 115], ["oral rehydration", "TREATMENT", 121, 137]]], ["Mental health treatment was unchanged in frequency but used telemedicine for daily 1:1 therapy and evaluation.", [["Mental health treatment", "TREATMENT", 0, 23], ["daily 1:1 therapy", "TREATMENT", 77, 94], ["evaluation", "TEST", 99, 109]]], ["Music, art, and movement therapies were conducted but modified with appropriate physical distancing from staff.DiscussionTo our knowledge, this is the first report of a COVID-19 outbreak among adolescents at an inpatient behavioral health facility.", [["adolescents", "ORGANISM", 193, 204], ["adolescents", "SPECIES", 193, 204], ["Music", "TREATMENT", 0, 5], ["movement therapies", "TREATMENT", 16, 34]]], ["This outbreak occurred very early in the spread of COVID-19 to the U.S. and highlights important issues to consider as the COVID-19 pandemic continues to unfold.", [["the COVID", "TREATMENT", 119, 128], ["very", "OBSERVATION_MODIFIER", 23, 27], ["early", "OBSERVATION_MODIFIER", 28, 33]]], ["Mental health needs of adolescents are expected to persist or increase, and meeting the needs of high-risk youth, including those requiring inpatient hospitalization, must be a priority.DiscussionReliance on the presence of symptoms to guide COVID-19 testing among youth hospitalized in an inpatient behavioral health facility is challenging.", [["adolescents", "ORGANISM", 23, 34], ["youth", "ORGANISM", 107, 112], ["youth", "ORGANISM", 265, 270], ["symptoms", "PROBLEM", 224, 232], ["COVID", "TEST", 242, 247]]], ["In our cohort, only 26% of positive patients presented with typical symptoms of cough, shortness of breath or fever, and one in five test-positive patients had no symptoms.", [["cough", "DISEASE", 80, 85], ["shortness of breath", "DISEASE", 87, 106], ["fever", "DISEASE", 110, 115], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 147, 155], ["typical symptoms", "PROBLEM", 60, 76], ["cough", "PROBLEM", 80, 85], ["shortness of breath", "PROBLEM", 87, 106], ["fever", "PROBLEM", 110, 115], ["symptoms", "PROBLEM", 163, 171], ["cough", "OBSERVATION", 80, 85]]], ["Somatic symptoms further complicate a symptom-based testing strategy in youth with mental health conditions.", [["Somatic symptoms", "PROBLEM", 0, 16], ["a symptom", "PROBLEM", 36, 45]]], ["The availability of onsite, same-day testing ultimately facilitated our efforts at infection control, although universal testing was not implemented based on the Department of Public Health guidance.", [["infection", "DISEASE", 83, 92], ["infection control", "TREATMENT", 83, 100], ["universal testing", "TEST", 111, 128]]], ["Universal testing may be a preferred strategy as test capabilities increase and would allow for improved characterization of COVID-19 in this population.", [["Universal testing", "TEST", 0, 17], ["test capabilities", "TEST", 49, 66], ["COVID", "TEST", 125, 130]]], ["The benefits of broader testing will need to be weighed against the downsides of isolating mentally ill youth as they await test results.DiscussionPhysical distancing in an inpatient pediatric psychiatric setting is not feasible or therapeutic.", [["mentally ill", "DISEASE", 91, 103], ["psychiatric", "DISEASE", 193, 204], ["broader testing", "TEST", 16, 31]]], ["Avoiding physical contact conflicts with the attachment and mental health needs of our patients and does not align with research on the positive effects of relational touch on child development [[8], [9], [10]].", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["Strategies to manage COVID-19 infection within this environment can be informed in part by existing guidance for shared or congregate housing [11], although the development of resources specific for inpatient behavioral health facilities that serve youth should be considered.DiscussionOur experience underscores the interdependence of medical and psychiatric care.", [["infection", "DISEASE", 30, 39], ["psychiatric", "DISEASE", 348, 359], ["COVID", "TEST", 21, 26], ["19 infection", "PROBLEM", 27, 39], ["medical and psychiatric care", "TREATMENT", 336, 364], ["infection", "OBSERVATION", 30, 39]]], ["The stressors of the pandemic may exacerbate demand for inpatient psychiatric resources [3].", [["psychiatric", "DISEASE", 66, 77]]], ["Within inpatient psychiatric units, COVID-19 outbreaks may require escalation of medical care, including transferring patients to medical hospitals.", [["psychiatric", "DISEASE", 17, 28], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["COVID", "TREATMENT", 36, 41], ["medical care", "TREATMENT", 81, 93]]], ["In our case, we leveraged an existing collaboration between a behavioral health facility and medical center to implement onsite testing protocols and medical care, thus avoiding unnecessary transfers to the local medical hospital for testing or hospitalization.", [["onsite testing protocols", "TEST", 121, 145], ["medical care", "TREATMENT", 150, 162], ["testing", "TEST", 234, 241]]], ["This allowed for continuity of mental health care for infected patients in the behavioral health setting.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["mental health care", "TREATMENT", 31, 49]]], ["Similar strategies may allow psychiatric settings to achieve medical standards of care and avoid overburdening local medical hospitals.DiscussionThe COVID-19 pandemic has also disrupted the typical inpatient\u2013outpatient mental health continuum of care.", [["psychiatric", "DISEASE", 29, 40], ["psychiatric settings", "TREATMENT", 29, 49], ["medical standards of care", "TREATMENT", 61, 86]]], ["Residential psychiatric services were recommended for all 19 of the affected patients at our facility at discharge.", [["psychiatric", "DISEASE", 12, 23], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["Many of these facilities were limiting admissions because of lack of resources to support COVID-19 patients and manage potential outbreaks.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["COVID", "TREATMENT", 90, 95]]], ["Strategies for remobilizing and maintaining appropriate ongoing care for patients who have COVID-19 infection and mental health needs are needed in this and future pandemics.DiscussionIn summary, our experience highlights challenges in addressing both medical and mental health needs among young people requiring inpatient behavioral health hospitalization during the COVID-19 pandemic.", [["infection", "DISEASE", 100, 109], ["patients", "ORGANISM", 73, 81], ["people", "ORGANISM", 296, 302], ["patients", "SPECIES", 73, 81], ["people", "SPECIES", 296, 302], ["remobilizing", "TREATMENT", 15, 27], ["COVID-19 infection", "PROBLEM", 91, 109], ["mental health needs", "PROBLEM", 114, 133], ["the COVID", "TEST", 364, 373], ["pandemic", "PROBLEM", 377, 385], ["infection", "OBSERVATION", 100, 109]]], ["Innovative treatment models and collaboration between medical and psychiatric health providers are needed to ensure safe and optimal care for this high-risk patient population.", [["psychiatric", "DISEASE", 66, 77], ["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["Innovative treatment models", "TREATMENT", 0, 27]]], ["These needs will become more urgent as mental health needs of youth escalate within the broader context of COVID-19, and it is critical that strategies are developed that meet developmental needs while achieving appropriate infection control.", [["infection", "DISEASE", 224, 233], ["appropriate infection control", "TREATMENT", 212, 241], ["infection", "OBSERVATION", 224, 233]]]], "PMC7298183": [["Related Work ::: IntroductionThe Latent Dirichlet Allocation [3] is very popular in text data analysis.", [["text data analysis", "TEST", 84, 102]]], ["Numerous extensions to Latent Dirichlet Allocation have been proposed, each customized for certain applications, as the Author-Topic Model [18], Correlated Topics Model [2] or the more generalized Structural Topic Model [17].", [["Latent Dirichlet Allocation", "TREATMENT", 23, 50], ["Latent", "OBSERVATION_MODIFIER", 23, 29], ["Dirichlet", "OBSERVATION", 30, 39]]], ["We focus on LDA as one of the most commonly used topic models and propose a methodology to increase reliability of findings drawn from the results of LDA.Related Work ::: IntroductionReassigning words to topics in the LDA is based on conditional distributions, thus it is stochastic.", [["LDA", "TREATMENT", 12, 15]]], ["However, several approaches exist to encounter this problem based on a certain selection criterion.", [["this problem", "PROBLEM", 47, 59]]], ["As an extension, Nguyen et al. [13] proposed to average different iterations of the Gibbs sampling procedure to achieve an increase of perplexity.", [["the Gibbs sampling procedure", "TREATMENT", 80, 108], ["an increase of perplexity", "PROBLEM", 120, 145], ["increase", "OBSERVATION_MODIFIER", 123, 131]]], ["In general, it was shown that optimizing likelihood-based measures like perplexity does not select the model that fits the data best regarding human judgements.", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148]]], ["In fact, these measures are negatively correlated with human judgements on topic quality [5].", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["They provide a validation technique called Word or Topic Intrusion which depends on a coding process by humans.", [["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["a validation technique", "TREATMENT", 13, 35]]], ["Measures without human interaction, but almost automated, and also aiming to optimize semantic coherence can be transferred from the Topic Coherence [12].", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22]]], ["Unfortunately, there is no validated procedure to get a selection criterion for LDA models from this topic\u2019s \u201cquality\u201d measure.", [["validated procedure", "TREATMENT", 27, 46], ["a selection criterion", "TEST", 54, 75], ["LDA models", "TREATMENT", 80, 90], ["no", "UNCERTAINTY", 24, 26]]], ["Instead, another option to overcome the weakness of instability of LDA is to start the first iteration of the Gibbs sampler with reasonably initialized topic assignments [11] of every token in all texts.", [["the weakness", "PROBLEM", 36, 48], ["instability of LDA", "PROBLEM", 52, 70], ["the Gibbs sampler", "TREATMENT", 106, 123]]], ["The initialization technique comes with the drawback of restricting the model to a subset of possible results.Contribution ::: IntroductionIn this paper, we propose an improvement of the Latent Dirichlet Allocation through a selection criterion of multiple LDA runs.", [["The initialization technique", "TREATMENT", 0, 28], ["improvement", "OBSERVATION_MODIFIER", 168, 179], ["Latent", "OBSERVATION_MODIFIER", 187, 193], ["Dirichlet Allocation", "OBSERVATION", 194, 214], ["multiple", "OBSERVATION_MODIFIER", 248, 256], ["LDA runs", "OBSERVATION", 257, 265]]], ["The improvement is made by increasing the reliability of results taken from LDA.", [["improvement", "OBSERVATION_MODIFIER", 4, 15]]], ["This particular increase is obtained by selecting the model that represents the center of the set of LDAs best.", [["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["We show that it generates reliable results in the sense that repetitions lie in a rather small sphere around the overall centered LDA, when applying the proposed methods to an example corpus of articles from the S\u00fcddeutsche Zeitung.Latent Dirichlet AllocationThe method we propose is based on the LDA [3] estimated by a Collapsed Gibbs sampler [6], which is a probabilistic topic model that is widely used in text data analysis.", [["a rather small sphere", "PROBLEM", 80, 101], ["a Collapsed Gibbs sampler", "PROBLEM", 318, 343], ["text data analysis", "TEST", 409, 427], ["small", "OBSERVATION_MODIFIER", 89, 94], ["sphere", "OBSERVATION_MODIFIER", 95, 101], ["overall", "OBSERVATION_MODIFIER", 113, 120], ["centered", "OBSERVATION_MODIFIER", 121, 129], ["LDA", "OBSERVATION", 130, 133]]], ["The LDA assumes that there is a topic distribution for every text, and it models them by assigning one topic from the set of topics", [["LDA", "OBSERVATION", 4, 7]]]], "PMC7270484": [["IntroductionCoronavirus disease 2019 (COVID-19), a newly emerging acute respiratory disease, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mainly transmitted via respiratory droplets [1].", [["respiratory", "ANATOMY", 72, 83], ["respiratory droplets", "ANATOMY", 194, 214], ["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory disease", "DISEASE", 66, 91], ["acute respiratory syndrome coronavirus", "DISEASE", 113, 151], ["SARS-CoV-2", "ORGANISM", 155, 165], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 106, 151], ["SARS-CoV-2", "SPECIES", 155, 165], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a newly emerging acute respiratory disease", "PROBLEM", 49, 91], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 106, 151], ["transmitted via respiratory droplets", "PROBLEM", 178, 214], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory disease", "OBSERVATION", 72, 91], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory syndrome", "OBSERVATION", 119, 139], ["respiratory droplets", "OBSERVATION", 194, 214]]], ["Compared with SARS-CoV and MERS-CoV, SARS-CoV-2 is well capable of sustained community transmission, with each case estimated to infect another 2\u22123 uninfected persons on average [2].", [["SARS", "DISEASE", 14, 18], ["SARS-CoV", "ORGANISM", 14, 22], ["MERS-CoV", "ORGANISM", 27, 35], ["SARS-CoV-2", "ORGANISM", 37, 47], ["persons", "ORGANISM", 159, 166], ["persons", "SPECIES", 159, 166], ["SARS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "TEST", 14, 18], ["MERS", "TEST", 27, 31]]], ["As of 3 April 2020, approximate one million COVID-19 cases and 40 000 deaths have been reported in more than 200 countries/regions around the world [3].", [["deaths", "DISEASE", 70, 76]]], ["Therefore, it is urgently needed to identify the risk factors associated with the severity and fatality of SARS-CoV-2 infection.IntroductionRecently, several clinical studies have noticed that hypertension was one of the most common comorbidities in patients with SARS-CoV-2 infection [4\u20136].", [["SARS-CoV-2 infection", "DISEASE", 107, 127], ["hypertension", "DISEASE", 193, 205], ["SARS-CoV-2 infection", "DISEASE", 264, 284], ["SARS-CoV-2", "ORGANISM", 107, 117], ["patients", "ORGANISM", 250, 258], ["SARS-CoV-2", "ORGANISM", 264, 274], ["patients", "SPECIES", 250, 258], ["SARS-CoV-2", "SPECIES", 107, 117], ["the risk factors", "PROBLEM", 45, 61], ["the severity", "PROBLEM", 78, 90], ["SARS", "PROBLEM", 107, 111], ["CoV-2 infection", "PROBLEM", 112, 127], ["several clinical studies", "TEST", 150, 174], ["hypertension", "PROBLEM", 193, 205], ["SARS", "PROBLEM", 264, 268], ["CoV-2 infection", "PROBLEM", 269, 284], ["infection", "OBSERVATION", 118, 127], ["hypertension", "OBSERVATION", 193, 205]]], ["For example, in one cohort of 191 patients from Wuhan, China, Zhou et al. reported that about half of the patients had different comorbidities, with hypertension being the most common (30%) [7].", [["hypertension", "DISEASE", 149, 161], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 106, 114], ["different comorbidities", "PROBLEM", 119, 142], ["hypertension", "PROBLEM", 149, 161], ["hypertension", "OBSERVATION", 149, 161]]], ["In a cohort of 138 hospitalised patients with COVID-19, Wang et al. observed that hypertension (31.2%), diabetes (10.1%), cardiovascular disease (14.5%) and malignancy (17.2%) were the most common coexisting medical conditions [8].", [["cardiovascular", "ANATOMY", 122, 136], ["malignancy", "ANATOMY", 157, 167], ["hypertension", "DISEASE", 82, 94], ["diabetes", "DISEASE", 104, 112], ["cardiovascular disease", "DISEASE", 122, 144], ["malignancy", "DISEASE", 157, 167], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 46, 51], ["hypertension", "PROBLEM", 82, 94], ["diabetes", "PROBLEM", 104, 112], ["cardiovascular disease", "PROBLEM", 122, 144], ["malignancy", "PROBLEM", 157, 167], ["hypertension", "OBSERVATION", 82, 94], ["cardiovascular", "ANATOMY", 122, 136], ["disease", "OBSERVATION", 137, 144], ["malignancy", "OBSERVATION", 157, 167]]], ["In addition, an analysis of an outpatient and inpatient cohort of 1099 patients with COVID-19 showed that 15% of the patients had a history of hypertension [9].", [["hypertension", "DISEASE", 143, 155], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 117, 125], ["an analysis", "TEST", 13, 24], ["COVID", "TEST", 85, 90], ["hypertension", "PROBLEM", 143, 155], ["hypertension", "OBSERVATION", 143, 155]]], ["However, published articles with different study designs and populations usually yield different estimates and effect sizes.", [["different study", "TEST", 33, 48], ["effect", "OBSERVATION_MODIFIER", 111, 117], ["sizes", "OBSERVATION_MODIFIER", 118, 123]]], ["Therefore, a comprehensive and systematic analysis is necessary because of this variability.IntroductionAs one of the most important public health problems in the 21st century, hypertension affects more than one billion individuals worldwide [10].", [["hypertension", "DISEASE", 177, 189], ["systematic analysis", "TEST", 31, 50], ["this variability", "PROBLEM", 75, 91], ["hypertension affects", "PROBLEM", 177, 197], ["hypertension", "OBSERVATION", 177, 189]]], ["However, the influence of hypertension on SARS-CoV-2 infection remains unclear.", [["hypertension", "DISEASE", 26, 38], ["SARS", "DISEASE", 42, 46], ["infection", "DISEASE", 53, 62], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "SPECIES", 42, 50], ["hypertension", "PROBLEM", 26, 38], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["2 infection", "PROBLEM", 51, 62], ["hypertension", "OBSERVATION", 26, 38], ["infection", "OBSERVATION", 53, 62]]], ["Therefore, we conducted the present meta-analysis to evaluate the associations of hypertension with the severity and fatality of SARS-CoV-2 infection.", [["hypertension", "DISEASE", 82, 94], ["SARS-CoV-2 infection", "DISEASE", 129, 149], ["SARS-CoV-2", "ORGANISM", 129, 139], ["SARS-CoV-2", "SPECIES", 129, 139], ["hypertension", "PROBLEM", 82, 94], ["the severity", "PROBLEM", 100, 112], ["SARS", "PROBLEM", 129, 133], ["CoV-2 infection", "PROBLEM", 134, 149], ["hypertension", "OBSERVATION", 82, 94], ["infection", "OBSERVATION", 140, 149]]], ["This assessment might be helpful to further understand the characteristics of SARS-CoV-2 infection in hypertensive patients.Search strategy and selection criteria ::: MethodsThis meta-analysis was conducted in accordance with the \u2018Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)\u2019 statement [11].", [["SARS", "DISEASE", 78, 82], ["infection", "DISEASE", 89, 98], ["hypertensive", "DISEASE", 102, 114], ["SARS-CoV-2", "ORGANISM", 78, 88], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["SARS-CoV-2", "SPECIES", 78, 88], ["This assessment", "TEST", 0, 15], ["SARS", "PROBLEM", 78, 82], ["CoV-2 infection in hypertensive patients", "PROBLEM", 83, 123], ["Methods", "TREATMENT", 167, 174], ["This meta-analysis", "TEST", 174, 192], ["Systematic Reviews", "TEST", 261, 279], ["infection", "OBSERVATION", 89, 98]]], ["We searched the medical subject heading (MeSH) terms of \u20182019-nCoV\u2019, \u2018NCIP\u2019, \u2018COVID-19\u2019 or \u2018SARS-CoV-2\u2019 and \u2018hypertension\u2019.", [["SARS", "DISEASE", 92, 96], ["hypertension", "DISEASE", 109, 121], ["COVID", "TEST", 78, 83], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["hypertension", "PROBLEM", 109, 121], ["hypertension", "OBSERVATION", 109, 121]]], ["Additionally, we performed manual searches on the references of selected articles to avoid omission.Search strategy and selection criteria ::: MethodsTo be included in this meta-analysis, the study had to: (1) COVID-19 cases: diagnosed according to the \u2018New Coronavirus Infected Pneumonia Diagnosis and Treatment Program (5th version)\u2019 [12].", [["Pneumonia", "DISEASE", 279, 288], ["manual searches", "TEST", 27, 42], ["Methods", "TREATMENT", 143, 150], ["the study", "TEST", 188, 197], ["New Coronavirus Infected Pneumonia", "PROBLEM", 254, 288], ["Treatment Program (5th version)", "TREATMENT", 303, 334], ["Coronavirus", "OBSERVATION_MODIFIER", 258, 269], ["Infected", "OBSERVATION_MODIFIER", 270, 278], ["Pneumonia", "OBSERVATION", 279, 288]]], ["All of the included COVID-19 cases should be laboratory confirmed hospitalised patients on the basis of positive qRT-PCR results for SARS-CoV-2 in swab samples; (2) clinical features: definite disease severity or fatality according to the \u2018New Coronavirus Infected Pneumonia Diagnosis and Treatment Program (5th version)\u2019 [12]; (3) parameters: clear information about hypertension; (4) study population: at least included 10 cases.", [["swab samples", "ANATOMY", 147, 159], ["SARS", "DISEASE", 133, 137], ["Pneumonia", "DISEASE", 265, 274], ["hypertension", "DISEASE", 368, 380], ["patients", "ORGANISM", 79, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 133, 143], ["swab samples", "CANCER", 147, 159], ["patients", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 133, 141], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["swab samples", "TEST", 147, 159], ["definite disease severity", "PROBLEM", 184, 209], ["fatality", "PROBLEM", 213, 221], ["New Coronavirus Infected Pneumonia", "PROBLEM", 240, 274], ["Treatment Program (5th version)", "TREATMENT", 289, 320], ["hypertension", "PROBLEM", 368, 380], ["definite", "UNCERTAINTY", 184, 192], ["disease", "OBSERVATION", 193, 200], ["Pneumonia", "OBSERVATION", 265, 274]]]], "PMC7359439": [["Problem description ::: IntroductionEven though several conventional techniques are utilized for detecting and classifying the facial expressions, still they did not detect and classify the facial expressions in a flexible manner (Mollahosseini et al. 2016).", [["facial", "ANATOMY", 127, 133], ["facial", "ANATOMY", 190, 196], ["facial", "ANATOMY", 127, 133], ["facial", "ANATOMY", 190, 196]]], ["The major reason for this issue lies in determining the accurate training dataset specifically for emotions like fear or sadness becomes a challenge.Objectives ::: IntroductionDepending upon the problems that are identified previously, this research paper has the objectives as follows: To effectively detect and classify the facial expressions, a GFE-HCA: graph-based feature extraction and hybrid classification approach are proposed.", [["facial", "ANATOMY", 326, 332], ["GFE", "DNA", 348, 351], ["sadness", "PROBLEM", 121, 128], ["graph-based feature extraction", "TREATMENT", 357, 387], ["hybrid classification approach", "TREATMENT", 392, 422], ["facial", "ANATOMY", 326, 332]]], ["Viola\u2013Jones algorithm is utilized to discover the facial image (Jensen 2008).", [["facial", "ANATOMY", 50, 56], ["facial", "ANATOMY", 50, 56]]], ["The features from facial parts are extracted by using the edge-based invariant feature transform method and then the dimensions of the extracted features are optimized by implementing the weighted visibility graph (Xie and Hu 2017).", [["facial parts", "ANATOMY", 18, 30], ["facial parts", "MULTI-TISSUE_STRUCTURE", 18, 30], ["facial", "ANATOMY", 18, 24], ["parts", "ANATOMY_MODIFIER", 25, 30], ["edge", "OBSERVATION_MODIFIER", 58, 62], ["invariant", "OBSERVATION_MODIFIER", 69, 78]]], ["Similarly, the shape-based features are extracted using facial shape appearances.", [["facial", "ANATOMY", 56, 62], ["shape", "OBSERVATION_MODIFIER", 15, 20], ["facial", "ANATOMY", 56, 62], ["shape", "OBSERVATION_MODIFIER", 63, 68]]], ["Finally, the facial expression is recognized and classified by proposing the neural network-based self-organizing classifier.Organization ::: IntroductionThe subsequent sections of this work is organized as follows: Sect.", [["facial", "ANATOMY", 13, 19], ["neural", "ANATOMY", 77, 83], ["sections", "ANATOMY", 169, 177], ["facial", "ANATOMY", 13, 19]]], ["2 analyses the traditional methods utilized for detecting and recognizing the facial expressions.", [["facial", "ANATOMY", 78, 84], ["the traditional methods", "TEST", 11, 34], ["facial", "ANATOMY", 78, 84]]], ["Section 3 elucidates the proposed method for accurate facial expression recognition.", [["facial", "ANATOMY", 54, 60]]], ["The proposed method offered better results compared to that of other pre-processing approaches.Pre-processing ::: Related worksA simple solution for emotion recognition proposed using the group of the convolutional neural network along with some image pre-processing techniques (Lopes et al. 2017).", [["neural network", "ANATOMY", 215, 229], ["neural network", "MULTI-TISSUE_STRUCTURE", 215, 229], ["A simple solution", "TREATMENT", 127, 144]]], ["It was used in real-time applications and took less time.Pre-processing ::: Related worksA novel system to recognize the facial expression, which was depending on the ensembles of descriptors that utilized various pre-processing approaches was proposed (Lumini et al. 2017).", [["facial", "ANATOMY", 121, 127], ["facial", "ANATOMY", 121, 127]]], ["This system performed well on both the datasets and attained increased performance rates.", [["increased performance rates", "PROBLEM", 61, 88]]], ["Also, this novel system offered better results with higher accuracy.Pre-processing ::: Related worksThe authors utilized stationary wavelet transform for extracting the features to recognize the facial expression (Qayyum et al. 2017).", [["facial", "ANATOMY", 195, 201], ["stationary wavelet transform", "TREATMENT", 121, 149], ["facial", "ANATOMY", 195, 201]]], ["Here the pre-processing was done using normalization histogram equalization for detecting the face more accurately.", [["normalization histogram equalization", "TEST", 39, 75]]], ["With the pre-processing step, the facial parts were determined effectively, and this helped to extract the features in an efficient way.", [["facial parts", "ANATOMY", 34, 46], ["facial", "ANATOMY", 34, 40]]], ["After this, the classification process was carried out to classify the facial expressions.", [["facial", "ANATOMY", 71, 77], ["facial", "ANATOMY", 71, 77]]], ["These results offered an increased average recognition rate for different datasets.", [["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["From the results, it was noted that this approach offered better recognition results with increased accuracy compared to that of the traditional techniques.Pre-processing ::: Related worksThe author introduced a novel ensemble of descriptors to recognize the facial expressions from the Patterns of the Oriented Edge Magnitudes (POEM) descriptor (Nanni et al. 2017).", [["facial", "ANATOMY", 259, 265], ["increased accuracy", "PROBLEM", 90, 108], ["the traditional techniques", "TEST", 129, 155], ["facial", "ANATOMY", 259, 265]]], ["Here, various ensembles were developed by using the pre-processing approaches.", [["the pre-processing approaches", "TREATMENT", 48, 77]]], ["This approach was evaluated with different datasets, such as LFW and FERET.", [["FERET", "DNA", 69, 74], ["This approach", "TREATMENT", 0, 13]]], ["The approach performed well on both the datasets with accurate results.Pre-processing ::: Related worksThis section discussed different traditional pre-processing techniques for different facial datasets.", [["This section", "TREATMENT", 103, 115], ["different facial datasets", "PROBLEM", 178, 203], ["facial", "ANATOMY", 188, 194]]], ["It included main benefits like high average recognition rate and less processing time, but the need for improving the accuracy is a constant challenge.Feature extraction ::: Related worksA novel approach was adopted for analyzing the facial expressions with the discovery of some common information from several expressions (Zhong et al. 2014).", [["facial", "ANATOMY", 234, 240], ["a constant challenge", "TREATMENT", 130, 150], ["high", "OBSERVATION_MODIFIER", 31, 35], ["average", "OBSERVATION_MODIFIER", 36, 43]]], ["For locating the distinct patches, two stages multi-task sparse learning was used.", [["the distinct patches", "PROBLEM", 13, 33], ["distinct", "OBSERVATION_MODIFIER", 17, 25], ["patches", "OBSERVATION_MODIFIER", 26, 33], ["two", "OBSERVATION_MODIFIER", 35, 38], ["stages", "OBSERVATION_MODIFIER", 39, 45]]], ["In this approach, the dominant patches were found for all the expressions.", [["dominant", "OBSERVATION_MODIFIER", 22, 30], ["patches", "OBSERVATION_MODIFIER", 31, 38]]], ["The specific patches were analyzed in the individual expression by combining both the related facial expression recognition and facial verification tasks.", [["facial", "ANATOMY", 94, 100], ["facial", "ANATOMY", 128, 134], ["The specific patches", "TREATMENT", 0, 20], ["facial verification tasks", "TEST", 128, 153], ["patches", "OBSERVATION_MODIFIER", 13, 20], ["facial", "ANATOMY", 94, 100], ["expression", "OBSERVATION", 101, 111], ["facial", "ANATOMY", 128, 134]]], ["The main advantage of this method was patch learning which provided better performance.Feature extraction ::: Related worksAn approach depending upon the multi-level Haar wavelet was used to extract the features of the appearance from the obvious face regions on dissimilar scales (Goyani and Patel 2017).", [["this method", "TREATMENT", 22, 33], ["patch learning", "TREATMENT", 38, 52], ["An approach", "TREATMENT", 123, 134], ["the multi-level Haar wavelet", "TREATMENT", 150, 178], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Initially, the approach segmented the most informative geometric elements like eyes, eyebrows, mouth by utilizing the Viola\u2013Jones cascade object detector.", [["eyes", "ANATOMY", 79, 83], ["eyebrows", "ANATOMY", 85, 93], ["mouth", "ANATOMY", 95, 100], ["eyes", "ORGAN", 79, 83], ["eyebrows", "ORGANISM_SUBDIVISION", 85, 93], ["mouth", "ORGANISM_SUBDIVISION", 95, 100], ["geometric elements", "OBSERVATION", 55, 73], ["eyes", "ANATOMY", 79, 83], ["eyebrows", "ANATOMY", 85, 93], ["mouth", "ANATOMY", 95, 100]]], ["The advantage of extracting the Haar features was easy computation and helped to represent the signals which were presented in low dimensions in an effective manner.", [["low dimensions", "OBSERVATION_MODIFIER", 127, 141]]], ["But, it was difficult to recognize the expressions in dynamic images.Feature extraction ::: Related worksA new feature extraction background which helped in signifying the differences in the facial expression as a linear mixture of localized basis functions was presented (Sariyanidi et al. 2017).", [["facial", "ANATOMY", 191, 197], ["dynamic images", "TEST", 54, 68], ["new", "OBSERVATION_MODIFIER", 107, 110], ["facial", "ANATOMY", 191, 197]]], ["Here, a sparse linear model was trained with the Gabor phase shifts, which was computed from the facial video.", [["facial", "ANATOMY", 97, 103], ["facial", "ANATOMY", 97, 103]]], ["The difficulties of generalization were addressed by this framework and achieved by similar learning parameters by recognizing both the posed and spontaneous micro-expressions.Feature extraction ::: Related worksThe authors announced a novel approach for extracting the noticeable areas of the face with Self-Organizing Map based Neural Network classifier (Liu et al. 2017).", [["spontaneous micro-expressions", "PROBLEM", 146, 175], ["a novel approach", "TREATMENT", 234, 250], ["face", "ANATOMY", 294, 298]]], ["Firstly, the normalization occurs on the prominent areas of similar position on the face.", [["normalization", "OBSERVATION", 13, 26], ["prominent", "OBSERVATION_MODIFIER", 41, 50], ["areas", "OBSERVATION_MODIFIER", 51, 56], ["similar", "OBSERVATION_MODIFIER", 60, 67], ["position", "OBSERVATION_MODIFIER", 68, 76], ["face", "ANATOMY", 84, 88]]], ["On the salient areas, the features such as LBP and HOG are extracted.", [["LBP", "DISEASE", 43, 46], ["LBP", "PROBLEM", 43, 46], ["LBP", "OBSERVATION", 43, 46]]], ["The Principal Component Analysis was used to decrease the dimension of the fusion features.", [["fusion features", "OBSERVATION", 75, 90]]], ["The peak expression frames are used in this method with the help of the salient area definitude method.", [["The peak expression frames", "PROBLEM", 0, 26], ["this method", "TREATMENT", 39, 50], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["expression frames", "OBSERVATION", 9, 26]]], ["The face expressions were classified using numerous classifiers.", [["face", "ANATOMY", 4, 8]]], ["The alignment of the particular areas with several expressions in the face was done through the normalization of salient regions.", [["several expressions in the face", "PROBLEM", 43, 74], ["alignment", "OBSERVATION_MODIFIER", 4, 13], ["several", "OBSERVATION_MODIFIER", 43, 50], ["expressions", "OBSERVATION", 51, 62], ["face", "ANATOMY", 70, 74]]], ["Besides, there were limitations in recognition which was not performed with inaccurate landmarks, and also there was no improvement in recognition with fewer image data.Feature extraction ::: Related worksA novel approach was presented to recognize the facial expression with three steps such as feature extraction, feature optimization and emotion recognition (Mistry et al. 2016).", [["facial", "ANATOMY", 253, 259], ["fewer image data", "TEST", 152, 168], ["feature extraction", "TREATMENT", 296, 314], ["no", "UNCERTAINTY", 117, 119], ["improvement", "OBSERVATION_MODIFIER", 120, 131]]], ["The face representations are originally extracted using altered Local Binary Patterns.", [["altered Local Binary Patterns", "PROBLEM", 56, 85], ["face", "ANATOMY", 4, 8], ["altered", "OBSERVATION_MODIFIER", 56, 63], ["Local", "OBSERVATION_MODIFIER", 64, 69], ["Binary Patterns", "OBSERVATION", 70, 85]]], ["The facial expressions are separated using embedded PSO algorithm through finding the important and discriminative features.", [["facial", "ANATOMY", 4, 10], ["embedded PSO algorithm", "TREATMENT", 43, 65], ["facial", "ANATOMY", 4, 10]]], ["The advantage of this work is computational cost and speed of the convergence.Feature extraction ::: Related worksThe author introduced a novel approach to discover the specificity of the expression variation in the face (Xie et al. 2017).", [["a novel approach", "TREATMENT", 136, 152], ["face", "ANATOMY", 216, 220]]], ["The specificity of the expression was signified through the triplet wise expression recognition in accordance with Action Unit (AU) and patch weight optimization.", [["patch weight optimization", "TREATMENT", 136, 161]]], ["To acquire better generalization, the active AUs are detected and presented in testing samples using sparse representation-based approach.", [["AUs", "CANCER", 45, 48], ["the active AUs", "PROBLEM", 34, 48], ["testing samples", "TEST", 79, 94], ["active", "OBSERVATION_MODIFIER", 38, 44], ["AUs", "OBSERVATION", 45, 48]]], ["The accuracy is enhanced in this approach, and the cross-database was better in its performance.", [["enhanced", "OBSERVATION_MODIFIER", 16, 24]]], ["In real-time applications, the recognition in cross-database was difficult for acquiring better results.Feature extraction ::: Related worksFrom this section, different traditional feature extraction techniques have discoursed.", [["this section", "TREATMENT", 145, 157]]], ["It includes some drawbacks like difficulty in acquiring better results, no improvement in recognition with fewer image data and difficulty in recognizing the expressions in dynamic images.Classification ::: Related worksAn automatic facial expression system for extracting the salient data from their video sequences was developed (Fang et al. 2014).", [["facial", "ANATOMY", 233, 239], ["fewer image data", "TEST", 107, 123], ["dynamic images", "TEST", 173, 187], ["their video sequences", "TEST", 295, 316], ["no", "UNCERTAINTY", 72, 74], ["improvement", "OBSERVATION_MODIFIER", 75, 86]]], ["The framework explored the parametric space, and it was tested with six machine learning techniques.", [["parametric space", "OBSERVATION", 27, 43]]], ["An entire collection of machine learning approaches were working with the specific task of expression in face recognition.", [["entire", "OBSERVATION_MODIFIER", 3, 9], ["collection", "OBSERVATION_MODIFIER", 10, 20]]], ["The Face Expression Recognition (FER) challenge offered the pre-trained huge dataset, and each CNN technique was initialized randomly.", [["the pre-trained huge dataset", "TREATMENT", 56, 84], ["each CNN technique", "TREATMENT", 90, 108]]], ["The multiple CNN model was included with two systems for learning the collaborative loads of their network responses.Classification ::: Related worksThe authors utilized the dataset for standard expression of face, and it was made by influencing the societal images and the deep model system was trained based on the standard database (Peng et al. 2016).", [["the societal images", "TEST", 246, 265], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["face", "ANATOMY", 209, 213], ["deep", "ANATOMY_MODIFIER", 274, 278]]], ["The specific keywords were used for image search, and it was obtained from social labelled images.", [["image search", "TEST", 36, 48], ["social labelled images", "TEST", 75, 97]]], ["The mislabeled images were removed by junk image cleaning.", [["The mislabeled images", "TEST", 0, 21]]], ["The spontaneous expressions were recognized by deep Convolutional Neural Network.Classification ::: Related worksFor emotion recognition, the author proposed a novel technique in which the recognition of the face is taken from the single image frame which used the combination of the geometric features as well as /the appearance with the help of Support Vector Machine classification (Ghimire et al. 2017a, b).", [["a novel technique", "TREATMENT", 158, 175], ["deep", "ANATOMY_MODIFIER", 47, 51], ["Neural Network", "OBSERVATION", 66, 80], ["face", "ANATOMY", 208, 212]]], ["By isolating the face region into the regular grid, appearance aspects for the facial expression recognitions were calculated.", [["face region", "ANATOMY", 17, 28], ["facial", "ANATOMY", 79, 85], ["face", "ANATOMY_MODIFIER", 17, 21], ["facial", "ANATOMY", 79, 85]]], ["Also, the geometric aspects are extracted from the respective areas.Classification ::: Related worksThe emotion recognition technique had been evaluated on Cohn-Kanade dataset.", [["geometric", "OBSERVATION_MODIFIER", 10, 19], ["respective", "OBSERVATION_MODIFIER", 51, 61], ["areas", "OBSERVATION_MODIFIER", 62, 67]]], ["Facial Expression Recognition and Analysis challenge (FERA) was introduced to detect the Action Units and intensity on more number of data where a broad set of videos comprising nine outlooks were generated (Valstar et al. 2017).", [["Analysis challenge", "TEST", 34, 52]]], ["The problems were in estimating the intensity in expression and also in detecting head poses were interpreted in this method.", [["head", "ANATOMY", 82, 86], ["head", "ORGANISM_SUBDIVISION", 82, 86], ["The problems", "PROBLEM", 0, 12]]], ["The geometric features used for the standard results improves the potential for the specific challenges.Classification ::: Related worksThe authors present a real-time facial expression recognition system on smart phones (Suk and Prabhakaran 2014).", [["facial", "ANATOMY", 168, 174]]], ["The system returns the recognized expression by the SVM classifiers for facial expression recognition with the dynamic features.", [["facial", "ANATOMY", 72, 78], ["facial expression recognition", "PROBLEM", 72, 101]]], ["The results of the work show that the system was effective on mobile devices with speed and accuracy.Classification ::: Related worksThe above study conveys that existing image processing techniques used for emotion recognition had problems such as inaccurate recognition of the emotion, less efficiency, which degrades the performance in categorizing the facial expressions.", [["facial", "ANATOMY", 356, 362], ["mobile devices", "TREATMENT", 62, 76], ["accuracy", "TEST", 92, 100], ["The above study", "TEST", 133, 148], ["emotion recognition", "TEST", 208, 227], ["less efficiency", "OBSERVATION_MODIFIER", 288, 303], ["facial", "ANATOMY", 356, 362]]], ["To solve these issues, the proposed work aims to introduce an efficient face recognition system by using improved feature extraction and classification techniques.Edge-based invariant transform ::: Proposed workAn edge is a point in a digital image on which the intensity deviates abruptly.", [["a digital image", "TEST", 233, 248], ["edge", "OBSERVATION_MODIFIER", 214, 218]]], ["The parts of the facial image are extracted by using the edge-based invariant transform.", [["facial", "ANATOMY", 17, 23], ["facial image", "MULTI-TISSUE_STRUCTURE", 17, 29], ["parts", "ANATOMY_MODIFIER", 4, 9], ["facial", "ANATOMY", 17, 23]]], ["The invariant features are extracted here for predicting the uniqueness among the emotions, by suppressing the common information of the images.", [["the images", "TEST", 133, 143], ["invariant", "OBSERVATION_MODIFIER", 4, 13]]], ["In this, the face parts are extracted initially by the prediction of edge regions on applying the Canny Edge detector (Ramadass et al. 2018) mechanism.", [["face", "ANATOMY", 13, 17], ["parts", "ANATOMY_MODIFIER", 18, 23], ["edge", "OBSERVATION_MODIFIER", 69, 73]]], ["It only requires minimum numerical computations and also satisfies the following specifications like good detection, noise sensitivity, good localization, speed and efficiency.", [["minimum numerical computations", "TREATMENT", 17, 47]]], ["The filtered coefficients of the parts are then estimated and the corners are predicted by using the filtered coefficients for each individual parts of the face.", [["coefficients", "OBSERVATION_MODIFIER", 13, 25], ["corners", "ANATOMY_MODIFIER", 66, 73], ["face", "ANATOMY", 156, 160]]], ["The invariant features are estimated by the detected corner in which the area, pixels and points are identified finally.", [["invariant", "OBSERVATION_MODIFIER", 4, 13], ["corner", "OBSERVATION_MODIFIER", 53, 59], ["area", "OBSERVATION_MODIFIER", 73, 77]]], ["The invariant transform depends on the appearance of the object in a specified point of interest and is invariant to the scaling images and rotation where the invariant features denote the detection of variations among different emotions.", [["the scaling images", "TEST", 117, 135], ["invariant", "OBSERVATION_MODIFIER", 4, 13], ["transform", "OBSERVATION_MODIFIER", 14, 23]]]], "bf8158826b92603f44c63960f20dffc8fb0357f2": [["IntroductionSince described in USA in 1987, porcine reproductive and respiratory syndrome (PRRS) characterized with respiratory illness in piglets and severe reproductive problems in sows and gilts (Music and Gagnon, 2010) has now been one of the most important diseases in pigs, leading to significant economic losses in swine industry worldwide (Li et al., 2007) .", [["respiratory", "ANATOMY", 116, 127], ["porcine reproductive and respiratory syndrome", "DISEASE", 44, 89], ["PRRS", "DISEASE", 91, 95], ["respiratory illness", "DISEASE", 116, 135], ["porcine reproductive", "ORGANISM", 44, 64], ["piglets", "ORGANISM", 139, 146], ["sows", "ORGANISM", 183, 187], ["pigs", "ORGANISM", 274, 278], ["piglets", "SPECIES", 139, 146], ["pigs", "SPECIES", 274, 278], ["swine", "SPECIES", 322, 327], ["PRRS", "SPECIES", 91, 95], ["pigs", "SPECIES", 274, 278], ["swine", "SPECIES", 322, 327], ["respiratory syndrome", "PROBLEM", 69, 89], ["respiratory illness in piglets", "PROBLEM", 116, 146], ["severe reproductive problems", "PROBLEM", 151, 179], ["respiratory syndrome", "OBSERVATION", 69, 89], ["respiratory illness", "OBSERVATION", 116, 135], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["diseases", "OBSERVATION", 262, 270], ["significant", "OBSERVATION_MODIFIER", 291, 302], ["economic", "OBSERVATION_MODIFIER", 303, 311], ["losses", "OBSERVATION", 312, 318]]], ["PRRS virus (PRRSV) is an enveloped positive single stranded RNA virus and belongs to the genus Arterivirus, family Arteriviridae, order Nidovirales (Cavanagh, 1997) .", [["PRRS virus", "ORGANISM", 0, 10], ["PRRSV", "ORGANISM", 12, 17], ["Arterivirus", "GENE_OR_GENE_PRODUCT", 95, 106], ["PRRS virus", "SPECIES", 0, 10], ["PRRSV", "SPECIES", 12, 17], ["PRRS virus", "SPECIES", 0, 10], ["PRRSV", "SPECIES", 12, 17], ["PRRS virus", "PROBLEM", 0, 10], ["an enveloped positive single stranded RNA virus", "PROBLEM", 22, 69], ["enveloped", "OBSERVATION_MODIFIER", 25, 34], ["positive", "OBSERVATION", 35, 43], ["stranded RNA virus", "OBSERVATION", 51, 69]]], ["PRRSV genome is approximately 15.4 kb in length and has 10 open reading frames (ORFs) (Yun and Lee, 2013) .", [["PRRSV", "ORGANISM", 0, 5], ["PRRSV genome", "DNA", 0, 12], ["open reading frames", "DNA", 59, 78], ["ORFs", "DNA", 80, 84], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV genome", "PROBLEM", 0, 12], ["approximately", "OBSERVATION_MODIFIER", 16, 29], ["15.4 kb", "OBSERVATION_MODIFIER", 30, 37]]], ["PRRSV exhibits a highly restricted host cell tropism for the cells of the monocyte/macrophage/dendritic lineages (Duan et al., 1997) .", [["cell", "ANATOMY", 40, 44], ["cells", "ANATOMY", 61, 66], ["monocyte", "ANATOMY", 74, 82], ["macrophage", "ANATOMY", 83, 93], ["dendritic lineages", "ANATOMY", 94, 112], ["PRRSV", "ORGANISM", 0, 5], ["host cell", "CELL", 35, 44], ["cells", "CELL", 61, 66], ["monocyte", "CELL", 74, 82], ["macrophage", "CELL", 83, 93], ["dendritic lineages", "CELL", 94, 112], ["monocyte/macrophage/dendritic lineages", "CELL_TYPE", 74, 112], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["the monocyte", "TEST", 70, 82], ["host cell tropism", "OBSERVATION", 35, 52], ["monocyte", "ANATOMY", 74, 82], ["macrophage", "ANATOMY", 83, 93], ["dendritic lineages", "OBSERVATION", 94, 112]]], ["Since 2006, there have been devastating outbreaks of atypical PRRS in China, which is characterized by high fever, high morbidity, and high mortality.", [["PRRS", "DISEASE", 62, 66], ["fever", "DISEASE", 108, 113], ["PRRS", "SPECIES", 62, 66], ["atypical PRRS in China", "PROBLEM", 53, 75], ["high fever", "PROBLEM", 103, 113], ["high morbidity", "PROBLEM", 115, 129], ["high mortality", "PROBLEM", 135, 149], ["devastating", "OBSERVATION_MODIFIER", 28, 39], ["outbreaks", "OBSERVATION_MODIFIER", 40, 49], ["atypical", "OBSERVATION_MODIFIER", 53, 61], ["PRRS", "OBSERVATION", 62, 66], ["high", "OBSERVATION_MODIFIER", 103, 107], ["fever", "OBSERVATION", 108, 113], ["high", "OBSERVATION_MODIFIER", 115, 119], ["morbidity", "OBSERVATION_MODIFIER", 120, 129], ["high", "OBSERVATION_MODIFIER", 135, 139], ["mortality", "OBSERVATION_MODIFIER", 140, 149]]], ["A highly pathogenic PRRSV (HP-PRRSV) isolate with a 30-amino-acid (30 aa) deletion in nonstructural protein (nsp2) was identified as the causative agent (Tian et al., 2007) .IntroductionThe acute phase of PRRSV infection primarily targets alveolar macrophages.", [["alveolar macrophages", "ANATOMY", 239, 259], ["30-amino-acid", "CHEMICAL", 52, 65], ["PRRSV infection", "DISEASE", 205, 220], ["amino-acid", "CHEMICAL", 55, 65], ["PRRSV", "ORGANISM", 20, 25], ["HP-PRRSV", "ORGANISM", 27, 35], ["nonstructural protein", "GENE_OR_GENE_PRODUCT", 86, 107], ["nsp2", "GENE_OR_GENE_PRODUCT", 109, 113], ["PRRSV", "ORGANISM", 205, 210], ["alveolar macrophages", "CELL", 239, 259], ["nonstructural protein", "PROTEIN", 86, 107], ["nsp2", "PROTEIN", 109, 113], ["alveolar macrophages", "CELL_TYPE", 239, 259], ["PRRSV", "SPECIES", 20, 25], ["PRRSV", "SPECIES", 20, 25], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 205, 210], ["A highly pathogenic PRRSV", "PROBLEM", 0, 25], ["a 30-amino-acid (30 aa) deletion in nonstructural protein (nsp2)", "PROBLEM", 50, 114], ["PRRSV infection", "PROBLEM", 205, 220], ["pathogenic PRRSV", "OBSERVATION", 9, 25], ["nonstructural protein", "OBSERVATION", 86, 107], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["phase", "OBSERVATION_MODIFIER", 196, 201], ["PRRSV infection", "OBSERVATION", 205, 220], ["alveolar macrophages", "OBSERVATION", 239, 259]]], ["The mechanistic basis for the acute phase of respiratory distress is likely a consequence of the release of inflammatory cytokines in the lung (Chand et al., 2012) .", [["respiratory", "ANATOMY", 45, 56], ["lung", "ANATOMY", 138, 142], ["respiratory distress", "DISEASE", 45, 65], ["lung", "ORGAN", 138, 142], ["inflammatory cytokines", "PROTEIN", 108, 130], ["respiratory distress", "PROBLEM", 45, 65], ["inflammatory cytokines in the lung", "PROBLEM", 108, 142], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["phase", "OBSERVATION_MODIFIER", 36, 41], ["respiratory distress", "OBSERVATION", 45, 65], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120], ["cytokines", "OBSERVATION", 121, 130], ["lung", "ANATOMY", 138, 142]]], ["The intensity of the disease appears to vary among isolates and variation in the pathogenicity of PRRSV has been observed in experimentally infected animals (Cho and Dee, 2006; Han et al., 2014) .", [["PRRSV", "ORGANISM", 98, 103], ["PRRSV", "SPECIES", 98, 103], ["the disease", "PROBLEM", 17, 28], ["PRRSV", "PROBLEM", 98, 103], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["disease", "OBSERVATION", 21, 28], ["infected", "OBSERVATION_MODIFIER", 140, 148]]], ["HP-PRRSV is reported to cause severe acute lung injury (Han et al., 2014) .", [["lung", "ANATOMY", 43, 47], ["acute lung injury", "DISEASE", 37, 54], ["HP-PRRSV", "ORGANISM", 0, 8], ["lung", "ORGAN", 43, 47], ["PRRSV", "SPECIES", 3, 8], ["PRRSV", "PROBLEM", 3, 8], ["severe acute lung injury", "PROBLEM", 30, 54], ["PRRSV", "OBSERVATION", 3, 8], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["lung", "ANATOMY", 43, 47], ["injury", "OBSERVATION", 48, 54]]], ["The lesions include destruction of lung structure with extensive hemorrhage and a large number of inflammatory cell infiltration into the alveolar spaces.", [["lesions", "ANATOMY", 4, 11], ["lung", "ANATOMY", 35, 39], ["cell", "ANATOMY", 111, 115], ["alveolar spaces", "ANATOMY", 138, 153], ["destruction of lung structure", "DISEASE", 20, 49], ["hemorrhage", "DISEASE", 65, 75], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["lung", "ORGAN", 35, 39], ["inflammatory cell", "CELL", 98, 115], ["alveolar", "MULTI-TISSUE_STRUCTURE", 138, 146], ["The lesions", "PROBLEM", 0, 11], ["destruction of lung structure", "PROBLEM", 20, 49], ["extensive hemorrhage", "PROBLEM", 55, 75], ["inflammatory cell infiltration into the alveolar spaces", "PROBLEM", 98, 153], ["lesions", "OBSERVATION", 4, 11], ["destruction", "OBSERVATION", 20, 31], ["lung", "ANATOMY", 35, 39], ["extensive", "OBSERVATION_MODIFIER", 55, 64], ["hemorrhage", "OBSERVATION", 65, 75], ["large", "OBSERVATION_MODIFIER", 82, 87], ["number", "OBSERVATION_MODIFIER", 88, 94], ["inflammatory cell infiltration", "OBSERVATION", 98, 128], ["alveolar", "ANATOMY_MODIFIER", 138, 146]]], ["Additionally, interstitial pneumonia also occurs, which is characterized by a marked thickening of the alveolar septa (Shang et al., 2013) .", [["interstitial", "ANATOMY", 14, 26], ["alveolar septa", "ANATOMY", 103, 117], ["interstitial pneumonia", "DISEASE", 14, 36], ["alveolar septa", "TISSUE", 103, 117], ["interstitial pneumonia", "PROBLEM", 14, 36], ["a marked thickening of the alveolar septa", "PROBLEM", 76, 117], ["interstitial", "ANATOMY_MODIFIER", 14, 26], ["pneumonia", "OBSERVATION", 27, 36], ["marked", "OBSERVATION_MODIFIER", 78, 84], ["thickening", "OBSERVATION", 85, 95], ["alveolar", "ANATOMY_MODIFIER", 103, 111], ["septa", "ANATOMY_MODIFIER", 112, 117]]], ["Upon infection, neutrophils are always the first to be recruited to the focus and cause capillary leak and pulmonary edema (Segel et al., 2011) .", [["neutrophils", "ANATOMY", 16, 27], ["capillary", "ANATOMY", 88, 97], ["pulmonary", "ANATOMY", 107, 116], ["infection", "DISEASE", 5, 14], ["pulmonary edema", "DISEASE", 107, 122], ["neutrophils", "CELL", 16, 27], ["capillary", "TISSUE", 88, 97], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 107, 122], ["neutrophils", "CELL_TYPE", 16, 27], ["infection", "PROBLEM", 5, 14], ["neutrophils", "TEST", 16, 27], ["capillary leak", "PROBLEM", 88, 102], ["pulmonary edema", "PROBLEM", 107, 122], ["infection", "OBSERVATION", 5, 14], ["capillary leak", "OBSERVATION", 88, 102], ["pulmonary", "ANATOMY", 107, 116], ["edema", "OBSERVATION", 117, 122]]], ["Compared with the pigs infected typical PRRSV strains, the number of neutrophils in the lungs of HP-PRRSV-infected pigs was significantly increased Han et al., 2014) .", [["neutrophils", "ANATOMY", 69, 80], ["lungs", "ANATOMY", 88, 93], ["pigs", "ORGANISM", 18, 22], ["PRRSV", "ORGANISM", 40, 45], ["neutrophils", "CELL", 69, 80], ["lungs", "ORGAN", 88, 93], ["HP-PRRSV", "ORGANISM", 97, 105], ["pigs", "ORGANISM", 115, 119], ["neutrophils", "CELL_TYPE", 69, 80], ["pigs", "SPECIES", 18, 22], ["PRRSV", "SPECIES", 40, 45], ["pigs", "SPECIES", 115, 119], ["pigs", "SPECIES", 18, 22], ["PRRSV", "SPECIES", 40, 45], ["pigs", "SPECIES", 115, 119], ["the pigs infected typical PRRSV strains", "PROBLEM", 14, 53], ["HP", "TEST", 97, 99], ["PRRSV", "PROBLEM", 100, 105], ["typical", "OBSERVATION_MODIFIER", 32, 39], ["PRRSV strains", "OBSERVATION", 40, 53], ["neutrophils", "OBSERVATION", 69, 80], ["lungs", "ANATOMY", 88, 93], ["infected", "OBSERVATION_MODIFIER", 106, 114], ["increased", "OBSERVATION_MODIFIER", 138, 147]]], ["IL-8 is the main chemokine and activator of neutrophils (Pease and Sabroe, 2002) .", [["neutrophils", "ANATOMY", 44, 55], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophils", "CELL", 44, 55], ["IL-8", "PROTEIN", 0, 4], ["chemokine", "PROTEIN", 17, 26], ["neutrophils", "CELL_TYPE", 44, 55], ["neutrophils", "TEST", 44, 55]]], ["Upon receiving inflammatory stimuli, IL-8 can be up-regulated in many different cell types, including fibroblasts, monocytes, and hepatocytes (Mukaida, 2000) .", [["cell", "ANATOMY", 80, 84], ["fibroblasts", "ANATOMY", 102, 113], ["monocytes", "ANATOMY", 115, 124], ["hepatocytes", "ANATOMY", 130, 141], ["IL-8", "GENE_OR_GENE_PRODUCT", 37, 41], ["cell", "CELL", 80, 84], ["fibroblasts", "CELL", 102, 113], ["monocytes", "CELL", 115, 124], ["hepatocytes", "CELL", 130, 141], ["IL-8", "PROTEIN", 37, 41], ["fibroblasts", "CELL_TYPE", 102, 113], ["monocytes", "CELL_TYPE", 115, 124], ["hepatocytes", "CELL_TYPE", 130, 141], ["inflammatory stimuli", "TEST", 15, 35], ["IL", "TEST", 37, 39], ["monocytes", "TEST", 115, 124], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27], ["different cell types", "OBSERVATION", 70, 90], ["fibroblasts", "ANATOMY", 102, 113], ["hepatocytes", "ANATOMY", 130, 141]]], ["Thus, we assume that IL-8 production might be induced and be related in the lung lesion upon PRRSV infection (Bohnet et al., 1997; Fujimori et al., 2003; Harada, 1994; Hay and Sarau, 2001; Jundi and Greene, 2015; .IntroductionGiven the important significance of IL-8 in the pathology of virus infection\uff0cwe dissected the underlying mechanism of IL-8 expression under PRRSV infection in the present study.", [["lung lesion", "ANATOMY", 76, 87], ["PRRSV infection", "DISEASE", 93, 108], ["PRRSV infection", "DISEASE", 366, 381], ["IL-8", "GENE_OR_GENE_PRODUCT", 21, 25], ["lung", "ORGAN", 76, 80], ["PRRSV", "ORGANISM", 93, 98], ["IL-8", "GENE_OR_GENE_PRODUCT", 262, 266], ["IL-8", "GENE_OR_GENE_PRODUCT", 344, 348], ["PRRSV", "ORGANISM", 366, 371], ["IL-8", "PROTEIN", 21, 25], ["IL-8", "PROTEIN", 262, 266], ["IL-8", "PROTEIN", 344, 348], ["PRRSV", "SPECIES", 93, 98], ["PRRSV", "SPECIES", 366, 371], ["IL-8 production", "TREATMENT", 21, 36], ["the lung lesion", "PROBLEM", 72, 87], ["PRRSV infection", "PROBLEM", 93, 108], ["virus infection\uff0cwe", "PROBLEM", 287, 305], ["PRRSV infection", "PROBLEM", 366, 381], ["the present study", "TEST", 385, 402], ["lung", "ANATOMY", 76, 80], ["lesion", "OBSERVATION", 81, 87], ["PRRSV infection", "OBSERVATION", 93, 108], ["PRRSV infection", "OBSERVATION", 366, 381]]], ["We demonstrate that HP-PRRSV induces IL-8 expression through the TAK-1/JNK/AP-1 pathways.PRRSV induces IL-8 production both in vitro and in vivoTo investigate whether PRRSV can induce IL-8 production, we infected porcine alveolar macrophages (PAMs) with different strains of PRRSV, including typical PRRSV strain CH-1a and HP-PRRSV strain HV.", [["alveolar macrophages", "ANATOMY", 221, 241], ["PAMs", "ANATOMY", 243, 247], ["HP-PRRSV", "ORGANISM", 20, 28], ["IL-8", "GENE_OR_GENE_PRODUCT", 37, 41], ["TAK-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["JNK", "GENE_OR_GENE_PRODUCT", 71, 74], ["AP-1", "GENE_OR_GENE_PRODUCT", 75, 79], ["PRRSV", "ORGANISM", 89, 94], ["IL-8", "GENE_OR_GENE_PRODUCT", 103, 107], ["PRRSV", "ORGANISM", 167, 172], ["IL-8", "GENE_OR_GENE_PRODUCT", 184, 188], ["porcine", "ORGANISM", 213, 220], ["alveolar macrophages", "CELL", 221, 241], ["PAMs", "CELL", 243, 247], ["PRRSV", "ORGANISM", 275, 280], ["PRRSV strain CH-1a", "ORGANISM", 300, 318], ["HP-PRRSV strain HV", "ORGANISM", 323, 341], ["IL-8", "PROTEIN", 37, 41], ["TAK", "PROTEIN", 65, 68], ["JNK", "PROTEIN", 71, 74], ["AP", "PROTEIN", 75, 77], ["IL-8", "PROTEIN", 103, 107], ["IL-8", "PROTEIN", 184, 188], ["porcine alveolar macrophages", "CELL_TYPE", 213, 241], ["PAMs", "CELL_TYPE", 243, 247], ["PRRSV", "SPECIES", 89, 94], ["porcine", "SPECIES", 213, 220], ["PRRSV", "SPECIES", 275, 280], ["PRRSV", "SPECIES", 300, 305], ["PRRSV", "SPECIES", 326, 331], ["PRRSV", "SPECIES", 23, 28], ["PRRSV", "SPECIES", 89, 94], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 275, 280], ["PRRSV strain CH-1a", "SPECIES", 300, 318], ["HP-PRRSV strain HV", "SPECIES", 323, 341], ["HP", "TEST", 20, 22], ["IL", "TEST", 37, 39], ["the TAK", "TEST", 61, 68], ["JNK/AP", "TEST", 71, 77], ["PRRSV induces IL", "TREATMENT", 89, 105], ["PRRSV", "PROBLEM", 167, 172], ["infected porcine alveolar macrophages", "PROBLEM", 204, 241], ["different strains of PRRSV", "PROBLEM", 254, 280], ["typical PRRSV strain CH", "PROBLEM", 292, 315], ["HP", "PROBLEM", 323, 325], ["PRRSV strain HV", "PROBLEM", 326, 341], ["infected", "OBSERVATION_MODIFIER", 204, 212], ["porcine", "OBSERVATION_MODIFIER", 213, 220], ["alveolar macrophages", "OBSERVATION", 221, 241], ["PRRSV strain", "OBSERVATION", 300, 312], ["PRRSV strain", "OBSERVATION", 326, 338]]], ["Our results showed that HV up-regulated IL-8 mRNA expression about 5, 8, 30, and 10 folds compared to the uninfected controls at 6, 12, 24, and 36 h post infection (hpi), respectively (Fig. 1A) .", [["infection", "DISEASE", 154, 163], ["IL-8", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-8 mRNA", "RNA", 40, 49], ["HV", "TEST", 24, 26], ["IL", "TEST", 40, 42], ["mRNA expression", "TEST", 45, 60], ["infection", "PROBLEM", 154, 163], ["infection", "OBSERVATION", 154, 163]]], ["CH-1a also induced IL-8 expression, but at a lower level.", [["CH-1a", "CHEMICAL", 0, 5], ["CH-1a", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-8", "GENE_OR_GENE_PRODUCT", 19, 23], ["IL-8", "PROTEIN", 19, 23], ["IL", "OBSERVATION", 19, 21]]], ["These data suggest that PRRSV-induced IL-8 production is not strain-dependent, but varies among stains.", [["PRRSV", "ORGANISM", 24, 29], ["IL-8", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL", "PROTEIN", 38, 40], ["PRRSV", "SPECIES", 24, 29], ["These data", "TEST", 0, 10], ["PRRSV", "PROBLEM", 24, 29], ["strain-dependent", "PROBLEM", 61, 77], ["PRRSV", "OBSERVATION", 24, 29]]], ["To confirm this result, we infected PAMs with HV and CH-1a at an MOI of 0.02, 0.1 or 1.", [["PAMs", "CELL", 36, 40]]], ["Our results indicated that the upregulation of IL-8 by both HV and CH-1a was in a dose dependent manner ( Fig. 1B and C) .", [["CH-1a", "CHEMICAL", 67, 72], ["IL-8", "GENE_OR_GENE_PRODUCT", 47, 51], ["CH-1a", "ORGANISM", 67, 72], ["IL-8", "PROTEIN", 47, 51], ["the upregulation of IL", "TREATMENT", 27, 49], ["a dose dependent manner", "TREATMENT", 80, 103]]], ["We also detected the cell viability after PRRSV infection, and found that infection with an MOI of 1 for 24 h or an MOI of 0.1 for 36 h led to significant PAM death (data not shown).", [["cell", "ANATOMY", 21, 25], ["PRRSV infection", "DISEASE", 42, 57], ["infection", "DISEASE", 74, 83], ["death", "DISEASE", 159, 164], ["cell", "CELL", 21, 25], ["PRRSV", "ORGANISM", 42, 47], ["PRRSV", "SPECIES", 42, 47], ["the cell viability", "PROBLEM", 17, 35], ["PRRSV infection", "PROBLEM", 42, 57], ["infection", "PROBLEM", 74, 83], ["an MOI", "TEST", 89, 95], ["an MOI", "TEST", 113, 119], ["significant PAM death", "PROBLEM", 143, 164], ["cell viability", "OBSERVATION", 21, 35], ["PRRSV infection", "OBSERVATION", 42, 57], ["infection", "OBSERVATION", 74, 83]]], ["Thus, we used MOI of 0.1 to infect PAMs in the following experiment.", [["MOI", "TREATMENT", 14, 17]]], ["Additionally, the IL-8 protein level induced by PRRSV was significantly increased (Fig. 1D) .PRRSV induces IL-8 production both in vitro and in vivoTo investigate whether HP-PRRSV has the ability to induce IL-8 production in vivo, four-week old pigs were intranasally infected with 2 ml of HV (10 5 TCID 50 /ml) for each piglet, and samples were collected at 5 days post infection for IL-8 and PRRSV analysis.", [["piglet", "ANATOMY", 321, 327], ["samples", "ANATOMY", 333, 340], ["infection", "DISEASE", 371, 380], ["IL-8", "GENE_OR_GENE_PRODUCT", 18, 22], ["PRRSV", "ORGANISM", 48, 53], ["PRRSV", "ORGANISM", 93, 98], ["IL-8", "GENE_OR_GENE_PRODUCT", 107, 111], ["HP-PRRSV", "ORGANISM", 171, 179], ["IL-8", "GENE_OR_GENE_PRODUCT", 206, 210], ["pigs", "ORGANISM", 245, 249], ["piglet", "ORGANISM", 321, 327], ["IL-8", "GENE_OR_GENE_PRODUCT", 385, 389], ["PRRSV", "ORGANISM", 394, 399], ["IL-8", "PROTEIN", 18, 22], ["IL-8", "PROTEIN", 107, 111], ["IL-8", "PROTEIN", 206, 210], ["IL", "PROTEIN", 385, 387], ["PRRSV", "SPECIES", 93, 98], ["pigs", "SPECIES", 245, 249], ["PRRSV", "SPECIES", 48, 53], ["PRRSV", "SPECIES", 93, 98], ["PRRSV", "SPECIES", 174, 179], ["pigs", "SPECIES", 245, 249], ["PRRSV", "SPECIES", 394, 399], ["the IL-8 protein level", "TREATMENT", 14, 36], ["PRRSV", "PROBLEM", 48, 53], ["PRRSV induces IL", "TREATMENT", 93, 109], ["HP", "PROBLEM", 171, 173], ["PRRSV", "PROBLEM", 174, 179], ["IL", "TEST", 206, 208], ["HV", "TREATMENT", 290, 292], ["infection", "PROBLEM", 371, 380], ["IL", "TEST", 385, 387], ["PRRSV analysis", "TEST", 394, 408], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["Our results showed that IL-8 mRNA expression was significantly induced in lungs and PAMs from PRRSV-infected piglets (Fig. 1E) .", [["lungs", "ANATOMY", 74, 79], ["PRRSV-infected", "DISEASE", 94, 108], ["IL-8", "GENE_OR_GENE_PRODUCT", 24, 28], ["lungs", "ORGAN", 74, 79], ["PAMs", "CELL", 84, 88], ["PRRSV", "ORGANISM", 94, 99], ["piglets", "ORGANISM", 109, 116], ["IL-8 mRNA", "RNA", 24, 33], ["PAMs", "CELL_TYPE", 84, 88], ["piglets", "SPECIES", 109, 116], ["PRRSV", "SPECIES", 94, 99], ["IL", "TEST", 24, 26], ["mRNA expression", "TEST", 29, 44], ["PAMs", "PROBLEM", 84, 88], ["PRRSV", "PROBLEM", 94, 99], ["lungs", "ANATOMY", 74, 79], ["PAMs", "OBSERVATION", 84, 88], ["infected piglets", "OBSERVATION", 100, 116]]], ["PRRSV infection was also analyzed in lungs and PAMs from PRRSV-infected piglets (Fig. 1F ).", [["lungs", "ANATOMY", 37, 42], ["PRRSV infection", "DISEASE", 0, 15], ["PRRSV-infected", "DISEASE", 57, 71], ["PRRSV", "ORGANISM", 0, 5], ["lungs", "ORGAN", 37, 42], ["PAMs", "CELL", 47, 51], ["PRRSV", "ORGANISM", 57, 62], ["piglets", "ORGANISM", 72, 79], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 57, 62], ["piglets", "SPECIES", 72, 79], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 57, 62], ["PRRSV infection", "PROBLEM", 0, 15], ["PAMs", "PROBLEM", 47, 51], ["PRRSV", "PROBLEM", 57, 62], ["infection", "OBSERVATION", 6, 15], ["lungs", "ANATOMY", 37, 42], ["PAMs", "OBSERVATION", 47, 51], ["infected piglets", "OBSERVATION", 63, 79]]], ["Collectively, these data indicate that PRRSV infection remarkably induces IL-8 production both in vivo and in vitro.JNK and NF-\u03baB signaling pathways are required for PRRSV induced IL-8 expressionTo dissect the signaling pathways involved in PRRSV-induced IL-8 production, PAMs were pretreated for 1 h with the inhibitors of the key signaling pathways, including JNK, NF-\u03baB, MEK, p38 MAPK, PI3K and PKC before PRRSV infection.", [["PRRSV infection", "DISEASE", 39, 54], ["PRRSV infection", "DISEASE", 409, 424], ["PRRSV", "ORGANISM", 39, 44], ["IL-8", "GENE_OR_GENE_PRODUCT", 74, 78], ["JNK", "GENE_OR_GENE_PRODUCT", 116, 119], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 124, 129], ["PRRSV", "ORGANISM", 166, 171], ["IL-8", "GENE_OR_GENE_PRODUCT", 180, 184], ["PRRSV", "ORGANISM", 241, 246], ["IL-8", "GENE_OR_GENE_PRODUCT", 255, 259], ["PAMs", "CELL", 272, 276], ["JNK", "GENE_OR_GENE_PRODUCT", 362, 365], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 367, 372], ["MEK", "GENE_OR_GENE_PRODUCT", 374, 377], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 379, 387], ["PI3K", "GENE_OR_GENE_PRODUCT", 389, 393], ["PKC", "GENE_OR_GENE_PRODUCT", 398, 401], ["PRRSV", "ORGANISM", 409, 414], ["IL-8", "PROTEIN", 74, 78], ["JNK", "PROTEIN", 116, 119], ["NF-\u03baB", "PROTEIN", 124, 129], ["IL-8", "PROTEIN", 180, 184], ["PAMs", "CELL_TYPE", 272, 276], ["JNK", "PROTEIN", 362, 365], ["NF-\u03baB", "PROTEIN", 367, 372], ["MEK", "PROTEIN", 374, 377], ["p38 MAPK", "PROTEIN", 379, 387], ["PI3K", "PROTEIN", 389, 393], ["PKC", "PROTEIN", 398, 401], ["PRRSV", "SPECIES", 39, 44], ["PRRSV", "SPECIES", 166, 171], ["PRRSV", "SPECIES", 241, 246], ["PRRSV", "SPECIES", 409, 414], ["these data", "TEST", 14, 24], ["PRRSV infection", "PROBLEM", 39, 54], ["IL", "TEST", 74, 76], ["JNK", "TEST", 116, 119], ["NF", "TEST", 124, 126], ["PRRSV induced IL", "TREATMENT", 166, 182], ["the signaling pathways", "PROBLEM", 206, 228], ["PRRSV", "PROBLEM", 241, 246], ["PAMs", "PROBLEM", 272, 276], ["the inhibitors", "TREATMENT", 306, 320], ["JNK", "TEST", 362, 365], ["NF", "TEST", 367, 369], ["MEK", "TEST", 374, 377], ["p38 MAPK", "TEST", 379, 387], ["PI3K", "TEST", 389, 393], ["PKC", "TEST", 398, 401], ["PRRSV infection", "PROBLEM", 409, 424], ["PRRSV infection", "OBSERVATION", 39, 54], ["infection", "OBSERVATION", 415, 424]]], ["Twenty-four hours later, the expression of IL-8 mRNA was analyzed.", [["IL-8", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-8 mRNA", "RNA", 43, 52], ["IL-8 mRNA", "TREATMENT", 43, 52]]], ["As shown in Fig. 2A , inhibitors of JNK (SP60125), p38 (SB203580), and NF-\u03baB (BAY11-7082) significantly inhibited IL-8 production induced by HV by 70%, 50%, and 90%, respectively.", [["SB203580", "CHEMICAL", 56, 64], ["BAY11-7082", "CHEMICAL", 78, 88], ["SP60125", "CHEMICAL", 41, 48], ["SB203580", "CHEMICAL", 56, 64], ["BAY11-7082", "CHEMICAL", 78, 88], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["JNK", "GENE_OR_GENE_PRODUCT", 36, 39], ["SP60125", "SIMPLE_CHEMICAL", 41, 48], ["p38", "GENE_OR_GENE_PRODUCT", 51, 54], ["SB203580", "SIMPLE_CHEMICAL", 56, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 71, 76], ["BAY11-7082", "SIMPLE_CHEMICAL", 78, 88], ["IL-8", "GENE_OR_GENE_PRODUCT", 114, 118], ["JNK", "PROTEIN", 36, 39], ["p38", "PROTEIN", 51, 54], ["NF-\u03baB", "PROTEIN", 71, 76], ["IL-8", "PROTEIN", 114, 118], ["JNK", "TEST", 36, 39], ["p38", "TEST", 51, 54], ["SB203580", "TEST", 56, 64], ["NF", "TEST", 71, 73], ["\u03baB", "TEST", 74, 76], ["BAY11", "TEST", 78, 83], ["IL", "TEST", 114, 116], ["HV", "TEST", 141, 143]]], ["While inhibition of MEK (PD98059), PKC (GF109203X) or PI3K (LY294002) only slightly decreased IL-8 mRNA expression.", [["PD98059", "CHEMICAL", 25, 32], ["GF109203X", "CHEMICAL", 40, 49], ["LY294002", "CHEMICAL", 60, 68], ["PD98059", "CHEMICAL", 25, 32], ["GF109203X", "CHEMICAL", 40, 49], ["LY294002", "CHEMICAL", 60, 68], ["MEK", "GENE_OR_GENE_PRODUCT", 20, 23], ["PD98059", "SIMPLE_CHEMICAL", 25, 32], ["PKC", "GENE_OR_GENE_PRODUCT", 35, 38], ["GF109203X", "SIMPLE_CHEMICAL", 40, 49], ["PI3K", "GENE_OR_GENE_PRODUCT", 54, 58], ["LY294002", "SIMPLE_CHEMICAL", 60, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 94, 98], ["MEK", "PROTEIN", 20, 23], ["PKC", "PROTEIN", 35, 38], ["PI3K", "PROTEIN", 54, 58], ["IL-8 mRNA", "RNA", 94, 103], ["MEK (PD98059", "TREATMENT", 20, 32], ["PKC (GF109203X", "TREATMENT", 35, 49], ["PI3K (LY294002", "TREATMENT", 54, 68], ["slightly decreased IL", "PROBLEM", 75, 96], ["slightly", "OBSERVATION_MODIFIER", 75, 83], ["decreased", "OBSERVATION_MODIFIER", 84, 93]]], ["These findings suggest that the JNK and NF-\u03baB pathways might be involved in PRRSV-induced IL-8 production.", [["JNK", "GENE_OR_GENE_PRODUCT", 32, 35], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["PRRSV", "ORGANISM", 76, 81], ["IL-8", "GENE_OR_GENE_PRODUCT", 90, 94], ["JNK", "PROTEIN", 32, 35], ["NF-\u03baB", "PROTEIN", 40, 45], ["PRRSV", "SPECIES", 76, 81], ["the JNK", "TEST", 28, 35], ["NF", "TEST", 40, 42], ["PRRSV", "PROBLEM", 76, 81]]], ["To confirm this, PAMs were treated with JNK inhibitor and NF-\u03baB inhibitor at different concentrations before PRRSV infection.", [["PRRSV infection", "DISEASE", 109, 124], ["PAMs", "CELL", 17, 21], ["JNK", "GENE_OR_GENE_PRODUCT", 40, 43], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 58, 63], ["PRRSV", "ORGANISM", 109, 114], ["PAMs", "CELL_TYPE", 17, 21], ["JNK", "PROTEIN", 40, 43], ["NF-\u03baB", "PROTEIN", 58, 63], ["PRRSV", "SPECIES", 109, 114], ["PAMs", "PROBLEM", 17, 21], ["JNK inhibitor", "TREATMENT", 40, 53], ["NF-\u03baB inhibitor", "TREATMENT", 58, 73], ["PRRSV infection", "PROBLEM", 109, 124], ["infection", "OBSERVATION", 115, 124]]], ["As shown in Fig. 2B , the inhibitory effects of both inhibitors were in a dose dependent manner.", [["both inhibitors", "TREATMENT", 48, 63]]], ["In addition, they also impaired IL-8 protein secretion (Fig. 2C) .", [["IL-8", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL-8 protein", "PROTEIN", 32, 44]]], ["We also analyzed PRRSV replication in the presence of JNK and NF-\u03baB inhibitors.", [["PRRSV", "ORGANISM", 17, 22], ["JNK", "GENE_OR_GENE_PRODUCT", 54, 57], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 62, 67], ["JNK", "PROTEIN", 54, 57], ["NF-\u03baB", "PROTEIN", 62, 67], ["PRRSV", "SPECIES", 17, 22], ["PRRSV replication", "TREATMENT", 17, 34], ["JNK", "TEST", 54, 57], ["NF", "TREATMENT", 62, 64], ["B inhibitors", "TREATMENT", 66, 78], ["PRRSV replication", "OBSERVATION", 17, 34]]], ["Our results showed that JNK and NF-\u03baB inhibitors at the used concentrations did not affect PRRSV replication (Fig. 2D ).", [["JNK", "GENE_OR_GENE_PRODUCT", 24, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 32, 37], ["PRRSV", "ORGANISM", 91, 96], ["JNK", "PROTEIN", 24, 27], ["PRRSV", "SPECIES", 91, 96], ["JNK", "TEST", 24, 27], ["NF-\u03baB inhibitors", "TREATMENT", 32, 48]]], ["To further investigate whether JNK and NF-\u03baB signaling pathways are activated in PRRSV-infected PAMs, JNK and I\u03baB phosphorylations were analyzed by western blot.", [["JNK", "GENE_OR_GENE_PRODUCT", 31, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 39, 44], ["PRRSV", "ORGANISM", 81, 86], ["PAMs", "CELL", 96, 100], ["JNK", "GENE_OR_GENE_PRODUCT", 102, 105], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 110, 113], ["JNK", "PROTEIN", 31, 34], ["NF-\u03baB", "PROTEIN", 39, 44], ["JNK", "PROTEIN", 102, 105], ["I\u03baB", "PROTEIN", 110, 113], ["PRRSV", "SPECIES", 81, 86], ["JNK", "TEST", 31, 34], ["NF", "TEST", 39, 41], ["B signaling pathways", "PROBLEM", 43, 63], ["PRRSV", "PROBLEM", 81, 86], ["infected PAMs", "PROBLEM", 87, 100], ["JNK", "TEST", 102, 105], ["I\u03baB phosphorylations", "TREATMENT", 110, 130], ["infected PAMs", "OBSERVATION", 87, 100]]], ["As shown in Fig. 2E and F, the phosphorylated JNK and I\u03baB were significantly increased at 12 h and 24 h post infection.", [["infection", "DISEASE", 109, 118], ["JNK", "GENE_OR_GENE_PRODUCT", 46, 49], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 54, 57], ["phosphorylated JNK", "PROTEIN", 31, 49], ["I\u03baB", "PROTEIN", 54, 57], ["the phosphorylated JNK", "TEST", 27, 49], ["I\u03baB", "TEST", 54, 57], ["infection", "PROBLEM", 109, 118], ["infection", "OBSERVATION", 109, 118]]], ["Meanwhile, I\u03baB was gradually degraded in PRRSV- infected cells.", [["cells", "ANATOMY", 57, 62], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 11, 14], ["PRRSV", "ORGANISM", 41, 46], ["cells", "CELL", 57, 62], ["I\u03baB", "PROTEIN", 11, 14], ["PRRSV- infected cells", "CELL_LINE", 41, 62], ["PRRSV", "SPECIES", 41, 46], ["infected cells", "OBSERVATION", 48, 62]]], ["Together, these results suggest that PRRSV infection induces IL-8 production by activating the JNK and NF-\u03baB pathways.JNK and NF-\u03baB signaling pathways are required for PRRSV induced IL-8 expression2.3.", [["PRRSV infection", "DISEASE", 37, 52], ["PRRSV", "ORGANISM", 37, 42], ["IL-8", "GENE_OR_GENE_PRODUCT", 61, 65], ["JNK", "GENE_OR_GENE_PRODUCT", 95, 98], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 103, 108], ["JNK", "GENE_OR_GENE_PRODUCT", 118, 121], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 126, 131], ["PRRSV", "ORGANISM", 168, 173], ["IL-8", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-8", "PROTEIN", 61, 65], ["JNK", "PROTEIN", 95, 98], ["NF-\u03baB", "PROTEIN", 103, 108], ["JNK", "PROTEIN", 118, 121], ["NF-\u03baB", "PROTEIN", 126, 131], ["IL-8 expression2.3", "PROTEIN", 182, 200], ["PRRSV", "SPECIES", 37, 42], ["PRRSV", "SPECIES", 168, 173], ["PRRSV infection", "PROBLEM", 37, 52], ["JNK", "TEST", 118, 121], ["NF", "TEST", 126, 128], ["PRRSV induced IL", "TREATMENT", 168, 184], ["PRRSV", "OBSERVATION_MODIFIER", 37, 42], ["infection", "OBSERVATION", 43, 52]]], ["TAK-1 is essential for PRRSV-activated JNK and NF-\u03baB signaling pathways Upon inflammatory stimulation, TAK-1 is activated and subsequently activates MAPK and NF-\u03baB signaling pathways.", [["TAK-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRRSV", "ORGANISM", 23, 28], ["JNK", "GENE_OR_GENE_PRODUCT", 39, 42], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 47, 52], ["TAK-1", "GENE_OR_GENE_PRODUCT", 103, 108], ["MAPK", "GENE_OR_GENE_PRODUCT", 149, 153], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 158, 163], ["TAK-1", "PROTEIN", 0, 5], ["JNK", "PROTEIN", 39, 42], ["NF-\u03baB", "PROTEIN", 47, 52], ["TAK-1", "PROTEIN", 103, 108], ["MAPK", "PROTEIN", 149, 153], ["NF-\u03baB", "PROTEIN", 158, 163], ["PRRSV", "SPECIES", 23, 28], ["PRRSV", "PROBLEM", 23, 28], ["NF", "TEST", 47, 49], ["inflammatory stimulation", "TREATMENT", 77, 101], ["MAPK", "TEST", 149, 153], ["NF", "TEST", 158, 160], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89]]], ["To investigate whether TAK-1 participates in PRRSV-induced IL-8 expression, PAMs were pretreated with TAK-1 inhibitor (5Z)-7-Oxozeaenol at different concentrations 1 h before PRRSV infection, and then IL-8 mRNA expression and protein production were analyzed.", [["TAK-1 inhibitor", "CHEMICAL", 102, 117], ["5Z)-7-Oxozeaenol", "CHEMICAL", 119, 135], ["PRRSV infection", "DISEASE", 175, 190], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 118, 135], ["TAK-1", "GENE_OR_GENE_PRODUCT", 23, 28], ["PRRSV", "ORGANISM", 45, 50], ["IL-8", "GENE_OR_GENE_PRODUCT", 59, 63], ["PAMs", "CELL", 76, 80], ["TAK-1", "GENE_OR_GENE_PRODUCT", 102, 107], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 118, 135], ["PRRSV", "ORGANISM", 175, 180], ["IL-8", "GENE_OR_GENE_PRODUCT", 201, 205], ["TAK-1", "PROTEIN", 23, 28], ["IL-8", "PROTEIN", 59, 63], ["PAMs", "CELL_TYPE", 76, 80], ["PRRSV", "SPECIES", 45, 50], ["PRRSV", "SPECIES", 175, 180], ["PRRSV-induced IL", "TREATMENT", 45, 61], ["PAMs", "PROBLEM", 76, 80], ["TAK-1 inhibitor", "TREATMENT", 102, 117], ["Oxozeaenol", "TREATMENT", 125, 135], ["PRRSV infection", "PROBLEM", 175, 190], ["IL", "TREATMENT", 201, 203], ["infection", "OBSERVATION", 181, 190]]], ["As shown in Fig. 3A and B, PRRSV-induced IL-8 expression was inhibited by (5Z)-7-Oxozeaenol in a dose dependent meaner.", [["(5Z)-7-Oxozeaenol", "CHEMICAL", 74, 91], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 74, 91], ["B", "GENE_OR_GENE_PRODUCT", 24, 25], ["PRRSV", "ORGANISM", 27, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 41, 45], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 74, 91], ["IL-8", "PROTEIN", 41, 45], ["PRRSV", "SPECIES", 27, 32], ["PRRSV-induced IL", "TREATMENT", 27, 43], ["Oxozeaenol", "TREATMENT", 81, 91], ["Fig", "OBSERVATION", 12, 15]]], ["(5Z)-7-Oxozeaenol also down-regulated IL-8 protein production by about 47%.", [["5Z)-7-Oxozeaenol", "CHEMICAL", 1, 17], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 0, 17], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 0, 17], ["IL-8", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-8", "PROTEIN", 38, 42], ["Oxozeaenol", "TREATMENT", 7, 17]]], ["(5Z)-7-Oxozeaenol did not affect PRRSV replication (Fig. 3C) .", [["5Z)-7-Oxozeaenol", "CHEMICAL", 1, 17], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 0, 17], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 0, 17], ["PRRSV", "ORGANISM", 33, 38], ["PRRSV", "SPECIES", 33, 38], ["Oxozeaenol", "TREATMENT", 7, 17]]], ["These results suggest that TAK-1 is essential for IL-8 production induced by PRRSV.", [["TAK-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 50, 54], ["PRRSV", "ORGANISM", 77, 82], ["TAK", "PROTEIN", 27, 30], ["IL-8", "PROTEIN", 50, 54], ["PRRSV", "SPECIES", 77, 82], ["PRRSV", "PROBLEM", 77, 82]]], ["To further verify this, we investigated whether TAK-1 signaling pathway was activated in PRRSV-infected PAMs.", [["TAK-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["PRRSV", "ORGANISM", 89, 94], ["PAMs", "CELL", 104, 108], ["TAK", "PROTEIN", 48, 51], ["PRRSV", "SPECIES", 89, 94], ["infected PAMs", "PROBLEM", 95, 108], ["infected PAMs", "OBSERVATION", 95, 108]]], ["As shown in Fig. 3D , TAK-1 phosphorylation was significantly up-regulated by PRRSV infection.", [["PRRSV infection", "DISEASE", 78, 93], ["TAK-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["PRRSV", "ORGANISM", 78, 83], ["TAK", "PROTEIN", 22, 25], ["PRRSV", "SPECIES", 78, 83], ["TAK-1 phosphorylation", "TEST", 22, 43], ["PRRSV infection", "PROBLEM", 78, 93], ["Fig", "OBSERVATION", 12, 15], ["PRRSV infection", "OBSERVATION", 78, 93]]], ["Next, to study whether JNK activation is through TAK-1, PAMs were pretreated with (5Z)-7-Oxozeaenol at different concentrations 1 h before PRRSV infection, and then JNK and I\u03baB phosphorylations were analyzed.", [["(5Z)-7-Oxozeaenol", "CHEMICAL", 82, 99], ["PRRSV infection", "DISEASE", 139, 154], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 82, 99], ["JNK", "GENE_OR_GENE_PRODUCT", 23, 26], ["TAK-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["PAMs", "CELL", 56, 60], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 82, 99], ["PRRSV", "ORGANISM", 139, 144], ["JNK", "GENE_OR_GENE_PRODUCT", 165, 168], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 173, 176], ["JNK", "PROTEIN", 23, 26], ["TAK", "PROTEIN", 49, 52], ["JNK", "PROTEIN", 165, 168], ["I\u03baB", "PROTEIN", 173, 176], ["PRRSV", "SPECIES", 139, 144], ["JNK activation", "TEST", 23, 37], ["PAMs", "PROBLEM", 56, 60], ["Oxozeaenol", "TREATMENT", 89, 99], ["PRRSV infection", "PROBLEM", 139, 154], ["JNK and I\u03baB phosphorylations", "TEST", 165, 193], ["infection", "OBSERVATION", 145, 154]]], ["As shown in Fig. 3E and F, phosphorylations of JNK and I\u03baB were inhibited by (5Z)-7-Oxozeaenol, suggesting that TAK-1 is required for PRRSV-induced JNK and NF-\u03baB pathway activations.AP-1 is critical for IL-8 expressionTo study the mechanisms underlying the transcriptional regulation of PRRSV-induced IL-8 production, a 2751-bp fragment flanking the 5\u2032 region of porcine IL-8 gene was cloned.", [["(5Z)-7-Oxozeaenol", "CHEMICAL", 77, 94], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 77, 94], ["JNK", "GENE_OR_GENE_PRODUCT", 47, 50], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 55, 58], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 77, 94], ["TAK-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["PRRSV", "ORGANISM", 134, 139], ["JNK", "GENE_OR_GENE_PRODUCT", 148, 151], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 156, 161], ["AP-1", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-8", "GENE_OR_GENE_PRODUCT", 203, 207], ["PRRSV", "ORGANISM", 287, 292], ["IL-8", "GENE_OR_GENE_PRODUCT", 301, 305], ["porcine", "ORGANISM", 363, 370], ["IL-8", "GENE_OR_GENE_PRODUCT", 371, 375], ["JNK", "PROTEIN", 47, 50], ["I\u03baB", "PROTEIN", 55, 58], ["TAK", "PROTEIN", 112, 115], ["JNK", "PROTEIN", 148, 151], ["NF-\u03baB", "PROTEIN", 156, 161], ["AP", "PROTEIN", 182, 184], ["IL-8", "PROTEIN", 203, 207], ["IL", "PROTEIN", 301, 303], ["2751-bp fragment", "DNA", 320, 336], ["5\u2032 region", "DNA", 350, 359], ["porcine IL-8 gene", "DNA", 363, 380], ["PRRSV", "SPECIES", 134, 139], ["PRRSV", "SPECIES", 287, 292], ["JNK", "TEST", 47, 50], ["Oxozeaenol", "TREATMENT", 84, 94], ["PRRSV", "PROBLEM", 134, 139], ["PRRSV", "PROBLEM", 287, 292], ["bp fragment flanking", "TREATMENT", 325, 345], ["porcine IL", "TREATMENT", 363, 373], ["Fig", "OBSERVATION", 12, 15]]], ["Using the bioinformatics approach (http://www.cbrc.jp/research/db/TFSEARCH.html), several putative transcriptional regulatory elements were found in the 5\u2032flanking region of the pIL-8 gene, including CREB, C/EBP \u03b2, AP-1, OCT-1, and NF-\u03baB.", [["pIL-8", "GENE_OR_GENE_PRODUCT", 178, 183], ["CREB", "GENE_OR_GENE_PRODUCT", 200, 204], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 206, 213], ["AP-1", "GENE_OR_GENE_PRODUCT", 215, 219], ["OCT-1", "GENE_OR_GENE_PRODUCT", 221, 226], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 232, 238], ["putative transcriptional regulatory elements", "DNA", 90, 134], ["5\u2032flanking region", "DNA", 153, 170], ["pIL-8 gene", "DNA", 178, 188], ["CREB", "PROTEIN", 200, 204], ["C/EBP \u03b2", "DNA", 206, 213], ["AP-1", "DNA", 215, 219], ["OCT-1", "DNA", 221, 226], ["NF", "DNA", 232, 234], ["the bioinformatics approach", "TEST", 6, 33], ["several putative transcriptional regulatory elements", "PROBLEM", 82, 134], ["the pIL", "TEST", 174, 181], ["CREB", "TEST", 200, 204], ["C/EBP", "TEST", 206, 211], ["AP", "TEST", 215, 217], ["OCT", "TEST", 221, 224], ["NF", "TEST", 232, 234], ["regulatory elements", "OBSERVATION", 115, 134]]], ["To evaluate the porcine IL-8 promoter activity and determine the region responsive to PRRSV infection, serial deletions starting from the 5\u2032-end of the promoter were generated and schematically shown in Fig. 4A .", [["PRRSV infection", "DISEASE", 86, 101], ["porcine", "ORGANISM", 16, 23], ["IL-8", "GENE_OR_GENE_PRODUCT", 24, 28], ["PRRSV", "ORGANISM", 86, 91], ["porcine IL-8 promoter", "DNA", 16, 37], ["5\u2032-end", "DNA", 138, 144], ["promoter", "DNA", 152, 160], ["PRRSV", "SPECIES", 86, 91], ["the porcine IL-8 promoter activity", "TREATMENT", 12, 46], ["PRRSV infection", "PROBLEM", 86, 101], ["serial deletions", "PROBLEM", 103, 119], ["PRRSV infection", "OBSERVATION", 86, 101]]], ["Luciferase reporter vectors were constructed, and then transfected into Marc-145 cells.", [["Marc-145 cells", "ANATOMY", 72, 86], ["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["Marc-145 cells", "CELL", 72, 86], ["Luciferase reporter vectors", "DNA", 0, 27], ["Marc-145 cells", "CELL_LINE", 72, 86], ["Luciferase reporter vectors", "TREATMENT", 0, 27]]], ["The luciferase activities were assessed with or without PRRSV infection.", [["PRRSV infection", "DISEASE", 56, 71], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["PRRSV", "ORGANISM", 56, 61], ["luciferase", "PROTEIN", 4, 14], ["PRRSV", "SPECIES", 56, 61], ["The luciferase activities", "TEST", 0, 25], ["PRRSV infection", "PROBLEM", 56, 71], ["infection", "OBSERVATION", 62, 71]]], ["Our results showed that deletion construct \u2212187/123-luc exhibited a 66% upregulation after PRRSV infection, while other constructs were not upregulated by virus infection (Fig. 4B ).", [["PRRSV infection", "DISEASE", 91, 106], ["infection", "DISEASE", 161, 170], ["luc", "GENE_OR_GENE_PRODUCT", 52, 55], ["PRRSV", "ORGANISM", 91, 96], ["deletion construct \u2212187/123-luc", "DNA", 24, 55], ["PRRSV", "SPECIES", 91, 96], ["deletion construct", "TEST", 24, 42], ["luc", "TEST", 52, 55], ["PRRSV infection", "PROBLEM", 91, 106], ["virus infection", "PROBLEM", 155, 170], ["infection", "OBSERVATION", 97, 106]]], ["When the promoter was truncated to \u2212108/123 and \u221276/123, the basal-level luciferase activity was low and there were no significant changes for the luciferase activity after PRRSV infection.", [["PRRSV infection", "DISEASE", 173, 188], ["\u2212108/123", "GENE_OR_GENE_PRODUCT", 35, 43], ["\u221276/123", "GENE_OR_GENE_PRODUCT", 48, 55], ["luciferase", "GENE_OR_GENE_PRODUCT", 73, 83], ["luciferase", "GENE_OR_GENE_PRODUCT", 147, 157], ["PRRSV", "ORGANISM", 173, 178], ["luciferase", "PROTEIN", 73, 83], ["luciferase", "PROTEIN", 147, 157], ["PRRSV", "SPECIES", 173, 178], ["the basal-level luciferase activity", "TEST", 57, 92], ["significant changes", "PROBLEM", 119, 138], ["the luciferase activity", "PROBLEM", 143, 166], ["PRRSV infection", "PROBLEM", 173, 188], ["basal", "ANATOMY_MODIFIER", 61, 66], ["no", "UNCERTAINTY", 116, 118], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["infection", "OBSERVATION", 179, 188]]], ["This observation suggests that the regulatory elements might exist in the region from \u2212187 to \u221276 bp in porcine IL-8 promoter and the responsive elements could be the putative AP-1 (\u2212138 to \u2212130)\uff0cC/EBP \u03b2 (\u2212107 to \u221290) and/or NF-\u03baB (\u221292 to \u221282).", [["IL-8", "GENE_OR_GENE_PRODUCT", 112, 116], ["AP-1", "GENE_OR_GENE_PRODUCT", 176, 180], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 196, 203], ["\u2212107 to \u221290", "GENE_OR_GENE_PRODUCT", 205, 216], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 225, 230], ["regulatory elements", "DNA", 35, 54], ["\u2212187 to \u221276 bp", "DNA", 86, 100], ["porcine IL-8 promoter", "DNA", 104, 125], ["responsive elements", "DNA", 134, 153], ["AP-1", "DNA", 176, 180], ["EBP \u03b2", "PROTEIN", 198, 203], ["NF-\u03baB", "PROTEIN", 225, 230], ["This observation", "TEST", 0, 16], ["the regulatory elements", "PROBLEM", 31, 54], ["bp in porcine IL", "TEST", 98, 114], ["the putative AP", "TEST", 163, 178], ["EBP \u03b2", "TEST", 198, 203], ["NF", "TEST", 225, 227], ["\u03baB", "TEST", 228, 230]]], ["We then deleted each of AP-1, NF-\u03baB and C/EBP \u03b2, two or all three of the binding sites from \u2212108/123-luc to generate new mutation vectors (Fig. 4C) .", [["AP-1", "GENE_OR_GENE_PRODUCT", 24, 28], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 30, 35], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 40, 47], ["luc", "GENE_OR_GENE_PRODUCT", 101, 104], ["AP", "PROTEIN", 24, 26], ["NF-\u03baB", "PROTEIN", 30, 35], ["C/EBP \u03b2", "DNA", 40, 47], ["binding sites", "DNA", 73, 86], ["\u2212108/123-luc", "DNA", 92, 104], ["AP", "TEST", 24, 26], ["NF", "TEST", 30, 32], ["C/EBP", "TREATMENT", 40, 45], ["new mutation vectors", "TREATMENT", 117, 137]]], ["Luciferase results showed that mutations with AP-1 binding site deletion significantly impaired IL-8 promoter activation (Fig. 4D ), suggesting that AP-1 biding site in porcine IL-8 promoter is the main responsive element for PRRSV infection.AP-1 is critical for IL-8 expressionThe transcription factor AP-1 has been extensively studied and believed to contribute to the production of pro-inflammatory cytokines and chemokines (Liu et al., 2007; Rahman et al., 2011) .", [["PRRSV infection", "DISEASE", 226, 241], ["AP-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-8", "GENE_OR_GENE_PRODUCT", 96, 100], ["AP-1", "GENE_OR_GENE_PRODUCT", 149, 153], ["porcine", "ORGANISM", 169, 176], ["IL-8", "GENE_OR_GENE_PRODUCT", 177, 181], ["PRRSV", "ORGANISM", 226, 231], ["AP-1", "GENE_OR_GENE_PRODUCT", 242, 246], ["IL-8", "GENE_OR_GENE_PRODUCT", 263, 267], ["AP-1", "GENE_OR_GENE_PRODUCT", 303, 307], ["AP-1 binding site", "DNA", 46, 63], ["IL-8 promoter", "DNA", 96, 109], ["AP-1 biding site", "DNA", 149, 165], ["porcine IL-8 promoter", "DNA", 169, 190], ["AP", "PROTEIN", 242, 244], ["IL-8", "PROTEIN", 263, 267], ["transcription factor", "PROTEIN", 282, 302], ["AP-1", "PROTEIN", 303, 307], ["pro-inflammatory cytokines", "PROTEIN", 385, 411], ["chemokines", "PROTEIN", 416, 426], ["PRRSV", "SPECIES", 226, 231], ["Luciferase results", "TEST", 0, 18], ["mutations with AP-1 binding site deletion", "PROBLEM", 31, 72], ["impaired IL", "PROBLEM", 87, 98], ["AP-1 biding site in porcine IL", "TREATMENT", 149, 179], ["PRRSV infection", "PROBLEM", 226, 241], ["The transcription factor AP", "TEST", 278, 305], ["pro-inflammatory cytokines", "PROBLEM", 385, 411], ["PRRSV infection", "OBSERVATION", 226, 241], ["pro-inflammatory cytokines", "OBSERVATION", 385, 411]]], ["AP-1 is a dimeric complex of c-Jun and c-Fos.", [["AP-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["c-Jun", "GENE_OR_GENE_PRODUCT", 29, 34], ["c-Fos", "GENE_OR_GENE_PRODUCT", 39, 44], ["AP", "PROTEIN", 0, 2], ["dimeric complex", "PROTEIN", 10, 25], ["c-Jun and c-Fos", "PROTEIN", 29, 44]]], ["To further evaluate the role of AP-1 in IL-8 induction by PRRSV infection, PAMs were pretreated with the c-Jun inhibitor SR11302 1 h before PRRSV infection.", [["PRRSV infection", "DISEASE", 58, 73], ["SR11302", "CHEMICAL", 121, 128], ["PRRSV infection", "DISEASE", 140, 155], ["SR11302", "CHEMICAL", 121, 128], ["AP-1", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 40, 44], ["PRRSV", "ORGANISM", 58, 63], ["PAMs", "CELL", 75, 79], ["c-Jun", "GENE_OR_GENE_PRODUCT", 105, 110], ["PRRSV", "ORGANISM", 140, 145], ["AP", "PROTEIN", 32, 34], ["IL-8", "PROTEIN", 40, 44], ["PAMs", "CELL_TYPE", 75, 79], ["Jun", "PROTEIN", 107, 110], ["PRRSV", "SPECIES", 58, 63], ["PRRSV", "SPECIES", 140, 145], ["AP", "TEST", 32, 34], ["PRRSV infection", "PROBLEM", 58, 73], ["PAMs", "PROBLEM", 75, 79], ["the c-Jun inhibitor SR", "TREATMENT", 101, 123], ["PRRSV infection", "PROBLEM", 140, 155], ["infection", "OBSERVATION", 64, 73], ["infection", "OBSERVATION", 146, 155]]], ["Twenty-four hours later, IL-8 production was analyzed.", [["IL-8", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL", "PROTEIN", 25, 27], ["IL-8 production", "TREATMENT", 25, 40]]], ["Our results showed that c-Jun inhibitor remarkably suppressed IL-8 production both at mRNA (B) PAMs were pretreated with TAK-1 inhibitor at 1 \u03bcM.", [["c-Jun", "GENE_OR_GENE_PRODUCT", 24, 29], ["IL-8", "GENE_OR_GENE_PRODUCT", 62, 66], ["TAK-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["Jun", "PROTEIN", 26, 29], ["IL-8", "PROTEIN", 62, 66], ["c-Jun inhibitor", "TREATMENT", 24, 39], ["IL", "TEST", 62, 64], ["TAK-1 inhibitor", "TREATMENT", 121, 136]]], ["IL-8 production in cell supernatants was detected at 24 hpi using ELISA.", [["cell supernatants", "ANATOMY", 19, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 19, 23], ["IL-8", "PROTEIN", 0, 4], ["IL", "TREATMENT", 0, 2], ["ELISA", "TEST", 66, 71]]], ["(C) PAMs were pretreated with 1 \u03bcM (5Z)-7-Oxozeaenol or DMSO for 1 h, and then cells were inoculated with or without PRRSV (MOI=0.1).", [["cells", "ANATOMY", 79, 84], ["5Z)-7-Oxozeaenol", "CHEMICAL", 36, 52], ["DMSO", "CHEMICAL", 56, 60], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 35, 52], ["DMSO", "CHEMICAL", 56, 60], ["5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 36, 52], ["DMSO", "SIMPLE_CHEMICAL", 56, 60], ["cells", "CELL", 79, 84], ["PRRSV", "ORGANISM", 117, 122], ["PRRSV", "SPECIES", 117, 122], ["PAMs", "PROBLEM", 4, 8], ["1 \u03bcM (5Z)", "TREATMENT", 30, 39], ["Oxozeaenol", "TREATMENT", 42, 52], ["DMSO", "TREATMENT", 56, 60], ["PRRSV", "PROBLEM", 117, 122]]], ["Twenty-four hours later, PRRSV ORF-7 mRNA was analyzed by real-time PCR.", [["PRRSV", "ORGANISM", 25, 30], ["ORF-7", "GENE_OR_GENE_PRODUCT", 31, 36], ["PRRSV ORF-7 mRNA", "RNA", 25, 41], ["PRRSV", "SPECIES", 25, 30], ["PRRSV ORF", "TEST", 25, 34]]], ["(D) PAMs were inoculated with PRRSV (MOI=0.1).", [["PRRSV", "ORGANISM", 30, 35], ["PRRSV", "SPECIES", 30, 35], ["PAMs", "PROBLEM", 4, 8], ["PRRSV", "PROBLEM", 30, 35], ["MOI", "TEST", 37, 40]]], ["Cells were then harvested at 6, 12, 24, and 36 h for p-TAK-1 and TAK-1 analysis by Western blotting.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["TAK-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["TAK-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["TAK", "PROTEIN", 55, 58], ["TAK", "PROTEIN", 65, 68], ["Cells", "TEST", 0, 5], ["p-TAK", "TEST", 53, 58]]], ["(E) PAMs were pretreated with the TAK-1 inhibitor at doses of 1 or 2 \u03bcM for 1 h, and then infected with HP-PRRSV (MOI=0.1).", [["TAK-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["HP-PRRSV", "ORGANISM", 104, 112], ["PAMs", "PROBLEM", 4, 8], ["the TAK-1 inhibitor", "TREATMENT", 30, 49], ["MOI", "TEST", 114, 117]]], ["At 24 hpi, cells were harvested for p-JNK and JNK analysis by Western blotting.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["JNK", "GENE_OR_GENE_PRODUCT", 38, 41], ["JNK", "GENE_OR_GENE_PRODUCT", 46, 49], ["JNK", "PROTEIN", 38, 41], ["JNK", "PROTEIN", 46, 49], ["JNK analysis", "TEST", 46, 58]]], ["(F) PAMs were pretreated with the TAK-1 inhibitor at doses of 0.1, 0.5, 1 or 2 \u03bcM for 1 h, and then infected with HV (MOI=0.1).", [["TAK-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["PAMs", "PROBLEM", 4, 8], ["the TAK-1 inhibitor", "TREATMENT", 30, 49], ["HV (MOI", "TREATMENT", 114, 121]]], ["At 24 hpi, cells were harvested for p-I\u03baB and I\u03baB analysis by Western blotting.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["p-I\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 46, 49], ["I\u03baB", "PROTEIN", 38, 41], ["I\u03baB", "PROTEIN", 46, 49], ["I\u03baB analysis", "TEST", 46, 58]]], ["Differences were evaluated by Student's t-test (, P < 0.05). and protein levels induced by PRRSV ( Fig. 5A and B) .", [["B", "GENE_OR_GENE_PRODUCT", 111, 112], ["PRRSV", "SPECIES", 91, 96], ["Student's t-test", "TEST", 30, 46], ["protein levels", "TEST", 65, 79]]], ["SR at the used concentrations did not affect PRRSV replication (Fig. 5C) .", [["PRRSV", "ORGANISM", 45, 50], ["PRRSV", "SPECIES", 45, 50]]], ["The role of c-Jun was also confirmed with siRNA knockdown.", [["c-Jun", "GENE_OR_GENE_PRODUCT", 12, 17], ["c-Jun", "PROTEIN", 12, 17], ["c-Jun", "TREATMENT", 12, 17], ["siRNA knockdown", "TREATMENT", 42, 57], ["siRNA knockdown", "OBSERVATION", 42, 57]]], ["PAMs were transfected with specific siRNA targeting c-Jun at 48 h before PRRSV infection, and IL-8 mRNA expression was then analyzed by real-time PCR at 24 hpi.", [["PRRSV infection", "DISEASE", 73, 88], ["PAMs", "CELL", 0, 4], ["c-Jun", "GENE_OR_GENE_PRODUCT", 52, 57], ["PRRSV", "ORGANISM", 73, 78], ["IL-8", "GENE_OR_GENE_PRODUCT", 94, 98], ["PAMs", "CELL_TYPE", 0, 4], ["Jun", "PROTEIN", 54, 57], ["IL-8 mRNA", "RNA", 94, 103], ["PRRSV", "SPECIES", 73, 78], ["PAMs", "PROBLEM", 0, 4], ["PRRSV infection", "PROBLEM", 73, 88], ["IL", "TREATMENT", 94, 96], ["infection", "OBSERVATION", 79, 88]]], ["As shown in Fig. 5D , knockdown of c-Jun significantly decreased the level of IL-8 expression by 49%.", [["c-Jun", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-8", "GENE_OR_GENE_PRODUCT", 78, 82], ["Jun", "PROTEIN", 37, 40], ["IL-8", "PROTEIN", 78, 82], ["IL", "TEST", 78, 80]]], ["Meanwhile, the knockdown efficiency was also confirmed (Fig. 5E) , and knockdown of c-Jun by siRNA did not affect PRRSV replication (Fig. 5F ).", [["c-Jun", "GENE_OR_GENE_PRODUCT", 84, 89], ["PRRSV", "ORGANISM", 114, 119], ["Jun", "PROTEIN", 86, 89], ["PRRSV", "SPECIES", 114, 119], ["the knockdown efficiency", "PROBLEM", 11, 35], ["c-Jun by siRNA", "PROBLEM", 84, 98], ["knockdown efficiency", "OBSERVATION", 15, 35]]], ["Knockdown of c-Fos (Fig. 5H) , the other subunit of AP-1, also suppressed IL-8 mRNA expression (Fig. 5G) .AP-1 is critical for IL-8 expressionTo investigate whether AP-1 pathway is activated in PAMs during the course of PRRSV infection, PAMs were infected with HV at an MOI of 0.5 and the phosphorylation of c-Jun was then evaluated using western blot.", [["PRRSV infection", "DISEASE", 220, 235], ["c-Fos", "GENE_OR_GENE_PRODUCT", 13, 18], ["Fig. 5H", "GENE_OR_GENE_PRODUCT", 20, 27], ["AP-1", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-8", "GENE_OR_GENE_PRODUCT", 74, 78], ["AP-1", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-8", "GENE_OR_GENE_PRODUCT", 127, 131], ["AP-1", "GENE_OR_GENE_PRODUCT", 165, 169], ["PAMs", "CELL", 194, 198], ["PRRSV", "ORGANISM", 220, 225], ["PAMs", "CELL", 237, 241], ["c-Jun", "GENE_OR_GENE_PRODUCT", 308, 313], ["c-Fos (Fig. 5H", "PROTEIN", 13, 27], ["AP", "PROTEIN", 52, 54], ["IL-8 mRNA", "RNA", 74, 83], ["AP", "PROTEIN", 106, 108], ["IL-8", "PROTEIN", 127, 131], ["AP", "PROTEIN", 165, 167], ["PAMs", "CELL_TYPE", 237, 241], ["c", "PROTEIN", 308, 309], ["Jun", "PROTEIN", 310, 313], ["PRRSV", "SPECIES", 220, 225], ["suppressed IL", "TREATMENT", 63, 76], ["PRRSV infection", "PROBLEM", 220, 235], ["PAMs", "PROBLEM", 237, 241], ["an MOI", "TEST", 267, 273], ["the phosphorylation of c-Jun", "TREATMENT", 285, 313], ["infection", "OBSERVATION", 226, 235]]], ["As shown in Fig. 6A , c-Jun phosphorylation was remarkably increased at 12, 24, and 36 hpi.", [["c-Jun", "GENE_OR_GENE_PRODUCT", 22, 27], ["Jun", "PROTEIN", 24, 27], ["c-Jun phosphorylation", "TEST", 22, 43], ["Fig", "OBSERVATION", 12, 15]]], ["Meanwhile, total c-Jun expression was also increased at 6 hpi and kept at high levels through the end of the experiment at 36 hpi. c-Jun activation was also confirmed by phosphorylated c-Jun accumulation in the nucleus (Fig. 6B) .AP-1 is critical for IL-8 expressionPrevious studies have demonstrated that c-Jun is located downstream of JNK.", [["nucleus", "ANATOMY", 211, 218], ["c-Jun", "GENE_OR_GENE_PRODUCT", 17, 22], ["c-Jun", "GENE_OR_GENE_PRODUCT", 131, 136], ["c-Jun", "GENE_OR_GENE_PRODUCT", 185, 190], ["nucleus", "CELLULAR_COMPONENT", 211, 218], ["AP-1", "GENE_OR_GENE_PRODUCT", 230, 234], ["IL-8", "GENE_OR_GENE_PRODUCT", 251, 255], ["c-Jun", "GENE_OR_GENE_PRODUCT", 306, 311], ["JNK", "GENE_OR_GENE_PRODUCT", 337, 340], ["Jun", "PROTEIN", 19, 22], ["Jun", "PROTEIN", 133, 136], ["Jun", "PROTEIN", 187, 190], ["AP", "PROTEIN", 230, 232], ["IL-8", "PROTEIN", 251, 255], ["Jun", "PROTEIN", 308, 311], ["JNK", "PROTEIN", 337, 340], ["total c-Jun expression", "TREATMENT", 11, 33], ["phosphorylated c-Jun accumulation in the nucleus", "PROBLEM", 170, 218], ["Previous studies", "TEST", 266, 282], ["Jun accumulation", "OBSERVATION", 187, 203], ["nucleus", "ANATOMY", 211, 218], ["JNK", "ANATOMY", 337, 340]]], ["To investigate whether the activation of JNK and TAK-1 signaling pathways is essential for c-Jun phosphorylation during PRRSV infection, PAMs were pretreated with different doses of SP or (5Z)-7-Oxozeaenol 1 h before PRRSV infection.", [["PRRSV infection", "DISEASE", 120, 135], ["SP", "CHEMICAL", 182, 184], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 188, 205], ["PRRSV infection", "DISEASE", 217, 232], ["(5Z)-7-Oxozeaenol", "CHEMICAL", 188, 205], ["JNK", "GENE_OR_GENE_PRODUCT", 41, 44], ["TAK-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["c-Jun", "GENE_OR_GENE_PRODUCT", 91, 96], ["PRRSV", "ORGANISM", 120, 125], ["PAMs", "CELL", 137, 141], ["SP", "SIMPLE_CHEMICAL", 182, 184], ["(5Z)-7-Oxozeaenol", "SIMPLE_CHEMICAL", 188, 205], ["PRRSV", "ORGANISM", 217, 222], ["JNK", "PROTEIN", 41, 44], ["TAK", "PROTEIN", 49, 52], ["Jun", "PROTEIN", 93, 96], ["PAMs", "CELL_TYPE", 137, 141], ["PRRSV", "SPECIES", 120, 125], ["PRRSV", "SPECIES", 217, 222], ["JNK", "TEST", 41, 44], ["TAK", "TEST", 49, 52], ["c-Jun phosphorylation", "PROBLEM", 91, 112], ["PRRSV infection", "PROBLEM", 120, 135], ["PAMs", "PROBLEM", 137, 141], ["SP or (5Z)", "TREATMENT", 182, 192], ["Oxozeaenol", "TREATMENT", 195, 205], ["PRRSV infection", "PROBLEM", 217, 232], ["infection", "OBSERVATION", 223, 232]]], ["At 24 h after PRRSV infection, c-Jun phosphorylation was analyzed by Western blot.", [["PRRSV infection", "DISEASE", 14, 29], ["PRRSV", "ORGANISM", 14, 19], ["c-Jun", "GENE_OR_GENE_PRODUCT", 31, 36], ["Jun", "PROTEIN", 33, 36], ["PRRSV", "SPECIES", 14, 19], ["PRRSV infection", "PROBLEM", 14, 29], ["c-Jun phosphorylation", "TREATMENT", 31, 52], ["infection", "OBSERVATION", 20, 29]]], ["As shown in Fig. 6C and D, c-Jun phosphorylation induced by PRRSV was significantly impaired by the JNK inhibitor SP and TAK-1 inhibitor (5Z)-7-Oxozeaenolin in a dose-dependent manner, suggesting that the activation of c-Jun by PRRSV is mediated by TAK-1/JNK pathways.", [["SP", "CHEMICAL", 114, 116], ["TAK-1 inhibitor", "CHEMICAL", 121, 136], ["5Z)-7-Oxozeaenolin", "CHEMICAL", 138, 156], ["(5Z)-7-Oxozeaenolin", "CHEMICAL", 137, 156], ["D", "SIMPLE_CHEMICAL", 24, 25], ["c-Jun", "GENE_OR_GENE_PRODUCT", 27, 32], ["PRRSV", "ORGANISM", 60, 65], ["JNK", "GENE_OR_GENE_PRODUCT", 100, 103], ["SP", "SIMPLE_CHEMICAL", 114, 116], ["TAK-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["(5Z)-7-Oxozeaenolin", "SIMPLE_CHEMICAL", 137, 156], ["c-Jun", "GENE_OR_GENE_PRODUCT", 219, 224], ["PRRSV", "ORGANISM", 228, 233], ["TAK-1", "GENE_OR_GENE_PRODUCT", 249, 254], ["JNK", "GENE_OR_GENE_PRODUCT", 255, 258], ["Jun", "PROTEIN", 29, 32], ["JNK", "PROTEIN", 100, 103], ["c-Jun", "PROTEIN", 219, 224], ["TAK", "PROTEIN", 249, 252], ["JNK", "PROTEIN", 255, 258], ["PRRSV", "SPECIES", 60, 65], ["PRRSV", "SPECIES", 228, 233], ["c-Jun phosphorylation", "TREATMENT", 27, 48], ["PRRSV", "PROBLEM", 60, 65], ["TAK-1 inhibitor", "TREATMENT", 121, 136], ["Oxozeaenolin", "TREATMENT", 144, 156], ["Fig", "OBSERVATION", 12, 15]]], ["To further confirm this observation in vivo, we collected the PAMs from HV-infected pigs, and western blot analysis showed that TAK-1, JNK, and c-Jun were also activated (Fig. 6E) .", [["PAMs", "CELL", 62, 66], ["pigs", "ORGANISM", 84, 88], ["TAK-1", "GENE_OR_GENE_PRODUCT", 128, 133], ["JNK", "GENE_OR_GENE_PRODUCT", 135, 138], ["c-Jun", "GENE_OR_GENE_PRODUCT", 144, 149], ["PAMs", "CELL_TYPE", 62, 66], ["TAK", "PROTEIN", 128, 131], ["JNK", "PROTEIN", 135, 138], ["c", "PROTEIN", 144, 145], ["Jun", "PROTEIN", 146, 149], ["pigs", "SPECIES", 84, 88], ["this observation", "TEST", 19, 35], ["infected pigs", "TREATMENT", 75, 88], ["western blot analysis", "TEST", 94, 115], ["TAK", "TEST", 128, 131], ["JNK", "TEST", 135, 138], ["c-Jun", "TREATMENT", 144, 149], ["infected pigs", "OBSERVATION", 75, 88]]], ["Collectively, these data indicate that PRRSV induces IL-8 production through TAK-1/JNK/AP-1 signaling pathways (Fig. 7) .DiscussionIn this study, we investigated how PRRSV induced IL-8 production.", [["PRRSV", "ORGANISM", 39, 44], ["IL-8", "GENE_OR_GENE_PRODUCT", 53, 57], ["TAK-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["JNK", "GENE_OR_GENE_PRODUCT", 83, 86], ["AP-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["PRRSV", "ORGANISM", 166, 171], ["IL-8", "GENE_OR_GENE_PRODUCT", 180, 184], ["IL-8", "PROTEIN", 53, 57], ["TAK", "PROTEIN", 77, 80], ["JNK", "PROTEIN", 83, 86], ["AP", "PROTEIN", 87, 89], ["PRRSV", "SPECIES", 39, 44], ["PRRSV", "SPECIES", 166, 171], ["these data", "TEST", 14, 24], ["PRRSV", "PROBLEM", 39, 44], ["IL", "TEST", 53, 55], ["TAK", "TEST", 77, 80], ["JNK/AP", "TEST", 83, 89], ["this study", "TEST", 134, 144]]], ["We showed that PRRSV induced IL-8 production in PAMs both in vitro and in vivo.", [["PRRSV", "ORGANISM", 15, 20], ["IL-8", "GENE_OR_GENE_PRODUCT", 29, 33], ["PAMs", "CELL", 48, 52], ["IL-8", "PROTEIN", 29, 33], ["PRRSV", "SPECIES", 15, 20], ["PRRSV induced IL", "TREATMENT", 15, 31]]], ["Subsequently, we demonstrated that PRRSV-induced IL-8 production was mainly dependent on the activation of TAK-1/JNK/AP-1 pathways.", [["PRRSV", "ORGANISM", 35, 40], ["IL-8", "GENE_OR_GENE_PRODUCT", 49, 53], ["TAK-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["JNK", "GENE_OR_GENE_PRODUCT", 113, 116], ["AP-1", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL-8", "PROTEIN", 49, 53], ["TAK", "PROTEIN", 107, 110], ["JNK", "PROTEIN", 113, 116], ["AP", "PROTEIN", 117, 119], ["PRRSV", "SPECIES", 35, 40], ["PRRSV", "TEST", 35, 40], ["TAK", "TEST", 107, 110], ["JNK/AP", "TEST", 113, 119], ["PRRSV", "OBSERVATION", 35, 40]]], ["It was demonstrated that infection with a highly pathogenic strain of PRRSV elicited a significant elevation of cytokines including IL-8 in BALF, serum and TBLN homogenates of pigs .", [["BALF", "ANATOMY", 140, 144], ["serum", "ANATOMY", 146, 151], ["TBLN homogenates", "ANATOMY", 156, 172], ["infection", "DISEASE", 25, 34], ["PRRSV", "ORGANISM", 70, 75], ["IL-8", "GENE_OR_GENE_PRODUCT", 132, 136], ["BALF", "ORGANISM_SUBSTANCE", 140, 144], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["TBLN homogenates", "TISSUE", 156, 172], ["pigs", "ORGANISM", 176, 180], ["cytokines", "PROTEIN", 112, 121], ["IL-8", "PROTEIN", 132, 136], ["pigs", "SPECIES", 176, 180], ["PRRSV", "SPECIES", 70, 75], ["pigs", "SPECIES", 176, 180], ["infection", "PROBLEM", 25, 34], ["a highly pathogenic strain of PRRSV", "PROBLEM", 40, 75], ["a significant elevation of cytokines", "PROBLEM", 85, 121], ["IL", "TEST", 132, 134], ["BALF", "TEST", 140, 144], ["serum", "TEST", 146, 151], ["infection", "OBSERVATION", 25, 34], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["elevation", "OBSERVATION_MODIFIER", 99, 108], ["BALF", "ANATOMY", 140, 144]]], ["In our study, we found that PRRSV infection induced IL-8 expression both in vivo and in vitro.", [["PRRSV infection", "DISEASE", 28, 43], ["PRRSV", "ORGANISM", 28, 33], ["IL-8", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-8", "PROTEIN", 52, 56], ["PRRSV", "SPECIES", 28, 33], ["our study", "TEST", 3, 12], ["PRRSV infection", "PROBLEM", 28, 43], ["IL-8 expression", "TREATMENT", 52, 67], ["PRRSV", "OBSERVATION_MODIFIER", 28, 33], ["infection", "OBSERVATION", 34, 43]]], ["Besides, PAMs infected with HP-PRRSV isolate induced higher level of IL-8 expression in PAMs than CH-1a, which is in accordance with another in vivo report (Han et al., 2014) .", [["HP-PRRSV", "ORGANISM", 28, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["PAMs", "CELL", 88, 92], ["CH-1a", "CELL", 98, 103], ["PAMs", "CELL_TYPE", 9, 13], ["IL-8", "PROTEIN", 69, 73], ["PAMs", "CELL_TYPE", 88, 92], ["PRRSV", "SPECIES", 31, 36], ["HP", "PROBLEM", 28, 30], ["PRRSV isolate", "TREATMENT", 31, 44], ["IL", "TEST", 69, 71]]], ["The extensive level of IL-8 and the neutrophils recruited to lungs should be of particular significance in the lung injury.", [["neutrophils", "ANATOMY", 36, 47], ["lungs", "ANATOMY", 61, 66], ["lung", "ANATOMY", 111, 115], ["lung injury", "DISEASE", 111, 122], ["IL-8", "GENE_OR_GENE_PRODUCT", 23, 27], ["neutrophils", "CELL", 36, 47], ["lungs", "ORGAN", 61, 66], ["lung", "ORGAN", 111, 115], ["IL-8", "PROTEIN", 23, 27], ["neutrophils", "CELL_TYPE", 36, 47], ["the lung injury", "PROBLEM", 107, 122], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["neutrophils", "ANATOMY", 36, 47], ["lungs", "ANATOMY", 61, 66], ["lung", "ANATOMY", 111, 115], ["injury", "OBSERVATION", 116, 122]]], ["After stimulation by pro-inflammatory cytokines, the activated neutrophils could release free radicals, inflammatory cytokines and proteases, which have contributions to lung lesions (Avasarala et al., 2013; Han et al., 2014; Ware and Matthay, 2000) .", [["neutrophils", "ANATOMY", 63, 74], ["lung lesions", "ANATOMY", 170, 182], ["lung lesions", "DISEASE", 170, 182], ["neutrophils", "CELL", 63, 74], ["lung lesions", "CANCER", 170, 182], ["pro-inflammatory cytokines", "PROTEIN", 21, 47], ["activated neutrophils", "CELL_TYPE", 53, 74], ["inflammatory cytokines", "PROTEIN", 104, 126], ["proteases", "PROTEIN", 131, 140], ["pro-inflammatory cytokines", "TEST", 21, 47], ["the activated neutrophils", "PROBLEM", 49, 74], ["inflammatory cytokines and proteases", "PROBLEM", 104, 140], ["lung lesions", "PROBLEM", 170, 182], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["lung", "ANATOMY", 170, 174], ["lesions", "OBSERVATION", 175, 182]]], ["Indeed, compared with traditional strain, HP-PRRSV isolate can cause much severer neutrophil infiltration and lung lesions (Han et al., 2014; Tian et al., 2007) .", [["neutrophil", "ANATOMY", 82, 92], ["lung lesions", "ANATOMY", 110, 122], ["lung lesions", "DISEASE", 110, 122], ["HP-PRRSV", "ORGANISM", 42, 50], ["neutrophil", "CELL", 82, 92], ["lung lesions", "CANCER", 110, 122], ["PRRSV", "SPECIES", 45, 50], ["traditional strain", "PROBLEM", 22, 40], ["HP", "TEST", 42, 44], ["much severer neutrophil infiltration", "PROBLEM", 69, 105], ["lung lesions", "PROBLEM", 110, 122], ["severer", "OBSERVATION_MODIFIER", 74, 81], ["neutrophil infiltration", "OBSERVATION", 82, 105], ["lung", "ANATOMY", 110, 114], ["lesions", "OBSERVATION", 115, 122]]], ["Therefore, it is reasonable to speculate that upon HP-PRRSV infection macrophages secret higher levels of IL-8, which recruits more neutrophils and eventually leads to tissue damage and dysfunction of the lung.DiscussionPrevious studies have indicated that maximal IL-8 protein expression requires NF-\u03baB activation as well as the activation of the MAP kinases ERK, JNK, and p38 (Li et al., 2002) .", [["macrophages", "ANATOMY", 70, 81], ["neutrophils", "ANATOMY", 132, 143], ["tissue", "ANATOMY", 168, 174], ["lung", "ANATOMY", 205, 209], ["infection", "DISEASE", 60, 69], ["tissue damage", "DISEASE", 168, 181], ["HP-PRRSV", "ORGANISM", 51, 59], ["macrophages", "CELL", 70, 81], ["IL-8", "GENE_OR_GENE_PRODUCT", 106, 110], ["neutrophils", "CELL", 132, 143], ["tissue", "TISSUE", 168, 174], ["lung", "ORGAN", 205, 209], ["IL-8", "GENE_OR_GENE_PRODUCT", 265, 269], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 298, 303], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 348, 359], ["ERK", "GENE_OR_GENE_PRODUCT", 360, 363], ["JNK", "GENE_OR_GENE_PRODUCT", 365, 368], ["p38", "GENE_OR_GENE_PRODUCT", 374, 377], ["macrophages", "CELL_TYPE", 70, 81], ["IL-8", "PROTEIN", 106, 110], ["neutrophils", "CELL_TYPE", 132, 143], ["IL-8", "PROTEIN", 265, 269], ["NF-\u03baB", "PROTEIN", 298, 303], ["MAP kinases", "PROTEIN", 348, 359], ["ERK", "PROTEIN", 360, 363], ["JNK", "PROTEIN", 365, 368], ["p38", "PROTEIN", 374, 377], ["PRRSV", "SPECIES", 54, 59], ["HP", "TEST", 51, 53], ["PRRSV infection macrophages", "PROBLEM", 54, 81], ["IL", "TEST", 106, 108], ["tissue damage", "PROBLEM", 168, 181], ["dysfunction of the lung", "PROBLEM", 186, 209], ["DiscussionPrevious studies", "TEST", 210, 236], ["maximal IL", "TEST", 257, 267], ["the MAP kinases ERK", "TEST", 344, 363], ["JNK", "TEST", 365, 368], ["p38", "TEST", 374, 377], ["infection", "OBSERVATION", 60, 69], ["more neutrophils", "OBSERVATION_MODIFIER", 127, 143], ["to tissue", "OBSERVATION_MODIFIER", 165, 174], ["damage", "OBSERVATION", 175, 181], ["dysfunction", "OBSERVATION", 186, 197], ["lung", "ANATOMY", 205, 209]]], ["In our study, NF-\u03baB inhibitor can reduce the up-regulated IL-8 production by PRRSV infection, indicating that PRRSV-induced IL-8 expression is partially dependent on NF-\u03baB pathway.", [["PRRSV infection", "DISEASE", 77, 92], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-8", "GENE_OR_GENE_PRODUCT", 58, 62], ["PRRSV", "ORGANISM", 77, 82], ["PRRSV", "ORGANISM", 110, 115], ["IL-8", "GENE_OR_GENE_PRODUCT", 124, 128], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 166, 171], ["NF-\u03baB", "PROTEIN", 14, 19], ["IL-8", "PROTEIN", 58, 62], ["IL-8", "PROTEIN", 124, 128], ["NF-\u03baB", "PROTEIN", 166, 171], ["PRRSV", "SPECIES", 77, 82], ["PRRSV", "SPECIES", 110, 115], ["our study", "TEST", 3, 12], ["NF-\u03baB inhibitor", "TREATMENT", 14, 29], ["the up-regulated IL", "TREATMENT", 41, 60], ["PRRSV infection", "PROBLEM", 77, 92], ["PRRSV-induced IL", "TREATMENT", 110, 126], ["PRRSV infection", "OBSERVATION", 77, 92]]], ["This is in agreement with the report regarding the significance of NF-\u03baB pathway in IL-8 expression induced by other stimulators (Ohkuni et al., 2011) .", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL-8", "GENE_OR_GENE_PRODUCT", 84, 88], ["NF-\u03baB", "PROTEIN", 67, 72], ["IL-8", "PROTEIN", 84, 88]]], ["Moreover, our results suggest that JNK pathway is more essential for PRRSV induced IL-8 expression as JNK and c-Jun inhibitor and siRNA knockdown of c-Jun and c-Fos significantly reduced IL-8 expression.", [["JNK", "GENE_OR_GENE_PRODUCT", 35, 38], ["PRRSV", "ORGANISM", 69, 74], ["IL-8", "GENE_OR_GENE_PRODUCT", 83, 87], ["JNK", "GENE_OR_GENE_PRODUCT", 102, 105], ["c-Jun", "GENE_OR_GENE_PRODUCT", 110, 115], ["c-Jun", "GENE_OR_GENE_PRODUCT", 149, 154], ["c-Fos", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-8", "GENE_OR_GENE_PRODUCT", 187, 191], ["JNK", "PROTEIN", 35, 38], ["IL-8", "PROTEIN", 83, 87], ["JNK", "PROTEIN", 102, 105], ["Jun", "PROTEIN", 112, 115], ["c-Jun and c-Fos", "PROTEIN", 149, 164], ["IL-8", "PROTEIN", 187, 191], ["PRRSV", "SPECIES", 69, 74], ["JNK pathway", "TEST", 35, 46], ["PRRSV induced IL", "TREATMENT", 69, 85], ["JNK", "TEST", 102, 105], ["c-Jun inhibitor", "TREATMENT", 110, 125], ["siRNA knockdown", "TREATMENT", 130, 145], ["c", "TEST", 149, 150]]], ["Similarly, under stimulation of HIV-1, HCV and Papillomavirus, the expression of IL-8 is also JNK dependent (Chen et al., 2015; Gangwani and Kumar, 2015; Saeed et al., 2015; Zhang et al., 2014) .", [["HIV-1", "ORGANISM", 32, 37], ["HCV", "ORGANISM", 39, 42], ["Papillomavirus", "ORGANISM", 47, 61], ["IL-8", "GENE_OR_GENE_PRODUCT", 81, 85], ["JNK", "GENE_OR_GENE_PRODUCT", 94, 97], ["IL-8", "PROTEIN", 81, 85], ["JNK", "PROTEIN", 94, 97], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["HCV", "SPECIES", 39, 42], ["Papillomavirus", "SPECIES", 47, 61], ["HIV", "TEST", 32, 35], ["HCV", "PROBLEM", 39, 42], ["JNK dependent", "PROBLEM", 94, 107]]], ["JNK isoforms are strongly activated in response to various cellular stresses (Cargnello and Roux, 2011) .", [["cellular", "ANATOMY", 59, 67], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular", "CELL", 59, 67], ["JNK isoforms", "PROTEIN", 0, 12], ["JNK isoforms", "TEST", 0, 12], ["various", "OBSERVATION_MODIFIER", 51, 58], ["cellular stresses", "OBSERVATION", 59, 76], ["Roux", "ANATOMY", 92, 96]]], ["And indeed, we found that PRRSV infection activated JNK, which is in agreement with other reports (Huo et al., 2013; Jing et al., 2014; Lee and Lee, 2012; Yin et al., 2012) .", [["PRRSV infection", "DISEASE", 26, 41], ["PRRSV", "ORGANISM", 26, 31], ["JNK", "GENE_OR_GENE_PRODUCT", 52, 55], ["JNK", "PROTEIN", 52, 55], ["PRRSV", "SPECIES", 26, 31], ["PRRSV infection activated JNK", "PROBLEM", 26, 55], ["PRRSV", "OBSERVATION_MODIFIER", 26, 31], ["infection", "OBSERVATION", 32, 41]]], ["Here, we need to indicate that even though JNK inhibitor SP and NF-\u03baB inhibitor BAY significantly inhibit IL-8 mRNA expression induced by PRRSV infection, they do not affect the protein level of IL-8 at the same level, suggesting that there may exist post transcription level regulations such as translation repress, which might be not affected by JNK and NF-kB inhibitors.", [["SP", "CHEMICAL", 57, 59], ["BAY", "CHEMICAL", 80, 83], ["PRRSV infection", "DISEASE", 138, 153], ["BAY", "CHEMICAL", 80, 83], ["JNK", "GENE_OR_GENE_PRODUCT", 43, 46], ["SP", "SIMPLE_CHEMICAL", 57, 59], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 64, 69], ["BAY", "SIMPLE_CHEMICAL", 80, 83], ["IL-8", "GENE_OR_GENE_PRODUCT", 106, 110], ["PRRSV", "ORGANISM", 138, 143], ["IL-8", "GENE_OR_GENE_PRODUCT", 195, 199], ["JNK", "GENE_OR_GENE_PRODUCT", 348, 351], ["NF-kB", "GENE_OR_GENE_PRODUCT", 356, 361], ["JNK", "PROTEIN", 43, 46], ["IL-8 mRNA", "RNA", 106, 115], ["IL-8", "PROTEIN", 195, 199], ["JNK", "PROTEIN", 348, 351], ["PRRSV", "SPECIES", 138, 143], ["JNK inhibitor SP", "PROBLEM", 43, 59], ["NF-\u03baB inhibitor", "TREATMENT", 64, 79], ["IL", "TEST", 106, 108], ["PRRSV infection", "PROBLEM", 138, 153], ["IL", "TEST", 195, 197], ["JNK", "TEST", 348, 351], ["NF-kB inhibitors", "TREATMENT", 356, 372], ["PRRSV infection", "OBSERVATION", 138, 153]]], ["Interestingly, it has been reported that ARE in IL-8 3\u2032 UTR can recruit TTP, which can repress RNA translation (Anderson and Kedersha, 2009; Eulalio et al., 2007; Franks and Lykke-Andersen, 2008; Winzen Y. Liu et al. Virology 506 (2017 ) 64-72 et al., 2007 .", [["IL-8 3", "GENE_OR_GENE_PRODUCT", 48, 54], ["TTP", "GENE_OR_GENE_PRODUCT", 72, 75], ["ARE", "DNA", 41, 44], ["UTR", "DNA", 56, 59], ["TTP", "PROTEIN", 72, 75], ["TTP", "PROBLEM", 72, 75], ["TTP", "OBSERVATION", 72, 75]]], ["The transcription factor c-Jun is a well-described substrate for JNKs.", [["c-Jun", "GENE_OR_GENE_PRODUCT", 25, 30], ["JNKs", "GENE_OR_GENE_PRODUCT", 65, 69], ["transcription factor", "PROTEIN", 4, 24], ["c", "PROTEIN", 25, 26], ["Jun", "PROTEIN", 27, 30], ["JNKs", "PROTEIN", 65, 69]]], ["The phosphorylation of c-Jun by JNK has been reported to potentiate the transcriptional capacity of c-Jun, thus enhancing its ability to engage in gene transcription as well as its own expression (Hazzalin and Mahadevan, 2002) .", [["c-Jun", "GENE_OR_GENE_PRODUCT", 23, 28], ["JNK", "GENE_OR_GENE_PRODUCT", 32, 35], ["c-Jun", "GENE_OR_GENE_PRODUCT", 100, 105], ["Jun", "PROTEIN", 25, 28], ["JNK", "PROTEIN", 32, 35], ["Jun", "PROTEIN", 102, 105], ["c-Jun", "PROBLEM", 100, 105]]], ["Our results also show significant phosphorylation and expression of c-Jun upon PRRSV infection, which is dependent on JNK activation.", [["infection", "DISEASE", 85, 94], ["c-Jun", "GENE_OR_GENE_PRODUCT", 68, 73], ["PRRSV", "ORGANISM", 79, 84], ["JNK", "GENE_OR_GENE_PRODUCT", 118, 121], ["Jun", "PROTEIN", 70, 73], ["JNK", "PROTEIN", 118, 121], ["PRRSV", "SPECIES", 79, 84], ["significant phosphorylation", "PROBLEM", 22, 49], ["c-Jun", "PROBLEM", 68, 73], ["PRRSV infection", "PROBLEM", 79, 94], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["phosphorylation", "OBSERVATION", 34, 49], ["PRRSV infection", "OBSERVATION", 79, 94], ["dependent", "OBSERVATION_MODIFIER", 105, 114], ["JNK activation", "OBSERVATION", 118, 132]]], ["It is reported that stabilization of IL-8 mRNA is modulated by the p38 mitogen-activated protein kinase pathway (Hoffmann, 2002; Winzen et al., 2007) .", [["IL-8", "GENE_OR_GENE_PRODUCT", 37, 41], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 67, 103], ["IL-8 mRNA", "RNA", 37, 46], ["p38 mitogen-activated protein kinase", "PROTEIN", 67, 103], ["stabilization of IL", "TREATMENT", 20, 39], ["the p38 mitogen", "TEST", 63, 78]]], ["Exposure to the inflammatory cytokine IL-1 has been shown to stabilize IL-8 mRNA through p38 mitogen-activated protein (MAP) kinase and MK2 (Winzen et al., 2007) .", [["IL-1", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-8", "GENE_OR_GENE_PRODUCT", 71, 75], ["p38 mitogen-activated protein (MAP) kinase", "GENE_OR_GENE_PRODUCT", 89, 131], ["MK2", "GENE_OR_GENE_PRODUCT", 136, 139], ["inflammatory cytokine IL-1", "PROTEIN", 16, 42], ["IL-8 mRNA", "RNA", 71, 80], ["p38 mitogen-activated protein (MAP) kinase", "PROTEIN", 89, 131], ["MK2", "PROTEIN", 136, 139], ["the inflammatory cytokine IL", "TEST", 12, 40], ["IL", "TEST", 71, 73], ["p38 mitogen", "TEST", 89, 100], ["kinase", "TEST", 125, 131], ["inflammatory", "OBSERVATION_MODIFIER", 16, 28]]], ["Interestingly, we found that p38 inhibitor also reduced IL-8 mRNA expression.DiscussionIn human and mouse IL-8 promoters, a sequence from nt +1 to \u2212133 within the 5\u2032flanking region of the IL-8 gene is essential and sufficient for the transcriptional regulation of the gene (Mukaida and Murayama, 1998) .", [["p38", "GENE_OR_GENE_PRODUCT", 29, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 56, 60], ["human", "ORGANISM", 90, 95], ["mouse", "ORGANISM", 100, 105], ["IL-8", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-8", "GENE_OR_GENE_PRODUCT", 188, 192], ["p38", "PROTEIN", 29, 32], ["IL-8 mRNA", "RNA", 56, 65], ["human and mouse IL-8 promoters", "DNA", 90, 120], ["nt +1 to \u2212133", "DNA", 138, 151], ["5\u2032flanking region", "DNA", 163, 180], ["IL-8 gene", "DNA", 188, 197], ["human", "SPECIES", 90, 95], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 90, 95], ["mouse", "SPECIES", 100, 105], ["p38 inhibitor", "TREATMENT", 29, 42], ["reduced IL", "PROBLEM", 48, 58]]], ["Analysis demonstrates that the promoter elements contain NF-\u03baB, AP-1, and C/EBP \u03b2 binding sites (Matsusaka et al., 1993; Mukaida and Murayama, 1998; Nourbakhsh et al., 2001) .", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 57, 62], ["AP-1", "GENE_OR_GENE_PRODUCT", 64, 68], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 74, 81], ["promoter elements", "DNA", 31, 48], ["NF-\u03baB, AP-1", "DNA", 57, 68], ["C/EBP \u03b2 binding sites", "DNA", 74, 95], ["Analysis", "TEST", 0, 8], ["NF", "TEST", 57, 59], ["AP", "TEST", 64, 66]]], ["The promoter is regulated in a cell type-specific fashion, requiring a NF-\u03baB element plus either an AP-1 or a C/EBP \u03b2 element (Chang et al., 2004; Wu et al., 1997) .", [["cell", "ANATOMY", 31, 35], ["cell", "CELL", 31, 35], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 71, 76], ["AP-1", "GENE_OR_GENE_PRODUCT", 100, 104], ["NF-\u03baB element", "DNA", 71, 84], ["AP-1", "DNA", 100, 104], ["C/EBP \u03b2 element", "DNA", 110, 125], ["a NF-\u03baB element", "TREATMENT", 69, 84], ["a C/EBP \u03b2 element", "TREATMENT", 108, 125]]], ["We cloned the 2751 bp-sequence in the 5\u2032 flanking region of the porcine IL-8 gene.", [["IL-8", "GENE_OR_GENE_PRODUCT", 72, 76], ["2751 bp-sequence", "DNA", 14, 30], ["5\u2032 flanking region", "DNA", 38, 56], ["porcine IL-8 gene", "DNA", 64, 81], ["the porcine IL", "TREATMENT", 60, 74]]], ["Truncation mutations indicated that the region from \u2212187 to +123 bp was essential for the porcine IL-8 promoter activity.", [["IL-8", "GENE_OR_GENE_PRODUCT", 98, 102], ["porcine IL-8 promoter", "DNA", 90, 111], ["Truncation mutations", "PROBLEM", 0, 20], ["bp", "TEST", 65, 67], ["the porcine IL", "TREATMENT", 86, 100]]], ["However, the longer promoter was not stimulated by PRRSV.", [["PRRSV", "ORGANISM", 51, 56], ["PRRSV", "SPECIES", 51, 56]]], ["The reason could be that there might exist some negative regulation elements in the upstream of the \u2212187 to +123 bp.", [["negative regulation elements", "DNA", 48, 76], ["\u2212187 to +123 bp", "DNA", 100, 115], ["bp", "TEST", 113, 115], ["negative", "OBSERVATION", 48, 56]]], ["Analysis showed that AP-1, C/EBP \u03b2, and NF-\u03baB elements existed in the region from \u2212187 to \u221276 bp.", [["AP-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 27, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["AP-1, C/EBP \u03b2", "DNA", 21, 34], ["NF-\u03baB elements", "DNA", 40, 54], ["\u2212187 to \u221276 bp", "DNA", 82, 96], ["Analysis", "TEST", 0, 8], ["AP", "TEST", 21, 23], ["C/EBP", "TEST", 27, 32], ["NF", "TEST", 40, 42], ["bp", "TEST", 94, 96], ["region", "ANATOMY_MODIFIER", 70, 76]]], ["Deletion of these three elements suggested that AP-1 element was the most significant one in PRRSV induced IL-8 expression.", [["AP-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["PRRSV", "ORGANISM", 93, 98], ["IL-8", "GENE_OR_GENE_PRODUCT", 107, 111], ["AP-1 element", "DNA", 48, 60], ["PRRSV", "SPECIES", 93, 98], ["Deletion of these three elements", "PROBLEM", 0, 32], ["AP-1 element", "PROBLEM", 48, 60]]], ["Similar result was reported with SARS-CoV (Chang et al., 2004) .DiscussionTAK1 is a key regulator of the innate immunity and the proinflammatory signaling pathway.", [["DiscussionTAK1", "GENE_OR_GENE_PRODUCT", 64, 78], ["DiscussionTAK1", "PROTEIN", 64, 78], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37]]], ["Many viruses have been reported to modulate the activity of TAK1 and thereby the NF-\u03baB and AP-1 pathways.", [["TAK1", "GENE_OR_GENE_PRODUCT", 60, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 81, 86], ["AP-1", "GENE_OR_GENE_PRODUCT", 91, 95], ["TAK1", "PROTEIN", 60, 64], ["AP", "PROTEIN", 91, 93], ["Many viruses", "PROBLEM", 0, 12], ["the NF", "TEST", 77, 83], ["viruses", "OBSERVATION", 5, 12]]], ["For example, the X protein of hepatitis B virus, LMP1 of Epstein-Barr virus, vGPCR of KHSV, ICP0 of herpes simplex virus type 1, RSV, and Tax of human T cell leukemia virus type 1 can activate NF-\u03baB or AP-1 signaling by targeting TAK1 (Bottero et al., 2011; Diao et al., 2005; Liu et al., 2014; Soni et al., 2007; Zhou et al., 2010) .", [["hepatitis B", "DISEASE", 30, 41], ["herpes simplex", "DISEASE", 100, 114], ["hepatitis B virus", "ORGANISM", 30, 47], ["LMP1", "GENE_OR_GENE_PRODUCT", 49, 53], ["Epstein-Barr virus", "ORGANISM", 57, 75], ["vGPCR", "GENE_OR_GENE_PRODUCT", 77, 82], ["KHSV", "GENE_OR_GENE_PRODUCT", 86, 90], ["ICP0", "GENE_OR_GENE_PRODUCT", 92, 96], ["herpes simplex virus type 1", "ORGANISM", 100, 127], ["RSV", "ORGANISM", 129, 132], ["Tax", "GENE_OR_GENE_PRODUCT", 138, 141], ["human T cell leukemia virus type 1", "ORGANISM", 145, 179], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 193, 198], ["AP-1", "GENE_OR_GENE_PRODUCT", 202, 206], ["TAK1", "GENE_OR_GENE_PRODUCT", 230, 234], ["X protein", "PROTEIN", 17, 26], ["LMP1", "PROTEIN", 49, 53], ["vGPCR", "PROTEIN", 77, 82], ["KHSV", "PROTEIN", 86, 90], ["ICP0", "PROTEIN", 92, 96], ["Tax", "PROTEIN", 138, 141], ["NF-\u03baB", "PROTEIN", 193, 198], ["AP", "PROTEIN", 202, 204], ["TAK1", "PROTEIN", 230, 234], ["hepatitis B virus", "SPECIES", 30, 47], ["herpes simplex virus", "SPECIES", 100, 120], ["human", "SPECIES", 145, 150], ["T cell leukemia virus", "SPECIES", 151, 172], ["hepatitis B virus", "SPECIES", 30, 47], ["Epstein-Barr virus", "SPECIES", 57, 75], ["KHSV", "SPECIES", 86, 90], ["herpes simplex virus type 1", "SPECIES", 100, 127], ["RSV", "SPECIES", 129, 132], ["human T cell leukemia virus type 1", "SPECIES", 145, 179], ["the X protein", "TEST", 13, 26], ["hepatitis B virus", "PROBLEM", 30, 47], ["Epstein", "TEST", 57, 64], ["Barr virus", "PROBLEM", 65, 75], ["vGPCR", "TEST", 77, 82], ["KHSV", "TEST", 86, 90], ["herpes simplex virus type 1", "PROBLEM", 100, 127], ["RSV", "PROBLEM", 129, 132], ["human T cell leukemia virus type", "PROBLEM", 145, 177], ["NF", "TEST", 193, 195], ["hepatitis", "OBSERVATION", 30, 39], ["herpes simplex", "OBSERVATION", 100, 114], ["cell leukemia virus", "OBSERVATION", 153, 172]]], ["TAK1 regulates JNK, p38 MAPKs and I\u03baB kinase (IKK) signaling pathways, leading to the activation of transcription factors AP-1 and NF-\u03baB (Sakurai, 2002) .", [["TAK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["JNK", "GENE_OR_GENE_PRODUCT", 15, 18], ["p38 MAPKs", "GENE_OR_GENE_PRODUCT", 20, 29], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 34, 44], ["IKK", "GENE_OR_GENE_PRODUCT", 46, 49], ["AP-1", "GENE_OR_GENE_PRODUCT", 122, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 131, 136], ["TAK1", "PROTEIN", 0, 4], ["JNK", "PROTEIN", 15, 18], ["p38 MAPKs", "PROTEIN", 20, 29], ["I\u03baB kinase", "PROTEIN", 34, 44], ["IKK", "PROTEIN", 46, 49], ["transcription factors", "PROTEIN", 100, 121], ["AP-1", "PROTEIN", 122, 126], ["NF-\u03baB", "PROTEIN", 131, 136], ["JNK", "TEST", 15, 18], ["p38 MAPKs", "TEST", 20, 29], ["I\u03baB kinase", "TEST", 34, 44], ["signaling pathways", "PROBLEM", 51, 69], ["transcription factors", "TEST", 100, 121], ["AP", "TEST", 122, 124]]], ["Consistent with this, we found that PRRSV significantly induced TAK-1 activation and PRRSV-induced IL-8 expression was TAK-1 dependent.", [["PRRSV", "ORGANISM", 36, 41], ["TAK-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["PRRSV", "ORGANISM", 85, 90], ["IL-8", "GENE_OR_GENE_PRODUCT", 99, 103], ["TAK-1", "GENE_OR_GENE_PRODUCT", 119, 124], ["TAK", "PROTEIN", 64, 67], ["IL-8", "PROTEIN", 99, 103], ["TAK", "PROTEIN", 119, 122], ["PRRSV", "SPECIES", 36, 41], ["PRRSV", "SPECIES", 85, 90], ["PRRSV", "PROBLEM", 36, 41], ["TAK", "TEST", 64, 67], ["PRRSV-induced IL", "TREATMENT", 85, 101]]], ["Similarly, TAK-1 participates in IL-8 expression under stimulation of other virus (Pera et al., 2012) .DiscussionIn summary, our study demonstrates that PRRSV inducesIL-8 expression is dependent on the activation of TAK-1/JNK/AP1 as well as NF-\u03baB pathways, in which AP-1 element is shown to be critical for IL-8 expression.", [["TAK-1", "GENE_OR_GENE_PRODUCT", 11, 16], ["IL-8", "GENE_OR_GENE_PRODUCT", 33, 37], ["PRRSV", "ORGANISM", 153, 158], ["inducesIL-8", "GENE_OR_GENE_PRODUCT", 159, 170], ["TAK-1", "GENE_OR_GENE_PRODUCT", 216, 221], ["JNK", "GENE_OR_GENE_PRODUCT", 222, 225], ["AP1", "GENE_OR_GENE_PRODUCT", 226, 229], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 241, 246], ["AP-1", "GENE_OR_GENE_PRODUCT", 266, 270], ["IL-8", "GENE_OR_GENE_PRODUCT", 307, 311], ["TAK", "PROTEIN", 11, 14], ["IL-8", "PROTEIN", 33, 37], ["TAK", "PROTEIN", 216, 219], ["JNK", "PROTEIN", 222, 225], ["AP1", "PROTEIN", 226, 229], ["NF-\u03baB", "PROTEIN", 241, 246], ["AP-1 element", "DNA", 266, 278], ["IL-8", "PROTEIN", 307, 311], ["PRRSV", "SPECIES", 153, 158], ["our study", "TEST", 125, 134], ["PRRSV inducesIL", "TEST", 153, 168], ["TAK", "TEST", 216, 219]]], ["This work may provide some insights into the molecular mechanisms of IL-8 regulation in pigs during PRRSV infection.Cells and virus preparationPAMs were obtained by postmortem lung lavage of 8-week-old specific-pathogen-free (SPF) pigs and maintained in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum (FBS) and penicillin-streptomycin.", [["Cells", "ANATOMY", 116, 121], ["lung lavage", "ANATOMY", 176, 187], ["fetal bovine serum", "ANATOMY", 297, 315], ["FBS", "ANATOMY", 317, 320], ["PRRSV infection", "DISEASE", 100, 115], ["penicillin", "CHEMICAL", 326, 336], ["streptomycin", "CHEMICAL", 337, 349], ["penicillin", "CHEMICAL", 326, 336], ["streptomycin", "CHEMICAL", 337, 349], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["pigs", "ORGANISM", 88, 92], ["PRRSV", "ORGANISM", 100, 105], ["Cells", "CELL", 116, 121], ["lung lavage", "ORGANISM_SUBSTANCE", 176, 187], ["pigs", "ORGANISM", 231, 235], ["bovine", "ORGANISM", 303, 309], ["serum", "ORGANISM_SUBSTANCE", 310, 315], ["FBS", "ORGANISM_SUBSTANCE", 317, 320], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 326, 349], ["IL-8", "PROTEIN", 69, 73], ["pigs", "SPECIES", 88, 92], ["PRRSV", "SPECIES", 100, 105], ["pigs", "SPECIES", 231, 235], ["bovine", "SPECIES", 303, 309], ["pigs", "SPECIES", 88, 92], ["PRRSV", "SPECIES", 100, 105], ["pigs", "SPECIES", 231, 235], ["bovine", "SPECIES", 303, 309], ["IL", "TREATMENT", 69, 71], ["PRRSV infection", "PROBLEM", 100, 115], ["virus preparationPAMs", "TREATMENT", 126, 147], ["postmortem lung lavage", "TEST", 165, 187], ["fetal bovine serum", "TEST", 297, 315], ["FBS", "TEST", 317, 320], ["penicillin", "TREATMENT", 326, 336], ["streptomycin", "TREATMENT", 337, 349], ["infection", "OBSERVATION", 106, 115], ["lung", "ANATOMY", 176, 180], ["lavage", "OBSERVATION", 181, 187]]], ["Marc-145 cells, which is a PRRSV-permissive cell line sub-cloned from MA-104 cells (African green monkey kidney cells), were maintained in Dulbecco's minimum essential medium (DME\u039c) supplemented with 10% heat-inactivated FBS and penicillin-streptomycin.", [["Marc-145 cells", "ANATOMY", 0, 14], ["cell line", "ANATOMY", 44, 53], ["MA-104 cells", "ANATOMY", 70, 82], ["kidney cells", "ANATOMY", 105, 117], ["FBS", "CHEMICAL", 221, 224], ["penicillin", "CHEMICAL", 229, 239], ["streptomycin", "CHEMICAL", 240, 252], ["penicillin", "CHEMICAL", 229, 239], ["streptomycin", "CHEMICAL", 240, 252], ["Marc-145 cells", "CELL", 0, 14], ["PRRSV", "ORGANISM", 27, 32], ["cell line", "CELL", 44, 53], ["MA-104 cells", "CELL", 70, 82], ["green monkey kidney cells", "CELL", 92, 117], ["FBS", "ORGANISM_SUBSTANCE", 221, 224], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 229, 252], ["Marc-145 cells", "CELL_LINE", 0, 14], ["PRRSV-permissive cell line", "CELL_LINE", 27, 53], ["MA-104 cells", "CELL_LINE", 70, 82], ["African green monkey kidney cells", "CELL_TYPE", 84, 117], ["green monkey", "SPECIES", 92, 104], ["African green monkey", "SPECIES", 84, 104], ["a PRRSV", "PROBLEM", 25, 32], ["MA", "TEST", 70, 72], ["African green monkey kidney cells", "TREATMENT", 84, 117], ["inactivated FBS", "TREATMENT", 209, 224], ["penicillin", "TREATMENT", 229, 239], ["streptomycin", "TREATMENT", 240, 252], ["145 cells", "OBSERVATION_MODIFIER", 5, 14], ["permissive cell line", "OBSERVATION", 33, 53]]], ["All the cells were cultured and maintained at 37\u00b0C with 5% CO 2 .", [["cells", "ANATOMY", 8, 13], ["CO 2", "CHEMICAL", 59, 63], ["cells", "CELL", 8, 13]]], ["PRRSV strain, CH-1a (the first type 2 PRRSV strain isolated in China), and HV (a highly pathogenic PRRSV isolate) were propagated in PAMs.", [["CH-1a", "CHEMICAL", 14, 19], ["PRRSV strain", "ORGANISM", 0, 12], ["CH-1a", "ORGANISM", 14, 19], ["PRRSV", "ORGANISM", 38, 43], ["PRRSV", "ORGANISM", 99, 104], ["PAMs", "CELL", 133, 137], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 38, 43], ["PRRSV", "SPECIES", 99, 104], ["PRRSV", "SPECIES", 0, 5], ["CH-1a", "SPECIES", 14, 19], ["PRRSV", "SPECIES", 38, 43], ["PRRSV", "SPECIES", 99, 104], ["PRRSV strain", "PROBLEM", 0, 12], ["HV", "PROBLEM", 75, 77]]], ["Virus preparations were titrated, and then stored at \u221280\u00b0C.Real-time PCRTotal RNAs were extracted from cells or tissues with TRIzol (Invitrogen) according to the manufacturer's instructions.", [["cells", "ANATOMY", 103, 108], ["tissues", "ANATOMY", 112, 119], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 103, 108], ["tissues", "TISSUE", 112, 119], ["PCRTotal RNAs", "RNA", 69, 82], ["Virus preparations", "TREATMENT", 0, 18], ["TRIzol (Invitrogen)", "TREATMENT", 125, 144]]], ["Reverse transcription was performed using M-MLV reverse transcriptase (Promega) with oligo (dT) 18 primer.", [["MLV reverse transcriptase", "PROTEIN", 44, 69], ["oligo (dT) 18 primer", "DNA", 85, 105], ["MLV reverse transcriptase (Promega)", "TREATMENT", 44, 79], ["oligo (dT)", "TREATMENT", 85, 95]]], ["Real-time PCR was performed using SYBR Premix Ex Taq (TaKaRa) and a ViiA 7 real-time PCR system (Applied Biosystems).", [["TaKaRa", "GENE_OR_GENE_PRODUCT", 54, 60], ["SYBR Premix Ex Taq", "PROTEIN", 34, 52], ["Real-time PCR", "TEST", 0, 13], ["SYBR Premix Ex Taq (TaKaRa)", "TREATMENT", 34, 61], ["a ViiA", "TREATMENT", 66, 72]]], ["For quantitative analysis of PRRSV in cells and tissues, quantitative PCR (qPCR) was performed as previously described (Du et al., 2016) .", [["cells", "ANATOMY", 38, 43], ["tissues", "ANATOMY", 48, 55], ["PRRSV", "ORGANISM", 29, 34], ["cells", "CELL", 38, 43], ["tissues", "TISSUE", 48, 55], ["PRRSV", "SPECIES", 29, 34], ["quantitative analysis", "TEST", 4, 25], ["PRRSV in cells and tissues", "PROBLEM", 29, 55], ["quantitative PCR", "TEST", 57, 73], ["PRRSV", "OBSERVATION", 29, 34], ["tissues", "ANATOMY", 48, 55]]], ["Relative analysis of gene expression was evaluated using the \u0394\u0394Ct method (Schmittgen and Livak, 2008) .", [["gene expression", "PROBLEM", 21, 36], ["gene expression", "OBSERVATION", 21, 36]]], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was set up as an endogenous control.", [["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 40], ["GAPDH", "GENE_OR_GENE_PRODUCT", 42, 47], ["Glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 0, 40], ["GAPDH", "PROTEIN", 42, 47], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)", "TREATMENT", 0, 48]]], ["The specific primers used were listed in Table 1 .Animal experimentFour-week-old SPF piglets were obtained from the Beijing Center for SPF Swine Breeding and Management and randomly divided into two groups (three piglets per group).", [["SPF", "ORGANISM", 81, 84], ["piglets", "ORGANISM", 85, 92], ["piglets", "ORGANISM", 213, 220], ["piglets", "SPECIES", 85, 92], ["The specific primers", "TREATMENT", 0, 20], ["SPF Swine Breeding", "TREATMENT", 135, 153], ["Management", "TREATMENT", 158, 168]]], ["All animal studies were performed according to protocols approved by the Animal Welfare Committee of China Agricultural University.", [["All animal studies", "TEST", 0, 18]]], ["Piglets were intranasally inoculated with 2 ml of PRRSV strain HV (10 5 TCID 50 virus/ml).", [["Piglets", "ORGANISM", 0, 7], ["PRRSV", "ORGANISM", 50, 55], ["Piglets", "SPECIES", 0, 7], ["PRRSV strain HV", "SPECIES", 50, 65], ["PRRSV strain HV", "PROBLEM", 50, 65]]], ["Samples were collected at 5 days post infection (dpi).Reagents and antibodiesNF-\u03baB inhibitor (BAY11-7082), protein kinase C (PKC) inhibitor (GF-109203X), MEK inhibitor (PD98059), p38 inhibitor (SB203580), JNK inhibitor (SP600125), and phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) were purchased from Cell Signaling Technology, Inc. LPS was obtained from Sigma-Aldrich.", [["Samples", "ANATOMY", 0, 7], ["Cell", "ANATOMY", 313, 317], ["infection", "DISEASE", 38, 47], ["BAY11-7082", "CHEMICAL", 94, 104], ["GF-109203X", "CHEMICAL", 141, 151], ["PD98059", "CHEMICAL", 169, 176], ["SB203580", "CHEMICAL", 194, 202], ["SP600125", "CHEMICAL", 220, 228], ["LY294002", "CHEMICAL", 283, 291], ["LPS", "CHEMICAL", 345, 348], ["BAY11-7082", "CHEMICAL", 94, 104], ["GF-109203X", "CHEMICAL", 141, 151], ["PD98059", "CHEMICAL", 169, 176], ["SB203580", "CHEMICAL", 194, 202], ["SP600125", "CHEMICAL", 220, 228], ["phosphatidylinositol", "CHEMICAL", 235, 255], ["LY294002", "CHEMICAL", 283, 291], ["antibodiesNF-\u03baB", "GENE_OR_GENE_PRODUCT", 67, 82], ["BAY11-7082", "SIMPLE_CHEMICAL", 94, 104], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 107, 123], ["PKC", "GENE_OR_GENE_PRODUCT", 125, 128], ["GF-109203X", "SIMPLE_CHEMICAL", 141, 151], ["MEK", "GENE_OR_GENE_PRODUCT", 154, 157], ["PD98059", "SIMPLE_CHEMICAL", 169, 176], ["p38", "GENE_OR_GENE_PRODUCT", 179, 182], ["SB203580", "SIMPLE_CHEMICAL", 194, 202], ["JNK", "GENE_OR_GENE_PRODUCT", 205, 208], ["SP600125", "SIMPLE_CHEMICAL", 220, 228], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 235, 264], ["PI3K", "GENE_OR_GENE_PRODUCT", 266, 270], ["LY294002", "SIMPLE_CHEMICAL", 283, 291], ["Cell", "CELL", 313, 317], ["Sigma-Aldrich", "ORGANISM", 367, 380], ["antibodiesNF", "PROTEIN", 67, 79], ["protein kinase C", "PROTEIN", 107, 123], ["PKC", "PROTEIN", 125, 128], ["MEK", "PROTEIN", 154, 157], ["JNK", "PROTEIN", 205, 208], ["PI3K", "PROTEIN", 266, 270], ["Samples", "TEST", 0, 7], ["infection", "PROBLEM", 38, 47], ["Reagents", "TEST", 54, 62], ["antibodiesNF", "TEST", 67, 79], ["BAY11", "TEST", 94, 99], ["protein kinase C (PKC) inhibitor", "TEST", 107, 139], ["GF", "TEST", 141, 143], ["MEK inhibitor", "TREATMENT", 154, 167], ["p38 inhibitor", "TREATMENT", 179, 192], ["JNK inhibitor", "TREATMENT", 205, 218], ["phosphatidylinositol", "TREATMENT", 235, 255], ["kinase (PI3K) inhibitor (LY294002", "TREATMENT", 258, 291]]], ["Enzyme-linked immunosorbent assay (Serti et al., 2010) kit for porcine IL-8 was purchased from R & D Systems.", [["porcine", "ORGANISM", 63, 70], ["IL-8", "GENE_OR_GENE_PRODUCT", 71, 75], ["Enzyme", "TEST", 0, 6], ["immunosorbent assay", "TEST", 14, 33], ["porcine IL", "TREATMENT", 63, 73]]], ["All inhibitors were reconstituted in dimethyl sulfoxide (DMSO), and DMSO was used as the solvent control for all experiments involving treatment with inhibitors.", [["dimethyl sulfoxide", "CHEMICAL", 37, 55], ["DMSO", "CHEMICAL", 57, 61], ["DMSO", "CHEMICAL", 68, 72], ["dimethyl sulfoxide", "CHEMICAL", 37, 55], ["DMSO", "CHEMICAL", 57, 61], ["DMSO", "CHEMICAL", 68, 72], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 37, 55], ["DMSO", "SIMPLE_CHEMICAL", 57, 61], ["DMSO", "SIMPLE_CHEMICAL", 68, 72], ["All inhibitors", "TREATMENT", 0, 14], ["dimethyl sulfoxide (DMSO", "TREATMENT", 37, 61], ["DMSO", "TREATMENT", 68, 72], ["the solvent control", "TREATMENT", 85, 104], ["treatment with inhibitors", "TREATMENT", 135, 160]]], ["A Dual-Glo luciferase assay system was purchased from Promega.", [["A Dual-Glo luciferase assay system", "TREATMENT", 0, 34]]], ["Antibodies against c-Jun, p-c-Jun, JNK, p-JNK, TAK-1, p-TAK-1, I\u03baB\u03b1 and p-I\u03baB\u03b1 were from Cell Signaling Technology, Inc. Antibody against \u03b2-actin was purchased from Sigma.Western blottingWhole-cell extracts were prepared as follows: Cells were washed twice with ice-cold PBS, and then lysed in radioimmuneprecipitation assay (RIPA) lysis buffer (Beyotime) with 100 U proteinase inhibitor (Cwbiotech) and 20 M NaF for 15 min on ice.", [["Cell", "ANATOMY", 89, 93], ["Whole-cell extracts", "ANATOMY", 187, 206], ["Cells", "ANATOMY", 233, 238], ["Cwbiotech", "CHEMICAL", 389, 398], ["NaF", "CHEMICAL", 409, 412], ["NaF", "CHEMICAL", 409, 412], ["c-Jun", "GENE_OR_GENE_PRODUCT", 19, 24], ["p-c-Jun", "GENE_OR_GENE_PRODUCT", 26, 33], ["JNK", "GENE_OR_GENE_PRODUCT", 35, 38], ["p-JNK", "GENE_OR_GENE_PRODUCT", 40, 45], ["TAK-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["p-TAK-1", "GENE_OR_GENE_PRODUCT", 54, 61], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 63, 67], ["p-I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 72, 78], ["Cell", "CELL", 89, 93], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 138, 145], ["cell extracts", "ORGANISM_SUBSTANCE", 193, 206], ["Cells", "CELL", 233, 238], ["Cwbiotech", "SIMPLE_CHEMICAL", 389, 398], ["NaF", "SIMPLE_CHEMICAL", 409, 412], ["c", "PROTEIN", 19, 20], ["Jun", "PROTEIN", 21, 24], ["Jun", "PROTEIN", 30, 33], ["JNK", "PROTEIN", 35, 38], ["p", "PROTEIN", 40, 41], ["JNK", "PROTEIN", 42, 45], ["TAK", "PROTEIN", 47, 50], ["p-TAK-1", "PROTEIN", 54, 61], ["I\u03baB\u03b1", "PROTEIN", 63, 67], ["p-I\u03baB\u03b1", "PROTEIN", 72, 78], ["\u03b2-actin", "PROTEIN", 138, 145], ["Antibodies", "TEST", 0, 10], ["JNK", "TEST", 35, 38], ["JNK", "TEST", 42, 45], ["TAK", "TEST", 47, 50], ["p-TAK", "TEST", 54, 59], ["Antibody", "TEST", 121, 129], ["ice-cold PBS", "TREATMENT", 262, 274], ["radioimmuneprecipitation assay (RIPA) lysis buffer", "TREATMENT", 294, 344], ["100 U proteinase inhibitor", "TREATMENT", 361, 387], ["JNK", "ANATOMY", 35, 38]]], ["The lysates were centrifuged at 10,000g for 10 min and the supernatant was aliquotedsiRNA knockdownCells were transfected with 200 pmol of small interfering RNA (siRNA) oligonucleotides specific for the c-Jun gene, c-Fos gene, or a nonspecific control (NC) (GenePharmaInc.) using HiPerFect Transfection Reagent (QIAGEN) according to the manufacturer's instructions.", [["lysates", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 59, 70], ["Cells", "ANATOMY", 99, 104], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["Cells", "CELL", 99, 104], ["c-Jun", "GENE_OR_GENE_PRODUCT", 203, 208], ["c-Fos", "GENE_OR_GENE_PRODUCT", 215, 220], ["small interfering RNA", "RNA", 139, 160], ["c-Jun gene", "DNA", 203, 213], ["c-Fos gene", "DNA", 215, 225], ["The lysates", "TREATMENT", 0, 11], ["aliquotedsiRNA knockdown", "TREATMENT", 75, 99], ["Cells", "TEST", 99, 104], ["small interfering RNA (siRNA) oligonucleotides", "TREATMENT", 139, 185], ["the c-Jun gene", "TREATMENT", 199, 213], ["a nonspecific control (NC", "TREATMENT", 230, 255], ["HiPerFect Transfection Reagent (QIAGEN)", "TREATMENT", 280, 319], ["small", "OBSERVATION_MODIFIER", 139, 144], ["interfering", "OBSERVATION", 145, 156]]], ["The efficiency of knockdown of protein expression was confirmed by Western blotting.Construction of porcine IL-8 promotersGenomic DNA was extracted from PAMs and purified by the use of a DNA extraction kit (TaKaRa).", [["porcine", "ORGANISM", 100, 107], ["IL-8", "GENE_OR_GENE_PRODUCT", 108, 112], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["DNA", "CELLULAR_COMPONENT", 187, 190], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 207, 213], ["porcine IL-8 promoters", "DNA", 100, 122], ["PAMs", "CELL_TYPE", 153, 157], ["knockdown of protein expression", "PROBLEM", 18, 49], ["Construction of porcine IL-8 promoters", "TREATMENT", 84, 122], ["Genomic DNA", "PROBLEM", 122, 133], ["a DNA extraction kit (TaKaRa)", "TREATMENT", 185, 214], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["knockdown", "OBSERVATION_MODIFIER", 18, 27], ["protein expression", "OBSERVATION", 31, 49]]], ["The fragment of the porcine IL-8 gene promoter flanking the 5\u2032 IL-8 gene (NC_010450.3) was cloned with specific primers.", [["IL-8", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 63, 67], ["NC_010450.3", "GENE_OR_GENE_PRODUCT", 74, 85], ["porcine IL-8 gene promoter", "DNA", 20, 46], ["IL-8 gene", "DNA", 63, 72], ["NC_010450.3", "DNA", 74, 85], ["The fragment of the porcine IL-8 gene promoter flanking", "TREATMENT", 0, 55], ["IL", "TEST", 63, 65], ["fragment", "OBSERVATION_MODIFIER", 4, 12]]], ["The obtained 2751-bp Susscrofa IL-8 promoter sequence (nucleotides \u22122628 to +123) relative to the transcription initiation site (+1) was subcloned into the luciferase (luc) reporter vector pGL3-basic at the NheI site (pGL \u22122628/+123-luc), and the nucleotide sequence was determined by DNA sequencing.", [["nucleotide", "CHEMICAL", 247, 257], ["IL-8", "GENE_OR_GENE_PRODUCT", 31, 35], ["luciferase", "GENE_OR_GENE_PRODUCT", 156, 166], ["luc", "GENE_OR_GENE_PRODUCT", 168, 171], ["pGL3", "GENE_OR_GENE_PRODUCT", 189, 193], ["NheI", "GENE_OR_GENE_PRODUCT", 207, 211], ["+123-luc", "GENE_OR_GENE_PRODUCT", 228, 236], ["DNA", "CELLULAR_COMPONENT", 285, 288], ["2751-bp Susscrofa IL-8 promoter sequence", "DNA", 13, 53], ["nucleotides \u22122628 to +123", "DNA", 55, 80], ["transcription initiation site", "DNA", 98, 127], ["luciferase (luc) reporter vector pGL3", "DNA", 156, 193], ["NheI site", "DNA", 207, 216], ["pGL", "DNA", 218, 221], ["luc", "DNA", 233, 236], ["bp Susscrofa IL", "TEST", 18, 33], ["nucleotides", "TEST", 55, 66], ["pGL", "TEST", 218, 221], ["the nucleotide sequence", "TEST", 243, 266], ["luciferase", "ANATOMY", 156, 166]]], ["The truncated mutants of the IL-8 promoter were then constructed and inserted into the luciferase reporter vector pGL3-basic (named as pGL3-1892/+123-luc, pGL3-1278/+123-luc, pGL3-939/+123-luc, pGL3-515/+123-luc, pGL3-187/+123-luc, pGL3-108/+123-luc, and pGL3-76/+123-luc).", [["IL-8", "GENE_OR_GENE_PRODUCT", 29, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 87, 97], ["pGL3", "GENE_OR_GENE_PRODUCT", 114, 118], ["pGL3-1892", "GENE_OR_GENE_PRODUCT", 135, 144], ["+123", "GENE_OR_GENE_PRODUCT", 145, 149], ["luc", "GENE_OR_GENE_PRODUCT", 150, 153], ["pGL3-1278", "GENE_OR_GENE_PRODUCT", 155, 164], ["luc", "GENE_OR_GENE_PRODUCT", 170, 173], ["pGL3", "GENE_OR_GENE_PRODUCT", 175, 179], ["pGL3", "GENE_OR_GENE_PRODUCT", 194, 198], ["pGL3", "GENE_OR_GENE_PRODUCT", 213, 217], ["pGL3-108", "GENE_OR_GENE_PRODUCT", 232, 240], ["+123-luc", "GENE_OR_GENE_PRODUCT", 241, 249], ["pGL3", "GENE_OR_GENE_PRODUCT", 255, 259], ["IL-8 promoter", "DNA", 29, 42], ["luciferase reporter vector pGL3", "DNA", 87, 118], ["pGL3-1892", "DNA", 135, 144], ["pGL3", "DNA", 155, 159], ["pGL3", "DNA", 175, 179], ["pGL3", "DNA", 194, 198], ["pGL3", "DNA", 213, 217], ["pGL3", "DNA", 232, 236], ["luc", "DNA", 246, 249], ["pGL3", "DNA", 255, 259], ["luc", "DNA", 268, 271], ["the IL-8 promoter", "TREATMENT", 25, 42], ["pGL3", "TEST", 155, 159], ["pGL3", "TEST", 175, 179], ["luc", "TEST", 189, 192], ["pGL3", "TEST", 194, 198], ["luc", "TEST", 208, 211], ["pGL3", "TEST", 213, 217], ["luc", "TEST", 227, 230], ["pGL3", "TEST", 232, 236], ["luc", "TEST", 246, 249], ["pGL3", "TEST", 255, 259]]], ["The truncated mutants of the IL-8 promoter were constructed using the primers listed in Table 2 .", [["IL-8", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-8 promoter", "DNA", 29, 42], ["the IL-8 promoter", "TREATMENT", 25, 42], ["the primers", "TREATMENT", 66, 77]]], ["The AP-1, NF-\u03baB, and C/EBP \u03b2 element deletion IL-8 promoters including \u2212187/ 123(\u0394AP-1)-luc, \u2212187/123(\u0394NF-\u03baB)-luc, \u2212187/123(\u0394C/EBP \u03b2)-luc, \u2212187/123(\u0394AP-1, NF-\u03baB)-luc, \u2212187/123(\u0394AP-1, C/EBP \u03b2)-luc, \u2212187/123(\u0394C/EBP \u03b2, NF-\u03baB)-luc and \u2212187/123(\u0394AP-1, NF-\u03baB, C/ EBP \u03b2)-luc were generated by overlapping PCR from the \u2212187/123 promoter pGL3 vector.", [["AP-1", "GENE_OR_GENE_PRODUCT", 4, 8], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 10, 15], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 21, 28], ["IL-8", "GENE_OR_GENE_PRODUCT", 46, 50], ["\u0394AP-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["luc", "GENE_OR_GENE_PRODUCT", 88, 91], ["\u0394NF-\u03baB", "GENE_OR_GENE_PRODUCT", 102, 108], ["\u0394C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 124, 132], ["\u0394AP-1", "GENE_OR_GENE_PRODUCT", 148, 153], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["\u0394AP-1", "GENE_OR_GENE_PRODUCT", 176, 181], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 183, 190], ["\u2212187/123", "GENE_OR_GENE_PRODUCT", 197, 205], ["\u0394C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 206, 214], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 216, 221], ["\u2212187/123", "GENE_OR_GENE_PRODUCT", 231, 239], ["\u0394AP-1", "GENE_OR_GENE_PRODUCT", 240, 245], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 247, 252], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 254, 262], ["luc", "GENE_OR_GENE_PRODUCT", 264, 267], ["pGL3", "GENE_OR_GENE_PRODUCT", 329, 333], ["AP-1, NF-\u03baB", "DNA", 4, 15], ["C/EBP \u03b2 element", "DNA", 21, 36], ["IL-8 promoters", "DNA", 46, 60], ["luc", "DNA", 88, 91], ["\u0394NF", "DNA", 102, 105], ["luc", "DNA", 110, 113], ["luc", "DNA", 134, 137], ["\u0394AP", "DNA", 148, 151], ["NF", "DNA", 155, 157], ["luc", "DNA", 162, 165], ["\u0394AP", "DNA", 176, 179], ["luc", "DNA", 192, 195], ["EBP \u03b2", "DNA", 209, 214], ["NF-\u03baB", "DNA", 216, 221], ["luc and \u2212187/123", "DNA", 223, 239], ["\u0394AP", "DNA", 240, 243], ["NF", "DNA", 247, 249], ["\u03baB", "DNA", 250, 252], ["C", "DNA", 254, 255], ["EBP \u03b2", "DNA", 257, 262], ["luc", "DNA", 264, 267], ["\u2212187/123 promoter pGL3 vector", "DNA", 311, 340], ["The AP", "TEST", 0, 6], ["NF", "TEST", 10, 12], ["C/EBP \u03b2 element deletion IL", "TEST", 21, 48], ["\u0394AP", "TEST", 81, 84], ["luc", "TEST", 88, 91], ["\u0394NF", "TEST", 102, 105], ["luc", "TEST", 110, 113], ["\u0394C", "TEST", 124, 126], ["EBP", "TEST", 127, 130], ["luc", "TEST", 134, 137], ["\u0394AP", "TEST", 148, 151], ["NF", "TEST", 155, 157], ["luc", "TEST", 162, 165], ["\u0394AP", "TEST", 176, 179], ["EBP", "TEST", 185, 188], ["luc", "TEST", 192, 195], ["\u2212", "TEST", 197, 198], ["\u0394C", "TEST", 206, 208], ["EBP", "TEST", 209, 212], ["NF", "TEST", 216, 218], ["luc", "TEST", 223, 226], ["\u2212", "TEST", 231, 232], ["\u0394AP", "TEST", 240, 243], ["NF", "TEST", 247, 249], ["B", "TEST", 251, 252], ["C/ EBP \u03b2", "TEST", 254, 262], ["overlapping PCR", "TEST", 286, 301]]], ["The mutated DNA was then subcloned into the pGL3-basic vector and verified by sequence analysis.Luciferase reporter assaysMarc-145 cells were seeded in 24-well plates at a cell density of 4\u00d710 4 cells per well.", [["Marc-145 cells", "ANATOMY", 122, 136], ["cell", "ANATOMY", 172, 176], ["4\u00d710 4 cells", "ANATOMY", 188, 200], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["pGL3", "GENE_OR_GENE_PRODUCT", 44, 48], ["Marc-145 cells", "CELL", 122, 136], ["cell", "CELL", 172, 176], ["cells", "CELL", 195, 200], ["mutated DNA", "DNA", 4, 15], ["pGL3-basic vector", "DNA", 44, 61], ["Marc-145 cells", "CELL_LINE", 122, 136], ["The mutated DNA", "TREATMENT", 0, 15], ["sequence analysis", "TEST", 78, 95], ["Luciferase reporter", "TEST", 96, 115], ["cell density", "OBSERVATION_MODIFIER", 172, 184]]], ["At 14-16 h after plating, cells were transfected with pGL3 and pRL-TK using Lipofectamine LTX and Plus reagents (Invitrogen). pRL-TK plasmid was used as a control for transfection efficiency.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["pGL3", "GENE_OR_GENE_PRODUCT", 54, 58], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 63, 69], ["Plus reagents", "SIMPLE_CHEMICAL", 98, 111], ["Invitrogen", "SIMPLE_CHEMICAL", 113, 123], ["pRL", "GENE_OR_GENE_PRODUCT", 126, 129], ["pGL3", "PROTEIN", 54, 58], ["pRL", "PROTEIN", 63, 66], ["pRL-TK plasmid", "DNA", 126, 140], ["plating", "TREATMENT", 17, 24], ["pGL3", "TEST", 54, 58], ["pRL", "TEST", 63, 66], ["Lipofectamine LTX", "TREATMENT", 76, 93], ["Plus reagents (Invitrogen)", "TREATMENT", 98, 124], ["pRL-TK plasmid", "TREATMENT", 126, 140], ["transfection efficiency", "PROBLEM", 167, 190]]], ["At 24 h after transfection, cells were infected with virus for 36 h or left uninfected.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["virus", "PROBLEM", 53, 58], ["left", "ANATOMY_MODIFIER", 71, 75], ["uninfected", "OBSERVATION", 76, 86]]], ["Cell extracts were prepared and analyzed for firefly and Renilla luciferase activities using the dual-luciferase reporter assay kit (Promega) according to the manufacturer's instructions.Statistical analysisAll the experiments were performed with at least three independent replicates.", [["Cell extracts", "ANATOMY", 0, 13], ["Cell extracts", "ORGANISM_SUBSTANCE", 0, 13], ["luciferase", "GENE_OR_GENE_PRODUCT", 65, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 102, 112], ["luciferase", "PROTEIN", 65, 75], ["Cell extracts", "TREATMENT", 0, 13], ["Renilla luciferase activities", "TEST", 57, 86], ["Statistical analysis", "TEST", 187, 207]]], ["Statistical analysis was performed using GraphPad Prism software, and differences in data were analyzed by Student's t-test.", [["Statistical analysis", "TEST", 0, 20], ["GraphPad Prism software", "TEST", 41, 64], ["Student's t-test", "TEST", 107, 123]]], ["Statistically significant was allowed if the P value was less than 0.05. *, P < 0.05.", [["the P value", "TEST", 41, 52]]]]}